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Abstract 
Background: There are a large number of viruses spread by mosquitoes, many of 
which cause debilitating, often fatal, neurological disease such as acute 
encephalitis. In this study we have used two different neurotropic viruses: 
Semliki Forest virus (SFV), and West Nile virus (WNV), both of which can cause 
severe panencephalitis in the mouse. The influx of leukocytes into the infected 
tissues is mediated by chemokines and is believed to be important for virus 
clearance. To date, we have only limited insights into the precise nature of 
chemokine involvement, and an improved understanding of these important axes 
provides a new target for the development of novel therapies. Hypothesis: 
Based on previous studies investigating the role of chemokines during 
neuroinflammation it was hypothesised that chemokines and other cytokines are 
highly upregulated during viral encephalitis, and the blockade of selected 
chemokine receptors would lead to altered disease outcome. It was also 
hypothesised that chemokine receptors would present plausible targets for the 
treatment of viral encephalitis. Results: To test these hypotheses, the 
chemokine expression pattern and the kinetics of chemokine mediated leukocyte 
recruitment during viral encephalitis were analysed in unprecedented detail by 
TaqMan low density array, and flow cytometry, respectively, and key chemokine 
receptor were identified as therapeutic targets. Both SFV and WNV exhibited a 
similar pattern of chemokine upregulation, although WNV induced significantly 
higher fold expression. The key chemokines upregulated were CCL2, 3, 5, 7, 
CXCL9 and CXCL10. The upregulation of chemokines coincided with leukocyte 
influx into the CNS. After identifying the key chemokines upregulated during 
viral encephalitis, next a selected panel of chemokine receptor antagonists was 
utilized to evaluate the hierarchy and relative importance of distinct chemokine 
receptors for CNS leukocyte influx, viral clearance, neuropathogenesis and host 
survival. We identified the CXCR3 axis as being the key instigator of CNS 
inflammation in response to alphavirus infection, placing it at the top of a 
hierarchal cascade that is followed by CCR2 and CCR5. Critically, inhibition of 
both CXCR3 and CCR2 simultaneously, significantly improved host survival to 
otherwise lethal encephalitis. Conclusion: These data suggest that chemokine 
receptors represent plausible therapeutic targets for viral encephalitis.  
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1.1 Innate and adaptive immunity  
The immune system is important for the protection of the host from infectious 
agents, tissue injury and harmful substances like toxins. To achieve this the 
immune system has to recognize the presence of pathogens, contain the spread 
of infection and eliminate the infectious agent from the body. Following this, 
the immune response must be regulated in order to prevent allergy and 
autoimmunity. Finally, to build up a protective and strong immune response 
against any subsequent reinfection, the immune system must be capable of 
generating an immunological memory by producing highly specific antibodies 
that can persist life long in the host. The immune response can be divided into 
two categories: innate and adaptive immune responses. Both systems are 
capable of discriminating between ‘self’ and ‘non self’ (1, 2). 
In this introduction I will give a brief overview of the immune system in general 
before specifically discussing immune responses in the CNS. I will then describe 
the role of chemokines and their receptors in the CNS, and discuss Semliki Forest 
virus and West Nile virus as models of viral encephalitis. These two pathogens, 
and in particular Semliki Forest virus, form the focus of my thesis.  Finally, I will 
discuss what is currently known in the field about the role of chemokines in the 
pathogenesis of viral encephalitis.  
1.1.1 Innate immunity 
The innate immunity is an important first line of defense, occurs within minutes 
after infection and is capable of containing the spread of an infection and 
eliminating the pathogen. There are two phases of innate immune responses: 
the immediate innate immune response (0-4 hours after infection), followed by 
the early induced innate immune response (4-96 hours after infection) (3, 4).  
To infect a host, a pathogen must first overcome the epithelial surfaces which 
provide a physical barrier against infectious agents. These epithelial surfaces are 
also able to produce a variety of antimicrobial enzymes, such as lysozymes, or 
antimicrobial peptides such as defensins, cathelicidin and histatin (5, 6). 
Lysozyme is a glycosidase and digests bacterial cell walls. Antimicrobial peptides 
are able to lyse bacterial cell walls. Another system of immediate host defence 
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is the complement system (7-9). This system is comprised of 30 soluble plasma 
proteins that act as pattern-recognition receptors and bind directly to pathogens 
and target them for lysis or phagocytosis by immune cells. 
The early induced innate immune response is initiated after the pathogen has 
passed the epithelial barrier and activated the complement system. Cells of the 
innate immune system such as phagocytes, mast cells and natural killer (NK) 
cells recognize characteristic components of pathogens called pathogen-
associated molecular patterns (PAMPS) or damage-associated molecular patterns 
(DAMPS) via pattern-recognition receptors (PRRs) (10, 11). The activation of 
PRRs leads to the release of pro-inflammatory cytokines which initiate 
inflammation and trigger an adaptive immune response in order to specifically 
target the invading pathogen. Furthermore phagocytes are pivotal for the direct 
killing of the infectious agent and release antimicrobial peptides and enzymes 
that are toxic to microbes (12).  
1.1.1.1 Pattern-recognition receptors (PRRs) 
PAMPS and DAMPS can be recognized by germ line encoded PRRs which can be 
soluble, membrane bound or cytoplasmic. PAMPS are highly conserved structures 
among microbes such as highly repetitive cell membrane components of bacteria 
(lipoteichoic acids, lipopolysaccharide) and fungi (β-glucan), unmethylated 
repeats of dinucleotide CpG, viral nucleic acid (double stranded or single 
stranded RNA) and other microbial structures (10). DAMPS are non-infectious, 
endogenous, molecules that are sequestered from the cytoplasm of dying cells 
due to cellular stress, toxic injury or hypoxia. Prototypical DAMPS are high-
mobility group box 1 proteins (HMGB1), heat shock proteins (HSPs), adenosine 5-
triphosphate (ATP), uric acid or hyaluronan (13). PRRs are expressed by all cells 
of the innate immune system but in particular by ‘professional’ immune cells 
such as macrophages and dendritic cells. 
1.1.1.2 Cells of the innate immune system 
Leukocytes are white blood cells and are pivotal for innate and adaptive 
immunity. Their role during viral encephalitis is not yet clear, as leukocytes can 
be either detrimental or beneficial for the pathogenesis of this disease (14). 
Leukocytes originate in the bone marrow and are derived from pluripotent 
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hematopoietic stem cells. These pluripotent hematopoietic stem cells give rise 
to two progenitors: lymphoid and myeloid progenitor cells. While lymphoid 
progenitor cells give rise to B-cells, T-cells and NK-cells, myeloid progenitor cells 
give rise to granulocytes, monocytes, macrophages, mast cells and dendritic 
cells (Fig. 1.1). Cells of the innate immune system comprise granulocytes, 
monocytes, macrophages, DCs and NK-cells.  Phagocytes are a group of innate 
immune cells which are specialised in the uptake of pathogens and apoptotic 
particles and are therefore important for viral clearance during infection. 
Professional phagocytes are comprised of monocytes, macrophages, DCs and 
granulocytes. Other non-professional phagocytes such as endothelial or epithelial 
cells are also capable of phagocytosis. 
 
Figure 1.1 Differentiation of hematopoietic cells 
Pluripotent stem cells differentiate into either lymphoid or myeloid progenitor cells. Lymphoid 
progenitor cells give rise to B-cells, T-cells and NK-cells. Myeloid progenitor cells give rise to 
immature DCs, and granulocyte/macrophage or megakaryocyte/erythrocyte progenitor cells 
which differentiate further into megakaryocytes or erythrocytes. Granulocytes, mast cells and 
monocytes are derived from granulocyte/macrophage progenitor cells. Adapted from (15). 
Granulocytes 
Granulocytes contain dense granules in their cytoplasm. There are three types of 
granulocytes which can be distinguished by different staining properties of the 
granules using haematoxylin and eosin staining: neutrophils (stain pink), 
eosinophils (stain red) and basophils (stain blue). Generally granulocytes exhibit 
a relatively short life span and are terminally differentiated cells. Eosinophils 
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and basophils will not be discussed as part of this thesis and are reviewed 
elsewhere (16, 17). 
Neutrophils are the most abundant white blood cell in the blood of humans and 
mice. During infection the number of neutrophils increases enormously and they 
are one of the first leukocytes recruited to the inflamed tissue, although this 
might be different in the CNS.  Activation of neutrophils will result in 
degranulation, secretion of cytokines and receptor-mediated phagocytosis of the 
pathogen.  There are three types of granules in the cytoplasm of neutrophils:  
azurophilic or primary granules, specific or secondary granules, and gelatinase or 
tertiary granules (18). The granules contain a plethora of antimicrobial proteins 
that are toxic to the pathogen. While azurophilic granules are the largest 
granules and contain myeloperoxidase, the other granules are myeloperoxidase 
negative. The granules show varying propensities for mobilisation. For instance, 
azurophilic granules are the most difficult to mobilise whereas tertiary granules 
are more readily released into the cytoplasm (19).  
Monocytes  
Monocytes are generated in the bone marrow and are released into the blood 
upon expression of the chemokine receptor CCR2. Depending on the context, 
monocytes can differentiate further into tissue macrophages, microglia or DCs 
(20). Monocytes are important for immunosurveillance in the blood and are 
capable of replenishing tissue macrophages or DC populations in the steady 
state. They also play a pivotal role during infection and inflammation where 
they exert antimicrobial activities (21, 22). During viral brain infections, 
monocytes play a critical role in the initiation of immune responses and antigen 
presentation of viral particles and differentiate into brain macrophages or 
microglia (23). This will be discussed in detail later. Murine monocytes can be 
divided into two different subsets on the basis of specific surface markers 
including Ly6C, CD62L, CCR2 and CX3CR1 (24). Monocytes that are Ly6Chi, 
CD62L+, CCR2+ and CX3CR1lo are referred to as ‘inflammatory’ or Ly6Chi 
monocytes. These Ly6Chi monocytes have a propensity to rapidly migrate to sites 
of infection and inflammation, and within the tissue they preferentially 
differentiate into macrophages or DCs that produce pro-inflammatory cytokines 
and antimicrobial proteins (25). Ly6Chi monocytes can downregulate the 
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expression of Ly6C and it has been suggested that they can become Ly6Clo 
monocytes (21). 
The second subset of monocytes circulating in the blood is characterised as 
Ly6Clo, CD62L-, CCR2- and CX3CR1hi and often referred to as ‘resident’ or Ly6Clo 
monocytes. These Ly6Clo monocytes circulate in the blood and migrate along 
luminal surfaces of the vascular endothelium. Since Ly6Clo monocytes 
preferentially circulate in the blood in steady state it has been proposed that 
these monocytes patrol the blood vessels and may play important roles in 
scavenging dead cells, oxidised lipids and pathogens (26). Furthermore, in 
response to tissue damage or infection, these Ly6Clo monocytes can rapidly 
extravasate into the inflamed tissue and become the main source of 
inflammatory monocytes during very early stages of inflammatory immune 
responses (26).  
Macrophages 
Macrophages are large tissue resident cells, present in almost every tissue of the 
body. Macrophages contain phagocytic granules and are highly efficient in 
removing cellular debris, apoptotic cells and pathogens. Upon detection of 
DAMPS or PAMPS, macrophages can become activated via PRRs, leading to 
changes in their morphology and physiology.  It has been suggested that 
activated macrophages can be divided into three different subsets depending on 
their activation phenotype: classically activated macrophages (M1), alternatively 
activated macrophages (M2), and regulatory macrophages which will not be 
discussed here (27-29). 
Classically activated macrophages, or M1 macrophages are mostly derived from 
‘inflammatory’ monocytes. These macrophages become activated after 
recognizing PAMPS or DAMPS and initiate the production of tumor necrosis factor 
(TNF). Furthermore the presence of IFN-γ, produced by NK-cells and T-helper 
(Th) cells in response to infection, can induce an M1 phenotype. Classically 
activated macrophages produce nitric oxide (NO) and reactive oxygen species 
(ROS) for antimicrobial defence (30, 31). In addition to that, M1 macrophages 
also produce inflammatory cytokines including TNF, IL-11, IL-6, IL-12, IL-23, IL-
27, chemokines such as CXCL9 and CXCL10, and matrix-metalloproteinases 
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(MMPs) for the degradation of extracellular matrix. Due to the upregulation of 
major histocompatibility (MHC) class II molecules on their cell surface, 
macrophages can also act as antigen presenting cells (APCs), bridging innate and 
adaptive immunity (28).  
Alternatively activated macrophages or M2 macrophages are important during 
parasitic infections and allergies, and promote wound healing (32). M2 
macrophages are activated in the presence of IL-4 and IL-13 which is produced 
by granulocytes, mast cells and Th2 cells (1). Compared to M1 macrophages, M2 
macrophages produce low levels of inflammatory cytokines and high levels of IL-
10 and transforming growth factor (TGF)-β.  
Macrophages show a high degree of plasticity, which allows them to perform 
different specific functions in response to environmental cues. This means that 
during pathological processes, macrophages are capable of switching their 
phenotype and adapting rapidly to a new environment. However, this plasticity 
makes it complicated to assign one specific phenotype to macrophages (28). For 
instance in the brain, macrophages become microglia, and are indistinguishable 
from these cells based on the markers available for flow cytometry. These 
microglia are then important during viral brain infections (4, 33). 
Dendritic cells (DCs) 
DCs, CD11c+MHC-II+ cells, are ‘professional’ antigen presenting cells, which 
means that they can ingest foreign particles by phagocytosis and present the 
antigen on the surface to lymphoid cells, such as T-cells. Therefore DCs form a 
crucial link between the innate and adaptive immune system. In comparison to 
macrophages, which are specialised in destroying pathogens, DCs are specialised 
in presenting antigens (34). DCs are derived from myeloid progenitor cells and 
most of the DCs exit the bone marrow as immature DCs (7). DCs are an 
extremely heterogeneous cell population and it is difficult to categorize them 
but DCs can be broadly divided into steady state conventional DCs and non-
conventional DCs including plasmacytoid DCs (pDCs) and monocyte derived DCs, 
although this is controversial as it has been shown that most DCs are derived 
from specific precursors in the bone marrow (21, 35, 36).  pDCs are a major 
source of type-I interferon, and are therefore important during viral infections. 
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Natural killer cells (NK-cells) 
NK-cells are derived from lymphoid progenitor cells and circulate in the blood 
after exiting the bone marrow. NK-cells are known for their ability to kill virus or 
bacteria infected cells and certain tumour cells, and are therefore important 
during infection (37). Their exact role during viral encephalitis is not yet 
understood, and there are sparse data investigating their role during brain 
infection.  
NK cells are filled with cytotoxic granules that can be released after binding the 
target cell. The cytotoxic granules contain perforin which forms pores through 
the target cell wall, granzyme (a serine protease) which induces apoptosis, and 
granulysin that is cytolytic. Furthermore upon activation NK-cells can produce 
large amounts of IFN-γ and also other pro-inflammatory cytokines such as TNF, 
and chemokines including CCL3, CCL4 and CCL5 (38, 39).  
NK-cell activation is tightly regulated by the expression of inhibiting and 
activating receptors on their surface. Inhibiting receptors usually bind to MHC 
class I molecules. The balance of inhibiting and activating receptors determines 
the activation status of NK-cells.  The lack of MHC-I in combination with other 
activating receptors such as IFN-α, IFN-β or IL-12 leads to NK-cell activation (37, 
40). 
1.1.2 Adaptive Immunity 
If a pathogen is able to overcome innate immunity, the adaptive immune 
response is induced, which is able to specifically recognize the antigen and 
eliminate it. Adaptive immunity is induced late during infection and needs 
approximately at least four days to generate activated effector lymphocytes 
from naïve T- and B-cells. Adaptive immunity uses somatic gene rearrangement 
to produce antigen specific receptors which means that these receptors are 
encoded in different gene segments that are then assembled to form T- and B-
cell receptor genes (41). This system allows the host to produce an enormous 
variety of different antigen specific receptors.  
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1.1.2.1 Cells of the adaptive immune system 
Lymphocytes are cells of the adaptive immune system and can be divided into T- 
and B-cells. Both cells are derived from lymphoid progenitor cells in the bone 
marrow. While B-cells mature in the bone marrow, T-cells need to migrate to 
the thymus for maturation. Lymphocytes that have not yet encountered an 
antigen are specified as naïve lymphocytes. Upon activation of naïve 
lymphocytes they become activated and turn into effector lymphocytes (41). 
T-cells 
T-cells are divided into different groups based on the expression of their lineage 
markers and functional activities. There are two distinct T-cell lineages known 
as CD4+ and CD8+ cells. On the basis of functional activity, T-cells can be divided 
into three groups: naïve, effector and memory T-cells. All T-cells have a T-cell 
receptor (TCR) which can bind to peptide antigen presented on MHC molecules 
on the surface of antigen presenting cells. The TCR assembles with the CD3 
surface molecule and forms the T-cell receptor complex (42).  T-cells have been 
shown to be important during viral encephalitis and their role in this context will 
be discussed in chapter 1.5. A brief overview of different subsets of T-cells will 
be presented here. 
CD4+ T helper cells are specialized in producing cytokines that can stimulate 
other immune effector cells or that can be toxic to the target cell. Furthermore 
CD4+ T-cells are also pivotal in providing help to B-cells for the production of 
high-affinity antibodies. The CD4 co-receptor recognizes only peptides bound on 
MHC-II molecules. These peptides are mostly derived from intracellular vesicles 
through phagocytosis or endocytosis and presented on APCs. There are at least 
six different effector types within the CD4+ T-cell population: Th1, Th2, Th9, 
Th17, Treg and TFH. Depending on the cytokine expression, activated naïve CD4+ 
T-cells can differentiate into different types of effector cells (43). In the 
presence of IL-12 and IFN-γ, T-cells preferentially differentiate into Th1 cells 
which mainly develop following bacterial or viral infections. Th1 cells mainly 
release the cytokines IL-2, IFN-γ and TNF-β (lymphotoxin). These cytokines in 
turn activate macrophages which then kill the invading pathogen. The expression 
of IL-4 favours the development of Th2 cells. Signature cytokines produced by 
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Th2 cells are IL-4, IL-5 and IL-13, which activate eosinophils, mast cells and 
plasma cells. Th2 cells control predominantly parasitic infections and play a role 
during allergies (44). A balance between Th1 and Th2 response decides on 
pathogen growth and immunopathology. In the context of viral encephalitis, the 
main focus is on Th1 cells, which have been shown to be important for the 
pathogenesis of viral infections in the CNS (45). 
Cytotoxic CD8+ T-cells are particularly important in viral infections, are 
specialized in the direct lysis of the pathogen or infected/malignant cell, and 
produce few cytokines. Kristensen et al. have shown that LCMV-specific CD8+ T-
cells produce IFN-γ, TNF and inflammatory chemokines such as CCL3, CCL4 and 
CCL5 (46). Viral clearance by CD8+ T-cells has also been implicated in 
demyelination in the CNS, suggesting a pathogenic role of these cells during 
brain infection (47). The CD8 co-receptor selectively recognizes peptides bound 
to MHC-I molecules. MHC-I molecules are expressed on most cells of the body 
and present antigens derived from proteins within the cytoplasm. This means 
that CD8+ T-cells are able to detect virally infected cells and kill them through 
lysis using their cytotoxic granules. Many CD8+ T-cells do not need additional co-
stimulatory signals after binding to MHC-I molecules. However during most viral 
infections CD8+ T-cells require additional help from CD4+ T-cells for their 
activation. This additional help prevents inadvertent activation of CD8+ T-cells, 
because cytotoxic granules would be destructive to many cells (48).  
B-cells 
B-cells are also able to present antigen to T-cells, produce cytokines, exert 
suppressive functions through the secretion of IL-10, and can differentiate into 
either antibody producing plasma cells or memory B-cells. After antigen binding 
via the B-cell receptor (BCR) B-cells become activated, proliferate and 
differentiate into either plasma cells, which are terminally differentiated cells 
that secrete antibodies, or memory cells.  The process of secretion of antibodies 
into blood or extracellular fluids is also known as humoral immunity (49, 50).  
The secreted antibodies protect the host against pathogens in three different 
ways: neutralization, opsonisation and complement activation, which all lead to 
phagocytosis by macrophages and other cells. On the basis of the constant 
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region, antibodies can be divided into five immunoglobulin classes: IgM, IgD, IgG, 
IgE and IgA. The IgG isotype is the most abundant antibody and has shown to be 
important during Semliki Forest virus (SFV) infection. Amor et al. have shown 
that SCID mice, lacking serum antiviral antibodies and infected with Semliki 
Forest virus develop high viremia and persistent CNS infection. After transfer of 
IgM, viremia was cleared, and in the presence of high titer IgG, the virus was 
cleared from the blood and CNS, suggesting that antibodies are essential for viral 
clearance (51).  
1.1.3 Cytokines during innate and adaptive immunity 
Cytokines are small proteins with a low molecular weight. Various cells in the 
host secrete them during innate and adaptive immunity in response to activating 
stimuli. Once secreted, they can act in an autocrine (affecting the same cell), 
paracrine (affecting adjacent cells) or endocrine manner (affecting distant 
cells). All cytokines have different biological effects on different target cells 
(pleiotropic). One of their main roles is to orchestrate innate and adaptive 
immune responses by activating and recruiting leukocytes to the site of 
inflammation (52). Interferons have been shown to be particularly important 
during virus infections and have been a focus in virology for a long time (53, 54). 
Interferons exert immediate antiviral effects and are able to bridge the innate 
with the adaptive immune system (55). TNF is important for the initiation of 
inflammation during viral infection. In my analysis I have focussed specifically on 
the expression of these two cytokines during viral encephalitis, although other 
important cytokines playing a role during infection were also measured.  
1.1.3.1 Interferon 
Interferon was discovered in 1957 by Isaacs and Lindenmann and they termed it 
interferon because this molecule was capable of interfering with viral replication 
(56). Interferon can be produced by almost all cells in the body in response to 
pathogen recognition, and plays a crucial role in the regulation of the activity of 
cells of the innate and adaptive immune system. The interferon family can be 
divided into three different groups: Type-I, type-II and type-III interferon.  
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Type-I interferon 
The group of type-I interferon is comprised of seven different classes: IFN-α (12 
subtypes), IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-τ and IFN-ω (57). All of these IFNs exist 
in humans with the exception of IFN-δ and IFN-τ which only exist in pigs and 
cattle (58, 59). Type-I interferon is usually not constitutively expressed in steady 
state, but is typically induced by PRRs after the recognition of pathogens such as 
viruses. One of the best characterised type-I interferons is IFN-α, predominantly 
expressed by leukocytes, and IFN-β particularly expressed by fibroblasts and 
endothelial cells (60). All type-I interferons bind to the IFNαβ receptor 
expressed on a variety of cells. IFN-β and IFN-α4 are immediately produced in 
response to interferon regulatory factor (IRF3) activation (61). The expression of 
IFN-β and IFN-α4 leads to the activation of IRF7 which in turn activates 
transcription of the full spectrum of IFNs (62, 63). The expression of type-I 
interferon induces the expression of interferon stimulated genes (ISGs) which are 
responsible for the antiviral and immunomodulatory effect of IFNs (64). The lack 
of type-I interferon during viral infection rapidly leads to death of infected mice 
(65, 66). Furthermore the expression of type-I interferon leads to the 
upregulation of MHC-II molecules on adjacent cells, which results in the 
activation of other immune cells.  
Type-II interferon 
This class of IFN consists of only one member, IFN-γ. This IFN is structurally 
unrelated to type-I IFNs and binds to a different receptor known as the IFN-γ 
receptor (IFNGR). Although IFN-γ is also important for immediate antiviral 
activities like type-I interferon, IFN-γ is mainly expressed during later stages of 
infection and is therefore particularly important during adaptive immune 
responses including Th1 development and B-cell isotype switching to IgG2a (66, 
67). Only certain cells such as NK-cells and Th1 CD4+ and CD8+ T-cells produce 
IFN-γ. NK-cells are the major source of IFN-γ during innate immune responses 
while Th1 CD4+ and CD8+ T-cells are the major sources of IFN-γ during adaptive 
immune responses (68). IFN-γ also leads to the upregulation of MHC-I and MHC-II 
expression which leads to the activation of CD8+ and CD4+ T-cells, respectively 
(69). Thus, IFN-γ has important immunomodulatory functions during infection 
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and inflammation and its ability to coordinate the transition from innate to 
adaptive immunity makes type-II interferon distinguishable from other IFNs.  
Interferon stimulated genes (ISGs) 
Many viral infections trigger the production of interferon which results in the 
production of specific ISGs that exert antiviral effector functions and target the 
viral life cycle (70). There are approximately 2000 genes that can be regulated 
by type-I IFNs but only a few of these (<40) ISGs have so far been shown to play 
a role during viral infection (70).  Little is known of the role of ISGs during viral 
encephalitis. ISGs can have various effector functions and form a diverse and 
overlapping network (71). Each virus induces a unique ‘ISG profile’ where some 
ISGs are very potent and others are only moderate virus inhibitors (72, 73). One 
of the best characterized ISGs is the double stranded (ds) RNA activated protein 
kinase R (PKR), also known as ‘eukaryotic translation initiation factor 2-alpha 
kinase 2’ (EIF2AK2). PKR inhibits virus replication and production of virion 
progeny and initiates apoptosis (74). It has been shown that other ISGs such as 
2’-5’ oligoadenylate synthetases (OAS) and RNase L are also activated by dsRNA 
and lead to the degradation of viral mRNA through activated endoribonucleases 
(75, 76). The myxovirus-resistance (Mx) proteins are IFN-inducible GTPases that 
inhibit trafficking or activity of viral polymerase (77). Mx proteins particularly 
bind to negative stranded RNA viruses such as bunyaviruses and influenza virus 
(78). Viperin, also known as radical-SAM-domain- containing-2 (RSAD2) protein, 
has been shown to promote IFN production by upregulating TLR7 and TLR9 
signalling pathways and to prevent the egress of influenza virus A from host cells 
(79). Another ISG, which promotes interferon production, is the zinc antiviral 
protein (ZAP) that is encoded by the gene ZC3HAV1. ZAP preferentially inhibits 
retroviruses, filoviruses and alphaviruses, and is initially induced by binding to 
modified 5’ RNA ends (27, 29, 80). Due to the potency of ISGs to interfere in 
viral replication, some viruses have evolved strategies to downregulate or block 
ISG activities and enhance viral replication, subsequently leading to a survival 
advantage (81, 82). 
1.1.3.2 Tumour necrosis factor (TNF) 
The TNF family consists of cytokines which have important functions in innate 
and adaptive immunity. TNF-α, also known as cachectin, is one of the best-
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characterized cytokine within the TNF family. TNF-α is mainly secreted by 
macrophages but can also be secreted by T-cells and NK-cells (83). TNF-α binds 
to two types of TNF receptors (TNFR): TNFR-I expressed on the plasma 
membrane of many cells with the exception of erythrocytes, and TNFR-II which 
is predominantly expressed on lymphocytes (84). If TNF binds to its cognate 
receptor a signalling cascade is initiated which ultimately results in apoptosis 
(85). During local infection, TNF leads to the upregulation of vascular adhesion 
molecules on the endothelium which promotes the interaction of circulating 
leukocytes with the vascular endothelium and extravasation of leukocytes into 
the inflamed tissue. This process is particularly important for the compromise of 
the intact blood-brain barrier during CNS infections, discussed in detail later.  
In regard to viral encephalitis, Chen et al. have shown that during Japanese 
encephalitis virus infection (JEV) TNF-α is secreted in the infected CNS by 
activated microglia. This process triggers the expression of inflammatory 
chemokines such as CCL5 by activating astrocytes, and leads subsequently to the 
infiltration of immune cells into the CNS (86). In another study using TNF 
deficient mice in a model of West Nile virus (WNV) infection, it was shown that 
TNF-α protects mice against lethal WNV infection by promoting the infiltration 
of leukocytes into the CNS (87). In agreement with this, Zhang et al. have 
demonstrated that TNF expression by neurons during WNV infection diminishes 
CXCL10 induced death of neuronal cells (88). 
1.2 Immune responses in the brain 
In the mammalian body, the central nervous system (CNS) is very complex and 
comprises a sophisticated network of neurons and glial cells, which will be 
discussed in further detail in 1.2.2. Basic functions such as regulation of body 
temperature, sleep or hunger, orientation and coordination of movements as 
well as higher functions such as memory, cognition and intellect are all 
controlled by the CNS and render the brain one of the most vital organs. From an 
immunological point of view the CNS is considered to be an immunoprivileged 
site due to the following features: lack of antigen presenting cells, low 
expression of MHC-I and MHC-II, lack of lymphatic vessels within the brain, 
absence of resident DCs, blood-brain barrier (BBB) and blood-cerebrospinal fluid 
barrier that restricts the number of leukocytes circulating through the CNS (89). 
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Despite the immunoprivilege of the brain it is now recognised that this is not 
absolute, and therefore the brain is still subject to immunosurveillance. The BBB 
and cerebrospinal fluid-brain barrier constitute a pivotal part of the protection 
of the brain, and they will be discussed in further detail in section 1.2.3. If the 
BBB is compromised due to infection or inflammation in the CNS, immune cells 
are able to infiltrate the brain and cause damage in the CNS, resulting in 
profound neurological deficits (90). Therefore immune responses in the brain 
must be highly regulated to prevent inadvertent CNS damage.  
1.2.1 Structure of the central nervous system  
The CNS consists of the brain and the spinal cord, which are protected by the 
skull or vertebral column, respectively. Underneath these, three layers of 
membranes surround the brain and are called collectively the meninges. The 
outermost membrane of the meninges is the dura mater and consists of a tough 
and fibrous coat. The intermediate membrane is the arachnoid mater and is a 
collagenous structure, and the innermost membrane or pia mater is a thin 
membrane attached to the surface of the brain and spinal cord. The gap 
between the arachnoid and pia mater is known as the subarachnoid space and is 
filled with cerebrospinal fluid. Some of the blood vessels supplying the brain run 
partially in the subarachnoid space (91).  
The brain itself can be divided into three parts: the forebrain, the midbrain and 
the hindbrain. Additionally the brain consists of two hemispheres, or halves, 
which are linked through fibres of the corpus callosum. To maximize the surface 
area of the cerebral hemisphere the surface is folded into ridges (gyri) and 
furrows (sulci) (92). The brain also contains a system of interlinked cavities filled 
with cerebrospinal fluid (CSF) that constitute the ventricular system. This system 
is comprised of the lateral ventricles (one in each cerebral hemisphere), third 
ventricle, cerebral aqueduct and the fourth ventricle. Each ventricle contains a 
choroid plexus where CSF is produced and secreted (93). 
1.2.2 Cells of the CNS 
The cells of the CNS can be broadly categorized into two groups: neurons and 
neuroglial cells or glia. Neurons are highly specialised cells in the nervous system 
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and are pivotal for the relay of information. The information within neurons is 
coded by changes in electrical energy. Glia are the most abundant cell type in 
the CNS and support neural function rather than processing information like 
neurons (94). 
1.2.2.1 Neurons 
Neurons consist of three main structures: the cell body, the dendrites and the 
axon. The cell body contains a nucleus and many organelles and inclusions 
including Nissl granules which consist of endoplasmatic reticulum. The dendrites 
are important for receiving information from other neurons and passing 
information on to axons which transfer messages to other neurons via a 
specialised region known as the synapse or nerve terminal (95). Many neurons 
are unique in their shape, function and location within the CNS and it is difficult 
to divide each neuron into specific groups. After development most neurons are 
terminally differentiated and do not replicate although limited neurogenesis 
occurs in the hippocampus. Therefore neurons must be particularly protected 
from damage and tissue injury (96). 
1.2.2.2 Glia 
Glia can be divided into macroglia or microglia. Macroglia are comprised of 
astrocytes, oligodendrocytes and NG2 cells which will not be discussed here and 
are reviewed by Nishiyama et al. (94, 97). Astrocytes are the most abundant 
type of glia and have a stellate morphology. They play important roles in 
synapse formation, modulation of synaptic connectivity, energy metabolism, 
axonal outgrowth and maintenance of the BBB. Astrocytes generate signals that 
are chemical rather than electrical. They are able to produce a variety of 
chemokines and pro-inflammatory cytokines in response to infection or 
inflammation, which will be discussed in further detail in chapter 1.3.6. Upon 
activation astrocytes start proliferating, change their morphology and increase 
their size (98).  
Oligodendrocytes are myelin-producing cells in the CNS and surround the axons 
of neurons. Myelin is a lipid-rich membrane and consists of glycosphingolipids 
and cholesterol. Furthermore myelin also contains myelin basic proteins (MBP) 
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and proteolipid protein (PLP) (99).  Each oligodendrocyte wraps the axon with 
myelin which allows fast transmission of information between neurons over long 
distances. Viral infection with Semliki Forest virus leads to the destruction of 
oligodendrocytes and results in viral demyelination (47). This will be discussed 
further in section 1.4.2.4.   
Microglia are the only immune cells of the CNS and express many of the common 
macrophage markers such as CD45, CD11b, F4/80, MHC-I and MHC-II, but 
expression of these markers is low compared to macrophages. Resident 
microglia, or parenchymal microglia, originate from embryonic progenitor cells 
in the yolk sac (100). These microglia can be distinguished from macrophages 
based on the low expression of CD45, MHC-I and MHC-II molecules. The other 
types of microglia found in the brain are derived from blood monocytes and are 
located in very specific areas of the brain. These microglia are indistinguishable 
from macrophages and are often referred to as perivascular, meningeal or 
choroid plexus macrophages (101). Both types of microglia are important for the 
recognition of pathogens, phagocytosis, antigen presentation, repair and 
protection of neurons. The function of microglia can be either protective or 
detrimental depending on the signal that the microglia receive from the 
environment (102). Upon activation microglia can kill neurons directly or 
indirectly through the release of pro-inflammatory cytokines which promote the 
influx of leukocytes into the CNS (103-105). Previous studies have shown that 
West Nile virus infection of the CNS results in an increase of activated microglia 
during infection, and that these cells are important for initiating immune 
responses in the brain after entry of virus by releasing inflammatory cytokines 
and removing infected neurons or glial cells (23, 106). In general microglia are 
very sensitive to changes in their environment and subsequently several 
regulatory mechanism need to be in place to prevent inadvertent activation of 
microglia and subsequent tissue damage (107).  
1.2.3 The blood-brain barrier and blood-cerebrospinal fluid 
barrier 
The blood-brain barrier (BBB) and blood-cerebrospinal fluid (blood-CSF) barrier 
are physical barriers to prevent the entrance of toxic molecules and pathogens 
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into the CNS, and maintain homeostasis within the brain tissue necessary for the 
delicate function of neurons and glial cells.  
1.2.3.1 Blood-brain barrier 
The BBB is composed of cerebral micro-vascular endothelial cells which are 
surrounded by the endothelial basement membrane, pericytes, located within 
the perivascular space, and astrocytic endfoot processes which constitute the 
‘glia limitans’ (Fig. 1.2) (108). Microglia and neurons contribute further to the 
stability of the BBB (109). The cerebral endothelial cells are characterised by 
the lack of transendothelial fenestration, low pinocytosis and presence of tight 
junctions (110, 111). The endothelial cells are additionally covered with the 
basement membrane which is composed of extracellular matrix proteins such as 
collagen and laminin (112) (Fig. 1.2). 
 
Figure 1.2 The blood brain barrier 
Cerebral endothelial cells of capillaries contain tight junctions to prevent entry of molecules and 
leukocytes into the brain parenchyma. Endothelial cells are surrounded by the basement 
membrane. The perivascular space is localised between the endothelium and glia limitans and 
contains pericytes and perivascular macrophages. The glia limitans consists of a parenchymal 
basement membrane and astrocytic end feet processes. The BBB is further surrounded by 
microglia which are important immune cells of the CNS. Adapted from (113). 
Endothelial cells are the first point of entry for many neurotropic viruses before 
they can spread within the CNS parenchyma. Therefore the BBB is an important 
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barrier during viral infections of the brain and protects the brain from entry of 
viruses and other substances, which could damage the brain tissue. Small 
lipophilic molecules, and gaseous molecules such as O2 and CO2, can diffuse 
freely across the lipid membrane of the BBB (114). In general hydrophilic 
molecules are restricted from crossing the BBB unless they bind to a specific 
carrier transporter molecule (115). The transport of large hydrophilic molecules, 
ions or proteins across the BBB is mediated via transporter proteins such as 
glucose and amino acid carriers and sodium pumps. 
1.2.3.2 Blood-CSF barrier 
The blood-CSF barrier is located in the ventricles where CSF is generated by 
secretory cells within the choroid plexus epithelium (CPE) (116). The choroid 
plexus consists of a highly vascularized and fenestrated endothelium allowing 
the migration of leukocytes across the capillary endothelial wall into the 
interstitial space (stroma). The stroma is lined with CPE which is derived from 
the adjacent ependyma covering the ventricles. The CPE contains tight junctions 
and forms the actual blood-CSF barrier which allows transportation of only small 
molecules across the barrier similar to the BBB (Fig. 1.3). The CSF circulates 
from the ventricles through the subarachnoid space of the brain and spinal cord 
and is reabsorbed into the blood via venous sinuses in the arachnoid membrane 
(93).  How CSF carries antigens into the cervical lymph nodes will be discussed in 
further detail in the following section. 
 
Figure 1.3 The blood-CSF barrier 
The choroid plexus is localized in the ventricles and comprises the blood-CSF barrier. The 
cerebral capillaries in the ventricles consist of a fenestrated endothelium allowing leukocytes to 
enter the stroma of the choroid plexus. The choroid plexus epithelium consists of a basement 
membrane and  tight junctions which prevent entry of leukocytes into the CSF. Furthermore 
choroid plexus epithelial cells produce CSF which circulates in the subarachnoid space 
throughout the brain and spinal cord.  
 Chapter 1. General Introduction 37 
 
   
1.2.4 Immunosurveillance in the healthy brain 
Even though the CNS is considered as ‘immune-sheltered’, pathogens are 
capable of entering the brain under certain circumstances and can cause damage 
to delicate neurons and glial cells. In the normal healthy CNS, microglia 
constantly sample their environment for the presence of antigens and contribute 
in this way to immunosurveillance in the CNS. Resident microglia, derived from 
embryonic progenitor cells, are the only immune cells of the CNS which are 
localised in the brain parenchyma (100). Other immune cells of the CNS are 
located outside the parenchyma and include meningeal macrophages in the 
meninges, choroid plexus macrophages and Kolmer’s epiplexus cells in the 
choroid plexus parenchyma and perivascular macrophages in the perivascular 
spaces of the brain parenchyma. These cells are also considered to be microglia, 
as they reside in the brain in steady state, but compared to other microglia, 
they are of myeloid origin (117).  
Compared to the periphery, cerebral APCs do not leave the CNS but soluble 
antigen present in the CSF or interstitial fluid of the brain can be transported to 
the deep cervical lymph nodes where it is presented to naive T-cells (118). CSF 
carrying the antigen drains across the cribriform plate and is transported 
alongside olfactory rootlets to the nasal mucosa from where it is drained into 
afferent lymphatic vessels to the deep cervical lymph node (Fig. 1.4). Thus, CSF 
can act as an equivalent of lymph, although less efficiently (116). 
In the healthy brain the CSF appears to be the only location where leukocytes 
traffic in and out of the CNS, although only a few leukocytes are able to do that. 
All other parts of the brain parenchyma are devoid of leukocytes in steady state. 
In the healthy CSF 90% of infiltrating leukocytes are memory T-cells, 5% B-cells 
and 5% monocytes (93). Granulocytes and DCs seem to be absent from the CNS. 
T-cells found in the CSF are mainly CD4+ central memory T-cells (TCM) (89, 119). 
These TCM enter the CSF via the choroid plexus through the interaction of CCR7, 
expressed on TCM, with CCL19, expressed on CPE cells. Additionally TCM also 
express L-selectin and ICAM1 which interacts with CPE cells, facilitating 
trafficking of TCM into the CSF (120, 121). TCM are the main leukocytes carrying 
out immune surveillance in the CSF, and are the most abundant leukocytes 
within the healthy CSF (119). If TCM recognise their antigen, they become 
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activated, acquire effector functions and initiate neuroinflammation. 
Additionally with the progression of neuroinflammation, for instance during viral 
infection of the brain, leukocyte infiltration becomes more evident across the 
CSF barrier, and ultimately leukocytes are able to cross the BBB due to the break 
down of the BBB as discussed in further detail in section 1.2.5. In the brain 
parenchyma only activated T-cells are able to cross the endothelial barrier. This 
is based on studies by Wekerle et al. who have demonstrated that radioactively 
labelled encephalitogenic T-cells in Lewis rats are capable of crossing the BBB 
whereas resting T-cells cannot cross this barrier (122). In the absence of the 
appropriate antigen, activated T-cells and TCM leave the CNS or die.  
 
Figure 1.4 Circulation of CSF in the brain and drainage of antigens and cerebral 
interstitial fluid into cervical lymph nodes 
The CSF circulates in the subarachnoid space of the meninges throughout the brain and spinal 
cord. Antigen and interstitial fluid from the brain parenchyma can drain into afferent lymphatics 
via the cribriform plate and nasal mucosa, from where they are carried into deep cervical lymph 
nodes. In the cervical lymph nodes antigen is finally presented to T-cells. Adapted from (93). 
1.2.5 Immune responses in the virally infected brain 
Virus infections of the CNS can lead to devastating neurological symptoms  that 
may result in death of the host. Immune responses in the host have to be 
balanced without damaging delicate and mostly non-renewable neurons. 
Therefore immune responses during viral encephalitis need to be tightly 
controlled to prevent damage by inflammatory and cytotoxic cells (123). Mouse 
models of viral encephalitis inform us about the consequences of immune 
responses in the brain. Well-characterised mouse models to study viral infection 
of neurons include West Nile virus (WNV), Semliki Forest virus (SFV) and 
lymphocytic choriomeningitis virus (LCMV) (123). In this thesis SFV and WNV 
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were used as models of infection. Other well-characterised mouse models of 
glial infection include mouse hepatitis virus (MHV). These models of viral 
encephalitis will be discussed in depth in sections 1.4 and 1.5.  
In general, immune responses to viral brain infection can be divided into three 
phases: innate immune responses of the CNS characterised by virus recognition 
and production of inflammatory cytokines, adaptive immune responses 
characterised by infiltration of leukocytes, followed by regulation of immune 
responses and viral clearance.  
During innate immune responses interferons exert antiviral effects and are able 
to slow down virus spread within the CNS as it has been shown that type-I IFN 
deficient mice succumbed earlier, and were unable to control viral spread (124). 
Damaged or stressed neurons produce many chemokines and cytokines, which in 
turn activate astrocytes and microglia, and therefore this process initiates 
neuroinflammation (125). Some of the cytokines and chemokines produced by 
neurons during viral encephalitis are IFN-γ, IFN-β, IL-6 and CX3CL1 (126, 127). 
Activated astrocytes and microglia are a major source of cytokines and 
chemokines during infection within the CNS, and these include TNF, IL-1β, IL-2, 
CCL2, CCL4, CCL5, CCL7 and CXCL10 (128-130). Furthermore activated microglia 
upregulate their MHC-I and MHC-II expression for subsequent antigen 
presentation. In response to CNS infection endothelial cells of the BBB start 
upregulating adhesion molecules, allowing leukocytes to enter the perivascular 
space of the BBB. During infection additional enzymes, known as matrix- 
metalloproteinases (MMPs), are produced by myeloid cells which are able to 
degrade components of the second barrier, the glia limitans (131, 132). Once the 
glia limitans is broken down, leukocytes are able to infiltrate the brain 
parenchyma.  
The second phase of the immune response to CNS infection comprises the 
recruitment of leukocytes into the brain in response to inflammatory chemokines 
and cytokines produced by activated neuronal and glial cells. Depending on the 
virus, the pathogen can enter the brain either through the BBB, blood-CSF 
barrier or blood-subarachnoid membrane barrier (133). Although priming of T-
cells can occur in the brain through viral antigens presented on the surface of 
activated microglia, T-cells are usually primed in secondary lymphoid tissues 
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outside the CNS (134-136). Viral infections of the CNS are initiated in the gut, 
respiratory tract or in the skin, after the bite of a mosquito. In support of this, a 
study by Stevenson et al. has shown that the inoculation of virus directly into 
the brain parenchyma, which lacks immunological activity, elicits minimal or no 
immune response, confirming that immune responses to neurotropic viruses 
usually start outside the CNS (137).  
Studies of lethal LCMV infection in mice demonstrated that neutrophils rapidly 
enter the brain, and this was associated with more severe disease outcome 
(138). However the role of neutrophils within the CNS is contentious and it is not 
yet clear when and how neutrophils enter the brain. The other leukocyte subset 
entering the brain during early stages of viral encephalitis are NK-cells. NK-cells 
have been shown to be able to target damaged neurons during very early stages 
of experimental autoimmune encephalomyelitis (EAE) (139). However there are 
very sparse data examining the role of NK-cells during brain infection, and 
therefore the implication of NK-cell infiltration into the brain remains unclear. 
T-cells, and in particular CD8+ T-cells, infiltrate the brain during the adaptive 
immune response (140, 141). Studies have demonstrated that the blockade of T-
cell entry into virally infected brains of T-cell deficient mice often results in 
higher viral loads and increased mortality rates of mice. However the role of T-
cell during viral encephalitis depends on the type of virus infection. B-cells 
arrive relatively late in the CNS during viral encephalitis, and these cells release 
antibodies predominantly of the IgA or IgG subclass (142). Antibodies have been 
shown to be pivotal in clearing viruses from infected neurons whereas T-cell 
mediated responses are more important for clearance of virus from glial cells. 
The reason for this is not yet clear.  
The last phase of an immune responses to a viral brain infection consists of virus 
clearance by producing neutralizing antibodies and downregulating inflammatory 
immune responses. Gangliosides produced by neurons have been shown to inhibit 
MHC expression by astrocytes, and inhibit IL-2 mediated T-cell proliferation 
(142, 143).  
In summary, immune responses in the brain can be both beneficial or 
detrimental depending on the extent of activation and timing during infection, 
and there are many contradictory studies which make a final conclusion difficult 
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(144-146).  Despite the mostly beneficial role of the innate immune responses 
during early stages of viral infection to control spread of the pathogen within 
the CNS, the large-scale influx of leukocytes for a prolonged time can cause 
profound damage to neurons and glial cells if the reaction is excessive or 
inappropriate.  
1.3 Chemokines and their receptors 
Chemokines are pivotal for pathological and physiological processes in the body, 
orchestrating recruitment and positioning of leukocytes in tissue (147). The 
chemokine superfamily exists only in vertebrates and comprises a large number 
of ligands and receptors. Many ligand and receptor genes form clusters in the 
genome, which suggests a rapid evolution of chemokines and their receptors 
(148). Inflammatory ligands and receptors are highly promiscuous due to the fact 
that a ligand is able to bind up to three different receptors and receptors can 
bind many different ligands. Therefore the chemokine network is a highly 
complex system. Chemokines and receptors can be divided into different 
categories based on their structure or function and this will be discussed in more 
detail in this chapter.  
1.3.1 Nomenclature and classification of chemokines 
Chemokines are small chemotactic cytokines (8-12 kDa) that have a 
characteristic structure and are able to direct leukocytes to specific sites in the 
body during inflammation or homeostasis (149). The characteristic structure of 
chemokines is the presence of four conserved cysteine residues, although XC 
chemokines lack two of the cysteines (Figure 1.5). The first cysteine residue is 
connected with the third, and the second residue with the fourth via disulphide 
bonds. There are approximately 45 chemokines in most mammals (47 in humans) 
(150). Some chemokines exist only in one species and complicate orthologous 
relationships between humans and mice. This is probably due to different 
evolutionary pressures on mice and humans by pathogens (148). Most 
chemokines are secreted as soluble proteins but there are two chemokines, 
CXCL16 and CX3CL1 that are membrane bound. The discovery of chemokines 
happened relatively quickly and initially chemokines were named according to 
their function. However the more chemokines were discovered the more 
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confusing the naming system became. In 1999 it was decided to develop a new 
nomenclature system, and it was suggested to divide chemokines into four 
families based on the position of the first two cysteine residues at the N-
terminus: CC, CXC, XC and CX3C (Fig. 1.5). Additionally chemokines were 
numbered within each family according to the date of discovery of the gene 
encoding the chemokine (147). A list of all chemokines and their corresponding 
chemokine receptors can be found in Table 1.1. 
 
Figure 1.5 Chemokine subfamilies 
 
Chemokines are divided into four subfamilies based on the position of conserved cysteine 
residues (C) and number of other amino acids (X) between the N-terminal cysteines. 
CC-chemokines 
The CC-chemokine family consists of approximately 28 members (CCL1-CCL28) 
and is the biggest group within the chemokine family. The CC-chemokines are 
also known as β-chemokines.  Some of these CC-chemokines exist in humans and 
not in mice, such as CCL13 to CCL16, whereas some chemokines such as CCL6, 
CCL9, CCL10 and CCL12 exist only in mice and not in humans (150). Furthermore 
some chemokines exist as isoforms such as CCL3 and CCL3L1 or CCL4 and 
CCL4L1, which have slightly different functions and exhibit a different affinity to 
their cognate receptor (151). Not all isoforms occur in one individual, and this 
shows that the chemokine system contains a high degree of ‘redundancy’. The 
characteristic of the CC-chemokine family is that the first two cysteine residues 
at the N-terminus are directly next to each other. Many of the CC-chemokines 
play an important role in leukocyte migration during inflammation (147). The 
expression of CC-chemokines specifically in the CNS during viral encephalitis 
shall be discussed later. 
CXC-chemokines 
The CXC-chemokine family consists of 17 members and they are also referred to 
as α-chemokines. The first two cysteine residues in CXC-chemokines are not 
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adjacent to each other but separated by one amino acid designated as X. Hence 
these chemokines are called CXC-chemokines. Similar to CC-chemokines, some 
CXC-chemokines exist in humans such as CXCL6 and CXCL8, but not in mice 
whereas CXCL15 exists only in mice and not in humans. Many CXC-chemokines 
have been shown to play an important role during angiogenesis (152). In the 
context of viral encephalitis CXCL9 and CXCL10 have been shown to be highly 
upregulated during LCMV and WNV infection (153, 154). 
XC-chemokines 
XC-chemokines lack the first and third cysteine residue and are also known as γ-
chemokines or lymphotactin (Figure 1.5). The XC-chemokine family consists of 
only two members, XCL1 and XCL2, although XCL2 exists in humans but not in 
mice. XC-chemokines are expressed on T-cells, NK-cells and NKT-cells during 
infection. The appropriate receptor XCR1 is expressed by a subpopulation of 
dendritic cells. Furthermore XCL1 and its receptor are constitutively expressed 
in the thymus where they are important for the establishment of self tolerance 
and play regulatory roles (155).  
CX3C-chemokine 
The CX3C chemokine family is also referred to as δ-chemokine family. This family 
only consists of one member known as CX3CL1, or fractalkine. CX3CL1 contains 
three amino acids between the first two cysteine residues at the N-terminus 
(Figure 1.5). This chemokine is membrane bound but can be cleaved into a 
soluble chemokine by specific proteases which are members of the ADAM (a 
disintergrin and metalloproteinase) family (156). Membrane bound CX3CL1 is 
highly expressed on endothelial and smooth muscle cells in the periphery. In the 
CNS CX3CL1 is highly expressed by neurons, and after cleavage, the soluble 
chemokine signals to the receptor expressed on microglia. CX3CL1 binding to 
microglia inhibits neurotoxic effector functions of microglia. If the CX3CL1-
CX3CR1 axis is disrupted it can lead to the initiation of degenerative CNS 
diseases such as Alzheimer’s or Parkinson’s (157, 158). 
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Table 1.1. Systematic nomenclature of chemokines 
Chemokines and their receptors are listed according to their systematic nomenclature 
Chemokines which only occur in humans or mice are indicated with (h) or (m) respectively, 
preceding the systematic name. Chemokines predominantly involved in homeostatic processes 
are highlighted in blue, inflammatory chemokines in red and dual-function chemokines in green. 
Unknown chemokine functions are not highlighted and left blank. 
  
CC-chemokine subfamily 
 
Systematic name Alternative name Chemokine receptor 
CCL1 I-309, TCA-3 CCR8 
CCL2 MCP-1, JE, MACF CCR2 
CCL3 MIP-1αS, MIP1-1α CCR1, CCR5 
hCCL3L1 MIP-1αP, MIP-1α CCR1, CCR3, CCR5 
CCL4 MIP-1β CCR5 
hCCL4L1 MIP-1β CCR5 
CCL5 RANTES CCR1, CCR3, CCR5 
mCCL6 C10, MRP-1 CCR1 
CCL7 MCP-3, MARC CCR1, CCR2, CCR3, CCR5 
CCL8 MCP-2 hCCR2, hCCR3, mCCR8 
mCCL9 MIP-1γ, MRP-1, CCF18 CCR1 
mCCL10 MIP1γ, MRP-1, CCF18 CCR1 
CCL11 Eotaxin 
CCR3, CCR5, (CXCR3 
antagonistic) 
mCCL12 MCP-5 CCR2 
hCCL13 MCP-4 CCR2, CCR3 
hCCL14 HCC-1 CCR1 
hCCL15 HCC-2, Lkn-1, MIP-1δ CCR1, CCR3 
hCCL16 HCC-4, LEC, LCC-1 
CCR1, CCR2, (CCR5 
antagonistic) 
CCL17 TARC CCR4 
hCCL18 DC-CK1, PARC PITPNM3, (CCL3 antagonistic) 
CCL19 ELC, MIP-3, exodus-3 CCR7 
CCL20 MIP-3α, LARC, exodus-1 CCR6 
CCL21 SLC, 6Ckine, exodus-2 CCR7 
CCL22 MDC, STCP-1, ABCD-1 CCR4 
hCCL23 MPIF-1 CCR1 
CCL24 Eotaxin-2, MPIF-2 CCR3 
CCL25 TECK CCR9 
hCCL26 
 
Eotaxin-3 
 
CCR3, CX3CR1 and CCR1, 
CCR2, (CCR5 antagonistic) 
CCL27 C-TACK, PESKY, Eskine CCR10 
CCL28 MEC CCR3, CCR10 
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CX3C-chemokine subfamily 
Systematic name Alternative name Chemokine receptor 
CX3CL1 Fractalkine, Neurotactin CX3CR1 
 
CXC-chemokine subfamily 
Systematic name Alternative name Chemokine receptor 
CXCL1 GROα, KC CXCR1, CXCR2 
CXCL2 GROβ, MIP-2 CXCR2 
CXCL3 GROγ, DCIP-1 CXCR2 
CXCL4 PF4 hCXCR3B 
CXCL5 ENA-78, mGCP-2, LIX CXCR2 
hCXCL6 GCP-2 CXCR1, CXCR2 
CXCL7 NAP-2 CXCR2 
hCXCL8 IL-8 CXCR1, CXCR2 
CXCL9 Mig CXCR3, (CCR3 antagonistic) 
CXCL10 IP-10 CXCR3, (CCR3 antagonistic) 
CXCL11 I-TAC 
CXCR3, CXCR7, (CCR3 
antagonistic) 
CXCL12 SDF-1 CXCR4, CXCR7 
CXCL13 BCA-1, BLC CXCR5 
CXCL14 BRAK, Bolekine unknown 
mCXCL15 Lungkine, WECHE unknown 
CXCL16 SCYB16, SR-PSOX CXCR6 
 
XC-chemokine subfamily 
Systematic name Alternative name Chemokine receptor 
XCL1 Lymphotactin, SCM-1α XCR1 
hXCL2 SCM-1β XCR1 
 
1.3.1.1 Homeostatic and inflammatory chemokines 
Chemokines can be categorized into groups not only structurally but also based 
on their function. The two biggest functional groups are homeostatic and 
inflammatory chemokines. However the classification into homeostatic and 
inflammatory chemokines is not always that clear and some homeostatic 
chemokines can be expressed under inflammatory conditions and vice versa. 
Chemokines that can display both homeostatic and inflammatory functions are 
also referred to as dual-function chemokines (159). A list of homeostatic, 
inflammatory and dual-function chemokines is found in Table 1.1. 
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Homeostatic chemokines 
Homeostatic chemokines are constitutively expressed at specific sites in the 
body including lymphoid organs, skin, gut and other organs (160). These 
chemokines play an important role for the basal trafficking of leukocytes under 
homeostasis. Thus they are important for the development of lymphocytes and 
the lymphoid organs and regulate the movement and localization of T-cells and 
DCs (161). The genes for homeostatic chemokines are often located outside the 
large CXC and CC chemokine chromosomal clusters and are often well conserved 
between species. Homeostatic chemokines are considered evolutionally ancient 
compared to inflammatory chemokines. Members of homeostatic chemokines 
include the ‘primordial’ chemokine CXCL12, also known as stromal derived 
factor (SDF), which is one of the most ancient chemokines (160). CXCL12 has 
been shown to be important for the movement of stem cells during 
development, homing of stem cells to the bone marrow and the maintenance of 
stem cells in the bone marrow (162, 163). Other homeostatic chemokines 
include the mucosal chemokines CCL25 and CCL28, the skin homing associated 
chemokines CCL17 and CCL27 and the chemokines involved in lymph node 
homing CCL19 and CCL21 (159).  
 
Inflammatory chemokines 
Inflammatory chemokines are predominantly expressed under inflammatory 
conditions in the body and are important for the recruitment of leukocytes to 
sites of infection or inflammation. Therefore these chemokines are important 
during viral infections. The genes for inflammatory chemokines are often 
clustered in the chromosome, such as CCL1-5 on chromosome 17, and CXCL1-11 
on chromosome 4 (150). The clustering of inflammatory chemokines in the 
chromosome suggests that they rapidly evolved in response to new pathogens 
that threatened the survival of the host (148). CCL1-5 attract a whole range of 
leukocytes including monocytes/macrophages and T-cells. CXCL1-8 are 
important for the recruitment of neutrophils and CXCL9-11 often play a role in 
the attraction of T-cells. However chemokines are highly promiscuous, can bind 
to many different chemokine receptors and therefore attract various different 
leukocytes depending on the context and location of inflammation. For instance 
CCL5 has been shown to bind to three different receptors, CCR1, CCR3 and 
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CCR5, recruit many different cells and is highly inducible. Generally 
inflammatory chemokines bind to many different receptors compared to 
homeostatic chemokines which usually bind only to one or two receptors (164).  
Dual-function chemokines 
This group of chemokines can have both homeostatic and inflammatory 
functions. Members of the dual-function chemokines include CCL2, CCL11, 
CCL17, CCL20, CCL22, CX3CL1 and both members of the XC family. CCL2 has 
been shown to be important for the exit of Ly6Chi monocytes from the bone 
marrow in steady state, but is also important for the recruitment of 
‘inflammatory’ monocytes into inflamed tissue (25, 160). 
1.3.2 Chemokine receptors 
Chemokine receptors are G-protein coupled receptors (GPCRs) containing a 
seven transmembrane spanning domain. Chemokine receptor genes are also 
clustered in the chromosome similar to chemokine ligands and many receptors 
can be found on the human chromosome 3, suggesting a rapid evolution of these 
genes through gene duplication, although other chromosomes also contain genes 
for chemokine receptors. Compared to ligands, chemokine receptors are well 
conserved between species, including mice and humans (148). Chemokine 
receptors are categorized into the same structural families (CC, CXC, XC and 
CX3C) as their ligands and are also numbered (159). Altogether there are 18 
chemokine receptors and four atypical chemokine receptors. The chemokine 
receptors can again be subdivided functionally into inflammatory and 
homeostatic chemokine receptors. Generally inflammatory chemokine receptors 
tend to bind many ligands (160). For instance, CCR3 binds up to 14 ligands, CCR1 
binds up to 10 different ligands and CCR5 is capable of binding up to 7 different 
chemokines. In comparison homeostatic chemokine receptors typically bind one 
or two chemokine ligands.  
Chemokines and their receptors also play an important role during viral 
infection. In response to this some viruses have developed different strategies to 
evade the immune system. Alcami and Lira have demonstrated that many DNA 
viruses are capable of producing their own chemokine and chemokine receptor 
homologues which mimic chemokines and their receptors in the host (165). For 
instance, the human herpes virus  (HHV)-6 encodes the chemokine receptor U51 
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which downregulates the transcription of CCL5. The cytomegalovirus (CMV) 
produces the chemokine receptor US28 which can modify the chemokine 
environment and deplete CC-chemokines from the site of infection (166). Virally 
encoded chemokines can also act as antagonists for chemokine receptor. For 
instance Yamin et al. have shown that the virally encoded chemokine vMIP-II of 
Kaposi’s sarcoma associated herpesvirus (KSHV) is capable of binding to two 
distinct chemokine receptors, CX3CR1 and CCR5. Both chemokine receptors are 
expressed on naïve and activated NK-cells. Hence the antagonism of both 
receptors by vMIP-II has been shown to inhibit the migration of NK-cells during 
infection, and therefore the virus is able to escape the attack by NK-cells (167). 
Thus, chemokines play an important role during viral infection and have put 
evolutionary pressure on viruses to evade the immune system. 
1.3.2.1 Chemokine receptor structure and classification 
All chemokine receptors have an approximate length of 350 amino acids and 
consist of an extracellular acidic N-terminus and an intracellular C-terminus. 
Generally the N-terminus is important for binding chemokines whereas the C-
terminus regulates downstream signalling events. Furthermore chemokine 
receptors contain three extracellular and three intracellular loops which are 
involved in chemokine binding and signal transduction, respectively (149). The 
second intracellular loop contains the conserved DRYLAIV motif and plays an 
important role in the coupling of G-proteins to the receptor (168, 169).  
There are four different chemokine receptor families: CCR, CXCR, XCR and 
CX3CR. The CC-chemokine receptor family consists of 10 members (CCR1-10) and 
the CXC-family is comprised of six receptors (CXCR1-6) (160). CXCR7 is 
considered as an atypical chemokine receptor. There is one XCR receptor 
(XCR1), binding XCL1 and hXCL2, that is expressed not only on neutrophils, T-
cells, NK-cells and B-cells but also on a subset of dendritic cells (155). The 
chemokine receptor CX3CR1 is expressed on ‘inflammatory’ monocytes, 
macrophages and microglia (170). Atypical chemokines receptors are 
characterized by the seeming absence of signalling after ligand binding 
compared to typical chemokine receptors, defined by the International Union of 
Pharmacologists (IUPHAR) (150, 171). Subsequently the atypical chemokine 
receptors have not been assigned a systematic chemokine receptor 
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nomenclature, and it has been suggested to categorize them as chemokine-
binding proteins (160, 172). 
There is little knowledge about the role of chemokine receptors during viral 
encephalitis but to date three receptors have been reported to be pivotal during 
viral encephalitis using different models of infections such as West Nile, 
lymphocytic choriomeningitis and mouse hepatitis virus (128, 173, 174). These 
chemokine receptors identified were: CXCR3, CCR2 and CCR5.  
1.3.3 Functions of chemokines and their receptors 
Chemokines are important during inflammatory and homeostatic conditions in 
the body and regulate leukocyte migration, hematopoiesis, angiogenesis, 
embryonic organ formation, lymphoid development and metastasis. One of the 
main roles of chemokines is the orchestration of leukocyte migration to specific 
sites in the body. During infection this process becomes crucial for pathogen 
removal and repair of damaged tissues. Therefore as one of my aims the kinetics 
of leukocyte infiltration during viral encephalitis will be investigated. The 
process of leukocyte migration into the inflamed tissue will be briefly discussed 
here. The role of chemokines in other contexts is beyond the scope of this work 
and is well reviewed in many scientific publications (175-177). 
The migration of leukocytes to sites of infection or inflammation is a multi-step 
process and involves essentially four steps: rolling of leukocytes via selectins, 
tight binding of leukocytes to the endothelium via chemokine mediated integrin 
activation, diapedesis and migration of leukocytes to the inflamed site within 
the tissue (Fig. 1.6) (178). 
In the first step the endothelium becomes activated in response to cytokines 
(TNF, IL-1β), lipopolysaccharide (LPS) or histamine leading to the rapid 
mobilisation of P-selectins from Weibel-Palade bodies (secretory storage 
granules in the endothelium) and platelet granules. Shortly after P-selectin 
mobilisation, E-selectin expression is transcriptionally upregulated by 
endothelial cells in response to cytokines. Selectins bind to carbohydrate 
structures on the surface of leukocytes including P-selectin glycoprotein 1 (PSGL-
1) or sialyl-Lewisx which binds preferentially to E-selectin (179). The binding of 
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selectins to ligands leads to the reversible binding of leukocytes to the 
endothelium and rolling of leukocytes along the surface due to the shear flow of 
the blood (180). 
 
Figure 1.6 Leukocyte migration across the endothelium into the tissue 
During the first step, leukocytes roll along the endothelium mediated by selectin binding. 
Chemokine receptors expressed on the surface of leukocytes bind to chemokines bound on 
glycosaminoglycans and this process leads to conformational changes and activation of integrin. 
In the subsequent step, leukocytes become firmly attached to the endothelium and this process 
allows diapedesis across the endothelial membrane. Once the leukocyte has entered the tissue, 
cells migrate to sites of infection mediated by chemokines. Adapted from Handel et al. (181). 
In the second step the rolling leukocyte binds to immobilised chemokines on the 
surface of the endothelium, which activates chemokine receptors to initiate a 
signalling cascade. During this process integrin is activated through 
conformational changes and binds to cell-adhesion molecules and extracellular 
matrix including fibronectin, laminin and collagen. Integrins consist of two 
transmembrane proteins known as α- and β-subchains which form a heterodimer. 
There are 18 α- and 8 β-subchains which can form 24 heterodimers (180, 182). 
Intracellular adhesion molecules (ICAMs) are mostly expressed on activated 
endothelium with the exception of ICAM-2. Once integrin is activated and binds 
to its ligand, leukocytes become tightly bound to the endothelium which leads to 
the arrest of the rolling leukocytes (183).  
In the third step leukocytes transmigrate through the endothelium and the whole 
process is referred to as diapedesis. The leukocytes can migrate into the tissue 
either transcellularly where leukocytes extravasate through the endothelial cell 
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directly, or paracellularly where leukocytes migrate through the junctions of 
endothelial cells (184). In order to penetrate the basal membrane of the 
endothelium, many cells express matrix metalloproteinase enzymes (185). In the 
CNS, leukocytes mainly cross the BBB via transcellular transport, due to tight 
junctions of the cerebral endothelium (114, 121). In the fourth and final step 
leukocytes migrate to the site of infection where they elicit their effector 
functions (186).  
1.3.4 The role of chemokine receptors in disease 
Chemokines are central in regulating leukocyte trafficking during infectious 
diseases such as viral, bacterial or parasitic infections, and during chronic and 
autoimmune diseases. Whereas chemokine-mediated leukocyte entry is mostly 
beneficial during acute inflammation or infection, chemokines can be 
detrimental during chronic infections such as rheumatoid arthritis, cancer and 
multiple sclerosis (MS) or experimental autoimmune encephalomyelitis (EAE). 
Thus, chemokines and their receptors are implicated in the pathogenesis of 
many diseases, and this highlights the importance of targeting chemokine 
receptors for therapy or prevention of disease. The specific role of chemokines 
during viral encephalitis, which is the focus of my thesis, will be discussed in 
further detail in chapter 1.5. However, to illustrate the importance of 
chemokines in disease, prominent examples of chemokine-mediated diseases 
such as HIV and MS/EAE will be briefly discussed here. The involvement of 
chemokines in many other diseases such as cancer will not be addressed here 
and are reviewed by Balkwill, Raman and Gerard et al.  
1.3.4.1 Human immunodeficiency virus (HIV) 
HIV is a retrovirus and was isolated from patient samples for the first time in 
1983. HIV has been shown to cause acquired immunodeficiency syndrome (AIDS) 
in the host with the progression of the disease (187). HIV infects cells through 
the interaction of the viral envelope glycoprotein 120 (gp120) with the host 
cellular surface receptor CD4 in conjunction with the co-receptors CCR5 or 
CXCR4 (188, 189). HIV-1 variants that use only CCR5 as co-receptor are referred 
to as R5, and those which use CXCR4 are referred to as X4. If both co-receptors, 
CCR5 and CXCR4, can be used by the virus for cell entry, HIV variants are 
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considered to be dual tropic and are known as R5/X4. CCR5 and CXCR4 are 
differentially expressed on the surface of leukocytes and therefore HIV-variants 
target different cells. During early stages of infection R5 tropic viruses dominate 
and are preferentially transmitted to other hosts (190). X4 tropic HIV-1 variants 
are found predominantly during later stages of infection and are associated with 
the decline of CD4+ T-cells and development of AIDS (191, 192). The presence of 
many CCR5 binding chemokine ligands, expressed by other cells, has shown to 
slow down disease progression, as the ligands for CCR5 bind to the receptor and 
therefore block binding sites of gp120 to CCR5 (193, 194). 
A loss-of function mutation in the CCR5 gene due to the deletion of 32 base pairs 
in the gene encoding CCR5 is designated as CCR5Δ32 mutation, and occurs 
naturally in some humans (195). Humans homozygous for this mutation are 
resistant to HIV because this mutation prevents the expression of functional 
CCR5 needed for cell entry of HIV. Approximately 1% of the whole Caucasian 
population of European origin are homozygous for the CCR5Δ32 mutation, and 
the occurrence of this mutation varies with the geographical region and can be 
as high as 16% within northern European populations (196). Based on these 
findings CCR5 became a focus of research for the prevention and treatment of 
HIV, although blockade of CCR5 is only effective in individuals infected with the 
R5 tropic strain.  The CCR5Δ32 mutation does not seem to cause any adverse 
effects in healthy humans carrying this mutation, but it has been shown recently 
that the people carrying this mutation might be more susceptible to severe 
forms of WNV characterised by panenecephalitis, which is a life threatening 
condition (197). In 2007 the Food and Drug Administration (FDA) has approved 
the use of the CCR5 blocker known as Maraviroc for the treatment of HIV (198, 
199). General caution has to be taken when Maraviroc treated patients become 
infected with WNV. Maraviroc and other chemokine blockers used in this thesis 
will be briefly discussed in the following section.  
The CXCR4 inhibitor, known as AMD3100, is also efficient in blocking HIV entry, 
but during clinical trials it was discovered that AMD3100 leads to the 
mobilisation of stem cells from the bone marrow into the blood (200, 201). 
Therefore this drug was later approved under the name Plerixafor or Mozobil, for 
the mobilisation of stem cells for the subsequent autologous transplantation of 
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stem cells in patients with leukemia such as non-Hodgkin’s lymphoma or 
multiple myeloma (202).  
1.3.4.2 Multiple Sclerosis/EAE 
Multiple sclerosis (MS) is an autoimmune disease in humans characterised by 
demyelination of axons, axonal loss and gliosis, leading to paralysis. The onset of 
the disease can be progressive or relapsing, characterised by remyelination and 
amelioration of disease. The most commonly and best-characterised mouse 
model of MS is EAE, which is induced by myelin specific Th1 and Th17 cells 
produced after immunisation of mice with myelin oligodendrocytes glycoprotein 
(MOG) in combination with adjuvant containing bacterial components. The 
symptoms of EAE in mice are similar to MS and are characterised by the large 
influx of inflammatory leukocytes, including myeloid cells and lymphoid cells, 
into the CNS. As a model, EAE plays a major role in the identification and 
characterisation of key aspects of neuroinflammation and immune-mediated 
tissue damage of the brain. Based on EAE studies three therapeutics for MS have 
been tested and validated in this model and were approved for the treatment of 
MS. Thus, EAE is a valuable model for studying immune responses in the brain, 
and many aspects of neuroinflammation are derived from these studies.  
Chemokines play an important role during EAE and MS, influencing the 
pathogenesis of the disease. This will be discussed in depth in 1.3.6.2. In brief, 
CCR1, CCR2, CCR5 and CXCR3 ligands are highly upregulated in the brain of MS 
patients and in EAE mice (203, 204). CXCR3 and CXCL10 deficient mice showed 
both increased susceptibility to EAE, suggesting that chemokine receptors play a 
role in the pathogenesis of the disease (205). In contrast to this CCR1, CCR2 and 
CCR6 deficient mice display an increased resistance to EAE characterised by 
delayed disease onset (206).  
1.3.5 Methods of targeting the chemokine system 
The chemokine system is highly complex with complicated binding patterns of 
chemokines and their receptors, and many studies have described the chemokine 
system as promiscuous or ‘redundant’, although Schall and Proudfoot have 
proposed the idea that this might not be entirely true (207). In recent years 
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chemokine receptors have been identified as possible targets for the treatment 
of various diseases such as HIV, MS and rheumatoid arthritis (198, 208). However 
a successful chemokine target for the treatment of viral encephalitis has not yet 
been identified and I attempted to explore this as part of this thesis.  
There are various possibilities how to antagonise the chemokine system such as 
the use of small molecule antagonists, modified chemokines or antibodies 
against a specific receptor(209). For instance it has been demonstrated during 
EAE that the use of the CCR1 inhibitor (BX 741) in mice has a similar effect to 
that of CCR1-/- mice suggesting that the antagonist is highly efficient and specific 
in blocking CCR1 (210). However, the design of new anti-chemokine compounds 
has been proven difficult, not only because of the redundancy of the chemokine 
system, but also because mouse chemokines and chemokine receptors are to 
some degree structurally different to the human counterpart or exist only in the 
mouse but not in humans, or vice versa.  
Another way to study the role of chemokines is to generate ‘knock out’ mice, 
deficient of a specific chemokine receptor gene. Most studies, including studies 
of viral encephalitis, have used this approach to examine the role of chemokines 
and their receptors in the pathogenesis of the disease. However one 
disadvantage of using gene deficient mice is that blockade of the chemokine 
receptor is absolute and cannot be modulated or varied with the disease 
progression. In contrast to this, using small molecule inhibitors allows 
adjustment of timing and dose during disease. Therefore in this thesis small 
molecule antagonists were selected over gene deficient mice to investigate the 
role of chemokine receptors during viral encephalitis, and this is the first time 
that these blockers were used in the context of viral brain infections. The role of 
the chemokine receptors CCR2, CCR5 and CXCR3 are a key focus point in my 
thesis, and therefore I will briefly introduce these receptors and the appropriate 
antagonists I have used for my studies.  
1.3.5.1 Blockade of CCR2  
CCR2 has been shown to be predominantly expressed on the surface of Ly6Chi 
monocytes (98%), DCs, and also on other leukocytes such as NK-cells, neutrophils 
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and 2-15% of T-cells, although this is regarded as controversial (25, 211, 212). 
CCR2 plays an important role during homeostatic and inflammatory processes. 
Studies using CCR2 deficient mice have shown that this receptor is implicated in 
the exit of monocytes from the bone marrow (213). Therefore CCR2-/- mice 
display severe monocytopenia which renders these mice more susceptible to 
certain infection such as bacterial infection with Listeria monocytogenes or viral 
infection with WNV (25, 214). However the lack of CCR2 can also be beneficial, 
as some studies using EAE as model of neuroinflammation have shown that  
CCR2-/- mice are less susceptible to the development of EAE (215). 
To block the function of CCR2 during viral encephalitis the CCR2 blocker 
RS504393 was used, which is a small molecule inhibitor. RS504393 is a 
spiropiperidine compound, identified after a high throughput screening of many 
chemical compounds (216). This compound has been shown to block the receptor 
by occupying a binding site within the CCR2 protein that includes the acidic 
residue Glu291. The specificity of the antagonist to bind CCR2 is 700-fold higher 
than for CCR1, and therefore RS504393 is considered to be a highly selective 
CCR2 antagonist. Furuichi et al. have shown that RS504393 blocks CCR2 binding 
in a dose dependent manner within 20 minutes after administration in a model 
of ischemia reperfusion injury in the kidney of mice (217). Additionally another 
study by Kitagawa et al. has shown that RS504393 was efficient in blocking CCR2 
in a similar fashion to CCR2-/- mice in a model of progressive fibrosis of the 
kidney of mice, confirming, again, the efficiency of CCR2 inhibition by RS504393 
(218). The compound RS504393 has a short half life and therefore the drug has 
to be administered to mice twice daily (217).  
1.3.5.2 Blockade of CCR5 
CCR5 has been shown to be highly expressed (>90%) on the surface of murine NK-
cells but is only weakly expressed on human NK-cells (212). Additionally CCR5 
expression in mice can also be found on 3-10% of CD4+ and 10-40% of CD8+ T-
cells, but is only weakly expressed on monocytes. CCR5 has become the focus of 
HIV research as people carrying the natural CCR5Δ32 mutation on both alleles 
are resistant to HIV infection, and heterozygous carriers exhibit partial 
resistance to HIV (195). In addition to this, CCR5 is also implicated in many other 
inflammatory diseases and infections. For instance CCR5 deficient mice are more 
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susceptible to parasitic infections such as Listeria monocytogenes or Toxoplasma 
gondii (219, 220). Contrary to this, CCR5 deficient mice show increased 
tolerance to LPS and reduced ulceration in a model of colitis using dextrane 
sulphate (219, 221). 
Two CCR5 blocker were used in this thesis: Maraviroc and DAPTA. Both drugs 
have been shown to be efficient in blocking CCR5. Maraviroc is an approved 
CCR5 inhibitor for the treatment of HIV. It was synthesised by a multi-step 
process by Pfizer, and this compound belongs to the group of imidazopyridine 
(198). Dorr et al. have shown that Maraviroc is an allosteric inhibitor, which 
binds to CCR5 in a non-competitive way, suggesting that the binding site of 
Maraviroc is different from chemokine ligands or HIV glycoprotein (gp120) 
binding sites (198). In addition to this Maraviroc does not only inhibit binding of 
other ligands to CCR5 but also inhibits signalling through CCR5. Maraviroc has a 
high potency of inhibiting gp120 protein binding to CCR5 and therefore acts 
antiviral. Many different HIV-1 R5 tropic isolates were used and tested for the 
efficiency of Maraviroc in inhibiting CCR5 binding. Dorr et al. have shown that 
Maraviroc works efficiently in all R5 tropic patient samples, including samples 
from patients resistant to antiretroviral medication (198). All clinical trials have 
so far shown that Maraviroc is a safe drug, which is orally bioavailable, and has 
no severe side effects. Maraviroc was also tested in rats and dogs, where it was 
found to be safe. The drug is 30% absorbed from the gut and can be detected in 
the blood within 1.5 hours post treatment in dogs (198, 222). 
The other CCR5 inhibitor D-Ala1-peptide T-amide (DAPTA) is a synthetic peptide 
which consists of 8 amino acids (185-192) of the gp120 V2 region of the envelope 
of HIV, and is characterised by a high threonine content (ASTTTNYT) (223). This 
small non-toxic peptide binds competitively to the CCR5 region and inhibits 
binding of gp120 and chemokine ligands to CCR5. Furthermore it was shown that 
DAPTA is 34-180 times more potent in inhibiting CCR5 than Maraviroc, and makes 
DAPTA a very potent CCR5 inhibitor (224). Based on studies by Polianova et al. 
the drug is administered to mice i.v. once daily, and levels of DAPTA can be 
detected within the blood and the CSF 30-60 min and 90-145 min, respectively, 
suggesting that DAPTA is capable of passing the CSF-brain barrier (223, 224). In 
support of this, Rosi et al. have shown that DAPTA attenuates 
neuroinflammation in rats after chronic LPS injection into the brain by inhibiting 
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CCR5 expression by microglia and astrocytes (225). This effect is also 
accompanied by a reduction of TNF and IL-1 secretion by activated glial cells.  
1.3.5.3 Blockade of CXCR3 
CXCR3 has been shown to be predominantly expressed on activated CD4+ and 
CD8+ T-cells (226). Expression of CXCR3 could also be found on few NK-cells and 
B-cells although at very low levels (227). No expression of CXCR3 was detected 
on neutrophils, eosinophils and monocytes. 
CXCR3 plays an important role during various inflammatory diseases such as MS, 
psoriasis, rheumatoid arthritis, and also during infection (228-231). There are a 
few studies using CXCR3 deficient mice in mouse models of viral encephalitis 
using MHV, WNV or LCMV, although this will be discussed in more depth in 
chapter 1.5. Due to the important role of CXCR3 during many inflammatory and 
infectious diseases, research has recently also focussed on developing CXCR3 
antagonists although only few are currently available. 
Here the CXCR3 antagonist, known as compound 21 was used. It is a imidazo-
pyrazine derivative synthesised by Amgen and has been shown to be a small 
molecule antagonist binding specifically to CXCR3 (232). This compound inhibits 
binding of appropriate ligands CXCL9, CXCL10 and CXCL11 to CXCR3, and Du et 
al. have shown that compound 21 was potent in binding CXCL10 in in-vitro assays 
(232). In addition to this the efficacy of compound 21 was also evaluated in mice 
using a bleomycin induced lung inflammation model. In this model, compound 21 
significantly reduced the infiltration of leukocytes into the inflamed lung, 
suggesting that this antagonist is potent in blocking CXCR3 (232). Compound 21 
is administered s.c. once daily, and reaches stable levels in the plasma of mice.  
1.3.6 The expression of chemokines in the CNS 
Neurons and glial cells are sensitive post-mitotic cells that need a certain 
environment for survival and optimal functioning. Therefore chemokines that 
attract leukocytes from the periphery must be carefully regulated in the brain to 
prevent the inadvertent recruitment of immune cells from the periphery into the 
CNS.  
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1.3.6.1 Constitutive chemokine expression in the healthy brain  
In principal, neurons, glial cells and vascular endothelial cells of the capillaries 
can produce chemokines in the CNS. To date, there is little data about 
chemokine expression in the CNS during homeostasis because most of the 
research is focussed on inflammatory conditions in the brain. Chemokines in the 
healthy brain play an important role during the development of the CNS and 
some chemokines are retained in the adult brain. In the adult brain, chemokines 
play important roles during neurogenesis, neuron-glia and glia-glia 
communication networks, can have neuro-hormonal properties and act as 
neurotransmitter (233). Many studies have reported that the chemokines CXCL12 
and CX3CL1 are constitutively expressed in the healthy brain (170, 234). CXCL12, 
and its corresponding chemokine receptor CXCR4, are highly expressed in the 
brain during development. The main source of CXCL12 is neurons. CXCL12 is 
important for the directional migration of neuronal progenitor cells to different 
areas of the brain (235). Soluble CX3CL1 is ubiquitously produced in the brain by 
neurons, and signals to CX3CR1 expressed on microglia. (236). Additionally it has 
been reported that the inflammatory chemokine CCL2 is also expressed in the 
healthy CNS of adult rats , although at low levels. For example, Purkinje neurons 
in the cerebellum and the dentate gyrus in the hippocampus have been shown to 
produce CCL2 in steady state (233, 237).  
Some chemokines such as CCL3 and CCL5 and the CXC chemokine CXCL8 are 
transiently expressed in the CNS during embryogenesis which suggests that they 
may be important for the development of organs and migration of neuronal and 
glial cells (238). The chemokine receptors expressed in the adult rat brain are 
CCR1, CXCR4, CXCR2 and CX3CR1. CCR1 is expressed on neurons in the 
cerebellum, CXCR4 on neurons and glial cells except oligodendrocytes and CXCR2 
on oligodendrocytes. CX3CR1 has been detected on microglia and macrophages in 
the meninges and choroid plexus (239, 240).  
1.3.6.2 Chemokine expression in the CNS during inflammation 
The recruitment of leukocytes into the CNS is a complex process and involves a 
variety of chemokines and cytokines. Blocking of chemokines and their receptors 
in various animal models has been shown to change leukocyte infiltrates within 
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the CNS. In all models of neuroinflammation, or infection, specific types of 
leukocytes enter the brain in response to chemokines, and this either 
contributes to pathogenesis or not. Only few studies have investigated the role 
of chemokines and their receptors during viral encephalitis, and these will be 
discussed in further detail in section 1.5. However studies of EAE informed us of 
the basic mechanism of neuroinflammation and helped us to understand the role 
of chemokine-mediated leukocyte entry into the CNS, which occurs in the brain 
not only during EAE, but also during viral encephalitis.  
In EAE the following chemokines were expressed in the brain: CCL2, CCL3, CCL4, 
CCL5, CCL20, CXCL1, CXCL8, CXCL9 and CXCL10. Most of the chemokines 
detected during EAE are inflammatory chemokines. The spatial and temporal 
expression patterns of these chemokine varies during the disease and complicate 
matters even further (241-243). For example CCL2, CXCL1 and CXCL10 are 
mainly expressed by astrocytes, and have often been associated with acute 
phases of EAE, whereas CCL2 and CCL20 have often been found in the relapsing 
phase (241). Chemokine receptors are also expressed during inflammation in the 
brain, including CCR1, CCR2, CCR5, CCR6, CXCR1, CXCR2 and CXCR3. Receptors 
and chemokines can be expressed by neurons, glial cells and infiltrating 
leukocytes (244). The main source of chemokines during neuroinflammation are 
astrocytes and microglia (241). To investigate the exact role of chemokines in 
relation to leukocyte recruitment and disease outcome, knock out models have 
been used for most studies. 
A large number of leukocytes infiltrating the brain of mice with EAE are 
monocytes which can develop into microglia once they enter the inflamed brain 
(139). It has been suggested that the CCL2-CCR2 axis is pivotal for the entry of 
monocytes into the brain. A study by Mildner et al. has demonstrated that in 
CCR2 deficient mice, intravenously injected with adoptively transferred CCR2+ 
Ly6Chi cells, CCR2+ monocytes preferentially and rapidly traffic into the brain 
(33). However CCR2- monocytes could not be detected in the inflamed brain of 
CCR2 deficient mice, which suggests that monocyte entry into the brain is CCR2 
dependent. Furthermore in other EAE studies, CCR2 deficient mice showed 
delayed disease onset, milder forms of EAE, reduced demyelination and reduced 
numbers of monocytes entering into the CNS (215). This suggests that CCR2-/- 
mice are less susceptible to EAE. However, it has been shown that the large 
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reduction of monocytes leads to increased infiltration of neutrophils into the 
brain as a compensatory mechanism. In support of this, Grainger et al. have 
recently demonstrated that CCR2 deficient mice develop a severe pathology in 
the gut during Toxoplama gondii infection characterised by increased influx and 
activation of neutrophils, expressing many inflammatory cytokines (245). The 
authors have shown that ‘inflammatory’ monocytes control the pathogenic 
potential and activation of neutrophils by secreting prostaglandin E2 (PGE2). Thus 
in the absence of monocytes, neutrophils are highly activated and recruited to 
the inflamed tissue.  
CCR1 deficient mice exhibit delayed disease onset and reduced severity of EAE 
due to impaired trafficking of monocytes and macrophages to the brain (246). In 
another study using CX3CR1 deficient mice it has been observed that the severity 
of EAE increases due to impaired trafficking of NK-cells to the brain. NK- cells 
express CX3CR1 on their surface and play an important role in regulating EAE 
severity (170). In contrast to CCR2, CCR1 and CX3CR1, CCR5 deficient mice have 
not exhibited any noticeable changes in EAE susceptibility and disease severity 
(247). Thus, CCR5 appears to play only a minor role in the pathogenesis of EAE.  
The CCR6-CCL20 axis has been shown to be important for the initiation of EAE 
(206). CCR6 is expressed on the surface of specific regulatory T-cells and Th17 
cells (248, 249). In the CNS epithelial cells of the choroid plexus constitutively 
express CCL20. Using CCR6 deficient mice Reboldi et al. have shown that these 
mice are highly resistant to EAE, and that T-cell infiltration into the CNS occurs 
in two waves during EAE (206). The first wave of cells entering the brain is 
CCR6+Th17 cells, which infiltrate the brain most likely through the choroid 
plexus of the CSF-brain barrier. The entry of Th17 cells is indispensable for the 
entry of the second wave of T-cells comprised of Th17 and Th1 cells, which 
enter the CNS through activated parenchymal postcapillary venules of the BBB. 
This is consistent with studies by Kivisäkk et al., who have demonstrated that T-
cells first accumulate in the meninges and subarachnoid space and subsequently 
appear in the brain parenchyma (250). Thus, the CCR6-CCL20 axis is pivotal for 
the initiation of neuroinflammation in mice and humans and controls immune 
surveillance of the CNS. 
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Studies investigating the role of CXCR3 during EAE have produced contrasting 
results with regard to disease outcome. Liu et al. have demonstrated that CXCR3 
deficient mice display more severe neurological symptoms during EAE, while T-
cell accumulation in the brain is not altered compared to wild type mice (251). 
The same result was obtained in another study by Muller et al., who have shown 
that CXCR3-/- mice have widespread lesions throughout the CNS and similar 
numbers of T-cells in the brain compared to WT mice (252). Thus, CXCR3 seems 
to have a beneficial role during EAE. In contrast to this, other studies have 
demonstrated that blocking CXCR3 in mice lead to a milder onset of EAE and 
decreasing numbers of T-cells within the CNS. Hence, CXCR3 appears to be 
pathological in these studies of EAE (253, 254). The exact role of CXCR3 during 
neuroinflammation remains unclear and will be a focus in my studies, using a 
mouse model of viral encephalitis as described later. 
Taken together, neuroinflammation results in the upregulation of many 
chemokines and cytokines which are able to modify leukocyte entry into the 
CNS. Thus, chemokines may potentially be good candidates for the development 
of new drug therapies for currently untreatable CNS diseases. However the 
complexity of the chemokine network makes this a challenging task and more 
studies are required to elucidate the exact dynamics of chemokines and their 
role in leukocyte attraction into the CNS.  
1.4 Viral encephalitis  
Viral encephalitis is an inflammation of the brain caused by viruses. If the 
infection of the brain involves areas such as meninges or spinal cord it is 
referred to as menigoencephalitis or encephalomyelitis, respectively. Meningitis 
is the most common form of viral CNS infection. Viral encephalitis is a relatively 
rare condition but can cause life threatening or fatal disease in the host 
depending on the affected brain area. According to the WHO there are annually 
50,000 cases of Japanese encephalitis worldwide with a mortality rate of around 
30-60% (255). Viruses which have an ability to infect cells of the CNS are 
referred to as neurotropic viruses. A list of medically important neurotropic 
viruses is shown in Table 1.2.  
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Table 1.2. Medically important neurotropic viruses 
DNA viruses are highlighted in blue, RNA virus in red and retroviruses in green  
Virus 
 
Target cell 
 
Geographical distribution 
 
DNA viruses 
  Herpes simplex virus 
 
Neurons Worldwide 
Cytomegalovirus Neurons Worldwide 
Adenovirus 
 
Neurons, 
ependyma 
Worldwide 
 
RNA viruses 
  Poliovirus Motor neurons India, Africa 
Japanese encephalitis virus Neurons Asia, Australia 
West Nile virus Neurons Europe, Africa, Americas 
Rabies Neurons Europe, Asia, Africa, Americas 
Equine encephalitis virus (Western, 
Eastern, Venezuelan) Neurons Americas 
Mumps 
 
Meninges, 
ependyma 
Worldwide 
 
Retroviruses 
  
HIV Microglia Worldwide 
Human T-lymphotropic virus I Astrocytes Japan, Caribbean 
 
Viruses can enter the CNS through various routes: direct entry through the BBB 
or blood-CSF barrier or by transport along axons of peripheral or olfactory nerves 
(256). The entry of virus across the BBB is more complex compared to entry via 
the blood-CSF barrier due to the intrinsic properties of the endothelium of the 
BBB. Generally viruses can cross the BBB or blood-CSF barrier directly by 
transcytosis or by infecting endothelial, meningeal or CPE cells, but can also be 
passively transported into the perivascular space of microvessels via migrating 
leukocytes. This mechanism is also known as the ‘Trojan-horse’ mechanism 
(123).   
Viral encephalitides that are transmitted to vertebrate hosts by blood feeding 
arthropods, such as mosquitoes or ticks, are collectively named arboviruses 
(257). Three major virus families are part of arboviruses: alphaviruses, 
flaviviruses and bunyaviruses. Due to global warming and increased travelling 
between different countries, arboviral encephalitides have spread to many parts 
of the world, and have therefore become an increasing concern for humans. A 
recent example is the outbreak of West Nile virus in the Americas in 1999 (258). 
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Arbovirus infections make up almost 30% of all emerging infectious diseases in 
the last decade (259). Despite the fact that arboviral encephalitides are 
relatively rare they can cause severe and permanent neurological symptoms that 
can result in death. For instance the mortality rates in humans for JEV infection 
is 30-60%, for Eastern equine encephalitis infections 50-70%, for Western equine 
encephalitis 3-7% and for West Nile virus infection 10% amongst human 
neuroinvasive WNV cases (260, 261). Currently there are hardly any vaccines 
available for these life-threatening virus infections and more research is 
necessary to explore potential therapeutics. 
There are several animal models available that are mostly low-risk to work with, 
providing us with the opportunity to enhance our knowledge of viral infections of 
the CNS. Semliki Forest virus (SFV), West Nile virus (WNV), lymphocytic 
choriomeningitis virus (LCMV) and mouse hepatitis virus (MHV) are amongst the 
most extensively studied mouse models of viral encephalitis and will be 
discussed in further detail in the following sections. As part of this thesis the 
main focus will be on Semliki Forest virus, belonging to genus alphaviruses, and 
this virus will be discussed in depth in the following sections.  
1.4.1 Alphaviruses 
The virus family Togaviridae consists of two genera: Alphavirus and Rubivirus. 
The genus Alphavirus consists of approximately 30 members, which can generally 
be divided into two groups based on their geographical distribution: Old World 
and New World viruses. Both groups contain medically important viruses that can 
cause a febrile illness accompanied by rash, joint pains or encephalitis which can 
be lethal in human and animal hosts (262). Alphaviruses are arboviruses and 
cycle naturally between the arthropod vector and the vertebrate host (263). 
Humans are usually dead-end hosts. Furthermore alphaviruses are geographically 
widely distributed with the exception of Antarctica. The incidence of infections 
in humans is generally low but regional outbreaks occur from time to time. A 
recent example in the past years is the large outbreak of chikungunya (CHIKV) in 
2005-2006 in the region of the Indian Ocean (264). Due to climate changes 
alphaviruses spread more readily to new areas and become endemic there (265, 
266).  
 Chapter 1. General Introduction 64 
 
   
Alphaviruses can be further divided into seven antigenically different complexes. 
Old World viruses possess a wide geographical distribution and usually cause 
arthralgia and rash, whereas New World viruses appear to be geographically 
confined to the Americas and typically cause encephalitis. Members of the Old 
World virus group include SFV, chikungunya (CHIKV), Ross River virus (RRV) and 
Sindbis virus (SINV) (262). The New World virus group consists of the Venezuelan 
equine encephalitis virus (VEEV), Eastern equine encephalitis virus (EEEV) and 
Western equine encephalitis virus (WEEV), with EEE being the most virulent 
equine encephalitis virus (267). Most of the New World viruses and a few of the 
Old World viruses such as SINV and SFV often cause encephalitis. However the 
severity of encephalitis is much higher among New World virus infections 
including EEEV, WEEV and VEEV (268-270). Good animal models, such as SFV, 
provide us with important insights into the pathogenesis of viral encephalitis and 
enable the development of new drugs. 
1.4.1.1 Structure and replication of Alphaviruses 
Alphaviruses are enveloped, spherical, single stranded (ss) positive RNA viruses, 
have a genome of approximately 12 kb which acts directly as messenger RNA 
(mRNA) (262). The genome consists of two open reading frames and encodes four 
non-structural proteins (nsP1-nsP4) close to the 5’ end and five structural 
proteins near the 3’ end of the genome (Figure 1.7). The first reading frame 
codes for the non-structural proteins which are necessary for viral replication 
and transcription, whereas the structural proteins are required for viral capsid 
and envelope production (262, 271, 272). The production of structural proteins is 
under the control of the subgenomic promoter which is activated during later 
stages of viral replication and leads to high levels of expression of subgenomic 
RNA. The two major structural proteins are E1 and E2, which form heterodimers 
on the envelope surface. Recently the structure of the alphavirus envelope has 
been unveiled and shows that the envelope consists of 80 spikes, each spike 
containing three E1/E2 heterodimers (273, 274). The E1 protein is important for 
membrane fusion and E2 initiates receptor binding (275-277).  
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Figure 1.7 Structure of the alphavirus genome 
The genome is comprised of non-structural and structural genes. The structural genes are 
regulated from the subgenomic promoter. Furthermore the genome consists of a methylated cap 
at the 5’ end and a polyadenylated 3’ end. 
 
The exact cellular receptors for cellular entry by alphaviruses remain unclear 
but some studies have reported MHC-I, laminin receptors and glycosaminoglycans 
as possible receptors for alphaviruses (278-280). After fusion with the cell 
membrane, alphaviruses are taken up into endosomal vesicles. The pH changes 
inside the vesicles trigger conformational changes in the viral envelope proteins 
and lead to fusion of the envelope with the endosomal membrane of the host 
(281, 282). Subsequently the virus is released into the cytoplasm of the cell 
where it initiates viral replication. Following viral replication the viral proteins 
assemble and are packed into immature virions. In the next step virions bud 
from the cell membrane to release mature virions  (Fig. 1.8) (283).  
 
Figure 1.8 Life cycle of alphaviruses 
Virus binds to a cellular receptor and is taken up into the cell inside via endocytosis. Depending 
on the pH, the virus envelope fuses with the endosome vesicle membrane, and virions are 
released into the cytoplasm. In the next step, viral RNA is directly translated into non-structural 
and later structural proteins. Parts of the structural polyprotein translocate into the 
endoplasmatic reticulum (ER) where protein modifications and processing takes place. Structural 
and non-structural proteins finally assemble into immature virions which bud from the cell 
membrane of the host. Mature virions are released from the cell surface. Adapted from (262). 
 
 Chapter 1. General Introduction 66 
 
   
1.4.2 Semliki Forest virus 
Semliki Forest virus (SFV) is a neuroinvasive low-risk pathogen, and is extensively 
used as model of viral encephalitis and demyelination. SFV was originally 
isolated in 1942 from a pool of female mosquitoes in the Semliki valley in 
Uganda (284). SFV is capable of infecting humans and animals including horses, 
monkeys, mice, rats, guinea pigs, rabbits and voles (285-287). However the 
natural host of SFV in the wild remains unknown. SFV occurs naturally 
throughout Africa and human outbreaks have been reported in 1987 in the 
Central African Republic where 23 patients showed symptoms of febrile illness, 
myalgia, arthralgia and headaches (288). The virus has been isolated from Aedes 
aegypti and Aedes africanus but also occurs in Culex and Anopheles species 
(288). To date, there is only one documented case of SFV induced death from 
1978. This report has shown that a scientist working with the virulent Osterrieth 
strain suddenly developed meningoencephalomyelitis accompanied with 
neurological symptoms. The virus was isolated from the brain, CSF and spinal 
cord of the patient and a high viral titre was observed in the CNS tissue (289). It 
remains unknown why this patient became infected with SFV but it has been 
suggested that the patient might have been immunosuppressed, and would 
therefore have been more susceptible to virulent SFV infection (289). Although 
this is the only documented case of death in a human caused by SFV, 
seroconversion in laboratory workers can be commonly detected (289).  
1.4.2.1 SFV strains 
SFV can be divided into virulent and avirulent strains. Generally the 
categorisation of viruses into virulent and avirulent is utilised to describe the 
pathogenicity of a virus. Virulent virus strains have the ability of causing a lethal 
disease in the host, and are capable of replicating within the host and 
overcoming protective immune responses. Avirulent virus strains do not usually 
cause illness in the host and are asymptomatic (290). However, depending on 
the immune status of the host avirulent viruses can cause disease and virulent 
strains can cause mild disease in the host. Thus, the classification of viruses into 
virulent and avirulent strains is not always that clear. The virulent strains of SFV 
include L10, V13, Osterrieth and the prototype strain, and the avirulent strains 
are comprised of A8, A7, A7(74) and MRS MP192/7 (257, 286, 291). The best-
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examined strains of SFV so far are L10, A7 and A7(74). The SFV strain L10 
originates from the first SFV isolates from Uganda and was passaged eight times 
intracerebrally through adult mouse brains and two times through baby mouse 
brains (286). The avirluent strain A7(74) was derived from a pool of mosquitoes 
(original strain AR2066) in 1959 in Mozambique and was passaged seven times 
through neonatal mouse brains (292).  
All strains of SFV are neurotropic but only virulent strains cause severe 
panencephalitis in mice within 5-7 days after infection. Avirulent strains usually 
only cause demyelination in the adult mouse that can last up to one month post 
infection and cause lethal encephalitis only in the developing mouse or in 
neonates. The age-dependent virulence and demyelination will be briefly 
discussed in sections 1.4.2.2 and 1.4.2.4. It was documented that SFV in the 
periphery infects a variety of cells that includes fibroblasts and skeletal, smooth 
and cardiac muscles. In the brain, all strains of SFV infect predominantly 
neurons and oligodendrocytes, and rarely endothelial, meningeal, ependymal 
and choroid plexus cells of the CNS (293, 294). Determinants of virulence are 
mainly located in the non-structural proteins of SFV and in particular in the nsp3 
gene. The nsp3 gene of avirulent viruses contain a deletion of 21 nucleotides and 
an opal termination codon. However other mutations within the genome have 
been identified and it has been shown that all mutations act synergistically with 
regard to virulence (295-297).  
1.4.2.2 Restricted replication in the CNS  
Virulence of A7(74) has been reported to be age-dependent in mice. All mice up 
to 14 days of age die due to severe panencephalitis, similar to virulent infection 
with L10 (298). From post natal day 16 onwards all mice survive, and the 
replication of SFV seems to be restricted to certain areas of the brain in 
perivascular foci (299). No budding and mature virions are detectable in the 
brains of adult mice infected with A7(74). Characteristics of avirulent infections 
of adult mouse brains are: low replication of virus, absence of virus budding and 
accumulation of viral capsid proteins in form of aggregates within infected cells. 
(51, 298, 300). The difference in virulence between neonatal mice and adult 
mice is not due to defects or immaturity of the immune response but is 
dependent on the maturity of the CNS (298, 301). Oliver et al. have shown that 
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neonatal mice still undergo synaptogenesis, axonogenesis, gliogenesis and 
myelination (299, 302). With the maturation of the brain they have shown that 
neurons shut down their metabolic processes, including smooth membrane 
production, and become refractory to apoptosis. A study by Scallan et al. have 
demonstrated that these gold compounds, administered intraperitoneally to SFV 
A7(74) infected mice, induce full replication of avirulent SFV in neurons of adult 
mice (303). Thus, there is substantial evidence that an avirulent infection with 
SFV can be converted into a virulent infection characterised by high virus 
replication and spread throughout the brain (304). This process appears to be 
dependent on the differentiation status of neurons. 
1.4.2.3 Immune responses to SFV and viral clearance 
After intraperitoneal infection of mice, viral titres of SFV are cleared from the 
blood within four days post infection. Between days four and ten the BBB 
becomes leaky and allows the migration and entry of leukocytes into the CNS. 
(294, 305). Viral RNA can be detected in the CNS as early as three days post 
infection and infectious virus particles are cleared from the brain by day eight, 
although viral RNA can persist in the CNS for much longer (306). In the brain, SFV 
is recognized by PRRs expressed on the surface of neurons and glial cells. This 
initiates the production of TNF-α, type-I and type-II interferon and several 
interleukins that include IL-1β (307).  
Leukocytes enter the brain between days three and four when the BBB is 
permeable. However the kinetics of leukocyte entry has not yet been 
determined for SFV infection, and this is one of the aims in this thesis. Studies 
using severely B- and T-cell deficient mice have shown that these mice are 
unable to clear viral infection (51). Furthermore, IFN seems to play a crucial role 
in disease severity as mice which lack functional type-I interferon succumb to 
infection within 48 hours post infection (308, 309). Thus, the immune response is 
necessary to control viral replication. However, leukocytes, and in particular 
CD8+ T-cells, can also play a pathogenic role during SFV infection of the brain. 
Subak-Sharpe et al. have demonstrated that the depletion of CD8+ T-cells results 
in the reduction of demyelination suggesting a pathogenic role of these cells 
(310).  
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IgM antibodies are important for viral clearance from the blood, whereas IgG is 
capable of clearing viral antigens from the blood and brain. Nu/nu mice which 
are deficient in T-cells but produce IgM, control viremia but have a persistent 
CNS infection (311). SCID mice, which are deficient in B- and T-cells and produce 
no immunoglobulins, have a persistent infection of SFV in the blood and brain. 
However, transfer of IgG sera from wild type mice into SCID mice resulted in 
viral clearance within and outside the CNS, suggesting that IgG is important for 
the clearance of SFV (51). This highlights the role of antibodies during SFV 
infection. 
T-cells also play an important role during SFV infection of the CNS. It has been 
demonstrated that depletion of CD8+ T-cells results in an enormous reduction in 
demyelination. This suggests that CD8+ T-cells are important for the elimination 
of infected oligodendrocytes. Further studies are required to confirm this 
hypothesis (308, 310). Depletion of CD4+ T-cells has led to the reduction of 
neuroinflammation (310). However the depletion of both CD4+ and CD8+ T-cells 
has significantly affected viral titres. Therefore it is most likely that T-cells play 
mostly pathogenic roles during viral encephalitis, characterised by 
demyelination and tissue damage of the brain as shown by Fazakerley et al. 
(312, 313). Histological analysis has shown that perivascular cuffs form around 
cerebral microvessels and peak after seven days post infection with SFV (307). 
MHC-I+ cells, cluster around sites of infection in the CNS. The expression of MHC-I 
and -II are both upregulated on activated microglia and astrocytes (307).  
1.4.2.4 Demyelination 
After SFV infection with the avirulent strain, the immune response eventually 
results in demyelination, starting approximately 14 days post infection (47, 312). 
Demyelination is most likely driven by pathogenic T-cell responses, and in 
particular by CD8+ T-cells, as mentioned before. A study has shown that by post 
infection day 20-30 most of the lesions in the brains of BALB/c mice are repaired 
due to various remyelination processes. In SJL mice, it has been shown that 
remyelination takes much longer, and lesions persist in the brain for up to 12 
months (314). Infection with the virulent strain of SFV, such as L10, does not 
result in demyelination because mice die before immune-mediated 
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demyelination processes start and therefore this process is seemingly obscured 
by death (267, 315). 
1.4.3 West Nile virus (WNV) 
WNV is a spherical and enveloped positive single stranded (ss) RNA virus with a 
genome size of approximately 11 kb (316). WNV belongs to the family Flaviridae, 
genus Flavivirus and is primarily transmitted by mosquitoes including Culex 
species and sometimes Aedes albopictus or Aedes vexans (317).  Within the 
genus Flavivirus, WNV belongs to the Japanese encephalitis serogoup (316). WNV 
was originally isolated from a patient with febrile illness in the West Nile district 
in Uganda in 1937 (318, 319). Cases of WNV infection have since been reported 
from other regions in Africa, Middle East, Asia and Australia (320, 321).  In 1999 
WNV caused an outbreak in North America starting in New York city, and over 
the years WNV has spread all over the Americas and has become endemic there 
(258, 322, 323).  
In humans 70-80% of WNV infections are asymptomatic (324). The incubation 
period is usually between 2 and 14 days and symptoms of WNV infection can 
generally be divided into either a mild febrile illness accompanied with 
headache, pains, myalgia and arthralgia, or into a neuroinvasive syndrome that 
includes symptoms like paralysis, meningitis and encephalitis. Of all 
symptomatic patients approximately 1% develop either encephalitis (60%) or 
meningitis (40%) that can result in death (261). This usually concerns immune-
compromised patients and the elderly (174, 325). The American East coast 
strain, designated as NY99, is highly neuroinvasive, leads to severe forms of 
encephalitis in mouse models and has been extensively studied over time in 
respect of pathogenesis (326, 327).  
1.4.3.1 WNV replication 
The 11 kb genome consists of one open reading frame that is translated into one 
polyprotein which is then cleaved by enzymes into three structural proteins (C, 
prM and E) and seven non-structural proteins known as NS1, NS2A, NS2B, NS3, 
NS4A, NS4B and NS5) (Figure 1.9). The structural proteins are important for 
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capsid and envelope production of the virus and the non-structural proteins are 
necessary for the replication process (316, 328, 329).  
WNV enters the cell by binding to an unknown cell receptor and is taken up into 
endosomes. The pH inside the endosomes becomes more acidic over time and 
finally triggers the fusion of virus with the membrane of the endosome which 
results in uncoating of the virus. The virus replicates in the cytoplasm and the 
(+) ssRNA genome is directly translated into protein. After production of 
structural proteins the virions assemble to mature virions and exit the cell via 
exocytosis (316, 330, 331).  
 
 
Figure 1.9 Genome of West Nile virus 
The genome of West Nile contains a methylated cap at the 5’ end but no polyadenylated 3’ end. 
The genome is comprised of structural and non-structural genes which are directly translated 
from the RNA genome. Adapted from (316). 
 
1.4.3.2 WNV infection of the CNS 
Infection of the CNS with WNV occurs within 5 days post infection can lead to 
meningitis, encephalitis or acute flaccid paralysis depending on which area of 
the CNS is affected. WNV can enter the CNS through three different routes: 
haematogenous route via BBB or blood-CSF barrier, retrograde axonal transport 
route via peripheral nerves and the olfactory route via infection of olfactory 
neurons to the olfactory bulb (129, 332, 333).  WNV can cross the BBB or blood-
CSF barrier through passive transport through the endothelial or choroid plexus 
cells or though direct infection of these cells (334, 335). The other possibility of 
crossing the BBB is through extravasation of infected leukocytes across the 
activated endothelium. (336, 337). The endothelium becomes activated in the 
presence of high levels of inflammatory cytokines that include TNF-α, or after 
activation of matrix-metalloproteinases (326, 338).  
WNV primarily infects neurons and, only in rare cases, glial and cerebral 
endothelial cells of capillaries. Infection of neurons can lead to apoptosis or 
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necrosis of the cell. The injury and subsequent damage of neurons can be 
directly induced through the virus or can be a consequence of immune responses 
in the CNS (326, 339). In either case, WNV infection of the CNS leads to the 
activation of microglia and to the infiltration of leukocytes into the perivascular 
space and into the brain parenchyma. High numbers of macrophages, CD4+ and 
CD8+ T-cells and plasma cells have been observed during WNV encephalitis. Viral 
brain lesions due to neuronal damage and loss, are predominantly found in the 
hippocampus, brain stem, cortex, thalamus spinal cord and cerebellum (340, 
341). Dying neurons can release inflammatory chemokines and cytokines such as 
CXCL10, IL1-β and TNF which can have detrimental effects on adjacent neurons 
that are uninfected and subsequently lead to neuronal loss (88, 342).  
1.4.3.3 Immune responses to WNV in the periphery and the CNS 
Immune responses are crucial for viral clearance, but must be tightly controlled 
in the brain to prevent neuronal damage and loss. Severely immune-
compromised mice show high viral loads and persistent infection of the CNS, 
highlighting the importance of cell-mediated immune responses in the brain 
(343). After initial infection with WNV, nucleic acid can be detected by PRRs at 
the site of infection which initiates the production of pro-inflammatory 
cytokines, chemokines and type-I interferons. Type-I interferons are key players 
in innate immunity and can be produced by many cells during infection. Mice 
deficient for the IFN-α/β receptor exhibited increased viral replication, 
widespread infection and rapid CNS invasion, which subsequently results in 
earlier death (344).  
Macrophages and DCs can be infected with WNV and are amongst the first cells 
involved in the recognition of WNV and antigen presentation outside the CNS 
(337, 345). Depletion of macrophages during WNV infection results in higher 
viremia and a 50% increase in mortality in mice, accompanied with enhanced 
neuroinvasiveness of WNV (346).  Furthermore monocytes, which are precursors 
of macrophages, are also important for viral clearance from the periphery and 
clearance of virus from the CNS (214). This function is dependent on the 
expression of CCR2. The role of chemokine receptor will be further discussed in 
section 1.5. 
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NK-cells and γ/δ T-cells both produce IFN-γ which is important for the 
dissemination of WNV. (347). However, only γ/δ T-cell deficient mice, but not 
NK-cell deficient mice, have displayed increased lethality, higher viral loads in 
peripheral tissues and more rapid dissemination of WNV in the CNS (348, 349). 
These studies have suggested that γ/δ T-cells are the main producers of IFN-γ. 
IFN-γ has direct antiviral activities and is primarily required for early innate 
immune responses in order to reduce viral spread in the periphery and 
neuroinvasion (347). Neutrophils have been shown to play a dual role during 
WNV. Bai et al. have shown that neutrophil depletion prior to WNV infection 
leads to reduced viral loads and increased survival whereas depletion after viral 
infection leads to increased viremia and enhanced mortality (350). Therefore 
the timing during infection is crucial and determines what role neutrophils play 
during WNV infection. During early stages of infection neutrophils are infected 
by WNV and contribute to the viral dissemination but during later stages of 
infection neutrophils are beneficial and contribute to viral clearance (350).  
B-cell deficient mice die due to persistent infection of the CNS and high viral 
titres in the blood and brain (351). Similar to SFV studies Diamond et al. have 
shown that the early transfer of IgM limits viremia and prevents dissemination 
into the CNS (352). T-cells are one of the key players during WNV infection. 
Depletion of CD4+ and CD8+ T-cells leads to persistent infection of the brain and 
enhanced neuronal loss and damage (140, 141, 348).  CD8+ T-cells are important 
for viral clearance from the brain but excessive CD8+ T-cell responses lead to 
neuropathology associated with loss and damage of uninfected neurons (353). 
Thus, CD8+ T-cell responses can be either beneficial or detrimental to CNS 
infection depending on the extent of viral infection and CD8+ T-cell 
accumulation in the brain. CD4+ T-cells also play important roles during WNV 
infection similar to SFV infection. Mice deficient in CD4+ T-cells exhibit higher 
mortality rates and viral titres in the CNS (141). CD4+ T-cells are important for 
providing help by priming B-cells and maintaining CD8+ T-cell responses. Finally 
Tregs seem to influence disease severity during WNV infection. Patients with a 
low number of Tregs were more likely to develop symptoms whereas patients with 
normal or increased levels of Tregs usually did not develop symptoms during WNV 
infection (354). Further studies are required to elicit their role during WNV 
pathogenesis. 
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1.5 The role of chemokines in the pathogenesis of 
neurotropic viruses 
Encephalitis caused by neutrotropic viruses is characterized by the activation of 
glial cells and neurons, increased permeability of the BBB and blood-CSF barrier, 
activation of vascular cerebral endothelium and, most importantly, by the large 
infiltration of leukocytes from the periphery into the perivascular space of 
capillaries or into the brain parenchyma (355). Several ‘knock out’ mouse 
models, deficient for CCR2, CCR5 and CXCR3, have shown that chemokines are 
pivotal in attracting leukocytes to sites of inflammation for viral clearance. 
However large influx of leukocytes into the CNS of virally infected mice is 
associated with pathology in the brain and can cause loss, and damage, of 
neurons and glial cells (356).  
Chemokines are induced in a highly specific manner during viral infection and 
orchestrate leukocyte infiltration into the CNS with the goal of removing 
infected cells and clearing the virus from the brain with minimal neurological 
damage to the brain. A clear chemokine expression pattern during viral brain 
infection has not yet been established (357). The chemokines expressed during 
viral enephalitis can be very distinct between different pathogens, and depend 
on virus strains and host factors including age and immune status of the host. 
Thus, the differential chemokine expression during viral infection highlights the 
complexity of the chemokine-mediated immune responses, and as part of this 
thesis I aim to conduct a thorough chemokine expression analysis during SFV and 
WNV infection.  
Some mouse models have examined cell-mediated immunity during viral 
encephalitis but the involvement of chemokines in these immune processes is 
still not fully understood and shall be analysed as part of this thesis. Amongst 
the best-characterised mouse models with regard to chemokine-mediated 
immune responses in the CNS during viral encephalitis are WNV, LCMV and MHV, 
although these studies have not comprehensively investigated the role of 
chemokines. Instead, the authors of these studies have selected a few 
chemokines and investigated their role using gene deficient mice. Small 
molecule antagonists have not been used in this context. The current knowledge 
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of the role of chemokines during WNV, LCMV and MHV encephalitis will be briefly 
introduced here and will build the basis for this thesis. 
1.5.1 Chemokine-mediated immune responses during WNV 
infection 
WNV infection of the CNS leads to the high expression of CCR2 (CCL2, CCL7 and 
CCl12), CCR5 (CCL3, CCL4 and CCL5) and CXCR3 (CXCL9 and CXCL10) ligands 
(153, 173, 358, 359). In particular CXCL10 and CCL5 have been shown to be 
highly expressed in WNV infected brains. Neurons appear to be the main source 
of chemokines but also astrocytes and microglia are able to express considerable 
amounts of chemokines such as CXCL10, CCL2 and CCL5 (360). The cellular 
infiltrate within the CNS during WNV infection of mice consists mainly of T-cells, 
NK-cells, monocytes and neutrophils (173). In humans the infiltrate is slightly 
different from mice and consists mainly of CD8+ T-cells and to a less extent CD4+ 
T-cells and B-cells. The T-cells are mainly found in the brain parenchyma and 
perivascular space. NK-cells and monocytes are mostly confined to the 
perivascular space (153, 361).  
Murine CCR5 is expressed on activated T-cells, NK-cells, activated microglia and 
a few monocytes (212). CCR5 seems to play a crucial role in the pathogenesis of 
WNV infection and is critical for survival (173, 362). A study conducted by Glass 
et al. has shown that CCR5 deficient mice cannot control viral loads in the CNS, 
have reduced numbers of CD4+ and CD8+ T-cells, NK-cells and macrophages 
entering the brain, which cumulatively results in rapid death and 100% lethality 
(173). However, mice can be rescued from this phenotype after adoptive 
transfer of CCR5+ splenocytes from wild type mice into CCR5-/- mice, and the 
survival rate after WNV infection can be restored to a similar level compared to 
that in infected wild type mice (173). The extent of viral clearance in the 
periphery has not been affected in CCR5-/- mice and therefore a CNS specific 
role of CCR5 has been suggested.  
In humans a mutation in the CCR5 gene, referred to as CCR5Δ32 mutation, leads 
to complete loss of function of CCR5 and is found in up to 1% of the Caucasian 
population. Humans who are homozygous for the mutation are naturally resistant 
to HIV infection (197). A few studies have shown that humans with the CCR5Δ32 
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mutation are more susceptible to symptomatic WNV disease, often associated 
with the development of meningitis or encephalitis (173, 361). Based on these 
studies it has been suggested that CCR5 is a crucial determinant of WNV 
severity. Later, these data were contradicted by two other studies that have 
shown that the CCR5Δ32 mutation does not correlate with symptomatic WNV 
infections (363, 364). Thus, the exact role of CCR5 during viral encephalitis 
remains unclear.  
CXCR3 is mainly expressed on T-cells and binds to CXCL9, CXCL10 or CXCL11. 
CXCL10 is one of the most highly upregulated chemokines during WNV infection 
and is primarily expressed by neurons very early during infection (153). CXCL10 
deficient mice exhibit a significant reduction in CD8+ T-cells, higher viral titres 
in the brain and enhanced mortality. However it should be noted that the effect 
of CXCL10 on the pathogenesis is specific to the CNS because viral titres and 
clearance of WNV in peripheral tissues have not been shown to be different from 
wild type infected mice (153). Thus, these data suggest a specific role for 
CXCL10 in the recruitment of CD8+ T-cells into the CNS, which results in reduced 
viral titres and mortality.  
CCR2 is mainly found on ‘inflammatory’ monocytes and binds to CCL2, CCL7 and 
CCL12 expressed in the inflamed brain (173, 214). A large number of these 
‘inflammatory’ monocytes enter the brain during WNV infection and it has been 
suggested that they give rise to microglia and perivascular macrophages (106). 
The role of monocytes in WNV infection has been shown to be protective, or 
pathogenic, depending on the route of virus administration. In the intranasal 
model, monocytes appear to be pathogenic and reduce survival, whilst in the 
intraperitoneal model monocyte entry into the CNS leads to an increase in 
survival and decreased viral titres (106, 346). Lim et al. have demonstrated that 
CCR2 deficient mice infected intraperitoneally with WNV die earlier and have 
enhanced viral titres in the CNS, suggesting a protective role of CCR2 (214). 
However the authors have suggested that CCR2 is not directly involved in 
monocyte trafficking to the CNS but is rather important for the egress of 
monocytes from the bone marrow. Thus, the monocytopenia observed in CCR2-/- 
mice leads to the subsequent enormous reduction of monocytes accumulating in 
the brain and is independent of the ability of monocytes to traffic into the brain. 
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Furthermore Lim et al. have shown that adoptively transferred CCR2+ but not 
CCR2- monocytes from wild type mice are capable of entering the CNS (214). 
This study suggests that CCR2 is critical for monocytosis and leads to the 
subsequent accumulation of monocytes in the brain where they play a protective 
role during WNV infection. Based on these data the role of CCR2 is not yet fully 
understood. 
CXCR4 is expressed on T-cells, NK-cells, neutrophils and many other leukocytes. 
CXCR4 is one of the ‘primordial’ chemokine receptors and depletion of CXCR4 in 
mouse embryos is lethal (365). The ligand CXCL12 is expressed by endothelial 
cells of cerebral microvessels and retains CXCR4+ leukocytes in the perivascular 
space and prevents the crossing of leukocytes into the brain parenchyma. 
McCandless et al. have shown that blocking CXCR4, with the blocker AMD3100, 
increases infiltration of CD8+ T-cells into the brain parenchyma and leads to 
enhanced viral clearance (366). This leads to a better disease outcome and 
enhanced survival in WNV infected mice.  Thus, blocking CXCR4 may be a 
potential way of treating acute viral encephalitis in the future.  
1.5.2 Lymphocytic choriomeningitis virus infection 
Lymphocytic choriomeningitis virus (LCMV) belongs to the family Arenaviridae 
and infects mice in nature. Intracranial injection of mice with LCMV leads to 
meningoencephalitis 6-8 days later resulting in death. The cellular infiltrate of 
LCMV in the CNS consists of macrophages, high numbers of CD8+ T-cells and only 
few CD4+ T-cells (320, 367, 368). T-cells have been shown to play a pathogenic 
role during LCMV infection and appear in the brain five days post infection. Most 
of the CD8+ T-cell deficient mice have been shown to survive fatal i.c. injection 
with LCMV. Additionally athymic nude mice, which are severely deficient in T-
cells, do not develop symptoms after LCMV infection (369, 370). Asensio and 
Campbell have conducted a study investigating chemokine expression during 
LCMV infection (128). They have observed that chemokines are upregulated as 
early as three days post infection. CXCL10 is the most highly upregulated 
chemokine in the CNS followed by CCL5, CCL2, CCL4 and CCL7. With the 
progression of the disease, chemokines are further upregulated and additional 
chemokines such as lymphotactin, CXCL16, CXCL2 and CCL3 are produced. It is 
worth noting that the expression of chemokines in the CNS is comparable to that 
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of peripheral tissues. CXCL10 has been shown to be produced mainly by resident 
cells of the brain including choroid plexus and meningeal cells. 
Furthermore Asensio and Campbell have investigated whether nude mice which 
are resistant to LCMV infection show altered chemokine expression patterns in 
the infected brain (128). No changes in chemokine expression have been 
detected in nude mice compared to healthy control mice, despite high viral 
titres in the brain (371). Thus, it has become evident that T-cell responses 
during LCMV are pathogenic and the presence of virus is not enough to alter 
chemokine expression in the CNS. Other factors such as type-I or type-II IFN, or 
TNF-α, have been suggested as possible candidates for the initiation of 
chemokine expression (372, 373). It has been reported that IFN-γ deficient mice 
upregulate chemokines to a certain extent but that the magnitude of expression 
was much lower compared to WT mice suggesting only a weak modulating 
function of IFN-γ (128).   
Several chemokine receptor ‘knock out’ mice have been used to investigate the 
role of chemokines during LCMV infection. CCL3, CCR5, CCR1 and CCR2 deficient 
mice all succumb to the disease and do not display a changed phenotype 
compared to WT mice (319, 374). Additionally the reduced infiltration of 
macrophages into the CNS in CCR1 and CCR2 knock out mice suggests that these 
receptors play a minor role in the attraction of macrophages and monocytes into 
the CNS (320).  
Studies using CXCR3 and CXCL10 deficient mice have both shown enhanced 
survival during LCMV infection with a marked reduction of CD8+ T-cell infiltration 
into the CNS (322, 323). Thus, CD8+ T-cells play a detrimental role in the 
pathogenesis of LCMV infection. Adoptive transfer of CXCR3+ CD8+ T-cells into 
CXCR3-/- mice results in a reversal of the phenotype and mice succumb to the 
disease. The generation of effector T-cells in the spleen of CXCR3-/- and   
CXCL10–/- mice is unaffected and CD8+ T-cells are still capable of trafficking into 
the CSF but with reduced efficiency. However the infiltration of CD8+ T-cells into 
the brain parenchyma in the absence of CXCR3 or CXCL10 is impaired (322, 323). 
This suggests that the CXCL10-CXCR3 axis is important for rapid positioning of T-
cells within virally infected brain parenchyma, although other chemokines 
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appear to be involved in attracting a few CD8+ T-cells into the brain. Infiltration 
of CD8+ T-cells into the brain parenchyma, and other important parts of the 
brain, is crucial for the outcome of LCMV infection. The other CXCR3 ligands 
(CXCL9 and CXCL11) have not shown any compensatory effect for CXCL10 and 
therefore CXCL10 appears to be the major player in the attraction of CD8+ T-
cells into the CNS (322). In contrast to these studies, WNV studies have shown 
that CXCR3 is beneficial for the pathogenesis of WNV infection, by attracting T-
cells into the brain (375).  
1.5.3 Mouse hepatitis virus infection 
Another well-studied model of viral encephalitis is mouse hepatitis virus (MHV) 
which belongs to the family of Coronaviridae. MHV is a positive ssRNA virus that 
can cause acute encephalomyelitis leading to death, or demyelination, in 
surviving mice (376). The outcome of MHV infection depends on the virus strain 
and route of virus inoculation. The neurotropic strain, JHMV, induces lethal 
encephalitis in mice and is characterised by a cellular infiltrate consisting mainly 
of macrophages and neutrophils. Hence, CCL2 and CXCL2 are highly expressed 
during JHMV infection, similar to WNV or LCMV infection. In comparison to 
JHMV, the neuroattenuated strain RA59 causes mild encephalitis which is cleared 
by day 7. The chemokine profile is different in these mice expressing mainly 
CXCL9 and CXCL10 (174). MHV infects glial cells including astrocytes, microglia 
and oligodendrocytes.  
Clearance of virus from astrocytes and microglia depends on the action of CD8+ 
T-cells by releasing perforin, and clearance from oligodendrocytes depends on 
IFN-γ (326, 377). In response to acute viral infection of the CNS, primarily CD4+ 
T-cells, CD8+ T-cells, NK-cells and macrophages enter the brain (330). Lane et 
al. have investigated the role of T-cells. They have shown that CD4-/- and CD8-/- 
mice have reduced demyelination, fewer leukocytes accumulating in the brain 
and increased viral titres, associated with higher mortality. In particular CD4-/- 
mice infected with MHV display reduced neuroinflammation and reduced levels 
of CCL5. Thus, CD4+ T-cells regulate neuroinflammation and extent of 
demyelination. This study is in agreement with WNV studies where similar results 
were found. However T-cell deficient mice exhibit higher survival and milder 
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symptoms during LCMV infection. Thus, the role of T-cells in the pathogenesis of 
viral encephalitis differs with the pathogen.  
The reduced expression of CCL5 during MHV infection has been shown to reduce 
macrophage numbers in the inflamed CNS which in turn might explain the 
reduction in demyelination (326). This has also been shown in studies using SFV 
as model of infection as discussed before (378). Infection of severely 
immunocompromised mice does not lead to demyelination despite higher viral 
titres in the CNS compared to wild type mice and highlights the importance of 
the immune system in the pathogenesis of MHV infection (328, 329). The role of 
NK-cells infiltrating the CNS during MHV infection is not yet clear. However 
Trifilo et al. have shown that NK-cells might be important for viral clearance 
within the CNS of mice during MHV infection, due to the secretion of IFN-γ from 
these cells (379). Generally data about the contributions of NK-cells to antiviral 
immunity within the CNS are sparse and need to be determined in detail.  
CXCL10 is upregulated very early during infection and can be detected in the 
brain within 24h post infection (129). CXCL10 has been shown to co-localise with 
MHV infected areas in the brain and the primary source of CXCL10 in the CNS has 
been identified as astrocytes even though microglia also produce this chemokine 
(129). Dufour et al. have reported that CXCL10-/- mice display reduced T-cell 
numbers in the CNS, reduced demyelination, lower IFN-γ levels and higher viral 
titres in the CNS, associated with higher mortality (380). This suggests that 
CXCL10 is important for the attraction of CXCR3+ T-cells into the CNS for viral 
clearance. Stiles et al. have then tested the hypothesis whether the loss of 
CXCL10 also leads to impaired effector T-cell generation (381). They have found 
that the generation of effector T-cells was not impaired in CXCL10 deficient 
mice infected with MHV, and they have confirmed that the role of CXCL10 during 
MHV encephalitis is only important for trafficking of T-cells into the CNS. In 
subsequent experiments Stiles et al. have investigated the role of CXCR3 during 
MHV infection by using CXCL10 neutralising antibodies or CXCR3 neutralising 
antiserum (381). The authors have demonstrated that the blockade of CXCR3 
resulted only in a modest decrease of CD4+ T-cell numbers within the CNS while 
the number of CD8+ T-cells was unaffected. Additionally viral titers in the brain 
were not altered, and survival was similar to untreated MHV-infected mice. The 
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reason for this discrepancy between receptor or ligand blocking during MHV 
infection remains unclear.  
Other chemokines reported to be upregulated during MHV infection are CCL2, 
CCL3, CCL4, CCL5, CCL7 and CXCL2 (129). The expression of CCR1, CCR2, CCR5 
and CXCR3 have also been found in the brain during infection. CCR2 deficient 
mice exhibit reduced T-cell and macrophages numbers accumulating in the brain 
and uncontrolled high viral titres, resulting in 100% mortality ten days post 
infection (334). Thus, CCR2 is an important chemokine receptor during MHV 
pathogenesis and is required for T-cell, and macrophage, entry into the CNS.  
CCR5 has been shown to be dispensable for the entry of CD8+ T-cells into the 
CNS but is important for antiviral activities of CD8+ T-cells using CCR5 deficient 
mice infected with MHV (1, 326, 382). In addition to this Glass et al. have shown 
that CCR5 is highly expressed by macrophages and microglia, and the infection 
of CCR5 deficient mice with MHV resulted in a significant reduction of 
macrophages entering the CNS (382). This reduction was furthermore shown to 
be associated with reduced demyelination. Thus, the authors have suggested 
that CCR5 is involved in demyelination by allowing macrophages to enter the 
brain during MHV infection, and it is these cells which aggravate demyelinating 
processes within the CNS of these mice.  These studies are in contrast to WNV 
studies where CCR5 is important and is indispensable for T-cells trafficking into 
the CNS, suggesting that CCR5 plays differential roles during viral encephalitis 
depending on the virus model used (173). 
Murine neutrophils express primarily CXCR2 and bind to CXCL1, CXCL2 and 
CXCL5. Neutrophils play a role in the breakdown of the BBB, and in this way 
these cells facilitate the entry of other leukocytes into the brain. During MHV 
infection neutrophils seem to play a protective role. Blocking of CXCR2 with an 
antibody almost completely blocks entry of neutrophils into the brain and leads 
to decreased MMP9 activity, reduced BBB permeability and higher viral titres. 
Subsequently all mice rapidly succumb to MHV infection (340, 383). Thus, CXCR2 
plays an important role in neutrophil attraction which is indispensable for 
survival of the host during MHV infection. However, during WNV studies Bai et 
al. have shown that neutrophils can play beneficial or detrimental roles in the 
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pathogenesis of WNV infection, depending on the timing of neutrophil depletion 
(350). 
In summary, the existing data on the role of chemokines during viral encephalitis 
have made it clear that chemokines may play differential roles during 
encephalitis, depending on the virus used for infection. It is not yet clear what 
role chemokines play during alphavirus infections. Additionally the analysis of 
chemokine expression during viral encephalitis has not been thoroughly analysed 
so far and it is possible that other chemokines might play important roles during 
brain infection. This will be addressed as part of my thesis.  
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1.6 Thesis aims 
As discussed in the general introduction, chemokines are important regulators of 
leukocyte trafficking in the body. The healthy CNS contains few leukocytes 
which exert immunosurveillance of the brain to enable fast detection in 
response to pathogens invading the CNS. Leukocytes within the brain can be 
either beneficial or detrimental to the host depending on the virus and strain 
used. Although mouse models of viral encephalitis such as WNV have been well 
described, a thorough picture of chemokine expression and chemokine-mediated 
leukocyte influx during viral encephalitis has not yet been established. In 
particular, there are sparse data on chemokine expression and their role in 
leukocyte recruitment for alphavirus encephalitides. Developing a deeper 
understanding of these key aspects of the encephalitic process is central to the 
ability to therapeutically manipulate it.    
Based on previous studies presented in chapter 1.5 it was hypothesized that 
chemokines are highly upregulated during viral encephalitis and lead to 
leukocyte infiltration into the CNS. Therefore the main aim of this thesis is to 
define the form and magnitude of chemokine expression and kinetics of 
leukocyte entry during viral encephalitis, using SFV as model of infection.  
Furthermore it has been demonstrated for some encephalitic viruses, such as 
WNV, that chemokine receptors can play a pivotal role in the pathogenesis of 
the infection. Therefore in addition to this, a further aim is to define the role 
of key chemokine receptors during viral encephalitis to identify relevant 
therapeutic targets for the treatment of viral CNS infections.  
In chapter 3 of this thesis I set out to perform a thorough analysis of chemokine 
expression during avirulent and virulent infection with SFV, identifying key 
chemokines upregulated in the brain during viral encephalitis.  
In chapter 4 the kinetics of distinct leukocyte subsets entering the CNS during 
viral encephalitis will be investigated and interpreted in the context of 
chemokine expression during SFV infection.  
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In chapter 5 a thorough analysis of chemokine expression in the CNS during 
lethal WNV infection will be conducted and compared to the expression of 
chemokines in the brain in response to SFV infection. 
In chapter 6 the role of key chemokine receptors during viral encephalitis will be 
determined using specific pharmacological chemokine receptor antagonists. This 
is the first time such pharmacological blockers are used in the context of viral 
encephalitis. 
   
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
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2.1 General reagents and buffers 
Plastics: All plastics used for experiments were purchased from Corning 
(Loughborough, UK) and Gibco (Invitrogen, Paisley, UK) unless indicated 
otherwise. 1.5 ml microcentrifuge tubes were purchased from Eppendorf 
(Stevenage, UK). QPCR plates were purchased from Starlab (Milton Keynes, UK) 
Tips: All tips were filter tips and purchased from Starlab. 
1% acid alcohol: 1% concentrated Hydrochloric acid (HCl) was added to 100 ml 
of 70% Ethanol 
Citrate buffer (0.1 M): 2.1 g citric acid monohydrate (Sigma, Poole, Dorset, UK) 
and 700 ml distilled water adjusted to pH6 using 2 M NaOH. Water was added 
again to make up a total volume of 1ml of buffer. 
Complete medium: RPMI1640, 10% heat inactivated fetal bovine calf serum, 
Penicillin (100 units/ml), Streptomycin (100 µg/ml) and L-Glutamine (2 mM) 
(Invitrogen, Paisley, UK). 
DAB solution: 1 drop of buffer stock solution, 2 drops DAB stock and 1 drop of 
Hydrogen Peroxide stock (all from Vector laboratories, Peterborough, UK) were 
added to distilled water and made up to a final volume of 1 ml. 
Digestion buffer: 9.6 ml 1x Hank’s balanced salt solution (HBSS) and 250 µl 
HEPES buffer (Sigma) were mixed. 
Eosin Y solution: 1% Eosin Y (Cell Path, Newtown, UK) was added to tap water 
ELISA wash buffer: 1x PBS (Invitrogen) was mixed with 0.5% Tween 20 (Sigma) 
FACS buffer: 500 ml Phosphate buffered saline (PBS) without Ca2+ and Mg2+ was 
mixed with 0.5% fetal calf serum (FCS) and 2 mM EDTA (all reagents from 
Invitrogen) 
10% complete GMEM: 10% new borne calf serum (NBCS) and 10% Trypthose 
phase broth was added to GMEM solution (all from Invitrogen) 
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0.5% Hydrogen Peroxide in Methanol: 5 ml of 30% H2O2 was mixed with 295 ml 
of Methanol (both from Sigma) 
4% Paraformaldehyde solution (PFA): 40 g of Paraformaldehyde powder (Sigma) 
were added to ~ 900 ml of heated (60°C) PBS and stir until powder dissolves. A 
few drops of 1N NaOH were added to raise the pH to 6.9. After PFA had 
dissolved, the solution was filtered and stored at -20°C for further use. 
PBSA: 0.75 g bovine serum albumin (BSA) in 100 ml PBS (both from Invitrogen) 
Rinsing buffer:  2 mM EDTA (Ambion, Paisley, UK) and 0.5% FCS (Sigma) were 
added to 1x HBSS (Gibco, Invitrogen)   
Scott’s tap water: 3.5 g sodium hydrogen carbonate and 20 g magnesium 
sulphate were added to 1 litre (l) of distilled water. Thymol (Sigma) was added 
to inhibit mould formation 
Sucrose solution: 20g sucrose (Sigma) was dissolved in 100 ml 10x Tris-Sodium-
EDTA buffer (TNE buffer) 
TE buffer: 10 mM Tris (HCl) pH8 and 1 mM EDTA were mixed 
10x TBST: To prepare 1 l 24.23 g Tris base (= 200 mM), 87.66 g NaCl (1.5 M) and 
10 ml Tween® 20 (1%) were added to 800 ml of distilled water. The solution was 
adjusted to pH 7.6 using concentrated HCl and diluted 1:10 to obtain 1x TBST 
10x TNE buffer: 15.76 g Tris (pH7.5), 3.7 g EDTA (5 mM) and 16.4 g NaCl (140 
mM) were dissolved in a final volume of 200 ml distilled water.  
2.2 Mice 
For all studies unless stated otherwise, wild type mice C57BL/6 were purchased 
from Harlan laboratories (Bichester, UK) and were given one week to acclimatise 
before any experimental procedures. Age and sex matched wild type (WT) and 
D6 deficient mice on a C57BL/6J (F11) background strain were bred in house for 
direct comparison studies. CCR2-null mice on a C57BL/6 background were kindly 
provided by Prof. Nibbs and originally purchased from Jackson laboratories 
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(Maine, USA). Both in-house bred and purchased mice were maintained at the 
University of Glasgow Central Research Facility (CRF) under specific pathogen 
free conditions and used between 8 and 12 weeks of age for all studies. All 
procedures were carried out in accordance with the United Kingdom Home 
Office regulations under the authority of the appropriate project and personal 
license. The group size of mice, used in each experiment, was selected based on 
previous studies to obtain statistical significance in accordance with the animals 
(Scientific Procedures) Act 1986, which has at its centre the ‘3Rs’concept: 
replacement, refinement and reduction.  
2.3 Viruses 
Virus stocks for Semliki Forest virus strain A7(74) and L10 were kindly provided 
by Prof. John Fazakerley (The Pirbright Institute, Pirbright, UK) and kept at         
-80°C. Both strains of SFV were stored at a stock concentration of 10x1010 
PFU/ml in PBSA.  West Nile virus (WNV) strain NY99 was stored and kept at the 
containment level 3 laboratory at the Animal Health and Veterinary Laboratory 
Agencies (AHVLA, Surrey, UK).  
2.4 Antibodies for flow cytometry 
Monoclonal antibodies, used for flow cytometry, were labelled with either 
Biotin, VioBlue (VB), fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), 
peridinin- chlorophyll-protein (PerCp), PE conjugated to cyanine 5.5 (PE-Cy5.5) 
or cyanine 7 (PE-Cy7), and allophycocyanin (APC) (Table 2.1). The antibodies 
against pDCA and CCR5 were biotinylated and therefore an additional incubation 
step with Streptavidin conjugated with the fluorochrome PE-Cy7 or APC was 
necessary for the detection of target cells. DRAQ7TM (Biostatus, Shepshed, UK), 
conjugated to APC-Cy7, is a fluorescent DNA dye, which was used to determine 
cell viability for all flow cytometry experiments. Cells infected with SFV L10 
strain were fixed and the fixable Viability Dye eFluor 780 (eBioscience, Hatfield, 
UK) was used to determine cell viability. 
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Table 2.1 List of antibodies and Streptavidin conjugates used for staining cells for flow 
cytometry 
 
  
Antibody Clone Isotype Dilution Source 
 
CD3e  145-2C11 armenian hamster 
IgG 
 1:40 eBioscience 
CD4 
 
GK1.5 rat IgG2b 1:140 eBioscience 
CD8a 
  
53-6.7 rat IgG2a 1:100 Biolegend 
CD11b  
 
M1/70 rat IgG2b 1:100 eBioscience 
CD11c N418 armenian hamster 
IgG 
1:200 eBioscience 
CD19  
 
1D3 rat IgG2a 1:140 BD Pharmingen 
CD44 
  
IM7 rat IgG2b 1:100 Biolegend 
CD45 
 
30-F11 rat IgG2b 1:100 BD Pharmingen 
CD62L  
 
MEL-14 rat IgG2a 1:140 eBioscience 
CD183 (CXCR3)  CXCR3-173 armenian hamster 
IgG 
1:100 eBioscience 
CD192 (CCR2) 475301 rat IgG2b  1:10 R&D systems 
 
CD194 (CCR4) 
   
2G12 armenian hamster 
IgG 
 1:40 
  
eBioscience 
 
CD195 (CCR5)  HM-CCR5-7A4 armenian hamster 
IgG 
 1:20 eBioscience 
CD335 (NKp46)  29A1.4 rat IgG2a  1:40 eBioscience 
F4/80  BM8 rat IgG2a 1:100 eBioscience 
Ly-6C  HK1.4 Rat IgG2c  1:80 eBioscience 
Ly-6G  
 
NK1.1 
 
1A8 
 
PK136 
rat IgG2a 
 
mouse IgG2a 
1:140 
 
 1:80 
BD Pharmingen 
 
eBioscience 
MHC-II (IA-IE) 
 
M5/114.15.2 rat IgG2b 1:140 eBioscience 
pDCA  
 
Streptavidin 
PE-Cy7 
 
Streptavidin APC 
JF05-1C2.4.1 
 
 
 
 
rat IgG2b  1:10 
 
1:100 
 
 
1:200 
Miltenyi 
 
BD Pharmingen 
 
 
eBioscience 
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2.5 Antibodies for immunohistochemistry (IHC) 
Purified monoclonal and polyclonal antibodies were used for formalin fixed and 
paraffin-embedded tissue sections. Antibodies to CCL2, Myeloperoxidase, NeuN 
and SFV nsp3 were polyclonal (Table 2.2).  
Table 2.2 Purified primary monoclonal and polyclonal antibodies used for 
immunohistochemistry 
Antibody Clone Isotype Dilution Source 
 
  CD3  
 
SP7 rabbit IgG 1:100 Vector laboratories 
CD45R/B220 RA3-6B2 rat IgG2a 1:500 Biolegend 
CD49b  DX5 rat IgM 1:100 Biolegend 
CCL2/JE/MCP-1 - goat IgG 1:50 R&D systems 
F4/80 Cl:A3-1 rat IgG2b 1:50 Serotec AbD 
Gr1 (Ly-6C/Ly-6G) 
 
MAC-2 
RB-8C5 
 
M3/38 
rat IgG2b 
 
rat IgG2a 
1:300 
 
1:500 
Biolegend 
 
Cedarlane 
Myeloperoxidase 
 
NeuN 
 
SFV nsp3 
 
- 
 
- 
rabbit IgG 
 
rabbit IgG 
 
rabbit IgG 
1:500 
 
1:500 
 
1:500 
DAKO 
 
Millipore 
 
kind gift from John 
Fazakerley (Pirbright 
Institute) 
 
Purified antibodies were detected using secondary antibodies conjugated to 
either biotin, fluorescein isothiocyanate (FITC), tetramethyl rhodamine 
isothiocyanate (TRITC) (Table 2.3). All secondary antibodies were used at a 
concentration of 5-10 µg/ml. Biotinylated secondary antibodies were then 
visualised by adding either Fluorescein or Texas Red Avidin D (Vector 
laboratories, Peterborough, UK) at a concentration of 10 µg/ml. Primary 
polyclonal rabbit antibodies were detected using the DAKO EnVision kit (DAKO, 
Ely, UK) as per manufacturer’s protocol. Reagents used for IHC are listed in 
Table 2.4. 
 
 
  
 Chapter 2. Materials and Methods 91 
 
   
Table 2.3 Secondary antibodies used for immunohistochemistry 
Antibody Dilution Source 
goat anti-rat IgG (H+L) Biotin 1:200 Vector laboratories 
goat anti-rat IgM TRITC 
 
goat anti-rabbit IgG (H+L) FITC 
 
1:200 
 
1:200 
Southern Biotech 
 
Southern Biotech 
horse anti-goat IgG (H+L) Biotin 
 
donkey anti-goat IgG (H+L) TRITC 
1:200 
 
 
1:200 
Vector laboratories 
 
Jackson Immuno Research 
laboratories 
 
 
Table 2.4 Serum and reagents used for immunohistochemistry 
Serum/Reagents  Source 
goat serum  Vector laboratories 
mouse serum  Invitrogen 
normal horse serum 
rabbit serum 
 
 
Vector laboratories 
Vector laboratories 
Fluorescein Avidin D 
DAB substrate kit for Peroxidase 
 
DAKO EnVision System-HRP (DAB) kit 
 
DAKO Proteinase K 
 
DAKO REAL™ Antibody Diluent 
 
ImmEdge™ Pen 
 
Texas Red Avidin D 
 
Tris buffered saline and Tween 20 
 
Vectashield® Hard Set Mounting Medium 
with DAPI 
 
Vectastain Elite ABC kit 
 
Vectastain Avidin/Biotin Block 
 
 Vector laboratories 
Vector laboratories 
DAKO 
 
DAKO 
 
DAKO 
 
Vector laboratories 
 
Vector laboratories 
 
Thermo scientific 
 
Vector laboratories 
 
 
Vector laboratories 
Vector laboratories 
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2.6 Primers for quantitative (Q)PCR 
All primers were synthesized by IDT (Leuven, Belgium) by standard DNA 
synthesis and desalted to remove small molecule impurities. Standard and 
QPCR primers (Tables 2.5-2.8) were resuspended in RNase free water to a 
concentration of 100 µM and then both, forward and reverse primers, were 
mixed 1:1 to obtain a final primer concentration of 50 µM. All primers in Tables 
2.5-2.8 are shown in the 5’-3’ orientation. Primers were designed using Primer3 
software (Whitehead Institute for Biomedical Research, Massachusetts, USA) as 
described in section 2.18.1. All primers were stored at -20°C once resuspended 
in water.  
2.7 Infection of mice with viruses 
For all in vivo experiments using Semliki Forest virus strain A7(74) or L10, 
intraperitoneal injections were conducted using 0.1 ml PBSA containing 5x103 
PFU SFV A7(74) or 2x105 PFU SFV L10. Mouse brains, spleens and serum were 
then collected at post infection days (PID) 3, 4, 5, 7 and 10.  
 
Trained staff of Prof Tony Fooks’s group at the Animal Health and Veterinary 
Laboratories Agency (AHVLA) carried out infections of mice with West Nile virus 
(WNV) in a containment level three laboratory. In brief, mice were 
anaesthetised with isoflurane and then inoculated intranasally with 105 PFU of 
WNV strain NY99 diluted in 50 µl serum-free Eagle’s minimal essential medium 
(EMEM) (Sigma). Brain tissue was harvested at PID 2, 4 and 6 for further analysis.  
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Table 2.5 Forward and reverse primers used for QPCR. All primers are in the 5’-3’ 
orientation.  
Gene  Primer sequence Product 
size 
Accession 
number 
 
CCBP2 (D6) 
 
forward 
reverse 
 
TTCTCCCACTGCTGCTTCAC 
TGCCATCTCAACATCACAGA 
 
93 
 
NM_001276719.1 
CCL2 forward 
reverse 
CTACCTGCTGCTACTCATTCA 
CCATTCCTTCTTGGGGTCA 
153 NM_011333.3 
CCL5 forward 
reverse 
CTGCTGCTTTGCCTACCTCT 
ACACACTTGGCGGTTCCTT 
124 NM_013653 
 
CCR2 forward 
reverse 
TGTGGGACAGAGGAAGTGG 
GGAGGCAGAAAATAGCAGCA 
 
130 NM_009915 
 
CD45 forward 
reverse 
CGCATCAGAAGGGGATAAAG 
TCCAGCAAAGAGCAACAGAA 
99 NM_001111316 
CX3CL1 forward 
reverse 
TCCTTGTGTCTCCTGGCTTT 
CGGTGTTGATGGTGATGGT 
125 NM_009142 
 
CXCL1 forward 
reverse 
GCTTGCCTTGACCCTGAA 
TGTCTTCTTTCTCCGTTACTTGG 
87 NM_008176 
 
CXCL10 forward 
reverse 
GCTCAAGTGGCTGGGATG 
GAGGACAAGGAGGGTGTGG 
111 NM_021274 
CXCR5 forward 
reverse 
CCTCTCCATCCACATCACCT 
AGTTTCCGCTTCGTTTTCCT 
148 NM_007551.2 
CXCR3 forward 
reverse 
AGTGCTTGTCCTCCTTGTAGT 
GGTGTTGTCCTTGTTGCTGA 
129 NM_009910.2 
GAPDH      forward 
reverse 
CAGCAAGGACACTGAGCAAG 
TATTATGGGGGTCTGGGATG 
93 NM_001001303 
 
IFN-alpha 4 forward 
reverse 
GCAATGACCTCCATCAGCA 
GTATGTCCTCACAGCCAGCA 
98 NM_010504 
 
 
IFN-beta 1 forward 
reverse 
CACAGCCCTCTCCATCAACT 
GCATCTTCTCCGTCATCTCC 
152 NM_010510 
 
IFN gamma forward 
reverse 
AGCAAGGCGAAAAAGGATG 
CTGGACCTGTGGGTTGTTG 
66 NM_008337  
 
IL-6 forward 
reverse 
TTCCATCCAGTTGCCTTCTT 
ATTTCCACGATTTCCCAGAG 
171 NM_031168  
 
IL-10 forward 
reverse 
CAACATACTGCTAACCGACTCCT 
TGGGGCATCACTTCTACCA 
105 NM_010548.1 
 
TBP forward 
reverse 
TGCTGTTGGTGATTGTTGGT 
AACTGGCTTGTGTGGGAAAG 
99 
 
NM_013684  
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Table 2.6 QPCR primer sequences for detecting viral gene targets 
 
Gene  Primer sequence Product 
size 
Accession 
number 
 
SFV E1 
 
forward 
reverse 
 
CGCATCACCTTCTTTTGTG 
CCAGACCACCCGAGATTTT 
 
173 
 
NC_003215 
 
SFV nsp3 forward 
reverse 
GCAAGAGGCAAACGAACAGA 
GGGAAAAGATGAGCAAACCA 
205 NC_003215 
 
WNV NS1 forward 
reverse 
GAACTCGCCAACAACACCTT 
ACCAAATCCAAAATCCTCCAC 
105 DQ211652 
 
 
 
Table 2.7 Standard primer sequences to detect viral gene targets 
 
Gene  Primer sequence Product size 
 
SFV E1 
 
forward 
reverse 
 
AAGTGAAGACAGCAGGTAAGGTG 
TATGAGTTGCCCCGAGTTTC 
 
 
 
446 
SFV nsp3 forward 
reverse 
  GCAATCCCTCAACCATCTATT 
  CCTTCTCGCACTTTACCTTCT 
 
556 
WNV NS1 
 
 
 
forward 
reverse 
 
  TGGAAATTGGCTGGAAGG 
  AGTTGTGTTGCTCTCTCTGACCT 
 
200 
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Table 2.8 Standard primers used to detect specific target gene. 
 
Gene      Primer sequence Product size 
CCL2 forward 
reverse 
CACCAGCACCAGCCAACT 
GCATCACAGTCCGAGTCACA 
 
519 
CCL5 forward 
reverse 
CCCTCACCATCATCCTCACT 
TCAGAATCAAGAAACCCTCTATCC 
 
280 
CCR2 
 
forward 
reverse 
AGGGGAGAGCAGAAGGCTAA 
CCCAGGAAGAGGTTGAGAGA 
 
212 
CD45 
 
forward 
reverse 
GGGTTGTTCTGTGCCTTGTT 
GCTGTCTTCCTGGGCTTTATT 
 
294 
CX3CL1 
 
forward 
reverse 
CTGCTGCTGGCTGGTTAGA 
TTTACAGGTGGGGCACTTTG 
 
473 
CXCL1 
 
forward 
reverse 
CTGGGATTCACCTCAAGAACA 
CTTTTCGCACAACACCCTTC 
 
469 
CXCL10 
 
forward 
reverse 
ATCCCTGCGAGCCTATCC 
AAACTTAGAACTGACGAGCCT 
 
524 
CXCR5 
 
forward 
reverse 
TCGCTCTGCACAAGATCAAT 
TAGAGGAAACGGGAGGTGAA 
 
289 
CXCR3 
 
forward 
reverse 
TGGGGTCTCTGTCTGCTCTT 
TTTGCCCTCTCCCTCTTCTCA 
 
889 
GAPDH 
 
forward 
reverse 
TGTCTCCTGCGACTTCAA 
TGCAGCGAACTTTATTGATG 
 
341 
IFN-alpha 4 forward 
reverse 
TGGCTAGGCTCTGTGCTTTC 
TCCAGAAAAGTCCTCTCC 
 
595 
 
IFN-beta 1 forward 
reverse 
GGCTTCCATCATGAACAACA 
TCCCACGTCAATCTTTCCTC 
 
399 
IFN gamma forward 
reverse 
ATCTGGAGGAACTGGCAAAA 
AGATACAACCCCGCAATCAC 
 
597 
IL-6 
 
forward 
reverse 
TCCAGAAACCGCTATGAAGT 
CTCCAGAAGACCAGAGGAAA 
 
370 
 
IL-10 
 
forward 
reverse 
ATGCTGCCTGCTCTTACTGAC 
TCACTCTTCACCTGCTCCACT 
 
414 
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 2.8 Tissue processing, embedding and sectioning 
2.8.1 Tissue processing 
SFV infected mice were euthanized in a carbon dioxide chamber and then 
perfused with 20 ml of cold PBS (Invitrogen). The brains were then removed 
from the skull and hemisected sagitally at the midsagittal plane into two halves. 
One half brain was immediately transferred into RNA later (Sigma) for gene 
expression analysis and stored at 4°C for up to 5 days. The other half brain was 
fixed in 4% paraformaldehyde (PFA) in 0.1 M PBS at 4°C for 24 hours for 
immunohistochemical analysis. For flow cytometry studies half brains were kept 
in Hank’s balanced salt solution (HBSS, Invitrogen). Fixed brains were then 
dehydrated using an automated tissue processor (Shandon Citadel 1000, Thermo 
Scientific, Loughborough, UK). For this, tissue sections were immersed in 
increasing concentrations of ethanol until dehydration was complete and then 
immersed in xylene before the tissue was finally infiltrated with the embedding 
medium paraffin wax (see details below). 
1. 70% Ethanol   1 hour 
2. 90% Ethanol   1 hour 
3. 95% Ethanol   1 hour 
4. 100% Ethanol   1x 1 hour, 1x 2 hours, 1x 2.5 hours 
5. Xylene    2x 1 hour and 1x 1.5 hours 
6. Molten paraffin wax  2x 4 hours at 60-65°C 
2.8.2 Tissue embedding 
After processing the tissue in the automated tissue processor, the samples were 
then placed into metal moulds and embedded in paraffin wax blocks 
(Histocenter 3, Thermo Scientific). The blocks were then cooled on an integral 
cold plate for several hours until the wax was set hard and stored at room 
temperature until sectioning. 
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2.8.3 Tissue sectioning 
Paraffin blocks were placed on crushed ice to harden the wax for better 
sectioning. Then, the brain sections were cut sagitally into 6-8 µm thick sections 
from lateral to medial on a microtome (Shandon Finesse 325, Thermo Scientific). 
Cut sections were floated onto a warm water bath set at 40°C to smooth out any 
creases and then lifted out onto charged poly-L-lysine coated glass slides (VWR, 
Lutterworth, UK). Next, the slides were placed on a histology hot plate 
(Raymond A Lamb Hotplate, Thermo Scientific) set at 55°C to allow the sections 
to dry for 1 hour. Once the sections were dried, slides were stored at room 
temperature until needed for staining. 
2.9 Haematoxylin and Eosin staining 
For basic histological examination of tissue, Haematoxylin and Eosin (H&E) 
staining was performed. Haematoxylin is a basic dye that forms a complex with 
metal cations like aluminium. The positively charged complex then reacts with 
negatively charged and basophilic cell components like nucleic acid in the 
nucleus and stains the nucleus blue as a result. Eosin is an acidic dye and is 
negatively charged. Subsequently it reacts with positively charged, acidophilic 
components of the cell like cytoplasm, intra- and extracellular matrix proteins 
and erythrocytes. The stain appears pink as a result.  At the beginning of the 
H&E staining, paraffin sections were first deparaffinized and then rehydrated by 
immersing slides in decreasing ethanol concentrations to prepare the tissue for 
the staining with water-soluble dyes. The steps are detailed below: 
1. Xylene    2x 3 min 
2. 100% Ethanol   2x 3min 
3. 95% Ethanol   2x 3min 
4. 90% Ethanol   3 min 
5. 70% Ethanol   3 min 
 
The sections were then rinsed in running tap water for 3 min and stained with 
Harris Haematoxylin (Cell Path, Newtown, UK) for 5 min. Excess stain was 
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removed by washing the slides under running tap water until the water ran 
clear. Next, the slides were immersed in 1% acid alcohol for a few seconds, 
quickly rinsed in running water and then placed in Scott’s tap water for 30 
seconds followed by rinsing slides again for a further 30 seconds. After staining 
with Haematoxylin and performing differentiation steps, the sections were 
finally counter-stained with 1% Eosin Y (Cell Path) for 2 minutes. To wash off 
excess stain, slides were washed under running tap water until the water ran 
clear. Stained sections were then dehydrated through a series of increasing 
ethanol concentrations and cleared in xylene before mounting sections with 
dibutyl phthalate xylene (DPX) mounting medium (Lyca Biosystems, Newcastle, 
UK). See details below: 
1. 70% Ethanol   30 s 
2. 90% Ethanol   30s 
3. 100% Ethanol   2x 1 min 
4. Xylene    2x 1 min 
5. DPX for mounting tissue sections 
 
Finally the coverslip was mounted over the tissue section using DPX mountant. 
Slides were allowed to dry for at least 1 hour before visualisation on the 
microscope. 
2.10 Immunohistochemistry 
2.10.1 Indirect immunostaining method 
Antibodies were detected using the indirect immunostaining method. This 
method is based on the use of labelled secondary antibodies which bind species 
specific primary antibodies (Fig. 2.1). Paraformaldehyde fixed, and paraffin 
embedded 6 µm thick brain sections were immersed in xylene for 2x 3 min to 
remove the wax and then dehydrated by incubating slides in a decreasing 
concentration of ethanol from 100% to 70% final concentration (as described in 
2.9). The slides were briefly washed in tap water for 5 min before proceeding to 
the antigen retrieval step. Fixation with either formalin or paraformaldehyde 
leads to cross-linking of amino acids of epitopes and subsequently leads to the 
 Chapter 2. Materials and Methods 99 
 
   
masking of the epitope of interest. Heat induced epitope retrieval (HIER) was 
used to reverse epitope masking and restore primary antibody binding capacity. 
For all immunohistochemical studies, 10 mM sodium citrate buffer at pH 6 was 
used except for staining using the primary antibody F4/80. In this case 
Proteinase K (DAKO) was used as a method of antigen retrieval instead of citrate 
buffer. For this, sections were incubated for 10 min at room temperature with 
Proteinase K and then briefly washed with TBST before proceeding to the next 
step. For antigen retrieval with citrate buffer, slides were transferred from 
water into hot (95°C) citrate buffer and boiled for 8 min on full power in the 
microwave. The slides were allowed to cool in the buffer and then briefly 
washed for 1 min with 1x Tris-buffered saline with 0.01% Tween 20 (TBST, 
Thermo Scientific). Brain sections were circled using the hydrophobic wax pen 
ImmEdge (DAKO).  
 
When biotinylated antibodies and streptavidin HRP were used, endogenous 
peroxidase activity was inhibited with 0.5% hydrogen peroxide (Sigma) in 
methanol for 30 min. Sections were then blocked with 20% horse serum 
containing 4 drops of Avidin block/ml (Vector laboratories). Next the blocking 
serum was quickly tapped off and primary antibody (see Table 2.2) was diluted 
in DAKO antibody diluent containing 2.5% normal horse serum, 2.5% mouse serum 
and 4 drops of Biotin block/ml (Vector laboratories) were added to each section, 
and incubated overnight at 4°C. The working concentration of primary antibodies 
was between 1-5 µg/ml unless stated otherwise.  
 
On the next day sections were incubated for 30 min at room temperature with 
either biotinylated or fluorochrome conjugated secondary antibody raised 
against the corresponding IgG (Table 2.3). Both types of secondary antibodies 
were used at a working concentration of 5-10 µg/ml. The fluorophore label was 
visualised directly on the microscope after mounting sections with Vectashield 
hard-set medium containing DAPI (Vector laboratories). A fluorescent 
microscope Axio Imager M2 (Carl Zeiss, Oberkochen, Germany) with Axiovision 
4.8 software (Carl Zeiss, Germany) was used for immunofluorescence 
microscopy. The biotin label was detected using streptavidin conjugated with a 
fluorophore like Fluorescein Avidin D or Texas Red Avidin D (Table 2.4). 
Fluorescein or Texas Red Avidin D were used at a concentration of 10 µg/ml and 
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diluted in PBS at pH 8. The slides were incubated for 40 min at room 
temperature before mounting the section with Vectashield hard-set mounting 
medium.  
 
 
Figure 2.1. Indirect immunostaining using two different antibodies.  
The primary antibody (blue) binds to antigen (AG). The secondary (red) antibody 
detects the primary antibody and is species specific, raised against the 
corresponding IgG. 
 
2.10.2 Immunofluorescence double staining 
For the detection of two antigens in paraffin fixed brain sections, an indirect 
staining method was used as described above. Primary antibodies raised in two 
different species were detected using fluorescently labelled secondary species 
specific antibodies. The staining was performed using both antibodies 
simultaneously. For antibodies raised in the same species the FITC antibody 
labelling kit was used to conjugate one of the primary antibodies directly to a 
fluorophore.  
2.10.3 Signal amplification using avidin/biotin complexes 
To enhance the sensitivity of low-density antigens (<10K molecules/cell) a signal 
amplification system was used. The ABC method is a patented procedure called 
the ‘preformed complex’ method developed by Vector laboratories. This method 
is based on high affinity of streptavidin for biotin. One mole avidin binds four 
moles of biotin. In the ABC method a preformed complex between avidin and 
biotin was added to biotinylated secondary antibodies using the Vectorstain Elite 
ABC kit according to the manufacturer’s instructions. Unoccupied biotin binding 
sites of the preformed avidin/biotin complex bind to the biotinylated secondary 
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antibody. This results in more enzyme attachment to the target than is possible 
using enzyme or fluorochrome labelled secondary antibodies alone.  
After incubation of slides with biotinylated secondary antibody, the sections 
were incubated with the avidin/biotin complex for 30 min before proceeding to 
the next step. The preformed complex was conjugated to HRP which was then 
visualised in the next step by adding 3,3'-diaminobenzidine (DAB) substrate to 
the samples. The sections were incubated for 3 min and the enzymatic reaction 
stopped with tap water. After washing the slides in tap water, all sections were 
then dehydrated through a series of increasing alcohol concentrations, as 
described in chapter 2.10, and mounted with mounting medium DPX (Leica 
Biosystems). Finally coverslips were carefully mounted on the DPX covered tissue 
sections and slides were allowed to dry for at least 1 hour before visualisation on 
the microscope. 
2.10.4 Signal amplification using chain polymer-conjugated 
technology 
A more potent amplification method is the chain polymer-conjugated technology 
(EnVision System) developed by DAKO cytomation (Fig. 2.2). This method is 
based on the use of an enzyme (HRP) labelled ‘spine’ molecule dextran. This 
molecule can bind up to ten molecules of antibody. Since this method does not 
use avidin and biotin, nonspecific background staining was eliminated. In this 
study three antibodies, CD3, Myeloperoxidase and SFV nsp3 viral protein, were 
detected using this method. All three antibodies were raised in rabbit. The HRP 
labelled polymer was detected using a 3,3'-diaminobenzidine (DAB) substrate-
chromogen which resulted in red/brown coloured staining of target cells. The 
detailed protocol is depicted below: 
1. Deparaffinize section in Xylene and rehydrate slides as detailed above                                                    
     through a series of decreasing Ethanol concentrations. 
2. TBST wash    5 min 
3. Antigen retrieval with Citrate buffer pH 6 for 8 min (see 2.10) 
4. TBST wash    5 min 
5. Peroxidase block    5 min 
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6. TBST wash    5 min 
7. primary antibody    45 min at room temperature   
8. TBST wash    5 min  
9. secondary antibody from kit           40 min at room temperature 
10. TBST wash    5 min 
11. DAB     up to 3 min until staining visible 
12. stop DAB reaction with tap water and dehydrate tissue sections as described    
       above. 
 
Figure 2.2. Chain polymer-conjugated technology (EnVision System) 
 
2.11 Isolation of mononuclear cells from the brain 
Half mouse brains from infected and healthy control mice were obtained as 
described in 2.8.1 and directly placed into ice-cold HBSS buffer. The brains were 
then finely minced with a scalpel and digested shaking on the Thermomixer 
Comfort (Eppendorf, Cambridge, UK) for 60 min at 37°C. Up to two brains were 
digested in 10 ml of digestion buffer containing 5U/ml DNase I (Sigma) and 0.08 
Wünsch units/ml Liberase TM research grade (Roche, Welwyn Garden City, UK). 
The digestion reaction was quenched with rinsing buffer containing 0.5% fetal 
calf serum (FCS) and the homogenized brains were passed through a 70 µm nylon 
cell strainer (BD Biosciences, Oxford, UK) to remove large tissue debris.  
The residual brain tissue that did not pass through was then mashed through the 
cell strainer with the back end of the plunger of a 5 ml syringe (BD Biosciences). 
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The brain cell suspension was then spun down twice at 300 g for 5 min at 4°C 
and the cell pellet was resuspended in Percoll (Sigma) and 1x HBSS to obtain 5-7 
ml of 30% (v/v) Percoll solution. After thorough mixing, the 30% Percoll cell 
suspension was underlayed with 5 ml of 70% (v/v) Percoll in 1x HBSS. The tubes 
were spun at 2000 g for 20 min at room temperature and leukocytes from the 
70%/30% interphase were collected and washed twice at 300 g for 5 min at 4°C 
with rinsing buffer before resuspending cells in ice cold FACS buffer. Cells were 
then counted using a haemocytometer and cell viability determined using 0.4% 
Trypan blue solution (Sigma). For flow cytometry, pooled cells were resuspended 
at a concentration of 5x 105-2x106 cells/ml in 100 µl FACS buffer. 
2.11.1 Isolation of mononuclear cells using Myelin removal 
beads 
As an alternative to the Percoll based method, mononuclear cells were isolated 
from mouse brains using the neural tissue dissociation kit with papain (Miltenyi, 
Bisley, UK) in combination with Myelin removal beads II (Miltenyi) according to 
the manufacturer’s instructions. In brief, brain tissue (up to 400 mg) was 
transferred into C-tubes (Miltenyi) and dissociated with a mix of enzyme 
solutions using the automated gentleMACS dissociator (Miltenyi), filtered through 
a 40 µm nylon cell strainer (BD Biosciences) and resuspended in 2 ml of FACS 
buffer. The brains were washed once more at 300 g for 5 min and then 
resuspended in 1.8 ml of FACS buffer. Following this, 200 µl Myelin removal 
beads II (Miltenyi) were added to each brain sample and incubated for 20 min at 
4°C. Next, cells were washed by adding 10x the labelling volume of FACS buffer 
(20 ml) and spun down at 300 g for 10 min. The supernatant was discarded and 
cells were resuspended in 2 ml FACS buffer. Depletion of magnetic labelled 
Myelin was performed on the autoMACS® Pro Separator (Miltenyi). After priming 
the instrument, tubes containing the sample were placed in row A, tubes 
containing the negative fraction in row B and tubes containing the positive 
fraction (labelled Myelin) in row C. For depletion the program ‘Deplete S’ was 
chosen on the machine and ran until the whole sample was processed. The 
negative fraction was used for further antibody labelling for flow cytometry. The 
positive fraction containing the Myelin was discarded. 
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2.12 Isolation of lymphocytes from spleen 
Spleens from mice were placed directly into ice-cold PBS for further processing. 
The spleens were transferred to a petri dish and splenocytes collected by cutting 
the spleen with a scalpel into half and squeezing cells out of the tissue with the 
back end of a plunger from a 5 ml syringe. Cells and spleen tissue fragments 
were then mashed through a 70 µm cell strainer (BD Biosciences), washed twice 
with RPMI (Sigma) and spun down at 300g for 5 min at 4°C. The cell pellet was 
treated with 2 ml of red cell lysis buffer (Miltenyi) for 10 min at room 
temperature. The cells were then spun down at 300g for 5 min and the pellet 
was checked visually for any remaining red cell debris. If the pellet still looked 
red, cells were treated once more with the red cell lysis buffer. Cells were 
finally resuspended in 1 ml FACS buffer and viable cells determined by staining 
with Trypan blue (Sigma) and then counted with a haemocytometer (Hawskley, 
Lansing, UK). Cells were resuspended at a final concentration of 3x106 cells/ml 
and kept on ice for further use.   
2.13 Processing of whole blood samples 
Blood was taken from mice by cardiac puncture and treated immediately with    
2 mM EDTA to prevent blood clotting. The blood was then spun down at 300 g for 
5 min and the supernatant (= plasma) was transferred to a fresh tube and frozen 
at -80°C for further analysis. If leukocytes were isolated from whole blood, the 
samples were treated with 2 ml red cell lysis buffer (Miltenyi) for 3 min at room 
temperature. Cells were spun down at 300 g for 5 min and resuspended in FACS 
buffer for flow cytometry analysis.  
2.14 Flow cytometry 
All flow cytometry studies were performed using 12x75 mm polystyrene tubes 
(BD Falcon). The resuspended cells (0.5- 2 x106 cells/tube) were incubated with 
Fc-receptor blocking reagent (Miltenyi) at a dilution of 1:20 for 10 min at 4°C to 
prevent non-specific binding through the Fc-receptor on antibodies. Cells were 
washed once with FACS buffer at 300 g for 5 min and then incubated with 
primary antibody (see Table 2.1) at a tested concentration for 15-20 min at 4°C 
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in the dark. Next, cells were washed twice with FACS buffer at 300g for 5 min 
each. 
For the use of biotinylated antibodies a further 10 min incubation step with 
fluorescently labelled streptavidin (Table 2.1) was necessary. Cells were 
resuspended in a final volume of 100 µl of FACS buffer for the final analyses. 
Shortly before data acquisition on the flow cytometer all samples were stained 
with 1 µl of DRAQ7 (Biostatus) to discriminate dead cells from viable cells. All 
data were acquired using a MACSQuant flow cytometer (Miltenyi) and analysed 
using FlowJo software (Tree Star Inc., Ashland, USA). Appropriate isotype and 
fluorescence minus one (FMO) controls were included in all studies. For brain 
samples a total of 5x105 cells were counted in each sample. 
2.15 RNA extraction from tissue  
Harvested mouse brains were stabilized in RNA later (Sigma) up to 5 days, to 
prevent RNA degradation. Each half brain was removed from RNA later and 
placed into a 2 ml microcentrifuge tube containing 1 ml of Trizol® reagent 
(Invitrogen). A 5 mm stainless steel bead (Qiagen, Manchester, UK) was added to 
each sample and brains were homogenized through high speed shaking at 50 Hz 
for 10 min using the TissueLyser LT machine (Qiagen). After homogenisation the 
samples were incubated for 5 min at room temperature to allow complete 
dissociation of tissue. Next, 0.2 ml of chloroform per 1 ml of Trizol was added to 
each sample which was then immediately shaken vigorously by hand.  
Samples were incubated for 2-3 min at room temperature and then centrifuged 
at 12 000 g for 15 min at 4°C for phase separation. Following this, three layers 
were formed: an upper aqueous layer containing RNA, an interphase/middle 
layer containing DNA and a lower red phenol-chloroform phase containing 
protein. Only the upper RNA containing aqueous layer was carefully transferred 
into a fresh 1.5 ml tube without disturbing the middle layer. Following this, an 
equal volume (approximately 550 µl) of 70% ethanol was added to each RNA 
sample (approximately 550 µl) to precipitate RNA. After mixing the samples by 
vortexing, total RNA was ‘cleaned’ up using the PureLink™ RNA Mini kit (Ambion, 
Life technologies), which can purify a maximum of 1 mg of RNA.  The RNA was 
bound, washed and eluted using Spin Cartridge columns according to the 
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manufacturer’s guidelines. Genomic DNA contamination was eliminated by 
performing an ‘on column’ DNase treatment with the PureLink® DNase. The 
DNase mixture (80 µl), containing 8 µl DNase reaction buffer, 10 µl DNase at a 
concentration of 3U/µl and 64 µl RNase free water, was added to each sample 
and incubated for 15 min at room temperature for ideal DNA digestion. 
Following this, the spin cartridge was washed with wash buffer I and II and 
eluted in 50 µl RNase free water. The final concentration of RNA was quantified 
using the NanoDrop 2000 spectrophotometer (Thermo Scientific) using 1 µl of 
RNA. RNase free water was used as a reference and to ‘blank’ the NanoDrop. 
The stock RNA was stored at -80°C until further use. 
2.15.1 Measurement of RNA quality and degradation 
RNA quality was determined using the Agilent 2100 Bioanalyser (Agilent 
Technologies, Cheshire, UK). With the Agilent RNA 6000 Nano kit (Agilent) a 
total of 25-500 ng/µl can be analysed. All West Nile virus infected RNA samples, 
used for TLDA, had a concentration of 194-430 ng/µl and all SFV infected RNA 
samples were diluted 1:10 with RNase free water to reach a concentration of 
100-200 ng/µl. The RNA quantity was determined and the RNA integrity number 
(RIN) calculated. The obtained RIN value allowed a numerical assessment of the 
RNA integrity and therefore a low RIN (<5) was considered as degraded RNA and 
a high RIN (>7) was considered as good quality RNA. RIN values of >8 were 
considered as high quality RNA (no degradation visible) and were used for 
subsequent TLDA analysis. In these samples two ribosomal RNA peaks, 18S and 
28S, were visible when analysing the electropherogram. 
2.16 Viral RNA extraction from serum and brain 
Serum and brain RNA samples from SFV infected mice were thawed. Viral RNA 
was extracted from brain and serum using the QIAamp viral RNA Mini kit 
(Qiagen). Carrier RNA was prepared at a concentration of 1 µg/ul in buffer AVE 
and aliquots were stored at -20°C. 2 µl of carrier RNA/AVE mix and 560 µl AVL 
buffer were used per 80-100 µl serum or brain sample. RNA was extracted 
according to the manufacturer’s guidelines and eluted in a final volume of 30 µl 
AVE buffer. Viral RNA was stored at -80°C and thawed only once.  
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2.17 cDNA synthesis 
Three different cDNA kits were used for the generation of cDNA from RNA 
samples. In early experiments the Quantitect Reverse transcription kit (Qiagen) 
was used. This kit consists of two steps: a genomic wipe-out step and the 
reverse transcription step using a mixture of random and oligo-dT primers 
according to the manufacturer’s instructions. In later experiments the 
Precision™ nanoscript Reverse Transcription kit (Primer design Ltd., 
Southampton, UK) was used to transcribe a total of 0.5-2 µg of RNA following the 
manufacturer’s guidelines. In the first step, the annealing step, RNase free 
water, oligo-dT and random nonamer primers were both added to each RNA 
sample to make up a final volume of 10 µl. The RNA was denatured in the PCR 
machine at 65°C for 5 min and then immediately cooled to 4°C until the master 
mix was added for the second step, the extension step. The master mix was 
made up as following: 
• nanoScript 10x buffer  2 µl 
• dNTP mix 10 mM each  1 µl 
• DTT 100 mM    2 µl 
• nanoScript enzyme   1 µl 
• RNase free water   4 µl 
 
For the –RT control addition of nanoScript enzyme was omitted. 10 µl of master 
mix was added to each sample on ice and samples then run on the PCR machine 
at the following conditions: 25°C for 5 min, 55°C for 20 min and 75°C for 15 min 
for heat inactivation. The cDNA samples (20 µl) were diluted with RNase free 
water 1:5, if total RNA was less than 3 µg, or 1:10, if total RNA used was more 
than 3µg. All cDNA samples were stored at -20°C until use.  
2.17.1 cDNA synthesis for TLDA and viral RNA samples 
For TaqMan low-density arrays (TLDAs), cDNA was synthesized using the High-
capacity RNA-to-cDNA kit (Applied Biosystems, Invitrogen) according to the 
manufacturer’s protocol. For all TLDA studies 1 µg of total RNA was used for the 
cDNA synthesis. A total volume of 20 µl cDNA per sample was stored undiluted at 
-20°C until use for TLDA studies.  Viral RNA was also transcribed into cDNA using 
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the High-capacity RNA-to-cDNA kit (Applied Biosystems, Invitrogen). For this, 9 
µl RNA and no RNase free water was used to set up the cDNA reaction. Undiluted 
cDNA was then diluted 1:10 for all samples and stored at -20°C.   
2.18 Quantitative (Q)PCR 
 Quantitative polymerase chain reaction (QPCR) or real time PCR is a method to 
assess quantitatively the number of transcripts in a sample by generating a 
standard curve and normalizing samples to a housekeeping gene, which has a 
high and stable expression in all tissues/cells. In all studies TATA-binding protein 
(TBP) was used as a housekeeping gene unless stated otherwise. The QPCR used 
in all studies is based on the SYBR Green method. SYBR green is a fluorescent 
DNA binding dye that binds double stranded DNA. Once SYBR green binds to DNA 
it emits a fluorescent signal that is directly proportional to the amount of 
transcript present in the tested sample.  
 
2.18.1 Primer design 
A set of ‘inner’ primers (QPCR primers) was designed to detect the gene of 
interest in the sample by QPCR using SYBR green (Tables 2.5 and 2.6). The set of 
‘outer’ primers were required for the generation of specific PCR products that 
act as standard templates and contain binding sites for the inner primers (Table 
2.7 and 2.8).  
All oligonucleotide primers were designed using Primer 3 software (available 
online at http://frodo.wi.mit.edu/). Primers were designed according to the 
following criteria: 
1. 18-23 base pair (bp) in length 
2. 40-65% GC content 
3. Tm (melting temperature of primers) between 59.5°C-61°C (60°C ideal) 
4. Maximum self complementarity = 2 and maximum 3’ self complementarity = 1 
5. Amplicon size for QPCR <150 bp 
6. no more than 4 G or C in a row 
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If no primers were suggested by the Primer3 software using the above-
mentioned parameters, the maximum self complementarity was increased from 
2 to 3 and the Tm was reduced to 59°C or the conditions were further relaxed 
until ‘inner’ primer pairs were suggested. The maximum 3’ self complementarity 
was not altered and remained 1 for all the primers designed. Outer primers were 
designed to amplify a region of the gene of interest where ‘inner’ primers could 
bind.  Therefore similar parameters as shown above were used for the design of 
‘outer’ primers but a higher self complementarity and a bigger product size of 
more than 150 bp was allowed.  To ensure specificity of primers, they were 
analysed using the BLAST analysis tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
2.18.2 Generation of DNA standards for absolute quantitative   
QPCR 
The generation of standard curves are necessary for quantifying the levels of 
gene expression of the unknown sample. Therefore a PCR product was generated 
by standard PCR using the ‘outer’ primer set (Tables 2.7 and 2.8). The standard 
PCR was performed using a ready-made master mix called red PCR master mix 
(Rovalab, Vh-bio, Gateshead, UK) containing 1.1x buffer, MgCl2, 1mM dNTPs and 
Taq DNA polymerase. To set up the PCR reaction, 45 µl of the Red PCR master 
mix, 4 µl of cDNA and 1 µl of primer mix (forward and reverse, 50 µM) were 
added into small 0.2 ml PCR tubes. PCR was performed on the Veriti™ thermal 
cycler machine (Applied Biosystems) at the following cycling conditions:  
1. 95°C    2 min 
2. 95°C   30 seconds 
3. 55°C*   30 seconds 
4. 68°C   1 min 
5. 68°C   10 min 
6. 4°C    until stored at -20°C in freezer 
* The annealing temperature was varied depending on the calculated Tm of the primer pairs 
The product generated was run on a 2% Agarose gel and visualized using 
ethidium bromide. A single band with a certain base pair size signifies that the 
 
x 35 cycles 
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standard PCR product has been amplified and can be used as a standard 
template for QPCR analysis. The sample was then purified using the QIAquick 
PCR purification kit (Qiagen) according to the manufacturer’s instruction and 
eluted in 30 µl of RNase free water. Next, the standards were 10 fold serially 
diluted. For the creation of a standard curve a range from 1x104 to 1x1010 fold 
dilution was used.  All samples should lie within the range of the standard curve 
to prevent erroneous results. Each of the standard dilutions was used as a 
template for QPCR. For relative expression the absolute copy number of the 
sample was compared to the absolute copy number of control samples and 
expressed as fold change. Each dilution was given an arbitrary copy number such 
as 106 copies for a dilution of 1x106.  
2.18.3 Calculation of the absolute copy numbers of standards 
The absolute level of transcripts of the standard can be calculated by measuring 
the optical density (OD) of the standard PCR products on a NanoDrop and by 
using a series of formulae: 
1) Calculate molecular weight (MW) of the standard (double stranded DNA): 
• Average molecular weight for a double stranded nucleotide= 660 Dalton 
• 660 Daltons x length of the standard in bp = MW of standard 
2) Calculate number of moles/µl: 
• Mass per µl/MW of DNA (=211,200) = Moles of standard/µl 
3) Convert Moles/µl into copy number: 
• 1 mole = 6.023 x 1023 molecules  (Avogadro’s constant) 
• Avogadro’s constant x Moles of standard/µl = Total copies/µl 
The number of total copies of standard/µl was then used to calculate the 
number of copies at each dilution of standards. The standard curve is essential 
to extrapolate the copy number of the gene of interest. 
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2.18.4 SYBR green QPCR 
Most QPCRs were performed using a 384 well plate containing a total of 10 µl of 
reaction volume. Each sample was analysed in triplicate on the QPCR machine. 
First a master mix was prepared for all samples containing per well: 
• 5 µl PerfeCTa SYBR green fast mix (Qanta Bioscience, Gaithersburg, MD, 
USA) 
• 0.3 µl ‘inner’ primer mix (each primer mixed at 50 pmol/µl) (Table 2.5 & 
2.6) 
• 4 µl nuclease free water (Ambion, Invitrogen) 
 
The master mix (9 µl) and 1 µl sample or standard cDNA was added to each well 
and spun down briefly for 1 min at 200 g to ensure that all reagents are at the 
bottom of the well. On each plate a non-template control with 1 µl RNase free 
water instead of cDNA, and a –RT control was added to determine the level of 
contamination with RNA or genomic DNA respectively. The plate was then run on 
the 7900HT QPCR machine (Applied Biosystems). The general QPCR conditions 
were:  
 
1. 94°C  10 min 
2. 94°C   3 s 
3. 60°C  30 s 
4. Dissociation step/Melting curve 
 
The melting curve is important to determine the specificity of the PCR primers. 
In some cases 96-well plates were used to analyse gene expression. In this case 
the amount of all reagents mentioned above were proportionally increased to 
reach a total volume of 20 µl per well. 96-well plates were run on the smaller 
7500 fast QPCR machine at the same conditions as mentioned above. The SDS 
software automatically created a threshold level of fluorescence that indicated 
exponential PCR amplification. The cycle value (= Ct value) was determined by 
the software, which calculated at which cycle number each sample crossed this 
specific threshold level. Using the Ct values, the software then calculated the 
absolute copy number on the basis of the standard curve. To prevent errors and 
x 40 cycles 
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to produce reliable results, the standard curve needed to have a coefficient of 
determination (R2) of more than 0.97 and a slope of 3.3. The slope means that 
the PCR product was amplified by a factor of 10 every 3.3 cycles and implies 
that the reaction was 100% efficient.  The formula for PCR efficiency is: 
10(-1/slope)-1 
 
2.18.5 Normalization of QPCR data 
The QPCR data obtained from all samples was then normalised using the 
housekeeping gene or ‘reference’ gene TBP. The housekeeping gene TBP is 
expressed in all cells. The amount of transcripts of the gene of interest can vary 
between samples due to RNA degradation, different amounts of RNA used in the 
cDNA synthesis or variations occurring during RNA extraction. The use of a 
housekeeping gene reduces this variation by normalizing samples. To calculate 
the absolute copy number of the sample, the estimated copy number of the 
target gene was divided through the copy number of the TBP gene. Since the 
values obtained were very low, all the samples were then multiplied by 104 or 
105, depending on how low the values were, and were denoted as copy number 
per 104 or 105 TBP.  
2.19 TaqMan low-density array (TLDA)  
TaqMan® low-density array microfluidic cards (Applied Biosystems) were 
designed using two different formats: 32 and 64 genes of interest.  The TLDA 
plates containing 32 genes contained probes for 17 chemokines of which the 
majority are typically classified as inflammatory chemokines. Additionally the 
plate also contained probes for IL-1β, TNF and type-I interferon which are 
inflammatory cytokines, and 3 anti-inflammatory cytokines (159). All chemokines 
and cytokines were selected based on publications investigating their role in 
inflammation in the mouse. The TLDA plate containing 64 genes contained 
probes for all murine chemokines with the exclusion of CCL10, CXCL4, CXCL7 and 
CXCL11 which have not been shown to be involved in viral inflammation. 
Additionally the plate also contained probes for 9, mostly inflammatory, 
cytokines, 4 pattern recognition factors, 2 transcriptions factors involved in the 
induction of interferon and 8 interferon inducible genes. These genes were, 
again, selected based on the literature of virus infection in mice infected with 
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WNV, Sinbis virus, LCMV, MHV, influenza and other viruses (71, 87, 359). Each 
TLDA plate contained two housekeeping genes, 18S, TBP and Eif3f, 18S for the 
32- and 64 gene plates, respectively. 
The Microfluidic card consisted of 384 wells which were preloaded with probes 
and primers for each gene (Appendix 1 A and B). Two or four samples were 
analysed per card containing 32 or 64 genes respectively and filled via a loading 
port. Into each loading port 100 µl reaction mix consisting of 2.5 µl cDNA (562 ng 
total RNA equivalent), 22.5 µl of RNase free water and 25 µl of 2× TaqMan 
Universal PCR Master Mix (Applied Biosystems) were added. The TaqMan array 
cards were run on a 7900HT fast real time machine for 40 cycles and data 
analysed using SDS 2.2 software and RQ Manager as per manufacturer’s 
instructions (Applied Biosystems). The relative amount of each target gene 
mRNA, was double normalized to an endogenous reference gene (18S) and 
healthy control sample (uninfected mouse brain) using the formula 2-ΔΔCT. On the 
TLDA plates containing 64 genes, the endogenous reference gene was Eif3f 
(eukaryotic translation initiation factor 3) because the Ct values of 18S were not 
consistent between samples.  
2.20 Measurement of chemokine levels in brains and 
serum of virally infected mice using ELISA 
2.20.1 Protein extraction from the brain 
Protein was extracted from virally infected brains by placing half mouse brains 
into 1 ml of T-Per tissue protein extraction reagent (Thermo Scientific) 
containing one complete mini EDTA free (Roche) tablet. Next, 5 mm stainless 
steel beads (Qiagen) were added to each sample and the brains were 
homogenized on the TissueLyser Lt (Qiagen) for 10 min at 50 Hz. The 
homogenized brains were then spun down at 16 000 g for 15 min. The interphase 
layer was transferred into a new 2 ml tube and samples stored at -80°C until 
further use.  
2.20.2 ELISA 
To measure chemokine levels of CXCL9 in the serum and brain of SFV infected 
mice, an Enzyme Linked Immunosorbent Assay (ELISA) was performed according 
 Chapter 2. Materials and Methods 114 
 
   
to the manufacturer’s instructions. 96 well microplates (Greiner Bio-One, 
Stonehouse, UK) were coated with 0.8 µg/ml capture antibody diluted in PBS 
and incubated overnight at 4°C. On the next day, plates were washed briefly 
with wash buffer containing 0.05% Tween® 20 in PBS (pH7.2-7.4), and then 
blocked with reagent diluent (R&D) containing 1% BSA in PBS for 1 hour at room 
temperature to prevent non-specific binding. In the meantime the standard 
solution was serially diluted 1:2 with reagent diluent seven times, starting from 
the top standard concentration at 1000 pg/ml. After blocking the plate, 100 µl 
of sample and standards were added to each well in duplicate and triplicate, 
respectively. The samples were diluted 1:2 and 1:5 with reagent diluent. The 
plate was covered and then incubated for two hours at room temperature. 
 Following incubation, the plates were washed two times with wash buffer and 
then incubated with 100 µl of detection antibody at 200 ng/ml for two hours at 
room temperature. After another two wash steps with wash buffer, the plates 
were then incubated with 100 µl of streptavidin-HRP (1:200 diluted) for 20 
minutes in the dark. The plates were washed again twice and 100 µl of substrate 
solution (R&D), containing tretramethylbenzidine in water, was added to each 
well and incubated for 20 min at room temperature in the dark. The reaction 
was stopped using 50 µl of stop solution (2N H2SO4) (R&D Systems) and the plate 
was read on the Tecan Sunrise™ microplate reader (Tecan, Maennedorf, 
Switzerland) set to 450 nm to measure optical density (OD). The wavelength 
correction was set to 540 nm to correct possible optical imperfections in the 
plate. Data were analysed using Magellan™ software (Tecan).   
2.21 Virus production and purification 
First 2x107 baby hamster kidney (BHK) cells in 100 ml of 10% complete GMEM 
were infected with SFV strain L10 at a multiplicity of infection (MOI) of 0.1. The 
MOI is the average number of virus infecting each cell and can be calculated 
from the plaque forming units (PFU) as follows:  
MOI= PFU of virus used for infection /number of cells 
Choosing a low MOI to grow virus in BHK cells reduces the production of 
defective virus particles. After infection of BHK cells with SFV L10 cells were 
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grown for approximately 3-4 days until the cells looked detached and dead. The 
supernatant was taken off and kept at 4°C until further use. 
Virus purification 
The BHK supernatant containing the virus was taken from the cold room and 
equally divided between two ‘buckets’ and spun down at 2,000 rpm for 30 min 
at 4°C to remove large cellular debris. The supernatant was then transferred to 
a fresh bottle and 23 g/l sodium chloride (NaCl) and 70 g/l polyethylene glycol 
(PEG) were added.  
The solution was then spun down at 8,000 rpm for 25 min to pull down PEG with 
attached virus. The supernatant was removed and the pellet was resuspended in 
10 ml of GMEM (Gibco, Invitrogen) and transferred into the centrifuge tube. The 
resuspended virus was then underlayed with 12 ml of 20% sucrose solution in 10x 
TNE buffer until two distinct layers were visible and topped with GMEM to equal 
the weight in all centrifuge tubes. Ultracentrifuges are extremely weight 
sensitive and therefore all buckets and centrifuge tubes were weighed before 
centrifugation. The tubes were then centrifuged at 25,000 rpm for 90 min at 4°C 
on the L8-70M Ultracentrifuge (Beckman, High Wycombe, UK). After the virus 
has been pulled through the sucrose cushion and was stuck on the bottom of the 
tube, the medium and sucrose was poured off and the sides of the tubes were 
dried with a paper towel. Following this, 400 µl of 1x TNE buffer was added to 
the tube containing the virus and incubated for 2 hours on ice. The solution was 
gently stirred every 30 min. After incubation, the solution was transferred into 
1.5 ml microcentrifuge tubes, frozen on dry ice and stored at -80°C until further 
use.  
2.22 Virus plaque assay 
On day one a 12-well plate was seeded with 3x105 BHK cells/well and 2 ml of 
10% GMEM was added into each well. The plate was incubated overnight until 
cells were 80% confluent.  
Next, a serial dilution at 1:2 of the virus stock starting from 1x10-2 until 1x10-10 
was prepared, using PBSA for the dilution. Following this, the supernatant of 
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BHK cells was removed and 200 µl of each dilution was added to each well in 
duplicate starting with the highest dilution (-2). The plate was incubated for 1 
hour at 37°C and gently shaken every 15 min. In the meantime 1.2% Avicell in 
water and 2% minimum essential medium (MEM) (Sigma) with 2% FBS, 1% L-
glutamine and HEPES buffer were prepared. Both solutions were mixed at a ratio 
of 1:1. After the incubation of the plates, the cells were covered with 3 ml of 
Avicell mix starting at the highest dilution. Once set, the plates were incubated 
at 37°C for at least three days.  
On day four, 3 ml of 10% formaldehyde was added to each well and incubated 
for 1 hour at room temperature. The formaldehyde was then removed and each 
well was covered with 0.1% Toluidine blue solution and incubated for 30 min. 
The Toluidine blue was removed and the plate was gently washed with water 
and left to dry. After drying plates, the plaques were counted and the dilution 
with only 2-70 plaques visible and calculated as follows: 
PFU/ml= average number of plaques (in duplicate)           
              amount of inoculum x dilution factor 
2.23 Administration of chemokine antagonists 
In this study four different chemokine antagonists were used (see below). The 
CCR2 (RS504393) and CCR5 (Maraviroc and DAPTA) blockers (Tocris Bioscience, 
Bristol, UK) and the CXCR3 blocker (compound 21) was a kind gift from Amgen 
Inc. (Thousand Oaks, CA, US).  
The CCR2 blocker, called RS504393, can be dissolved in DMSO up to 10 mM. 
Therefore 10 mg of blocker was dissolved in 4 ml to reach a final concentration 
of 2.5mg/ml. Mice were dosed twice orally with 5 mg/kg/day in PBS by oral 
gavage in a volume of 300 µl.  The blocker was administered to mice between 
PID 3-7 during SFV infection. Brains and serum were harvested on post infection 
day PID 7 for flow cytometry analysis, QPCR and ELISA. Control mice were also 
infected with SFV but were given PBS and DMSO (6.6% DMSO solution) only 
without CCR2 blocker. 
The CCR5 blocker Maraviroc was dissolved in 50% DMSO and PBS to a stock 
concentration of 10mg/ml. Mice were injected intraperitoneally (i.p) once daily 
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with 25 mg/kg/day of Maraviroc in PBS in a volume of 300 µl. The blocker was 
administered from PID 3-7. On PID7 brains and serum were harvested for further 
analysis.  Control mice were injected with 300 µl of DMSO in PBS only at the 
same concentration as the treatment group. The other CCR5 blocker D-ala-
peptide T-amide (DAPTA) was soluble to 1mg/ml in water. The mice were then 
injected subcutaneously (s.c) with 1 mg/kg once daily in a volume of 200 µl 
water. The control mice were injected s.c with water only. The blocker was 
administered from PID 3 until PID 7 like Maraviroc. 
Compound 21 (CXCR3 blocker) is a very organic compound and care had to be 
taken to dissolve the compound. First a stock solution was prepared by dissolving 
compound 21 in 100% DMSO to a concentration of 7.9 mg/ml. The stock solution 
was stored at -20°C for further use. 4 ml of the stock solution was then mixed 
with 2 ml of 50% PEG400 (Sigma) and 2 ml of water. The water was added very 
slowly to prevent the compound falling out of solution. Mice were injected s.c 
once daily at a concentration of 10 mg/kg. The treatment was administered to 
mice between PID 3-7 during SFV infection. Control mice were injected with 
DMSO, PEG400 and water only at the same concentration as the treatment 
group.  
2.24 Statistical analyses 
All data were analysed using the Prism 4 software (GraphPad, San Diego, CA, 
US). Results are shown as mean ± standard deviation (SD) unless stated 
otherwise. To determine if data were normally distributed a normality test was 
performed using the D’Agostino and Pearson omnibus K2 or Shapiro-Wilks test. 
Normally distributed data were analysed using the unpaired two-tailed student’s 
t-test if two groups were compared. If more than two groups were compared a 
One-way ANOVA or Two-way ANOVA was performed using the Tukey-Kramer, 
Bonferroni or Dunnett’s post-test If the data was nonparametric, a Mann-
Whitney U test or Kruskal Wallis test with a Dunn’s post test was performed. The 
figure legends indicate which statistical test was used for each graph. A p-value 
of <0.05 was considered as statistically significant and suggests that the null 
hypothesis can be rejected and the observed difference is not a consequence of 
random sampling. The sample size was determined based on previous studies.
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3.1 Introduction and aims 
Neurons are post-mitotic and mainly non-regenerating cells within the CNS and 
need a delicate and finely balanced environment to elicit their appropriate 
function. As a consequence, immune responses in the brain must be tightly 
controlled to maintain homeostasis and subsequently the brain is considered to 
be an ‘immune privileged’ site (93, 122); MHC-I expression, antibodies, 
complement and pro-inflammatory cytokines are generally absent and there are 
no lymphatic vessels within the CNS. Additionally there is a low abundance of 
leukocytes detectable in the CSF, mainly memory T-cells. Despite the ‘immune-
privilege’, resident and leukocyte derived microglia constantly exert immune-
surveillance to protect the brain from invading pathogens (384). 
Viruses are capable of invading the brain and often elicit life-threating CNS 
immune responses characterised by breakdown of the BBB and consequent 
leukocyte infiltration into the brain. As discussed in the introduction, 
chemokines are essential for controlling the migration and positioning of 
leukocytes and only a few chemokines, such as CX3CL1 and CXCL12, have been 
reported to be constitutively expressed in the healthy CNS (204). Viral infections 
of the CNS can trigger substantial chemokine expression by glia and neurons, 
although the function and relevance of chemokines in attracting antiviral 
leukocyte subsets into the CNS has yet to be fully elucidated (385, 386). A 
partial chemokine expression analysis in the virally infected CNS has only been 
conducted for LCMV and MHV infected mice but not in great detail (128, 129). In 
addition to that the expression of some of the inflammatory CC and CXC 
chemokines has also been investigated during WNV infection, and this is 
discussed in the introductory chapter 1.5 (197, 214). Depending on the virus or 
strain used, chemokine-mediated leukocyte influx into the infected CNS has 
been shown to be beneficial or detrimental for disease outcome (340, 356, 361). 
However to understand chemokine-mediated leukocyte migration into the CNS in 
greater detail, it was first necessary to establish a clearer picture of the 
expression of chemokines during viral encephalitis.  
Therefore the main aim of this chapter was to identify, in unprecedented 
detail, the form and magnitude of chemotactic cues expressed by the virus-
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infected brain. Developing a deeper understanding of this key aspect of the 
encephalitic process is central to our ability to therapeutically manipulate it.  
Furthermore the expression of cytokines and antiviral genes in the brain is also 
very important for initiating innate immune responses in the CNS, to rapidly 
clear virus from this delicate tissue. Therefore another aim was to identify 
cytokines and genes involved in innate immune responses during viral 
encephalitis.  
As a model of infection, Semliki Forest Virus (SFV) has been used for most of the 
studies in this thesis. The advantage of working with SFV is that it is a low-risk 
pathogen, which has been previously used in experimental systems in vitro and 
in vivo, to study the pathogenesis of neurotropic viruses (309, 378). SFV strains 
A7(74) and L10 have been used for all SFV studies, to determine whether varying 
degrees of virulence have an effect on the expression of chemokines and 
cytokines during viral encephalitis. The pathogenesis of viral encephalitis 
following infection with strain A7(74) has been well documented and is discussed 
in chapter 1.4 (293, 309, 378). However, symptoms arising during the virulent 
infection with L10 have not yet been documented. In this chapter, I additionally 
set out to describe, for the first time, neuropathological symptoms developing 
during L10 infection of mice. 
3.2 Determination of viral titers in the blood and brain 
during Semliki Forest virus infection   
Before defining levels of chemokine and cytokine expression in the brain during 
SFV infection, viral titers in the blood and brain were determined by QPCR, to 
test the efficiency of SFV as a model of viral encephalitis in C57BL/6 mice. 
Previous studies have reported that the blood brain barrier becomes leaky 
between days 4 and 10 after acute viral encephalitis (294, 305).  Since the focus 
of this study was to analyse chemokine expression and leukocyte infiltration 
during acute viral encephalitis, mice were infected with an i.p. inoculum of 
5x103 PFU with strains A7(74) or L10 as suggested by previous studies (298). 
While mice were successfully infected with A7(74) using this dose, L10 mice did 
not become ill as expected and previously described by Gates et al., where 
BALB/c mice succumbed to the disease on PID 4 (387). Subsequently the 
 Chapter 3. Characterization of chemokine and cytokine in CNS during SFV infection       121 
   
inoculation dose of L10 was increased to 5x104 and 2x105 PFU, and the majority 
of mice finally succumbed to lethal L10 infection between PID 5-6 using 2x105 
PFU (Fig. 3.1). Blood and brain samples were collected from A7(74) infected 
mice on PID 3, 4, 5, 7 and 10 and compared to healthy control samples. During 
L10 infection samples were taken from mice on PID 4, when mice were still 
asymptomatic, and between PID 5-6, when mice were terminally ill and were 
subsequently euthanized according to the Home Office regulations.   
 
Figure 3.1 Determining the dose of initial virus concentration of L10 for initiating 
lethal infection of mice 
Mice were infected with different doses of SFV strain L10 as indicated and survival was analysed. 
The experiment was terminated 14 days post infection. n=10 mice per group. 
 
To determine viral titers in the blood, plasma samples were tested for the 
presence of viral transcripts, measuring the expression of E1, a viral capsid 
protein of SFV. During A7(74) infection, viral titers in the plasma reached high 
levels by PID 3 and slowly decreased over time (Fig. 3.2 A). By PID 7 the virus 
was almost cleared from the plasma. During L10 infection the viral titer in the 
plasma attained higher levels reaching almost 1x108 E1 copies/ml plasma. In 
comparison to avirulent infection with SFV, during L10 infection, virus was not 
cleared from the plasma and the titer remained elevated until mice died or were 
terminally ill (Fig. 3.2 B).  
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Figure 3.2 Viral titers in the plasma of mice infected with SFV strain A7(74) or L10 
Mice were inoculated i.p. with 5000 or 2x106 PFU of SFV strain A7(74) or L10, respectively, and 
whole blood was collected on post infection day (PID) 3, 4, 5, 7 and 10. Viral gene transcripts for 
E1 in the plasma of mice were quantified by QPCR. (A) Viral titer in mice infected with strain 
A7(74) or (B) L10 with n=4-7 or n=3-4 mice, respectively, per time point. (Kruskal-Wallis test 
with Dunn’s post test; * p<0.05, *** p<0.001) 
 
In the brains of SFV A7(74) infected mice, viral copy numbers significantly 
increased over the time course of infection and seemed to peak on PID 7. On PID 
10, a slight but not significant reduction in viral copy numbers was observed 
(Fig. 3.3 A).  During L10 infection CNS viral E1 transcript levels were only slightly 
elevated on PID 4 but quickly increased to high levels by PID 5 or 6, when mice 
became terminally ill and had to be euthanized (Fig. 3.3 B). 
Thus, these results demonstrate that SFV A7(74) is cleared from the blood while 
simultaneously replicating to a high titer within the CNS. In the brain, the 
number of viral transcripts of SFV reached maximal levels on PID 7. By PID 10 
SFV titers slowly appeared to be decreasing. This is in line with findings from a 
previous study by Fazakerley et al., where they have shown that SFV cannot be 
detected by day 8 using a virus plaque assay and by day 14 using in-situ 
hybridisation (298). In contrast, virus RNA during SFV L10 infection was not 
reduced with the progression of the disease in the blood or the brain, and mice 
succumbed a few days post infection.  
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Figure 3.3   Viral titer in the brains of mice infected with SFV strain A7(74) or L10 
Mice were inoculated with 5000 or 2x106 PFU of SFV A7(74) or L10, respectively, and brains were 
collected on post infection day (PID) 3, 4, 5, 7 and 10. Viral gene transcripts for E1 were assayed 
by QPCR, and absolute copy numbers calculated and normalized to TATA binding protein (TBP). 
Each sample was tested in triplicate. (A) E1 gene transcripts during A7(74) and (B) L10 infection 
with n=6-7 mice and n=4-7 mice, respectively, per time point. (Kruskal-Wallis test with Dunn’s 
post test; * p<0.05, ** p<0.01, *** p<0.001) 
 
3.3 Neuropathology during avirulent and virulent SFV 
infection  
Having investigated viral titers during infection with avirulent and virulent 
strains of SFV, in the next experiment mice were examined for pathological 
changes in the brain. Firstly, mice were infected with SFV A7(74) or L10, and 
brains were collected for immunohistochemistry. Brains were fixed in 
paraformaldehyde, processed and embedded in paraffin before being cut into 6 
µm thick sections and stained for the viral non-structural protein 3 (nsp3).  
Infection of mice with SFV A7(74) does not induce any overt signs of disease in 
mice, but staining for viral nsp3 in the brains of infected mice revealed many 
perivascular foci, particularly around the hippocampus, striatum and frontal 
cortex (Fig. 3.4 A-E). The shape of infected neurons appeared normal throughout 
infection. The cerebellum contained fewer infected cells compared to other 
parts of the brain, and, on the basis of cell morphology and localisation of these 
cells, infection within this part of the brain appeared to affect mostly Purkinje 
neurons (Fig. 3.4 E).  
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The clinical picture of disease in L10 infected mice has not been documented in 
previous studies, and will briefly be described here. All the mice appeared to be 
healthy on PID 4 with no signs of disease but on PID 5-6 mice developed a sudden 
onset of the disease, and mice succumbed rapidly thereafter within a few hours. 
The typical signs of prolonged illness usually observed in sick mice, such as 
ruffled fur and weight loss, were not observed during L10 infection. Due to the 
sudden onset of the disease, mice were monitored every four hours to check 
their health status. Once the mice became sick, they often displayed severe 
neurological defects ranging from hind- or forelimb paralysis (Fig. 3.5 A-C), 
seizures, loss of orientation (Fig. 3.5 D), ataxia. One mouse also developed 
narcoleptic behaviour in so far as this mouse would constantly fall asleep while 
being fully active during the waking state.  The most common sign observed was 
hindlimb paralysis and only occasionally one of the other signs was observed. 
Histological examination of brains from terminally ill mice revealed extensive 
infection throughout the brain with perivascular foci and cuffings (Fig. 3.6 A-D).  
Taken together, infection with A7(74) is asymptomatic in mice, whereas 
infection with L10 results in the development of a severe neurological disease, 
which is rapidly fatal to mice. During both infections, viral proteins could be 
detected within the brain by immunohistochemistry, showing widespread 
infection within the parenchyma although the distribution of perivascular foci 
and infected neurons was wider during L10 infection compared with A7(74). 
Previous studies have also shown that the spinal cord is affected by SFV 
infection, which would explain the development of paralysis in a large number of 
these mice (378).  
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Figure 3.4 SFV nsp3 staining within mouse brains following infection with A7(74) 
C57BL/6 mice were infected i.p. with SFV A7(74) and brains were harvested on day 7. The brains 
were fixed in formalin, embedded in paraffin and cut into 6 µm thick sections. Brain sections 
were stained with anti-mouse SFV nsp3 antibody using the DAKO Envision system. Viral protein 
was detected throughout the brain. (A) Perivascular foci of SFV within the limbic system, and (B) 
staining with the appropriate isotype control, both at 5x magnification. (C) Uninfected control 
brain stained for nsp3. Magnification 5x. (D) SFV infected neurons in the brain, magnification 
40x. (E) Infected neuronal cells in the cerebellum and (F) in cortical areas of the brain. Both 
images were taken at 20x magnification. Images are representative of 7 mice per time point. 
Arrows indicate SFV infected neurons 
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Figure 3.5 Neuropathological changes in mice following infection with SFV using 
the virulent strain L10 
Mice were infected i.p. with SFV strain L10. Mice became ill between post infection days 5-6 and 
showed various neurological signs. (A) Mouse with complete or (B) partial hind limb paralysis. (C) 
Mouse with fore limb paralysis and (D) loss of orientation. Images are representative of 10 mice.  
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Figure 3.6 SFV nsp3 staining within L10 infected mouse brains 
C57BL/6 mice were infected i.p. with SFV L10 and brains were harvested from terminally ill mice 
(PID5-6). The brains were formalin-fixed, embedded in paraffin and cut into 6 µm thick sections. 
Brain sections were stained with anti-mouse SFV nsp3 antibody using the DAKO EnVision system. 
Viral protein was detected throughout the brain. (A, B and D) Infected cells within the limbic 
system and (C) in the cerebellum. Magnification at 20x (A and C) and 40x (B and D). 
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3.4 Assessment of RNA quality of mouse brains 
samples infected with SFV strain A7(74) or L10 
To test the brain samples from A7(74) or L10 infected mice by TLDA, the RNA 
quality was first assessed using the Agilent Bioanalyser. All RNA samples for 
chemokine expression analysis were of high quality displaying an RNA Integrity 
number (RIN) >8 (Fig. 3.7 and 3.8). The definition of the RIN value is explained 
in more detail in the Materials and Methods section 2.18.1. The 
electropherogram for each sample showed a distinct and clear 18S and 28S band, 
which, again, is an indicator of high quality RNA (Fig. 3.7 A and B, Fig. 3.8 A and 
B). RIN values for all A7(74) and L10 sample, analysed by TLDA, are shown in 
Appendix 2 A and B.  
 
Figure 3.7 Assessment of RNA quality isolated from mouse brains infected with SFV  
strain A7(74) 
Total RNA was isolated from healthy controls and SFV A7(74) infected brains over the time 
course of infection and the RNA quality was analysed using the Agilent Bioanalyser. (A) 
Representative gel-like image of total RNA isolated from murine brains. Lane L: size marker 
(nucleotides, nt); Lane 1-3: healthy control brains; Lane 4-5: brains from post infection day 3; 
The distinct ribosomal RNA bands 18S and 28S were observed for all samples. (B) 
Electropherograms are shown for all 5 samples. The x-axis represents the amplicon size (nt), 
while the y-axis represents fluorescence units (FU). The RNA integrity number (RIN) was 
calculated and is indicated on the left hand corner of each electropherogram. The larger 28S 
ribosomal peak closely follows the 18S peak. High RIN values, and distinct 18S and 28S ribosomal 
bands characterize high quality RNA.  
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Figure 3.8 Assessment of RNA quality isolated from L10 infected mouse brains 
Total RNA was isolated from healthy controls and SFV L10 infected brains over the time course of 
infection and the RNA quality was analysed using the Agilent Bioanalyser. (A) Representative gel-
like image of isolated RNA. Lane L: size marker (nucleotides, nt); Lane 1-6: samples from 
terminally ill mice displaying several different neurological symptoms; Lane 7-9: samples from 
infected mice before the onset of symptoms; Lane 10-12: healthy uninfected control samples. 
Distinct ribosomal RNA bands 18S and 28S were observed for all samples. (B) Representative 
electropherogram showing the RNA profile of a high quality RNA sample. The x-axis represents 
the amplicon size (nt), while the y-axis represents fluorescence units (FU). The RNA integrity 
number (RIN) was calculated and is indicated on the left hand corner of each electropherogram.  
3.5 Chemokine expression during avirulent infection 
with SFV A7(74) 
Having determined viral titers in the brain and blood, and characterised 
neuropathological changes during avirulent and virulent infection with SFV, the 
next goal was to examine chemokine expression during infection with the 
avirulent strain A7(74) and virulent strain L10. To identify the chemokine 
expression profile during A7(74) infection, mice were infected with the virus for 
10 days and brains were collected on PID 3, 4, 5, 7 and 10 to perform TaqMan 
low density array analysis (TLDA) and QPCR. For TLDA analysis, the microfluidic 
cards were first designed in the lab and finally manufactured by Applied 
Biosystems. A 384-well format was selected, containing 32 genes, including most 
inflammatory CC- and CXC- chemokines, CX3CL1, XCL1, and a few inflammatory 
cytokines and innate immune response genes, known to play a role during viral 
infections.  In Figure 3.9 and 3.11 only the most highly upregulated chemokines 
are shown. The fold change of other chemokines that are not or only minimally 
upregulated during SFV infection is presented in Appendix 3. TLDA results of 
cytokine and innate immune response gene expression are presented in section 
3.7. Similar to chemokines only a limited number of cytokines is shown in Fig. 
3.20. A detailed list of fold changes for each cytokine and other innate immune 
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genes is shown in Appendix 3. The table containing all genes selected for TLDA 
analysis of A7(74) samples is shown in Appendix 1A.  
3.5.1 CC-chemokine expression 
The results obtained from the TLDA analysis demonstrate that CCL2 and CCL5 
were the most upregulated CC-chemokines (Fig. 3.9), both being upregulated by 
more than 100-fold during viral encephalitis compared with an uninfected 
healthy control brain. The maximal upregulation was reached 7-10 days post 
infection. mRNA levels for CCL3, CCL4, CCL7 and CCL8 were significantly (t-test; 
p<0.01) upregulated on day 7, but the magnitude of expression was lower than 
that of CCL2 and CCL5. The expression of CCL11 was only minimally elevated 
during SFV infection (approximately 1.5-fold) compared with baseline but did 
not reach statistical significance. CCL20 was not up- or downregulated in 
response to viral infection and expression was similar to uninfected mouse brains 
(data not shown).  
 
Figure 3.9 CC-chemokine expression during viral infection of the brain with SFV 
A7(74) 
cDNA from high-quality RNA samples, isolated from infected mouse brains on post infection day 
(PID) 3, 4, 5, 7 and 10, was analysed for the expression levels of CC-chemokines using TLDA 
analysis. Samples from each time point (n=4-5 mice) were double normalized; firstly, to the 
housekeeping gene 18S and secondly, to an uninfected healthy control brain (mean relative 
quantification (RQ) value set to 1). The RQ values are depicted as mRNA fold changes, 
represented on the y-axis. Samples with a RQ values >1 signify upregulation of gene transcripts 
compared to the healthy control brain. Each sample was tested in triplicate. Data represent 
mean ± SD 
 Chapter 3. Characterization of chemokine and cytokine in CNS during SFV infection       131 
   
In general, the expression of all CC-chemokines on PID 3 and 4 was relatively 
similar to control brains (relative quantification (RQ) value =1). Most chemokines 
were maximally upregulated between PID 7 and 10, which coincided with high 
viral titers in the brain as illustrated in Fig. 3.3 A. 
 
 
Figure 3.10 Validation of TLDA results by QPCR for the genes CCL2 and CCL5 during 
SFV infection of the brain with A7(74) 
Two chemokines, CCL2 and CCL5, were highly upregulated during viral infection of the brain, 
and were validated by QPCR. The relative gene expression compared to uninfected control brains 
and normalised to TATA binding protein (TBP) is shown on the y-axis. (A) CCL2 expression by 
QPCR (left panel) and mRNA fold change compared to an uninfected control brain measured by 
TLDA (right panel). (B) CCL5 expression by QPCR (left panel) and fold changes evaluated by TLDA 
analysis (right panel). n=3 mice for QPCR and n=4-5 mice for TLDA analysis. Each sample was 
tested in triplicate. Data are presented as mean ± SD. PID= post infection day (Kruskal-Wallis 
test with Dunn’s post test; * p<0.05) 
The expression of CCL2 and CCL5 was most upregulated during SFV A7(74) 
infection compared to healthy control. A QPCR analysis was performed to 
validate the CCL2 and CCL5 upregulation in infected brains. CCL2 expression was 
significantly (p<0.05) upregulated on PID 7 compared with controls, before 
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decreasing by PID 10 (Fig. 3.10 A). This decrease was not statistically significant. 
CCL5 expression was significantly (p<0.05) upregulated by PID 10 compared to 
PID 3 samples (Fig. 3.10 B). Both results obtained by QPCR validate the TLDA 
results and confirm the strong upregulation of CCL2 and CCL5 expression in 
response to SFV A7(74) infection of the brain (Fig. 3.10). 
3.5.2 CXC-chemokine expression 
CXCL9 and CXCL10 were the most highly upregulated CXC-chemokines during 
A7(74) infection, increasing more than 300-fold and 500-fold, respectively, 
relative to a healthy uninfected control brain (Fig. 3.11 A). The maximal 
upregulation was obtained at 7 days post infection. The chemokine CXCL16 was 
also significantly upregulated during viral encephalitis, showing a 12-fold 
upregulation compared with healthy control mouse brains. CXCL1 was minimally 
elevated compared with baseline levels, but the mRNA fold change of CXCL1 
over the time course of infection was not significantly altered (p>0.05). The 
expression of the other CXC-chemokines CXCL2, CXCL3, CXCL5 were unchanged 
compared with healthy control brains, suggesting a minor involvement of these 
chemokines during SFV encephalitis.  
The ‘homeostatic’ chemokine CXCL12 has been reported to play a role in the 
maintenance and homeostasis of the blood-brain barrier (388). Disruption of the 
polarised expression of CXCL12 on the BBB during neuroinflammation has been 
shown to promote leukocyte infiltration into the CNS (389). Therefore the 
expression of CXCL12 was also examined by TLDA. The results show that CXCL12 
expression is downregulated in comparison to healthy control brains but this did 
not reach statistical significance (p>0.05) (Fig. 3.11 B). In general, maximal 
upregulation of all CXC-chemokines was seen by PID 7. CXCL9 and CXCL10 were 
upregulated very early during infection, being 5-10 fold upregulated by PID 3, 
although this was not statistically significant (Fig. 3.11 A).  
To examine, if the expression of the two major upregulated chemokines CXCL9 
and CXCL10, and CXCL1 is reproducibly elevated during SFV A7(74) infection 
relative to healthy uninfected control brains, a QPCR analysis was performed to 
validate the results obtained through TLDA analysis. Levels of CXCL9 expression 
were significantly (p<0.05) upregulated in the brain on PID 7, followed by a 
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decrease of expression on PID 10 (Fig. 3.12 A). CXCL9 protein levels were also 
significantly (p<0.01) upregulated in the blood on post infection day 5, and 
reached maximal levels at this time point (Fig. 3.12 B). 
CXCL10 transcripts were also significantly upregulated in the brain on PID 7 
(p<0.01) and 10 (p<0.05) compared to PID 3 samples (Fig. 3.13 A). CXCL1 was 
only minimally upregulated (<5 fold) in the brain during infection compared to 
an uninfected control brain using TLDA analysis. QPCR analysis confirmed that 
CXCL1 expression was not significantly different during avirulent infection 
compared with controls (Fig. 3.13 B). 
CXCR5 is commonly known to be mainly expressed on B-cells and binds to the 
ligand CXCL13 (390). The expression of CXCR5 was measured by QPCR only since 
this chemokine receptor was not included on the TLDA plates. It was found that 
CXCR5 is significantly upregulated on PID 7 and 10 (p<0.05), suggesting the 
possibility of B-cell infiltration into the virally infected brains at these two time 
points (Fig. 3.14).  
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Figure 3.11 Identification of CXC-chemokines upregulated during viral infection of 
the brain with SFV A7(74) 
RNA isolated from SFV infected brains was analysed for the expression of CXC chemokines by 
TLDA. Samples from each time point (n=4-5 mice) were double normalized; firstly, to the 
housekeeping gene 18S and secondly, to an uninfected healthy control brain (mean relative 
quantification (RQ) value set to 1). The y-axis represents fold changes of CXC chemokine 
expression compared to a healthy control brain. Samples with a RQ value >1 are upregulated, 
and RQ values <1 are downregulated compared to the uninfected control. (A) Upregulation of 
specific CXC-chemokines. (B) Fold change of CXCL12 over the time course of infection. Each 
sample was tested in triplicate. Data represent mean ± SD. PID=post infection day (Kruskal- 
Wallis test; * p<0.05, ** p<0.01) 
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Figure 3.12 Validation of CXCL9 expression by QPCR and concentration of CXCL9 in 
the plasma during SFV infection 
The relative expression of CXCL9 was validated by QPCR and compared to results obtained from 
TLDA analysis. (A) Relative expression of CXCL9 determined by QPCR (left panel) and fold 
increase of CXCL9 expression relative to an uninfected control brain measured by TLDA (right 
panel). Data represent mean ± SD, n=3 mice for QPCR and n=4-5 mice for TLDA analysis. Each 
sample was tested in triplicate. (B) Concentration of CXCL9 measured by ELISA. The results are 
representative of 5 mice per time point. Each sample was tested in duplicate. PID=post infection 
day ((A) Kruskal-Wallis test with Dunn’s post test and (B) One-way ANOVA with Tukey’s post test; 
* p<0.05, *** p<0.001) 
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Figure 3.13 Validation of TLDA results by QPCR for CXCL10 and CXCL1 expression 
during SFV infection of the brain with strain A7(74) 
The expression of CXCL10 and CXCL1 was validated by QPCR and compared to results obtained 
from TLDA analysis. (A) Relative expression of CXCL10 compared to uninfected controls 
determined by QPCR (left panel), and fold increase of CXCL10 expression relative to an 
uninfected control brain measured by TLDA (right panel). (B) Relative expression of CXCL1 
determined by QPCR (left panel) and fold change evaluated by TLDA (right panel). Data are 
presented as mean ± SD, n=3 mice for QPCR and n=4-5 mice for TLDA analysis. Each sample was 
tested in triplicate.  ((A) Kruskal-Wallis test with Dunn’s post test and (B) student’s t-test; * 
p<0.05, ** p<0.01) 
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Figure 3.14 Expression of the chemokine receptor CXCR5 in SFV A7(74) infected 
brains over time 
Absolute copy numbers of CXCR5 were measured by QPCR. Data were normalized to 1x 104 copies 
of TATA binding protein (TBP). Data represent means ± SD, n=3 mice per time point. PID= post 
infection day (Kruskal-Wallis test with Dunn’s post test; * p<0.05) 
3.5.3 CX3CL1 chemokine expression 
CX3CL1 is constitutively and highly expressed in the healthy CNS of mice. TLDA 
results reveal that the expression of CX3CL1 was not significantly altered during 
viral infection with SFV A7(74) compared with healthy uninfected mouse brains 
(Fig. 3.15 B). Validation by QPCR confirmed this result (Fig. 3.15 A). Generally, 
CX3CL1 is highly expressed in control and infected brain samples but there is no 
difference in expression between both groups during SFV driven viral 
encephalitis.  
 
Figure 3.15 Validation of CX3CL1 expression during SFV A7(74) infection   
Absolute copy numbers were calculated for the expression of (A) CX3CL1 and normalized to 1x 
104 copies of TATA binding protein (TBP). Samples from uninfected and infected mice from post 
infection day (PID) 7 were compared (n=3-4 mice). (B) The fold change of CX3CL1 over the time 
course of infection is shown relative to the expression of an uninfected control brain (measured 
by TLDA analysis). Results are shown as mean ± SD. (student’s t-test; not significant) 
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Taken together, these results demonstrate that chemokines are selectively 
upregulated during SFV A7(74) infection. Some chemokines were highly 
upregulated, including CCL2, CCL5, CXCL9 and CXCL10. The expression of some 
chemokines, including CCL11, CXCL12 and CX3CL1, was not significantly altered 
compared to uninfected healthy mouse brains, highlighting the differential 
expression of chemokines during viral encephalitis. Therefore, the expression 
profile of chemokines in the CNS, obtained during SFV infection, suggests that 
induction of chemokine expression after avirulent SFV infection is not a random 
process, but appears to be a relatively specific and selective process. I will next 
examined whether this is also the case during virulent infection with SFV using 
strain L10.  
3.6 Chemokine expression during virulent infection 
with SFV L10 
After inoculation of mice with L10, mice were monitored daily several times 
until the onset of neurological symptoms. As described above, mice became ill 
very suddenly and displayed severe neurological symptoms. To examine whether 
there is a difference in the magnitude and type of chemokines expressed before 
and after the onset of clinical signs, brains were collected from asymptomatic 
mice on PID 4 and from terminally ill mice, displaying severe neurological signs. 
The term asymptomatic was defined as the absence of any signs of illness or 
condition, and the term symptomatic was used for mice exhibiting signs of 
sickness. Signs of disease typically started between day 5 and 6 post infection. 
Once mice became severely ill, they were immediately euthanized in accordance 
with Home Office regulations.  
After testing the RNA quality, samples were analysed by TLDA for the expression 
of chemokines, cytokines, interferon stimulated genes (ISGs), pattern 
recognition factors (PRRs) and genes involved in innate immune responses. I first 
designed the TLDA plates and these were then manufactured by Applied 
Biosystems. A 384-well format was selected containing 64 genes, including all 
CC-, CXC, XC and CX3C chemokines, allowing a more comprehensive analysis of 
chemokines compared to section 3.5. A complete list of all 64 genes assayed by 
the second set of TLDA analyses is shown in Appendix 1 B.  
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3.6.1 CC-chemokine expression 
TLDA analysis revealed that the expression levels of CCL2, CCL5 and CCL7 were 
more than 1000-fold upregulated following L10 infection, and the levels of CCL3, 
CCL4, CCL8 and CCL12 were approximately 100-600 fold upregulated relative to 
an uninfected healthy control mouse brain (RQ value set to 1) (Fig. 3.16 A). 
Chemokine expression CCL21-CCL28 was either downregulated or unchanged 
relative to the healthy controls (Fig. 3.16 B). When comparing asymptomatic and 
symptomatic mice, the magnitude of CC-chemokine expression was always more 
up- or downregulated in brains of terminally ill mice except for CCL26 
(unchanged expression). There was a significant difference in expression 
between symptomatic and asymptomatic mice for CCL1-CCL5, CCL11, CCL24 and 
CCL27 (Fig. 3.16 A and B).  
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Figure 3.16 Identification of the CC-chemokine expression profile during viral 
encephalitis at different stages of disease severity 
All mice were inoculated i.p. with L10, and RNA was isolated from infected brains shortly before 
the onset of symptoms and at the end stage of the disease (between PID 5-6). The expression of 
(A) CCL1-12 and (B) CCL17-CCL28 was measured by TLDA. All samples were normalized to an 
endogenous control Eif3f and calibrated against an uninfected control brain (relative 
quantification value (RQ) =1). The fold increases or decreases are depicted on the y-axis. Data 
are shown as mean ± SD, n=3-6 mice per group. Each sample was tested in triplicate. (Student’s 
t-test; * p<0.05) 
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3.6.2 CXC-chemokine expression 
The biggest changes in CXC-chemokines were CXCL2, CXCL9 and CXCL10, which 
were more than 2000 fold upregulated (Fig. 3.17 A). The expression of CXCL1, 
CXCL3, CXCL13 and CXCL17 was approximately 100-300 fold upregulated during 
L10 infection. The expression of some chemokines such as CXCL5, CXCL12, 
CXCL14 and CXCL15 was not significantly altered and expression was similar to 
healthy control brains. The comparison between asymptomatic and symptomatic 
infection of mice revealed that the magnitude of expression was many fold 
higher during symptomatic infection. In particular, there was a significant 
difference in expression between asymptomatic and symptomatic mice for 
CXCL1-3, CXCL9, CXCL10 and CXCL16 (Fig. 3.17 A). For instance, CXCL10 
expression in symptomatic mice was 2800 fold upregulated compared to 
baseline, whereas in asymptomatic mice, CXCL10 was only 88-fold upregulated 
compared to healthy control mice. This amounted to an approximately 30-fold 
difference between the two groups.  
Validation by QPCR showed that the baseline level of CXCL10 expression in 
control mice is relatively high, with more than 100 mRNA copies per 1x104 TBP. 
The expression levels of CXCL10 in terminally ill mice were significantly 
increased compared to baseline levels with more than 10,000 copies per 1x104 
TBP (Fig. 3.17 B). QPCR also confirmed the significant increase in CXCL1 
expression levels  compared to controls (Fig. 3.17 C).  
3.6.3 CX3CL1- and XCL1-chemokine expression  
Due to the constitutive and high expression of CX3CL1 in the brain, the 
expression of CX3CL1 expression was also measured by TLDA. The results 
demonstrate that CX3CL1 expression levels were not significantly altered during 
viral infection with L10 compared with healthy uninfected mouse brains (Fig. 
3.18). The expression of the chemokine XCL1 was approximately 10-fold and 4-
fold upregulated during symptomatic and asymptomatic infection with L10, 
respectively (Fig. 3.18). However this result was not statistically significant. 
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Figure 3.17 Identification of the CXC-chemokine expression profile during viral 
encephalitis at different stages of disease severity 
All mice were inoculated i.p. with L10, and RNA was isolated from infected brains shortly before 
the onset of symptoms and at the end stage of the disease (between PID 5-6). (A) The expression 
of CXCL1-CXCL17 was measured by TLDA. All samples were normalized to an endogenous control 
Eif3f and calibrated against an uninfected control brain (relative quantification (RQ) value=1). 
The fold increases or decreases are depicted on the y-axis. Validation of (B) CXCL10 and (C) 
CXCL1 expression by QPCR. The copy numbers of each gene were normalized to TATA binding 
protein (TBP). All data are shown as mean ± SD, n=3-6 mice per group. Each sample was tested 
in triplicate. (TLDA samples: Student’s t-test; * p<0.05; QPCR samples: Kruskal-Wallis test; * 
p<0.05) 
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Figure 3.18 Expression of CX3CL1 and XCL1 during L10 infection of the brain  
All mice were inoculated i.p. with L10 and RNA was isolated from infected brains shortly before 
the onset of symptoms and at the end stage of the disease (between PID 5-6). The fold increase 
of CX3CL1 and XCL1 expression relative to an uninfected control brain was measured by TLDA and 
normalized to an endogenous control Eif3f. Each sample was tested in triplicate and data are 
represented as mean ± SD, n=3-6 mice/group. 
 
3.6.4 Summary of chemokine expression resulting from 
avirulent and virulent SFV infection of the brain using 
strains A7(74) and L10 
In order to determine the key chemokines upregulated during viral encephalitis 
with SFV, the chemokine patterns of CC- and CXC-chemokines during avirulent 
and virulent infection were compared although experiments were not performed 
simultaneously. A comparison of all gene fold changes in the CNS of SFV A7/74 
and L10 infected mice are depicted in Appendix 3. The results, obtained by 
TLDA, showed that the expression pattern of CC- and CXC-chemokines was 
somewhat similar between A7(74) and L10 infection, but the magnitude of 
upregulation in L10 infected brains was generally much higher. For instance the 
most upregulated chemokine during A7(74) infection was CXCL10, with an 
approximate 500-fold upregulation of transcripts compared to an uninfected 
healthy control brain. During L10 infection, CXCL10 was 2800 fold upregulated, 
amounting to a 5.6-fold increase compared to A7(74) infected brains. A key 
difference between A7(74) and L10 infection is the high upregulation of CXCL1 
and CXCL2 in L10 infected brains, which were not, or only minimally (p>0.05), 
upregulated during avirulent infection with SFV. In general, there was a 
significant difference between A7(74) and L10 infection with regards to gene 
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expression levels of CCL2, CCL5, CXCL1, CXCL9 and CXCL10. All chemokines 
tested were many fold more strongly upregulated during L10 infection (Fig. 3.19 
A and B).  
Overall, the results in this chapter demonstrate that chemokines are selectively 
upregulated during CNS infection with SFV. The magnitude of expression is 
dependent on the virus strain and disease severity. Virulent infection of the 
brain induces a substantially more robust, comprehensive and rapid induction of 
chemokines than observed with the avirulent A7(74) strain. During L10 infection 
the chemokine expression varied with disease progression. Asymptomatic 
infection by L10 induced much weaker upregulation of chemokines. Key 
chemokines identified during SFV encephalitis were CCL2, CCL5, CXCL9 and 
CXCL10, which were all highly upregulated during infection. Additionally the 
expression of CCL20, CXCL1, CXCL2 and CXCL3 were only associated with 
symptomatic L10 encephalitis. CXCL1-CXCL3 are known to be chemoattractant 
for neutrophils. The implications of these results will be discussed in further 
detail in the discussion (section 3.8).  
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Figure 3.19 Comparison of chemokine expression between avirulent and virulent 
infection of the brain 
Mice were infected with SFV using the strain A7(74) or L10. Mouse brains infected with A7(74) on 
post infection day (PID) 7 were compared to brains collected from L10 infected mice at the end 
stage of disease (between PID 5-6). Chemokine expression was measured by TLDA and double 
normalized to an endogenous control Eif3f and an uninfected control brain (relative 
quantification value=1). The y-axis represents fold changes of gene expression (values>1 
upregulation, values<1 downregulation). Each column represents the mean ± SD, n=5 for A7(74) 
group and n=6 for L10 group. Each sample was tested in triplicate. (Student’s t-test; * p<0.05) 
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3.7 Expression of cytokines and genes involved in 
innate immune responses to viral infection during 
SFV encephalitis 
After the characterisation of chemokines upregulated during infection with SFV, 
the expression of cytokines, PRRs, ISGs and other genes, involved in innate 
immunity, were determined following infection with A7(74) and L10 strains. 
These genes have been shown to be pivotal for virus clearance, such as IFNs, and 
induction of innate immune responses by PRRs (10, 53). Additionally ISGs are 
induced in the presence of IFN and are also important for effective innate 
immune responses to viral infections (70). Studies using WNV or other 
encephalitic viruses have shown that cytokines, PRRs and ISGs are highly induced 
during viral infection and are important for disease outcome (130, 391). Here I 
wanted to test whether these genes are also induced during avirulent and 
virulent SFV encephalitis. 
3.7.1 A7(74) infection 
Mice were infected with SFV A7(74) for 10 days and brains were collected on PID 
3, 4, 5, 7 and 10 and from controls. Brains were analysed for the expression of 
inflammatory cytokines, retinoic acid-inducible gene (RIG)-I and interferon 
regulatory factor (IRF) 7. RIG-I and IRF7 have been shown to be important for 
the induction of antiviral immune responses such as the production of interferon 
and proinflammatory cytokines (e.g. IL-1β, TNF) after recognition of virus (392, 
393). Amongst cytokines, the expression of most IFNs (α, β, γ, ε and κ), TNF, IL-
1β, IL-6 and IL-10 were examined during SFV infection. In particular IFNs have 
been reported to play a major role during viral infections and are critically 
important for effective antiviral immune responses (394-396). All probes and 
primers for these selected cytokines and innate immune genes were included on 
the customised TLDA plates, used previously for the analysis of chemokine 
expression (see section 3.4). 
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Figure 3.20 Expression of genes involved in innate immunity during viral brain 
infection with SFV A7(74) 
Mice were infected with SFV A7(74) and brains were collected on post infection day (PID) 3,4, 5, 
7 and 10. (A and B) The expression of gene transcripts was measured by TLDA, and normalized to 
an endogenous control 18S and uninfected control brain (relative quantification (RQ) value=1). 
The fold increase is depicted on the y-axis. A Kruskal-Wallis test was performed; overall 
significance is shown as * p<0.05 and ** p<0.01. (C) Absolute copy numbers of IFN-α, β and γ were 
normalized to TATA binding protein (TBP). A One-Way ANOVA with Tukey’s post test was 
performed for IFN-α samples, and a Mann-Whitney U test was performed for IFN-β and γ samples. 
All results represent n=4-5 mice per time point. Data are shown as mean ± SD. Each gene was 
tested in triplicate. 
The genes RIG-I and IRF7 were both upregulated during A7(74) infection with 
IRF7 reaching an approximately 32-fold upregulation relative to uninfected 
mouse brains (Fig. 3.20 A). TNF was significantly (p<0.01) upregulated over the 
time course of infection, peaking on PID 7. On PID 7 a 60-fold upregulation was 
reached compared to an uninfected control brain. IL-1β expression increased 
significantly (p<0.05) on PID 7 relative to a control mouse brain. IL-6 and IFN-κ 
were not significantly upregulated, and expression was similar to that in control 
brains (Fig. 3.20 B). The cytokines IL-10 and IFN-ε were not altered during SFV 
infection. Unfortunately the expression of IFN-α, -β and  -γ could not be 
evaluated by TLDA because the expression of these IFNs was too low in control 
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samples and resulted in a RQ value of zero. Therefore a comparison of IFN 
expression between control and SFV infected samples was not possible. To this 
end, the expression was assessed by QPCR (Fig. 3.20 C). IFN expression was 
uniformly low in all control samples with less than 10 copies per 1x104 TBP. The 
maximal expression of IFNs was reached on PID 7 and was significantly different 
to control samples (IFN-α: p<0.01; IFN-β and IFN-γ: p<0.05).  On PID7 the 
expression of IFN-α was 4-fold, IFN-β 22-fold and IFN-γ 52 fold upregulated 
compared with healthy control samples. 
3.7.2 L10 infection 
The expression of cytokines, PRRs and ISGs was also determined by TLDA for L10 
infected brains in asymptomatic and symptomatic mice. Within the PRR group, 
expression levels of MDA-5 and RIG-I were more than 100-fold upregulated during 
symptomatic infection compared to an uninfected control brain (Fig. 3.21 A). 
Interestingly, TLRs, known to play a major role in pathogen recognition, were 
only less than 10-fold upregulated relative to controls during asymptomatic and 
symptomatic L10 infection. In symptomatic mice all ISGs were more than 10-fold 
upregulated, except TLR7 (Fig. 3.21 A). All PRRs and ISGs were statistically 
significantly different, when comparing asymptomatic with symptomatic mouse 
brains, with the exception of TLR7 again.  
Within the cytokine group, type-I and type-II interferons were more than 1000-
fold upregulated compared to levels in healthy control brains during 
symptomatic stages of L10 infection. Additionally, the expression of TNF was 
1636-fold and 20-fold upregulated during symptomatic and asymptomatic stages 
of L10 infection, respectively, compared to resting levels. Neither IL-4 nor 
transforming growth factor β (TGF-β) expression levels were significantly 
upregulated, compared to expression levels in a healthy control brain. When 
comparing asymptomatic with symptomatic mice, cytokine expression was 
always higher in samples from symptomatic mice and reached statistical 
significance in most of the cases (Fig. 3.21 B).  
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Figure 3.21 Expression of genes involved in innate immunity during viral brain 
infection with SFV L10 
Brains from L10 infected mice were collected shortly before the onset of disease (PID 4) and at 
the end stage of disease, accompanied with severe neurological symptoms. (A) Fold change of 
interferon-stimulated genes and pattern-recognition factors, and (B) cytokines, relative to an 
uninfected control brain (relative quantification value=1) and normalized to an endogenous gene 
Eif3f, were measured by TLDA. Representative results of n=3-6 mice per group. Each gene was 
tested in triplicate. Results are shown as mean ± SD. (Student’s t-test; * p<0.05, ** p<0.01) 
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3.7.3 Expression of CD45 during A7(74) and L10 infection 
In addition to determining the expression of cytokines and innate immune genes 
during SFV infection, the expression of the pan-leukocyte marker CD45 was also 
assessed by TLDA and QPCR, to evaluate the extent of leukocyte infiltration into 
the CNS.  During A7(74) infection upregulation of transcript levels started 
between PID 5 and PID 7, reaching maximal upregulation (7-fold) by PID 7 (Fig. 
3.22 A).  Validation by QPCR confirmed that the expression of CD45 was maximal 
on PID 7 (Fig. 3.22 B). The expression of CD45 on PID 7 was highly significantly 
upregulated compared to controls (p<0.01). Between PID 3 and PID 5, expression 
of CD45 was unaltered and comparable to healthy control mouse brains. The 
maximal expression of CD45 was reached on PID 7 and was significantly 
increased (p<0.001) compared to controls.  
For studies involving L10 infection CD45 expression was only assessed by QPCR 
because the CD45 gene was not part of the panel of genes, selected for TLDA 
analysis. CD45 was significantly (p<0.01) higher in asymptomatic mice compared 
to healthy controls (Fig. 3.22 C). Asymptomatic mice also displayed a higher 
CD45 expression compared to controls but the result did not reach statistical 
significance (p>0.05).  
Taken together, the results presented in this chapter demonstrate that cytokines 
and innate immune genes are selectively upregulated during viral infection. 
Compared to chemokine expression, shown in section 3.4 and 3.5, the expression 
of cytokines and innate immune genes was generally lower. Major cytokines 
upregulated during SFV infection were type-I and type-II IFNs and TNF. CD45 was 
consistently and significantly (p<0.05), upregulated by PID 7 suggesting 
infiltration of CD45+ leukocytes into the CNS. The infiltration of leukocytes into 
the CNS will be examined in great detail in chapter 4.  
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Figure 3.22 Expression of CD45 during viral infection of the brain with SFV 
(A and B) Mice were infected with A7(74) and brains collected over the time course of infection. 
Isolated RNA was analysed for the expression of CD45. (A) TLDA analysis of relative CD45 
expression over time of infection. Each sample (n=4-5 mice per time point) was double 
normalized to an endogenous control 18S and uninfected control brain (relative quantification 
value=1). Values >1 signify upregulation. Overall significance was determined using the Kruskal-
Wallis test; * p<0.05. (B) Absolute copy numbers of CD45 were measured by QPCR and normalised 
to TATA binding protein (TBP). (C) Mice were infected with L10 and brains collected before and 
after the onset of symptoms. The absolute copy number of CD45 transcripts was measured by 
QPCR and normalized to TBP. Representative results of n=3-6 mice per group. Data shown as 
mean ± SD. Each sample was tested in triplicate. (Kruskal-Wallis test with Dunn’s post test; * 
p<0.05, ** p<0.01) 
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3.8 Discussion and summary 
First, a model for SFV infection in C57BL/6 mice was established using avirulent 
and virulent strains. Infection of mice using both viral strains was successful and 
mice developed viral encephalitis similar to that described by Fazakerley et al. 
(298). Previous studies suggested using a dose of 5x104 PFU/ml of avirulent or 
virulent SFV strains for inoculation of BALB/c mice (298, 387). While this dose 
worked well for infection of C57BL/6 mice with A7(74), the dose had to be 
optimised for L10 infection as the C57BL/6 mice were not getting sick at the 
given dose. A 40-fold higher concentration of L10 was inoculated i.p. to induce 
sickness in the majority of C57BL/6 mice. From this it is possible that C57BL/6 
mice are less susceptible to L10 infection than BALB/c mice. In support of this, 
previous studies by Reiner et al. and Liu et al. have shown that the two mouse 
strains have different immune responses to pathogenic agents due to their 
different genetic backgrounds making them differentially susceptible to certain 
diseases (397, 398). From these studies it has been shown that C57BL/6 mice 
induce predominantly Th1 immune responses whereas BALB/c mice induce 
preferentially Th2 responses. Although different pathogens were used in these 
studies, such as parasites and bacteria, in part this could explain the reduced 
susceptibility of C57BL/6 mice to L10 infection compared to infection within 
BALB/c mice, and would explain the requirement for a higher dose of L10 for 
disease induction.  
It has been shown by Fazakerley et al. that viremia during A7(74) and L10 
infection reach similar levels of viral titers (298). However, here it was shown 
that viremia in L10 mice was approximately 100-fold higher compared to viremia 
in A7(74) infected mice. This discrepancy could be explained by the use of a 40 
times higher inoculation dose of L10 virus compared to the dose of A7(74) virus. 
The overt signs of L10 infection have been described in this study for the first 
time. Surprisingly, L10 infection led to different signs of disease in nearly all the 
mice and resulted in a broad range of symptoms. Additionally, 60%-70% of mice 
succumbed to death between 5-6 days post infection. BALB/c mice have been 
shown to get sick by PID 4, and all mice died by PID 6 (309). This again supports 
the hypothesis that pathogenesis might differ with mouse strains. 
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One of the main aims of this chapter was to define the magnitude and form of 
chemokine expression during SFV infection by TLDA analysis. In brief, 
chemokines were selectively upregulated during avirulent and virulent infection 
of the brain. Chemokine upregulation in infected mouse brains increased 
concomitantly with viral SFV titers in the brain. This increase is depicted in 
Figure 3.23 using the example of CCL2 and CXCL10 gene expression compared to 
nsp3 expression of SFV. 
 
Figure 3.23 Expression of CXCL10 and CCL2 in SFV infected brains compared to viral 
titer 
(A and B) Mice were infected with A7(74) and brains collected over the time course of infection 
(PID= post infection day). Isolated RNA was analysed for the expression of SFV nsp3, CXCL10 and 
CCL2. (A) Copy numbers of CXCL10 and SFV nsp3 per 104 and 103 TATA-binding protein (TBP), 
respectively. (B) Copy numbers of CCL2 and SFV nsp3 per 104 and 103 TBP, respectively. 
 
 It was noted that the magnitude of expression depends on the disease severity 
and viral strain used. Infection of mice with L10 induced a strong and robust 
upregulation of chemokines including CCL20, CXCL1, CXCL2 and CXCL3 which 
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were only minimally increased, or not expressed, during avirulent infection with 
A7(74). Shirato et al. have found similar results regarding chemokine expression 
during lethal and non-lethal infection of mice with WNV (358). They have 
assayed only a limited set of chemokines, but nonetheless they have 
demonstrated that the expression level of chemokines on PID 3 is similar 
following infection with both viral strains of WNV, but by PID 7, most 
chemokines are significantly increased during lethal WNV infection compared to 
non-lethal infection. Thus, this study supports those reported here that 
chemokines are differentially expressed in the virally infected brain, depending 
on the strain used and progression of the disease. Again, not all chemokines are 
upregulated during viral encephalitis and this suggests that induction of 
chemokine expression is relatively specific. 
Five chemokines have been identified being highly upregulated during SFV 
infection, regardless of disease progression or strain used. These chemokines 
were CCL2, CCL5, CCL7, CXCL9 and CXCL10. During avirulent and asymptomatic 
L10 infection, these chemokines were more than 100-fold upregulated, and 
during symptomatic L10 infection these chemokines were more than 1000-fold 
increased, relative to controls. These chemokines have also been reported to be 
upregulated during other viral encephalitides, suggesting that they might be 
important for different types of viral encephalitis in general, and thus make 
them and their receptors attractive targets for therapeutic interventions (128, 
129, 358). 
Amongst all chemokines, CXCL9 and CXCL10 have been identified as the major 
upregulated chemokines during SFV infection, using both strains. It was noted 
that the expression of CXCL10 was upregulated as early as 3 days post infection 
and subsequently highlights this chemokine as being the earliest upregulated 
chemokine during SFV infection. Parsons et al. have shown that the blood brain 
barrier becomes leaky between PID 4 and PID 10 (399). Therefore the source of 
CXCL10 expression during earlier time points of SFV infection is likely to be 
neurons or glial cells. In support of this, Klein et al. have shown that CXCL10 is 
predominantly produced by neurons in the WNV infected CNS (153). Furthermore 
it has also been shown by previous studies that CXCL10 expression parallels 
levels of viral titers in the brain of WNV and LCMV infected mice (153, 322). 
CXCL9 expression was also highly upregulated very early during SFV infection but 
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the cellular source of this chemokine remains unclear. Some studies report that 
microglia are the main source of CXCL9, and expression is solely induced by IFN-γ 
(400). The CXCL9/CXCL10-CXCR3 axis will be explored in further detail in 
chapter 6. 
The expression of CCL2, CCL5 and CCL7 was also strongly increased during SFV 
infection. The upregulation of the expression of these chemokines started by PID 
5, and levels of CCL2 and CCL7 peaked on PID 7 while CCL5 levels peaked on PID 
10. These findings suggest that the cellular source of CCL2, CCL5 and CCL7 might 
be different, or that the molecular cues required for inducing chemokine 
expression are distinct. It was noted that the chemokine expression pattern of 
these three chemokines correlated with the influx of leukocytes into the CNS 
(399). This result supports the hypothesis that these chemokines are 
predominantly expressed by infiltrating leukocytes rather than neuronal and glial 
cells.  
CCL2 is an important chemokine expressed in the CNS of mice infected with 
MHV, LCMV and WNV (128, 214, 401). In these studies the CCL2-CCR2 axis has 
been shown to be pivotal for the migration of monocytes into the CNS, where 
they can differentiate into microglia during the repair phase of the brain. 
Furthermore Getts et al. have shown that a deficiency of CCL2 results in 
reduced mortality during WNV infection and they have proposed a pathogenic 
role of CCL2 during viral encephalitis (106). However the exact role of CCL2 
during viral brain infection is not clear because another study linked CCL2 
expression with enhanced survival during WNV infection, which suggests a 
beneficial role of this chemokine during viral encephalitis (346). The CCL2-CCR2 
axis during SFV infection is investigated in further detail in chapter 6. 
CCL5 was the only chemokine during SFV infection, whose expression peaked on 
PID 10 instead of PID 7. Thus, during later time points of acute infection CCL5 is 
likely to be expressed by cells infiltrating, or by neurons and glial cells that are 
induced to express CCL5. During WNV, MHV and LCMV infection, CCL5 has also 
been identified as a key CC-chemokine upregulated in the CNS (128, 173, 336). 
Therefore the expression of CCL5 in the CNS appears to be important during 
different types of viral brain infections.  The cellular source of CCL5 was not 
investigated in this study but it has been proposed by previous studies that T-
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cells are an important source during WNV infection (402). However astrocytes 
and neurons are also capable of producing CCL5 during neuroinflammation such 
as EAE, or in response to dsRNA viral mimics (385, 403). The CCR5 axis will be, 
again, investigated in more detail in chapter 6. 
Of note is the differential expression of CXCL1, CXCL2 and CXCL3 during SFV 
infection. While these chemokines are only minimally, or not, expressed during 
avirulent and asymptomatic L10 infection, CXCL1-CXCL3 expression was strongly 
upregulated in terminally ill mice infected with the virulent strain L10. CXCL2 
was the third most strongly upregulated CXC chemokine after CXCL9 and 
CXCL10. Since CXCL1-CXCL3 are chemoattractants for CXCR2+ neutrophils it was 
hypothesised that a large number of neutrophils might enter the CNS during 
later stages of L10 infection. This hypothesis will be investigated in more detail 
in chapter 4. 
Furthermore it was shown here that the expression of CX3CL1 in the CNS is not 
changed during SFV infection compared to healthy control mouse brains. 
Previous studies have suggested that CX3CL1 is more implicated in 
neurodegenerative diseases than viral infections (404).  
Analysis of the cytokine and innate immunity gene expression during SFV 
infection revealed that the highest upregulation occurred by PID 7. This 
correlates with both peak leukocyte influx and viral RNA load, suggesting that 
these cytokines are predominantly released by either; infiltrating leukocytes or 
from resident neurons and glial cells that induced to express them indirectly by 
leukocyte entry.  The main cytokines identified during avirulent and virulent 
infection with SFV were type-I and type-II interferons and TNF. TNF was already 
upregulated by PID 3 during A7(74) infection and on PID 4 during L10 infection. 
As mentioned before on PID3 or PID4, the BBB is unlikely to be permeable yet 
(305). Therefore the source of TNF expression is most likely neurons or glia. 
During WNV infection of the brain, neurons have been shown to express TNF. 
This cytokine has been demonstrated to exert neuroprotective functions during 
viral encephalitis (88). 
Amongst innate immunity genes, RIG-I and IRF7 were both highly upregulated 
during SFV infection. IRF7 expression was induced very early during A7(74) 
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infection, suggesting that neurons and astrocytes are capable of inducing innate 
immune responses. Additionally, analysis of ISGs during L10 infection revealed 
that almost all ISGs were highly upregulated (>100 fold) during viral 
encephalitis. This is in line with the high expression of interferons which induce 
the expression of ISGs. Interestingly, TLR3 and TLR7 expression, shown to be 
induced in the presence of viral dsRNA and ssRNA, respectively, was only 
moderately increased during L10 infection (405). This contrasts with another 
study, where specific TLRs were found to be highly upregulated in response to 
SFV infection using BABL/c and 129 mice (406). A reason for this discrepancy 
could be the use of different mouse strains. In this study C57BL/6 mice were 
used, which are genetically different from BALB/c and 129 mice (397, 398). The 
expression of CD45 was assessed by QPCR to determine the extent of leukocyte 
infiltration during SFV infection. However, the expression of CD45 has to be 
carefully interpreted because microglia also express CD45. Therefore the extent 
of leukocyte infiltration cannot be determined based on the mRNA levels of 
CD45 only.  
In the next chapter the numbers of leukocytes entering the CNS will be assessed 
by flow cytometry and leukocyte subsets will be identified based on the 
expression of various surface markers.  
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4.1 Introduction and aims 
In the previous chapter, a thorough analysis of chemokine expression was 
conducted, identifying 5 chemokines that are highly upregulated during viral 
encephalitis. As discussed in the general introduction chapter, chemokines are 
important regulators of leukocyte trafficking, and due to the strong increase of 
CCL2, CCL5, CXCL9, CXCL10 it was hypothesised that many T-cells, monocytes 
and NK-cells infiltrate the brain during SFV infection. However other 
chemokines were also upregulated and therefore other leukocyte subsets might 
additionally enter the virally infected CNS. To test this hypothesis I therefore 
sought to define the kinetics of leukocyte subsets entering the CNS during 
avirulent and virulent infection with SFV. 
One of the hallmarks of the healthy CNS is the low abundance of leukocytes, 
and most of these are in the CSF. In contrast to other organs in the body, the 
majority of leukocytes in the CNS are memory T-cells and predominantly CD4+ 
T-cells (119). An influx of leukocytes into the CNS has been observed using 
different types of viral infections. However what role leukocytes play in the 
CNS during pathogenesis remains unclear. Studies using WNV as a model of 
infection have shown that T-cells and monocytes are beneficial for survival and 
virus clearance (106, 140, 141). In contrast to this, other viral encephalitis 
studies using LCMV as a model of infection, have reported that monocytes and 
other leukocyte subsets in the CNS are pathogenic and enhance mortality (154, 
367, 369).  
For alphaviruses little is known about chemokine-mediated leukocyte 
infiltration into the CNS. Therefore defining the kinetics of leukocyte entry into 
the CNS during viral encephalitis could be key for the development of 
therapeutic interventions. One study by Parsons and Webb has demonstrated 
that leukocytes enter the brain and spinal cord during SFV infection, but to 
date, the temporal infiltration of leukocyte subsets into the infected CNS has 
not been examined yet (399). Furthermore the authors have shown that the 
BBB becomes permeable for leukocytes between PID 4 and PID 10. Therefore in 
this study I investigated entry of leukocyte subsets between 3 and 10 days post 
infection. 
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Flow cytometry was used to identify leukocyte subsets and to investigate 
kinetics of leukocyte entry into the CNS. For most of this study the avirulent 
strain A7(74) was used, because mice infected with L10 succumb before 
mounting an effective immune response. Therefore using strain A7(74) seems 
more suitable for studying leukocyte infiltration into the CNS. Some preliminary 
data on leukocyte entry into the brains of mice infected with the virulent strain 
L10 shall be presented at the end for comparison. 
4.2 Optimisation of leukocyte isolation from SFV 
infected brains  
In the previous chapter it was noted that chemokines are highly and selectively 
upregulated during viral encephalitis using SFV strain A7(74) and L10. To 
explore how this relates to infiltration of leukocytes into the brain, mice were 
infected with SFV strain A7(74) for 10 days, and brains were collected from 
control, PID 4, 5, 7 and 10, and analysed by flow cytometry. Neural tissue from 
mice typically contains a lot of myelin debris that can interfere with antibody 
binding during flow cytometry. Therefore it was necessary to remove myelin 
debris prior to antibody staining for flow cytometric analysis, without 
compromising the number of live cells. Brain cells were isolated from the CNS 
using two different methods: by myelin depletion or by Percoll density 
gradients. Both isolation techniques were tested and compared.  
Initially, myelin removal beads were used to isolate leukocytes from healthy 
control mouse brains. This method had the advantage over the use of density 
gradients that the number of mice per time point could be reduced, as the 
yield of cells from one mouse brain was high enough to perform flow cytometry 
after myelin depletion. CD45hi leukocytes counted before and after the use of 
myelin removal beads were compared by flow cytometry. Unpurified neural 
cells, before myelin depletion, were analysed first (Fig. 4.1 A). It was shown 
that the brain contained an enormous quantity of myelin debris that was 
defined as SSChiFSClo, and was located outside the P1 gate (see arrow Fig. 4.1 
A). After exclusion of DRAQ7+ dead cells, live cells (P2 gate) were examined for 
the presence of doublets, and single cells (P3 gate) were further gated on CD45 
versus SSC. According to the literature, CD45- and CD45int cells (P5 gate) have 
been described as microglia, whereas CD45hi cells (P4 gate) have been 
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identified as leukocytes (407, 408) Most cells were CD45 low or intermediate, 
typical of microglial cells. After depletion of myelin from the brain sample, the 
amount of SSChiFSClo myelin debris was reduced and more CD45hi leukocytes 
could be seen (Fig. 4.1 B). After dead cell exclusion, CD45hi and CD45int cells 
were identified within the P4 and P5 gate, respectively. Compared to brain 
samples containing myelin, samples depleted of myelin displayed higher purity 
of CD45hi cells within the P4 and P5 gate. However the number of CD45hi cells 
within the living cell population was still considerably low and comprised only 
0.33% of total cells after using myelin removal beads. 
Next, Percoll density gradients were used to isolate mononuclear cells from 
murine brains (Fig. 4.1 C). This method required a larger number of mice per 
time point because mouse brains had to be pooled, in order to achieve an 
adequate number of cells to perform flow cytometry. The advantage of this 
method was that cells were highly purified and enriched in mononuclear cells. 
In addition to mononuclear cells, microglia are also enriched and can be 
collected from the interphase of the 30%/70% Percoll layer. Due to the density 
gradient, myelin debris, neurons and granulocytes were largely removed from 
the brain samples. After gating on CD45hi cells and performing dead cell 
exclusion, three distinct cell populations became visible based on the 
expression of CD45: a CD45hi, CD45int and CD45- cell population (Fig. 4.1 C). 
After the use of density gradients the frequency of CD45hi cells was increased 
from 0.33% of live cells in myelin-depleted samples to 8.73% in Percoll isolated 
samples. This amounts to an approximately 26-fold increase in leukocyte 
numbers using Percoll density gradients. 
Overall, the comparison of different isolation techniques showed that the use 
of density gradients is the preferred method of choice for isolating 
mononuclear cells from the brain because these cells were highly purified and 
enriched and allowed a clear distinction between microglia and leukocytes 
based on the expression of CD45. Subsequently, this method was used for the 
remainder of this thesis for all flow cytometric analyses. However, one 
disadvantage of using the Percoll method is that neutrophils cannot be isolated 
from brain samples. For subsequent analyses, the dead cell marker DRAQ7 was 
used to select for total live cells in all samples, and doublet exclusion was 
performed using SSC-Area versus Height (Fig. 4.1). 
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Figure 4.1. Isolation of leukocytes from SFV infected brains using myelin removal 
beads or density gradients 
Mononuclear cells were isolated from murine brains infected with SFV A7(74) and different 
methods were used to isolate CD45hi leukocytes for flow cytometry. The efficiency of CD45+ cell 
isolation from brains for each method was determined by flow cytometry. (A) Brain cells 
isolated before the use of Myelin removal beads. (B) Brain cells obtained after the use of 
Myelin removal beads. (C) Mononuclear cell enrichment using the Percoll method. Panels on the 
left identify lymphocytes and myeloid cells (gate P1), gate P2 shows total live cells, gate P3 
depicts single cells, and panels on the right identify CD45hi leukocytes (gate P4) and CD45int 
microglia (gate P5).  
4.3 Increase of CD45hi cells within SFV A7(74) 
infected brains 
To investigate brain leukocyte infiltration following SFV infection and to 
identify specific leukocyte subsets, all cells were subsequently gated on CD45hi 
cells. It was noted that the CD45hi cell population significantly increased with 
the duration of infection (Fig. 4.2 A-C). The increase of leukocyte numbers 
within the CNS first became apparent on PID 5 and reached maximal levels on 
PID 10, when an average of 20% of all live single cells were CD45hi leukocytes 
(Fig. 4.2 C). The fold increases of mean leukocyte numbers in the CNS during 
SFV infection are shown in Table 4.1. Leukocytes were next analysed and 
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categorised into different subsets based on the expression of NK-cell, T-cell, B-
cell and myeloid cell markers.  
Table 4.1 Fold increases of leukocytes within SFV infected brains relative to 
healthy control mouse brains.  
Mice were infected with SFV A7(74) and brain cells were isolated using Percoll density 
gradients. CD45hi cells were counted by flow cytometry. The numbers of leukocytes in the CNS 
are presented as mean percentage ± SD. Results are representative of 10 pooled mouse brains 
per time point and 3 individual experiments. 
 Control PID 4 PID 5 PID 7 PID 10 
Mean ± SD 2.89 ±0.923 2.44± 0.722 4.90 ± 1.48 13.76 ±2.98 20.14 ±4.72 
Fold increase  0.9 1.8 4.9 7.2 
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Figure 4.2. Identification of CD45hi leukocytes in the brain 
Mononuclear cells were isolated from murine brains infected with SFV A7(74) and analysed for 
the expression of CD45 by flow cytometry. Doublet exclusion was performed for all samples. (A) 
Expression of CD45 on total live single cells over the time course of infection. Gate 1= CD45int 
cells and gate 2= CD45hi cells. (B) Histograms: 1 = Isotype; 2-5 = differential expression of CD45 
over the time course of infection; 6 = CD45 staining of cells from control (shaded) and post 
infection day (PID) 10 (blue) samples. (C) Proportion of CD45hi leukocytes within gate 2 at each 
time point post infection. Results are representative of 10 pooled mouse brains per time point 
and 3 individual experiments. Data are presented as mean± SD. (One-Way ANOVA with Tukey’s 
post test; * p<0.05, *** p<0.001). 
 
4.4 NK-cells are one of the first cells infiltrating the 
brain during SFV infection 
After the identification of CD45hi cells within the brain, leukocytes were 
analysed for the combined expression of NK1.1 and Nkp46. Both markers 
together are expressed on NK-cells (409). The proportion of NK1.1+NKp46+ cells 
amongst total live CD45hi cells in the brain increased significantly between PID 
4 and PID 5 compared to controls (p<0.05), and decreased to lower levels at 
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later time points (Fig. 4.3 A and B). Despite the decrease of proportions of 
NK1.1+NKp46+ cells over time within the CD45hi cell compartment, the 
frequencies of NK1.1+NKp46+ cells per 104 isolated live brain cells reached 
maximal levels by PID 10 (Fig. 4.3 C) although this did not reach statistical 
significance. Histological analysis showed that CD49b+ cells were localised in 
cortical regions of the brain by PID 5, and infiltrated the brain parenchyma in 
the cortex and also appeared in meningeal areas (Fig. 4.3 D and E). CD49b is a 
pan NK-cell marker.  
4.5 Identification of myeloid cells during SFV 
infection 
Next, the viable CD45hi cell population was examined for the presence of 
CD11b+ cells during SFV infection. Myeloid cells typically express this marker as 
do microglia, but microglia are not CD45hi but rather CD45lo-CD45int (407, 410). 
The results demonstrate that the frequency of CD11b+ cells within CD45hi cells 
increases from approximately 49% of CD45hi CD11b+ cells in healthy control 
brains to approximately 64% of cells by PID 4 and PID 5, decreasing thereafter 
to below control levels (Fig. 4.4 A and B). However assessment of the numbers 
of CD11b+ cells per 104 live brain cells showed that the number of CD11b+ cells 
increased significantly (p<0.05) by PID 5 and reached maximal levels on PID 7 
(p<0.01) (Fig. 4.4 C). These differences in proportions and numbers reflect 
changes in the other leukocyte populations entering the brain during viral 
encephalitis. 
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Figure 4.3.  NK-cells enter the brain early during SFV infection  
Mice were infected with SFV A7(74) and brains were collected on post infection day (PID) 4, 5, 
7 and 10 and compared to control brains. NK-cells were identified on the basis of NK1.1 and 
Nkp46 expression. All cells analysed were gated on live single CD45hi cells. (A) Representative 
dot plots of NK1.1 and Nkp46 expression within CD45hi cells at each time point post infection. 
Isotype control is shown on the left. (B) Proportions of NK1.1+Nkp46+ cells within CD45hi cells 
over time. (C) Number of NK1+Nkp46+ cells per 104 isolated live brain cells. Data are 
represented as mean ± SD of 5-10 pooled mouse brains per time point from 3 individual 
experiments. (D and E) Fluorescent images of brain sections from infected brain on PID5 and 
isotype control, stained for CD49b+ NK-cells, and mounted with Vectashield plus DAPI (blue cell 
nuclei). Magnification at (D) 10x and (E) 20x. ((B) One-way ANOVA with Dunnett’s post test and 
(C) Kruskal-Wallis test with Dunn’s post test; both * p<0.05) 
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Figure 4.4. Identification of myeloid cells entering the brain during SFV infection 
Mice were infected with SFV A7(74) for 10 days and the number of myeloid cells (CD11b+) was 
determined by flow cytometry on post infection day (PID) 4, 5, 7 and 10. (A) Representative 
dot plots of CD11b staining on live single CD45hi cells. (B) Proportions of CD11b+ cells within 
total live CD45hi compartment at each time point. (C) Number of CD11b+ cells per 104 isolated 
live brain cells. Data are represented as mean ± SD of 5-10 pooled mouse brains per time point 
from 3 individual experiments. (One-way ANOVA with Tukey’s post tests; * p<0.05,** p<0.01 *** 
p<0.001) 
 
4.5.1 Identification of residual neutrophils, and Ly6Chi 
monocytes and Ly6Clo cells in the brain during SFV 
infection 
Following on from this the CD11b+ compartment was then further 
characterised.  To that end, two markers were used to discriminate between 
neutrophils and monocytes/macrophages: Ly6G and Ly6C (Fig. 4.5 A). Ly6G is a 
marker specifically expressed on neutrophils. Amongst CD45hi cells, the 
percentage and number per 104 isolated brain cells of Ly6G+ cells was not 
significantly changed over the time course of infection (Fig. 4.5 B). Of note, 
Percoll density gradients remove most of the neutrophils from the sample, and 
the residual neutrophils shown on the dot plots represent residual neutrophils, 
which were not removed from the brain samples. However, the number of 
neutrophils was minimally increased by PID 4 similar to proportional numbers at 
this time point (Fig. 4.5 B). Immunohistochemical staining for myeloperoxidase, 
an enzyme present within granules of neutrophils, revealed that neutrophils 
are not apparent in the brain of infected mice at any time point analysed (data 
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not shown here). Therefore it is very likely that neutrophils do not, or only 
minimally, enter the brain during SFV infection. This will be discussed later.  
The number of Ly6G- cells per 104 isolated brain cells significantly increased by 
PID 5 (p<0.001), and stayed elevated until PID 10 (Fig. 4.5 C). Similar to this, 
the proportion of Ly6G- cells was also significantly increased by PID 5 (p<0.05), 
but proportions decreased by PID 7 to levels similar to control levels. Therefore 
proportions of Ly6G- cells were not significantly changed by PID 7 and 10 
compared to proportions in control mouse brains. Next, the Ly6G- fraction 
within the CD45hiCD11b+ compartment was further analysed based on intensity 
of Ly6C expression. The proportion of Ly6C- cells within Ly6G- cells was high 
(approximately 64% ± 12 SD) in control samples and significantly (p<0.05) 
decreased by PID 7 and 10 to approximately 25% (Fig. 4.5 E). Based on recent 
studies this cell fraction consists mainly of macrophages and DCs (24). 
Unfortunately a distinction between macrophages and DCs was not possible, as 
the staining for F4/80 did not work well. It is not clear why this antibody did 
not work in this study but it is possible that the enzymatic digestion of brain 
tissue for the isolation of mononuclear cells affects the F4/80 antibody 
staining. However immunohistochemical staining for MAC-2, a marker 
expressed on macrophages, showed that MAC-2+ cells, which are known as 
macrophages, were localised in the sulcus, meninges (Fig. 4.6 A and B) and also 
near blood vessels in cortical regions of SFV infected brains on PID 5 (Fig. 4.6 
D). No MAC-2+ cells were detectable in brain sections from infected mice from 
PID 7 and PID 10. The appropriate isotype control was used (4.6 C). 
The Ly6Cint cell compartment was not significantly altered during viral 
infection, and proportions were similar to steady state (Fig. 4.5 E). Lastly the 
proportion of Ly6Chi cells during SFV infection was initially low (11.5% ±2.5 SD) 
in control samples but increased significantly (p<0.05) by PID 4. The 
proportions of these cells increased even further by PID 7 and 10, reaching 
approximately 60% of cells within the Ly6G- cell compartment. Previous studies 
have categorised Ly6Chi cells as ‘inflammatory monocytes’ (24, 411). In support 
of this other studies have shown that during viral infection mostly Ly6Chi 
monocytes enter the brain (23). Therefore it is most likely that the Ly6Chi cells 
detected during SFV infection and shown here are ‘inflammatory’ monocytes.  
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4.6 Identification of plasmacytoid DCs cells during 
SFV infection 
Expression data presented in chapter 3 showed that type-I interferon was 
highly induced during SFV encephalitis. pDCs are known to be a source of 
interferon, and therefore I wanted to test whether these cells were capable of 
entering the brain by using the markers CD11c and pDC (412). Previous studies 
have shown that during neuroinflammation such as MS or EAE, and during WNV 
infection pDCs inifltrate the brain during inflammation and secrete high 
amounts of IFN-α (93, 413). First cells were gated on CD11b+ and MHC-II+ cells 
(not shown here) before examining expression of CD11c and pDCA (Fig. 4.7 A 
and B). In control and PID 4 samples, no CD11c+pDCA+ cells could be detected. 
However by PID 5 a small population of CD11c+pDCA+ cells appeared in infected 
brains. This cell population increased further in number and proportions, and 
by PID 7 the number of CD11c+pDCA+ per 104 isolated live brain cells was 
significantly increased (p<0.05) compared to control mouse brains (Fig. 4.7 C). 
However the number of CD11c+pDCA+ cells decreased 2.8-fold by PID 10.   The 
proportion of CD11c+pDCA+ cells was not significantly changed during SFV 
infection of the brain. Of note is that the number of pDCs entering the brain 
during infection was quite low. 
Other subsets of DCs could not be identified here, as the flow cytometric 
staining was limited to 7 markers. Additionally the marker F4/80 did not work 
well, and this would make a distinction between macrophages and DCs 
difficult. 
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Figure 4.5. Identification of monocytes, macrophages and neutrophils in the brain 
during SFV infection 
Mice were infected with SFV A7(74) for 10 days and the number of myeloid cells was 
determined by flow cytometry from controls and at 4, 5, 7 and 10 days post infection (PID). (A) 
Representative dot plots of Ly6G and Ly6C expression on CD11b+ cells gated on live 
CD45hiCD11b+ cells at each time point. Appropriate Isotype control is shown in the left panel. 
(B) Numbers of Ly6G+ cells per 104 isolated live brain cells, and proportions amongst CD45hi 
cells. (C) Numbers of Ly6G- cells per 104 isolated live brain cells, and (D) proportions amongst 
total live CD45hi cells. (E) Proportions of Ly6C-, Ly6Cint and Ly6Chi fractions within the 
CD11b+Ly6G- cell compartment. Data are represented as mean ± SD of 5-10 pooled mouse 
brains per time point from 3 individual experiments. (One-way ANOVA with Tukey’s post test; * 
p<0.05, ** p<0.01, *** p<0.001) 
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Figure 4.6. Immunohistochemical staining for macrophages within the CNS of 
infected mice 
Mice were infected with SFV A7(74) for 5 days and brains were collected for analysis by 
immunohistochemistry. Brains were fixed in formalin, embedded in paraffin and cut into 6 µm 
thick sections for staining. (A) Fluorescent image of MAC-2 staining in an infected brain at 10x 
and (B) 20x magnification. (C) Isotype control staining for MAC-2 in a SFV infected mouse brain 
at 10x magnification. (D) Fluorescent staining of a blood vessel from infected brains for the 
detection of MAC-2+ macrophages at 20x magnification. Fluorescently stained brain sections 
were mounted with Vectashield plus DAPI (cell nuclei blue).  
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Figure 4.7. Identification of plasmacytoid DCs in SFV infected murine brains  
Mice were infected with SFV A7(74) for 10 days and the number of CD11c+pDCA+ cells was 
determined by flow cytometry on post infection day (PID) 4, 5, 7 and 10. (A) Representative 
dot plots of pDCA and CD11c expression within gated live CD45hiCD11b+ cells at each time 
point.  (B) Histogram represents staining with the appropriate isotype control (grey), and 
staining of pDC in control (red) and PID 10 samples (blue). (C) Number and proportion of 
CD11c+pDCA+ cells per 104 isolated live brain cells amongst total CD45hi cells. Data are 
represented as mean ± SD of 4-8 pooled mouse brains per time point from 3 individual 
experiments. (One-way ANOVA with Tukey’s post test; * p<0.05) 
 
4.7 Identification of T-cells in SFV infected brains 
Given the strong induction of CXCL9 and CXCL10, both CXCR3 ligands, following 
viral infection of the brain, it was hypothesised that a large number of T-cells 
would enter the CNS during SFV encephalitis. To test this hypothesis, CD45hi 
leukocytes were stained for the CD3, CD4 and CD8 T-cell markers and analysed 
by flow cytometry. CD45hi cells in control samples comprised approximately 
20% CD3+ T-cells (Fig. 4.8 A and B). On PID 4 and PID 5 the proportions of CD3-
T-cells were not significantly altered compared with controls. However, on PID 
7 the proportion of CD3+ T-cells within the CD45hi cell compartment rose to 
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almost 40%, and increased by an additional 20% by PID 10. A significant increase 
(p<0.05) of cell numbers of CD3+ T-cells per 104 isolated live brain cells was 
seen at PID 7 and PID 10 matching the significant increase (p<0.05) in 
proportions of CD3+ T-cells within the CD45hi cell population at both time points 
(Fig. 4.8 B). Thus, a large number of T-cells enter the brain between PID 7 and 
PID 10. 
Next, the CD3+ T-cells were further analysed for the expression of CD4 or CD8 
(Fig. 4.8 C). While the proportions of CD3+CD4+ T-cells did not change 
significantly over time, the CD3+CD8+ T-cell fraction increased approximately 2-
fold by PID 7 (p<0.05) and 4-fold by PID 10 (p<0.01). These data suggest that 
CD8+ T-cells preferentially accumulate in SFV infected brains. Staining by 
immunohistochemistry, using an antibody for CD3, revealed that T-cells were 
localised throughout the brain and were able to infiltrate deep into the brain 
parenchyma (Fig. 4.8 D). In particular, T-cells were localised in the 
perivascular space of capillaries, in the cortex and in the meninges (Fig. 4.8 D 
and E). Clusters of T-cells could also be detected in the dentate gyrus of the 
hippocampus, cerebellum and around ventricles (Fig. 4.8 F). 
4.7.1 Phenotypic characterisation of T-cells in the brain 
Next, CD3+ T-cells were further phenotyped based on the expression of CD44, 
CD62L, CCR5 and CXCR3. Effector cells have been defined as CD3+CD44hiCD62Llo 
and memory cells as CD3+CD44hiCD62Lhi (414). It was found that >80% of all CD3+ 
T-cells were effector cells on PID 7 and PID 10 (Fig. 4.9 A). In control samples, 
a few memory T-cells were additionally found in the CNS, but this cell 
population was dramatically reduced within the CD3+ T-cell population from 
18% of memory T-cells in healthy control brains to 2.42% of cells on PID 10. A 
significant increase in numbers of effector cells per 104 isolated live brain cells 
was observed on PID 7 (p<0.01) and PID 10 (p<0.001) (Fig. 4.9 B). Within the 
CD3+ T-cell population the proportion of CD44hiCD62Llo cells also significantly 
increased by PID 7 and PID 10 (both p<0.001) and matched the increase in 
numbers per 104 isolated live brain cells (Fig. 4.9 B). 
Staining for the chemokine receptor CXCR3 revealed, in keeping with high 
expression of CXCL9 and CXCL10, that the majority of T-cells (70-80% of CD3+ 
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T-cells) expressed CXCR3 between PID 7 and PID 10 (Fig. 4.9 C). Within the 
CD3+ T-cell population the increase in proportions of CXCR3+ cells on PID 10 was 
significant (p<0.05) compared to resting mice. In support of this, the number of 
CXCR3+ cells within 1x104 live brain cells was also significantly increased by PID 
7 (p<0.01) and PID 10 (p<0.001).  
Within the CD3+ T-cell compartment the proportion of CCR5+ cells, a receptor 
mainly found on inflammatory cells, was significantly increased at PID 7 and PID 
10 (both p<0.05) compared to controls (Fig. 4.9 D). This is in agreement with 
the significant increase of CCR5+ cell numbers within 104 isolated live brain 
cells at PID 7 (p<0.05) and PID 10 (p<0.001) compared with healthy control 
brains (Fig. 4.9 D). 
Thus, CD3+ T-cells accumulate in the brain by PID 7 and are capable of 
infiltrating deep into the brain parenchyma. Most T-cells on PID 7 and 10 
displayed the CD8+CD44hiCD62Llo phenotype, and most CD3+ cells were CXCR3+ 
and CCR5+.  
 
 
 
 
 
 
 
 Chapter 4. Identification of leukocyte subsets infiltrating the CNS during SFV infection       175 
   
 
 
Figure 4.8. Accumulation of CD3+ T-cells in the brain during SFV infection 
Mice were infected with SFV A7(74) for 10 days and the number of CD3+ T-cells was determined 
by flow cytometry on the days indicated. (A) Representative dot plots of CD3+ cells gated on 
live CD45hi cells at each time point. A histogram (panel on the right) shows the shift of CD3 
expression on cells from control (red) and PID 10 samples (blue). Shaded histogram represents 
staining with the appropriate isotype control. (B) Number and proportion of CD3+ cells amongst 
total CD45hi cells, respectively. (C) Proportions of CD4+ and CD8+ T-cells of total live CD45hi 
cells. (D) CD3 staining in the brain parenchyma, cortex and the meninges including negative 
control staining. (E) Perivascular T-cells and (F) foci of T-cells in the dentate gyrus of the 
hippocampus at 10x and 20x magnification, respectively. Negative control of CD3 staining is 
shown on the left. All immunohistochemistry images are taken from infected brains on PID 7. 
Cell nuclei were visualized with DAB counterstain. Flow cytometry data are represented as 
mean ± SD of 5-10 pooled mouse brains per time point from 3 individual experiments. ((B) 
Kruskal-Wallis test with Dunn’s post test and (C) two-way ANOVA with Bonferroni’s post test; * 
p<0.05, ** p<0.01) 
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Figure 4.9. Phenotypic characterization of T-cells from the brains of SFV infected 
mice 
Mice were infected with SFV A7(74) for 10 days and cells were isolated from the brains on post 
infection day (PID) 4, 5, 7, and 10 and from controls, and analysed by flow cytometry. (A) 
Representative dot plots of CD44 and CD62L staining of CD45hiCD3+ cells at each time point. (B) 
Numbers and proportions of CD44+CD62Llo cells per 104 live brain cells and amongst CD3+ cells, 
respectively. (C) Histogram, showing differential expression of CXCR3 on cells of control (red) 
and PID10 samples (blue). Shaded histogram represents staining with the appropriate isotype 
control. The proportion and absolute number of CD3+ CXCR3+ cells are shown in the middle and 
on the left. (D) Histogram showing differential expression of CCR5 on cells of control (red), PID 
10 samples (blue) and in isotype controls (shaded). The proportion of CD3+CCR5+ cells of total 
CD3+ T-cells and number of CD3+CCR5+ cells within 104 live brain cells. Data are represented as 
mean ± SD of 5-10 pooled mouse brains per time point from 3 individual experiments. (One-way 
ANOVA with Tukey’s post test; * p<0.05, ** p<0.01, *** p<0.001) 
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4.8 Accumulation of B-cells in the brain during later 
stages of SFV infection 
QPCR results reported in the previous chapter revealed a significant 
upregulation of CXCR5 mRNA expression, a chemokine receptor predominantly 
expressed on B-cells. To determine whether B-cells enter the CNS during SFV 
infection, leukocytes were stained for CD19, a marker for B-cells, and cells 
were analysed by flow cytometry. The results demonstrate that B-cells 
infiltrate the brain during later stages of SFV infection, on PID 10 (Fig. 4.10 A). 
Both, cell numbers per 104 isolated live brain cells and proportions within the 
CD45hi cell population of CD19+ cells showed a significant increase in cell 
numbers only at PID 10 (both p<0.01) (Fig. 4.10 B).  
Analysis by immunohistochemistry, using an antibody for B220, confirmed that 
B220+ B-cells enter the brain predominantly on PID 10 (Fig. 4.10 C and D). 
Infected brain sections from PID 7 contained only few B-cells. Sections from 
control, PID 4 and PID 5 samples were negative for B220 staining. Thus, B-cells 
appear to infiltrate the brain during later stages of SFV infection. After 
infiltration, B-cells were mainly localised around ventricles and along the 
sulcus suggesting that B-cells possibly enter the brain via the CSF-blood barrier 
(Fig. 4.10 C). Double staining for CD3+ T-cells and B220+ cells showed that 
often these cells cluster together in areas of the ventricles (Fig. 4.11 A). For 
instance a cluster of T- and B-cells was found in the choroid plexus of the 
lateral ventricle (Fig. 4.11 B, C and D). In general, T-cells seemed to be more 
capable of infiltrating the brain parenchyma than B-cells which were 
exclusively located around ventricles.  
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Figure 4.10. B-cells enter the brains of mice late during acute encephalitic 
infection with SFV 
Mice were infected with SFV A7(74) for 10 days and cells were isolated from the brains on post 
infection day (PID) 4, 5, 7, and 10 and from controls for analysis by flow cytometry. (A) 
Representative dot plots of CD19 and CD45 on CD45hi cells at each time point. (B) Absolute 
number of CD19+ cells per 104 isolated live brain cells and proportions of CD19+ cells within 
total live CD45hi cells. (C) Fluorescent staining for B220+ cells in SFV infected brains on PID 10. 
(D) Staining with appropriate isotype control. Brain sections were mounted with Vectashield 
plus DAPI (cell nuclei blue). Magnification at 20x. Flow cytometry data are represented as 
mean ± SD of 5-10 pooled mouse brains per time point from 3 individual experiments. (One-way 
ANOVA with Tukey’s post test; ** p<0.01) 
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Figure 4.11. Double staining of B-cells and T-cells in SFV infected brains 
Mice were infected with SFV A7(74) for 10 days and brains were collected, fixed in formalin, 
embedded in paraffin, and cut into 6 µm thick sections for immunohistochemistry. Brain 
sections from post infection day 10 were fluorescently stained with anti-mouse B220 and CD3 
antibodies. (A and C) T-cells and B-cell were observed around the ventricles and the sulcus, 
and (B and C) in the choroid plexus. (D) Staining with the appropriate isotype control. 
Magnification at 10x (A, C and D) and 40x (B).  
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4.9 Leukocyte infiltration into the CNS during L10 
infection 
To date, the kinetics of leukocyte entry into the brain during L10 infection 
have not been determined and are examined here for the first time. Due to the 
strong upregulation of chemokines during L10 infection, it was expected that a 
large number of leukocytes would infiltrate the brain during lethal infection 
with SFV L10. Mice were infected and brains collected from terminally ill mice, 
and analysed by flow cytometry. Control mouse brains were also collected for 
comparison. A density gradient was used to isolate mononuclear cells from 
brains. For flow cytometry analysis of all L10 samples, the same gating strategy 
has been used, as described in section 4.2, to identify CD45hi cells. The number 
of CD45hi cells was significantly increased (p<0.05) and constituted 
approximately 18% of all live cells compared to control samples, where 
leukocytes constituted approximately 1% of all live cells (Fig. 4.12 A). 
4.9.1 Identification of myeloid cells in L10 infected brains 
Firstly, amongst viable CD45hi cells, the absolute number and proportion of 
CD11b+ cells was determined. Compared to controls, the proportion of CD11b+ 
cells within the CD45hi population was increased during L10 infection but the 
result did not reach statistical significance. The number of CD11b+ cells per 104 
isolated live brain cells was also assessed, and the results show that the 
number was increased in the brains of terminally ill mice (Fig. 4.12 B) but this 
was not statistically significant (student’s t-test). Within the CD11b+ cell 
population most cells in control and infected brain samples were Ly6G-Ly6Chi, 
and less than 10% of CD11b+ cells were Ly6G-Ly6C- (Fig. 4.12 C) suggesting that 
the majority of cells in the brain were monocytes. However numbers revealed 
that Ly6Chi cells were much higher in infected samples compared to healthy 
controls. The number of Ly6C- cells in both samples was similar (Fig. 4.12 C). 
Hardly any Ly6G+ cells were found in the brains of control and infected mice. A 
clearer examination of monocytes, macrophages and DCs was not possible as 
the staining was limited to 7 colours, and additionally the marker F4/80 did not 
work well. 
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4.9.2 Identification of T-cells and NK-cells in L10 infected 
brains 
Having identified the proportion of CD11b+ cells in L10 infected murine brains, 
the number of T-cells and NK-cells was next examined due to the high 
upregulation of T-cell and NK-cell attracting chemokines during SFV infection 
(chapter 3). Amongst CD45hi cells the proportion of CD3+ T-cells did not differ 
in control mice compared to L10 infected mice. However analysis of the 
numbers of CD3+ T-cells per 104 isolated live brain cells showed that the 
number of cells was 15-fold increased in infected mice. This result could not be 
analysed statistically as this experiment was only performed once (Fig. 4.13 A). 
The comparison of CD8+ T-cell and CD4+ T-cell numbers in L10 infected brains 
revealed that the proportion of CD8+ T-cells within the CD45hi cell population in 
infected mice was increased compared to the proportion of CD4+ T-cells. In 
control brains both T-cell subsets were present at an almost equal ratio (Fig. 
4.13 B). 
NK-cells were detected in L10 infected brains, using the surface markers NK1.1 
and Nkp46. The proportion of NK-cells within the CD45hi cell population was 
increased in L10 infected brains compared to control brains (Fig. 4.13 C).  This 
increase in NK-cells was matched by an increase in cell numbers per 104 
isolated live brain cells.  
Taken together, a large number of CD45hi cells entered the brain during L10 
infection when mice became terminally ill. It appears from these data that the 
majority of CD45hi cells are myeloid cells, and mainly Ly6Chi monocytes. 
Additionally T-cell and NK-cell infiltration was observed but the extent of 
infiltration appeared to be less. The experiment needs to be repeated to 
achieve statistical significance and to confirm these preliminary data.  
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Figure 4.12. Infiltration of CD45hi cells and accumulation of myeloid cells in the 
brains of mice infected with the virulent strain L10  
Mice were infected with SFV L10 and brains cells were isolated from terminally ill mice on post 
infection day (PID) 5 and analysed by flow cytometry. (A) Representative dot plots of CD45 
expression versus FSC on total live single cells in control (left panel) and L10 infected brains 
(middle panel). The proportion of CD45hi cells of total live cells is shown on the right.  (B) 
Representative dot plots of CD11b+ cells (left side). The proportion of CD11b+ amongst total 
CD45hi cells and number per 104 isolated live brain cells. (C) Dot plots of Ly6G and Ly6C by 
CD45hiCD11b+ cells. The proportion of Ly6G- cells in control and infected brain samples is shown 
on the left. Number of Ly6G- cells per 1x104 brain cells is shown on the right. Data are 
represented as mean ± SD of 3-4 pooled mouse brains and from 1 individual experiment. 
(Student’s t-test; all not significant) 
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Figure 4.13. Accumulation of T-cells and NK-cells in the brains of mice infected 
with the virulent strain L10 
Mice were infected with SFV L10 and brain cells were isolated from terminally ill mice on post 
infection day (PID) 5 and analysed by flow cytometry. (A) Representative dot plots of CD3 and 
CD4 expression on cells amongst total live CD45hi cells in control (left FACS panel) and L10 
infected brains (right FACS panel). The proportion of CD3+ cells amongst live CD45hi cells and 
numbers per 104 live brain cells was determined. (B) Proportion of CD4+ and CD8+ T-cells of 
total live CD45hi cells. (C) Representative plots of NK1.1 and Nkp46 expression on cells amongst 
total live CD45hi cells in control (left FACS panel) and L10 infected brains (right FACS panel). 
The proportion of NK1.1+ and Nkp46+ cells amongst CD45hi cells and number per 104 live brain 
cells was calculated. Data are represented as mean ± SD of 3-4 pooled mouse brains from 1 
individual experiment. 
 
4.10 Discussion and summary 
It was hypothesised that a large number of leukocytes infiltrate the CNS during 
lethal SFV encephalitis based on the previous findings, reported in chapter 3, 
that many leukocyte attracting chemokines are highly upregulated in the CNS 
of mice infected with SFV L10. A few studies using the avirulent strain A7(74) 
have shown that leukocytes enter the brain during SFV infection between 4 and 
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10 days post infection (307, 399). In these studies leukocyte infiltration has 
been observed in the CSF, brain parenchyma and spinal cord of mice. Morris et 
al. have partly characterised the cellular infiltrate within the CNS during SFV 
infection but only by immunohistochemistry (307). They have shown that many 
T-cells and F4/80+ macrophages are detectable in brains by 7 days post 
infection when infiltration was maximal.  
In this chapter, for the first time, the timing of specific leukocyte subsets, 
entering the CNS during SFV infection, has been determined by flow cytometry. 
Due to the difficulty of isolating mononuclear cells from the murine CNS, brains 
had to be pooled to obtain sufficient numbers of cells for flow cytometry. The 
results demonstrate that leukocyte numbers increase almost 2-fold by PID 5 
compared to resting mice. Leukocyte infiltration was maximal on PID 10. This is 
in contrast to previous findings where maximal leukocyte numbers were 
observed on PID 7 (51, 399). This discrepancy could be due to the different 
mouse strains used. Previous SFV studies have used BALB/c mice whereas in 
this study C57BL/6 mice were chosen for analysis. Furthermore the number of 
leukocytes entering the brain during SFV infection increased concomitantly 
with the upregulation of inflammatory chemokine expression. This is depicted 
in Figure 4.14 comparing the percentage of CD45 influx with the copy numbers 
of CXCL10 and CCL2 in the infected CNS. Furthermore, the high number of 
leukocytes in control brains most likely arises from insufficient blood perfusion, 
and is therefore a result of blood contamination. 
One of the first leukocytes entering SFV infected mouse brains were a few 
Ly6G+ neutrophils on PID 4, and NK-cells and monocytes/macrophages on PID 5. 
However for the following reasons, it is most likely that these neutrophils arose 
in the brain due to insufficient brain perfusion and not leukocyte infiltration. 
Firstly, it has been reported that neutrophils enter the brain only under 
extreme conditions such as during severe bacterial or viral infections (415). 
Extravasated neutrophils in the CNS, have been associated with the break-down 
of the BBB and often cause severe tissue damage due to the release of 
cytotoxic and antimicrobial products from their granules (89, 415). Therefore 
neutrophils in healthy brains would be dangerous for the delicate CNS 
environment.  
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Figure 4.14. Expression of CXCL10 and CCL2 compared with CD45 influx into SFV 
infected mouse brains 
Mice were infected with SFV A7/74 and brains were collected over the time course of infection 
(PID= post infection day). Isolated RNA was analysed by QPCR for the expression of CXCL10 and 
CCL2. The CD45 influx was measured by FACS analysis and the percentage of CD45 influx per 
104 brain cells is depicted. (A) Transcript numbers of CXCL10 per 104 TATA binding protein 
(TBP) and percentage of CD45 influx are shown. (B) Transcript numbers of CCL2 per 104 TBP 
and percentage of CD45 influx are shown. 
 
Secondly, the use of Percoll density gradients for the isolation of mononuclear 
cells from murine brains, typically leads to the loss of neutrophils within the 
mononuclear cell fraction at the 30% and 70% interphase, which is used for 
subsequent flow cytometric analysis. The residual neutrophils within the 
isolated mononuclear cell fraction of the brain from infected and control mice, 
detectable by flow cytometry, are most likely a result of blood contamination. 
Thus, neutrophils are usually not or only at very low levels present in isolated 
brain cells using this method. Thirdly, immunohistochemical staining for 
neutrophils in control brain sections was negative for these cells. Therefore the 
presence of neutrophils in healthy brains is highly unlikely. Lastly, chemokine 
expression in the healthy CNS revealed that neutrophil attracting chemokines 
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are not, or only minimally, expressed in the brain. Thus, it is unlikely that the 
relatively high proportions of neutrophils observed in healthy control brains are 
infiltrating neutrophils and it is therefore suggested that they are a result of 
blood contamination. This residual amount of neutrophils and possibly other 
leukocytes detected in SFV infected brains is taken into consideration when 
comparing control mouse brains with SFV infected brains. Neutrophil numbers 
in SFV infected brains that are significantly higher than in controls brains are 
considered to be entering the brain as a consequence of viral encephalitis.  
Data on NK-cell trafficking into the CNS are sparse but some previous studies 
have shown that NK-cells enter the brain during early stages of acute viral 
encephalitis using WNV or VEEV as models of infection (348, 416). During SFV 
infection the relative proportion of NK-cells was increased as early as PID 4, 
when the BBB has been reported to become permeable (399). The relatively 
high proportion of NK-cells in control and PID 4 samples was possibly a result of 
blood contamination due to insufficient brain perfusion, as control brains do 
not contain resident NK-cells (139). Indeed, analysis of the numbers of 
NK1.1+Nkp46+ per 104 isolated brain cells showed that NK-cells enter the brain 
from PID 5 onwards when leukocyte infiltration was twice as high compared to 
healthy control brains. These findings are also consistent with 
immunohistochemical analyses where NK-cells were detected in the brain by 
PID 5. The exact role of NK-cells in the brain is not clear but a study by 
Alsharifi et al. has shown that NK-cell depletion during SFV infection leads to a 
more rapid disease progression during virulent infection suggesting that NK-
cells are beneficial (417). However the mortality rate in control and NK-cell 
depleted mice was unchanged. This is in contrast to another study by Shrestha 
et al. which has demonstrated that NK-cells do not influence WNV pathogenesis 
in the CNS (348). However both studies have shown that NK-cells enter the CNS 
during early stages of brain infection, and these observations are in agreement 
with my results. 
The other leukocyte subsets observed on PID 4 were CD11b+Ly6C+ or Ly6C- cells. 
Based on the expression of Ly6G, Ly6C and MHC-II, the CD11b+Ly6Chi or 
CD11b+Ly6C- cells could be defined as monocytes or macrophages, respectively. 
However, immunohistochemical staining specific for macrophages, using the 
antibody MAC-2, revealed that macrophages enter the brain during SFV 
 Chapter 4. Identification of leukocyte subsets infiltrating the CNS during SFV infection       187 
   
infection, and are localised mainly in meningeal areas of the brain. Of note, 
staining for macrophages in the CNS has to be carefully considered because 
microglia express similar markers as macrophages (117). This makes it difficult 
to distinguish between these two cell populations by immunohistochemistry. 
The majority of CD11b+ cells were Ly6Chi cells. In previous studies these cells 
have been described as ‘inflammatory’ monocytes (24). In agreement with my 
results Mildner et al. have shown through bone marrow chimeric and adoptive 
transfer studies that inflammatory Ly6ChiCCR2+ monocytes preferentially 
accumulate in irradiated mouse brains (33). This increase in Ly6Chi monocytes 
seems to be a hallmark of viral brain infections (23, 106). Numerous studies 
using encephalitic viruses have shown that Ly6Chi monocytes infiltrate the brain 
during infection (23). For example, during WNV infection only Ly6Chi cells are 
recruited to the brain and it has been shown that these cells can differentiate 
into ‘inflammatory’ macrophages, CD11c+DCs and CD45int microglia once they 
enter the CNS (106).  
On PID 7 the number of leukocytes was approximately 5-fold increased. At this 
time point many T-cells entered the CNS during SFV infection. Histological 
studies by Morris et al. have revealed that the cellular infiltrate on PID 7 and 
PID 10 was mainly comprised of CD3+ T-cells and in particular of CD8+ T-cells 
(307). The number of CD4+ T-cells has been shown to be less evident in 
infected mouse brains. In support of this, I have found similar results in this 
study. The T-cell infiltration peaked on PID 10 and not PID 7, as observed in the 
previous study by Morris et al (307). T-cells on PID 10 represented almost 64% 
of all leukocytes at this time point. In addition to flow cytometric results, 
immunohistochemistry revealed that CD3+ T-cells do not appear to enter SFV 
infected brains before PID 7. This is in agreement with data presented by 
Morris et al. who demonstrated that T-cells infiltrate the CNS mainly between 
PID 7 and PID 10 (307). Most T-cells were able to penetrate deep into the brain 
parenchyma. This is in line with studies using WNV as a model of infection 
where it has been shown that T-cell numbers are strongly increased in the 
infected brain and are localised deep in the brain parenchyma (321).  
In this study CD8+ T-cells were significantly increased by PID 7 and 10, and were 
generally more abundant than CD4+ T-cells within the CNS of SFV infected 
mice.  CD8+ T-cells appear to play important roles during viral infections of the 
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brain including WNV, LCMV and MHV (140, 141, 418, 419). These cells have 
been shown to be important for virus clearance and destruction of infected 
cells. Furthermore it has also been reported that the majority of T-cells during 
neuroinflammation are effector T-cells (420). In agreement with these previous 
studies, healthy brains contained few cells with the CD44+CD62L+ phenotype of 
effector T-cells. With disease progression the number and proportions of 
effector T-cells were increased by PID 7 and 10.  
After further phenotyping most of the T-cells on PID 7 and PID 10 expressed the 
chemokine receptors CXCR3 and CCR5, confirming the presence of activated 
and inflammatory T-cells within the inflamed brain. CXCR3 is an important 
chemokine receptor during many viral infections of the brain as discussed in 
the general introduction. A study by Zhang et al. has demonstrated that CXCR3 
deficient mice exhibit enhanced mortality and reduced clearance of WNV in the 
CNS due to a significant reduction in CD8+ T-cell entry into the brain (375). 
CCR5 has also been reported to be pivotal during WNV infection. Glass et al. 
have shown that many cell types, such as monocytes, T-cells and NK-cells, 
express CCR5, and CCR5 deficiency in mice results in increased mortality, 
reduced leukocyte infiltration and higher viral titers (173). What role CXCR3 
and CCR5 play during SFV infections shall be discussed in further detail in 
chapter 6.  
Beside the large infiltration of T-cells into the CNS on PID 7, some CD11c+pDCA+ 
cells entered the brain during SFV infection. There are hardly any existing data 
on the presence of pDCs in the brain of virally infected mice, but EAE and MS 
studies have shown that these cells enter the CSF during neuroinflammation, 
and secrete high amounts of IFN-α (413). In support of this Bailey-Bucktrout et 
al. have shown that during EAE pDCs, which enter the brain during 
inflammation, activate many CNS inflammation, which in turn activate 
inflammatory cytokines, contributing this way to neuroinflammation (421). 
Furthermore the authors demonstrated that pDC depleted mice display an 
increase in clinical EAE severity, and upon pDC reconstitution the severity of 
the disease is immediately ameliorated, suggesting that pDCs have regulatory 
effects during EAE. The role of pDCs during viral encephalitis is not yet clear 
and shall be addressed in the future. The identification of other DC subsets was 
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not possible as only a limited number of markers could be used for the 7-colour 
flow cytometry. 
Morris et al. have demonstrated that B-cells enter the brain late during viral 
infection with SFV strain A7(74). They have demonstrated by 
immunohistochemistry that B-cells enter the brain on PID 7, and reach maximal 
levels between PID 14 and PID 21 (307). In addition to that, B-cells have been 
shown to be associated with inflammatory lesions and perivascular cuffs (51). 
These observations are in agreement with findings presented here. However B-
cells entered the SFV infected brain later compared to previous studies. This is 
consistent with results obtained by immunohistochemistry flow cytometry. The 
differential use of mouse strains in this and previous studies could in part 
explain the temporal difference in B-cell infiltration into the CNS.  
Next, the kinetics of leukocyte entry during L10 infection of mice was defined 
for the first time. Leukocyte numbers were 16-fold increased compared to 
resting mice. The fold increase during L10 infection was higher compared to 
avirulent infection with strain A7(74).  Therefore it is possible that the extent 
of leukocyte infiltration depends on the virus strain used. However it is not 
clear whether leukocyte infiltration is a beneficial or detrimental process 
during viral encephalitis. Of note is the loss of the distinct CD45int microglial 
cell population in L10 infected mice. This could be explained due to the 
following reasons. First, it is possible that the CD45int microglial cell population 
was lost during the process of mononuclear cell isolation. Second, CD45int 
microglia could have upregulated their CD45 expression and become CD45hi in 
response to lethal infection with SFV. However this possibility seems unlikely as 
many studies have reported that activated microglia become only CD45int and 
not CD45hi during activation of microglia in neuroinflammation (117, 407, 410, 
422). Due to time constraints the L10 experiment was only performed once, 
and therefore further tests are required to draw firm conclusions from these 
preliminary results.  
There is a significant amount of knowledge regarding leukocyte trafficking 
during WNV infection but little is know about the detailed chemokine 
expression profile within the CNS of infected mice. Therefore a thorough 
chemokine expression analysis will be performed in the next chapter to 
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determine if the same chemokine pattern can also be found during brain 
infections using a virus from a different virus family. A common denominator 
with regards to chemokine expression would allow the design of appropriate 
intervention strategies for encephalitic processes in general. 
Although I was able to localize some leukocytes subsets within the avirally 
infected CNS, such as NK-cells, T-cells and macrophages, co-staining with 
chemokines did not work. This might have been due to the fact that brain 
tissue was embedded in paraffin rather than snap frozen. Therefore another 
alternative to localize chemokine expression within the infected CNS would be 
to use in-situ hybridization (ISH). Due to time constrains ISH was not performed 
and should be used in future experiments.                                                                 
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5.1 Introduction and aims 
Chemokines are important regulators of leukocyte trafficking in the body. As 
discussed in detail in the general introduction (chapter 1), chemokines play 
important roles during viral encephalitis. To date the expression and role of 
chemokines during viral brain infection have not been well characterised. In 
chapter 3 it was shown that chemokines are strongly, and selectively, 
upregulated in the CNS of mice infected with SFV. Concomitantly with the high 
expression of chemokines in the brain, it was shown that a large number of 
leukocytes infiltrate the infected CNS during SFV, and this is discussed in detail 
in chapter 4. The key chemokines upregulated during SFV infection were also 
found to be increased in other viral infections such as LCMV or MHV (128, 129). It 
was therefore hypothesised that the chemokine expression profile during viral 
encephalitis is similar between different pathogens. To test this hypothesis a 
different model of viral encephalitis was used to investigate if the chemokine 
expression profile is pathogen-specific.  
WNV was chosen as a model of infection since chemokines appear to play a 
pivotal role in the pathogenesis of WNV encephalitis. For example, it has been 
demonstrated that CCR5 is important for survival during WNV infection and 
clearance of virus by attracting the appropriate leukocytes into the CNS (362). 
However chemokines in the CNS of WNV infected mice have only been partly 
analysed in previous studies (214, 358). In particular CCL2 and CCL5 have been 
identified as important chemokines during WNV encephalitis (423, 424). To 
establish a detailed and clear picture of chemokine expression during WNV 
infection of the brain, the other aim of this chapter was to investigate the form 
and magnitude of chemokine expression during WNV induced encephalitis in 
detail. 
Furthermore cytokines and PRRs have also been shown to be involved during 
WNV infection (54, 72, 425). Subsequently in this chapter, I also investigated 
the expression of specific cytokines, and two selected PRRs, during WNV 
infection of the CNS.  
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5.2 Determination of viral titers in the blood and brain 
during West Nile virus infection   
First, C57BL/6 mice were inoculated intranasally with the suggested dose of 
2x104 PFU of WNV strain NY99 (426). Brains and blood were collected from 
control and infected mice at 2, 3, and 5 days post infection. The viral titers in 
the brain and blood were measured by QPCR to evaluate the functionality of 
WNV as model of infection. The viral titer in the blood reached a high titer of 
approximately 1x108 viral copies per 1 ml blood on PID 2 and stayed elevated 
throughout the infection until death after PID 6 (Fig. 5.1 A). The titer in the 
blood was slightly reduced on PID 6 but the difference was not statistically 
significant. 
Viral titers in the brain were initially low on post infection day 2. However viral 
transcripts quickly increased to more than 1x106 viral copies per 1x104 
housekeeping gene TATA-binding protein (TBP) by PID 4 and PID 6 (Fig. 5.1 B). 
The increase of viral transcripts on PID 6 was significantly different (p<0.01) to 
uninfected control brains. When mice became critically ill after PID 6, they were 
euthanized according to Home Office regulations. 
 
Figure 5.1 Viral titers in the blood and brain of WNV infected mice 
Mice were inoculated intranasally with WNV strain NY99. Brains and blood were collected from 
infected mice on post infection day (PID) 2, 4 and 6, and from healthy control mice. Viral gene 
transcripts for NS1 were quantified by QPCR. (A) Viral titer in the blood and (B) brains of 
infected and healthy mice with n=3 mice per time point. (Kruskal Wallis test with Dunn’s post 
test; ** p<0.01)  
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These data demonstrate that viral transcripts can be reliably and reproducibly 
detected in the brain and blood of WNV infected mice and confirms the 
efficiency of this model of infection to study viral encephalitis. 
5.3 Histological analysis of WNV infected brains 
To localise virus-infected cells and to investigate pathological changes in WNV 
infected mouse brains, immunohistochemistry was performed. Prior to staining, 
infected brains were fixed in formalin, embedded in paraffin and cut into 6 µm 
thick sections. Histological analysis of brain sections from infected mice 
revealed that perivascular cuffings form around blood vessels on PID 4 and PID 6, 
indicating leukocyte infiltration into the perivascular space of the BBB of 
cerebral capillaries (Fig. 5.2 A and B). Next, brain sections from infected mice 
were stained for viral protein NS1. On PID 4 a few viral particles could be 
detected, and by PID 5 virus had spread throughout the brain (Fig. 5.3). Mice 
became severely ill on PID 6, displaying neurological symptoms including 
paralysis of fore or hind limbs, and succumbed to the disease shortly afterwards. 
 
Figure 5.2 Perivascular cuffings forming around blood vessels during WNV infection 
After intranasal infection of mice with WNV strain NY99, perivascular cuffings (see arrows) 
appeared in the brain around blood vessels. (A) Haematoxylin and Eosin staining of a brain vessel 
on post infection day (PID) 6. (B) Cuff development within the brain of mice on PID 6. Brown 
staining indicates CXCL10 immunolabelling. Other cells were counterstained with hematoxylin. 
All images were taken from rostral regions of the brain. (A) Magnification at 40x and (B) 20x. 
n=3-4 mice. Help with this staining was kindly provided by Dr Nick Johnson, AHVLA, Surrey, UK. 
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Figure 5.3 Staining for viral protein in WNV infected mouse brains 
Mice were infected intranasally with WNV strain NY99, and brains were collected from infected 
mice on post infection day (PID) 2, 4 and 5, and from healthy control mice. Brain sections were 
formalin-fixed and paraffin embedded, and stained for viral protein NS1. Shown are infected 
neurons (brown staining, see arrows) scattered throughout the brain. Six µm thick sections were 
cut for immunohistochemistry. Brain sections were taken from rostral-, mid- and hind brain 
areas. All images are representative of 3-4 mice per time point. Magnification of all images at 
20x. Help with this staining was kindly provided by Dr Nick Johnson, AHVLA, Surrey, UK. 
 
5.4 Chemokine expression during WNV infection 
After determining viral titers in mice and investigating pathological changes in 
the CNS during WNV infection, it was next examined which chemokines are 
upregulated during WNV encephalitis. In chapter 3 it was demonstrated that 
chemokines are highly and selectively upregulated during SFV infection. 
Furthermore it was also shown that the magnitude of chemokine expression was 
dependent on the virus strain and disease severity.  
To test whether chemokines in WNV infected brains were upregulated in a 
similar fashion to SFV infection, brains were collected from mice infected with 
WNV strain NY99, which is a lethal and neuroinvasive strain of WNV. As in 
chapter 3 chemokine expression was measured by TLDA. To this end the same 
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TLDA plates as in described in chapter 3 were used for analysis of WNV infected 
samples. In brief, a 384-well format was selected, containing 32 genes, including 
most inflammatory CC- and CXC- chemokines, CX3CL1, XCL1, and a few 
inflammatory cytokines and innate immune response genes, known to play a role 
during viral infections. 
To test control and WNV infected brain samples by TLDA, the RNA quality was 
first assessed using the Agilent Bioanalyser. All samples were of high quality with 
a RIN greater than 8 (Fig. 5.4 A). The electropherogram for each sample showed 
a clear 18S and 28S band, which, again, is an indicator of high quality RNA. A 
representative electropherogram of one sample is illustrated in Fig. 5.4 B. The 
RIN values for each analysed sample are listed in Appendix 2 C. 
 
Figure 5.4 Assessment of RNA quality, isolated from WNV infection brains 
Total RNA was extracted from healthy control and WNV infected brains over the time course of 
infection and RNA quality was assessed for TLDA analysis using the Agilent Bioanalyser. (A) Gel-
like image of extracted RNA from murine brains. Lane L: size marker  (number of nucleotides, 
nt); Lane 1-3: healthy control samples; Lane 4-6: post infection day (PID) 2 samples; Lane 7-9: 
PID 4 samples; Lane 10-12: PID 6 samples. (B) Representative electropherogram showing the RNA 
profile of a high quality RNA sample. The x-axis represents amplicon size (nt), while the y-axis 
represents fluorescence units (FU). The RNA integrity number (RIN) was calculated and is 
indicated on the upper left hand corner of the electropherogram.  
 
5.4.1 CC-chemokine expression 
Chemokine expression on PID 2 was generally very low and comparable to 
healthy control mouse brains. The expression of CCL2 and CCL4 was more than 
two-fold upregulated at this point (Fig. 5.5). The expression profile between PID 
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4 and PID 6 was relatively similar but the magnitude of expression was several 
fold higher on PID 6 when mice were terminally ill (Fig. 5.5). In summary, 
chemokines CCL2-CCL7 were more than 100-fold upregulated on PID 4 and more 
than 1000-fold upregulated on PID 6. The most upregulated CC-chemokines 
during WNV infection of the brain were CCL2, CCL4 and CCL5. CCL2 expression 
on PID 4 was upregulated on average 309-fold ±114 SD compared to resting mice. 
By PID 6 a further 8.5-fold upregulation was noticed. The expression levels of 
CCL4 and CCL5 on PID 4 were 724±344 SD and 377±151 SD fold increased, 
respectively, compared to healthy mice. By PID 6 both chemokines were more 
than 3000-fold upregulated compared to controls. The expression levels of 
CCL20 and CCL11 were only moderately upregulated compared to other CC 
chemokines. 
To examine, if the expression of CCL2 and CCL5 is reproducibly elevated during 
WNV infection relative to healthy uninfected control brains, a QPCR analysis was 
performed to validate the results obtained from the TLDA analysis. The 
expression of CCL2 was significantly (p<0.05) increased by PID 6 compared to 
controls (Fig. 5.6 A). CCL5 was also significantly upregulated by PID 4 and PID 6 
(both p<0.05) compared to healthy controls (Fig. 5.6 B). The expression of CCL5 
was 330-fold and 1402-fold upregulated on PID 4 and 5, respectively. Thus, QPCR 
results are in agreement with results obtained from TLDA analysis and 
demonstrate strong upregulation of CCL2 and CCL5 during WNV infection. 
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Figure 5.5 Identification of CC-chemokine expression patterns during WNV 
infection with strain NY99 
All mice were infected with WNV intranasally, and RNA was isolated from infected brains on post 
infection day (PID) 2, 4 and 6, and from healthy controls. The expression of CC-chemokines was 
measured by TLDA. Each gene was double normalized to an endogenous control 18S and to an 
uninfected healthy control brain. The relative quantification (RQ) values are depicted as mRNA 
fold changes and are shown on the y-axis. The RQ value of an uninfected control brain was set to 
1. Data are shown as mean ± SD, n=3 mice per time point. Each gene was tested in triplicate.  
 
 
Figure 5.6 Validation of CCL2 and CCL5 expression by QPCR during WNV infection 
The expression of CCL2 and CCL5 transcripts was highly upregulated during WNV infection, as 
shown by TLDA analysis. Therefore these genes were selected for validation by QPCR. The 
absolute copy number of each gene was measured and normalized to 1x104 copies of TATA-
binding protein (TBP). Shown is the expression of (A) CCL2 and (B) CCL5. Each gene was tested in 
triplicate; Data presented as mean ± SD with n=3 mice per time point; PID=post infection day; 
(Kruskal-Wallis test with Dunn’s post test; * p<0.05) 
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5.4.2 CXC-chemokine expression 
On PID 2 CXCL9 and CXCL10 were 3- and 9-fold upregulated, respectively, while 
other CXC-chemokines were only minimally, or not, upregulated compared to 
resting mice (Fig. 5.7). On PID 4 other chemokines such as CXCL1, CXCL2 and 
CXCL16 were moderately upregulated compared to controls (Fig. 5.7). CXCL9 
and CXCL10 levels were the earliest and highest upregulated CXC-chemokines in 
WNV infected brains. The expression of CXCL9 was 331-fold ±116 SD 
upregulated, and CXCL10 levels were 2350-fold ±671 SD increased relative to 
resting mouse brains, making CXCL10 the most upregulated chemokines on PID 4.  
On PID 6 the chemokine expression levels were similar to that on PID 4 but 
generally the magnitude of expression was markedly higher. For example, levels 
of CXCL1 and CXCL2 were rapidly 20-fold and 89-fold upregulated, respectively, 
between PID 4 and PID 6. The expression of CXCL9 was 6923-fold upregulated by 
PID 6 compared to controls, which resulted in CXCL9 being the most upregulated 
chemokine on PID 6. The expression of CXCL10 was also highly, 2603-fold ±379 
SD, upregulated on PID 4 compared to controls but the level of expression 
increased only minimally between PID 4 and PID 6. The expression levels of 
CXCL5 and CXCL12 were similar to controls.  
Due to the rapid upregulation of CXCL1 and CXCL2, and the strong upregulation 
of CXCL10, a QPCR analysis was performed to validate the results obtained by 
TLDA analysis. CXCL1 was significantly upregulated by PID 4 (p<0.05) and PID 6 
(p<0.05) compared to controls (Fig. 5.8 A). CXCL2 was significantly upregulated 
by PID 6, showing a 330-fold increase compared to controls (Fig. 5.8 B). CXCL10 
expression was also significantly upregulated on PID 4 and PID 6 (both p<0.05) 
(Fig. 5.8 C). Overall, these QPCR results were in agreement with the TLDA 
results but the magnitude of CXCL1 and CXCL2 expression was slightly lower as 
assessed by QPCR. 
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Figure 5.7 Identification of CXC chemokine expression patterns during WNV 
infection with strain NY99  
All mice were infected intranasally with WNV, and RNA was isolated from infected brains on post 
infection day (PID) 2, 4 and 6, and from healthy controls. The expression of CXC-chemokines was 
measured by TLDA. Each gene was double normalized to an endogenous control 18S and to an 
uninfected healthy control brain. The relative quantification (RQ) values are depicted as mRNA 
fold changes and shown on the y-axis. The RQ value of an uninfected control brain is set to 1. 
Data are presented as mean ± SD with n=3 mice per time point. Each gene was tested in 
triplicate. 
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Figure 5.8 Validation of CXCL1, CXCL2 and CXCL10 expression by QPCR 
The expression of CXCL1, CXCL2 and CXCL10 was highly upregulated by TLDA analysis during WNV 
infection and therefore these genes were selected for validation by QPCR. The absolute copy 
numbers of each gene were measured and normalized to 1x104 copies of TATA-binding protein 
(TBP). Shown are the expression of (A) CXCL1, (B) CXCL2 and (C) CXCL10 by QPCR. Each gene was 
tested in triplicate. Data are presented as mean ± SD with n=3-4 mice per time point. PID=post 
infection day. (Kruskal-Wallis test with Dunn’s post test; * p<0.05) 
 
5.4.3 CX3CL1 and CXCR5 expression 
The expression level of CX3CL1 was similar to that in healthy control brains (Fig. 
5.9). On PID 6 CX3CL1 expression was 0.6-fold downregulated compared to 
expression levels at other time points but this result was not statistically 
significant. 
CXCR5 is mainly expressed on B-cells and binds to the ligand CXCL13. The 
expression of CXCR5 was measured by QPCR only, since this chemokine receptor 
and its ligand were not included on the TLDA plates. Here we showed that 
CXCR5 is significantly (p<0.05) upregulated on PID 6, suggesting the possibility of 
B-cell infiltration into the CNS of terminally ill mice infected with WNV (Fig. 
5.10).  
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Figure 5.9 Expression of CX3CL1 during WNV infection relative to an uninfected 
healthy mouse brain by TLDA 
After infection of mice intranasally with WNV, RNA was isolated on post infection day (PID) 2, 4, 
and 6 from infected and control mice. The expression of CX3CL1 was double normalized to an 
endogenous control 18S and to an uninfected healthy control brain. The relative quantification 
(RQ) values are depicted as mRNA fold changes and are shown on the y-axis. The RQ value of an 
uninfected control brain was set to 1. Data are presented as mean ± SD with n=3 mice per time 
point. (One-way ANOVA with Tukey’s post test; results were not significant) 
 
 
 
 
Figure 5.10 The expression of CXCR5 in WNV infected brains  
Mice were infected intranasally with strain NY99. Absolute copy numbers in infected and control 
mouse brains were measured in control and WNV infected samples by QPCR at the time indicated 
on the x-axis. Data were normalized to 1x104 copies of TATA binding protein (TBP). Data are 
presented as mean ± SD with n=3 mice per time point. (Kruskal-Wallis test with Dunn’s post test; 
* p<0.05) 
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5.5 Expression of cytokines and genes involved in 
innate immune responses to viral infection with 
WNV 
After the characterisation of chemokine expression during WNV encephalitis, the 
expression of cytokines and PRRs, involved in innate immunity, was determined. 
On PID 2 cytokines were generally not, or minimally, upregulated. However IRF7 
and RIG-I were 22-fold ±6 SD and 132-fold ±10 SD upregulated, respectively, 
compared to control brains (Fig. 5.11). These two PRRs were consistently 
increased during WNV infection. On PID 4 most cytokines and PRRs were more 
than 100-fold upregulated with the exception of TGF-β and IL-1β (Fig. 5.11). IFN-
α was the most upregulated cytokine during WNV infection, reaching a 1890-fold 
±532 SD increase on PID 4 and a 3730-fold ±1298 SD upregulation by PID 6. On 
PID 6 the expression profile of PRRs and cytokines was similar to that on PID 4 
but cytokine expression was several fold higher (Fig. 5.11). Most cytokines were 
more than 1000-fold increased compared to resting mouse brains with the 
exception, again, of TGF-β and IL-1β. Thus, cytokines and PRRs, similar to 
chemokines, are selectively and highly upregulated in the CNS of WNV infected 
mice. 
The result of IFN-β expression obtained by TLDA analysis was validated by QPCR. 
IFN-β was significantly (p<0.05) and rapidly upregulated by PID 4 and PID 6. The 
fold increase compared to controls was calculated and amounted to a 270-fold 
and 350-fold upregulation by PID 4 and PID 6, respectively (Fig. 5.12 A). 
Unfortunately the expression of IFN-γ could not be evaluated by TLDA because 
the expression was too low in control samples and resulted in a RQ value of zero, 
which made subsequent comparisons impossible. To this end, the expression of 
IFN-γ was assessed by QPCR (Fig. 5.12 B). It was shown that IFN-γ levels were 
indeed very low in control brain samples, and the copy numbers of IFN-γ were 
significantly (p<0.05) higher by PID 4 and PID 6. However, the maximal 
upregulation of IFN-γ expression was later, on PID 6, compared to maximal levels 
of IFN-β expression by PID 4. Fold changes between controls and infected 
samples were calculated. IFN-γ was 13-fold and 411-fold upregulated by PID 4 
and PID 6, respectively. 
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Figure 5.11 Expression of cytokines and genes involved in innate immune responses 
during WNV infection of the brain 
Mice were infected i.n. with WNV strain NY99, and brains were collected for TLDA analysis on 
post infection day (PID) 2, 4, and 6 and from healthy control mice. Each gene was double 
normalized to an endogenous control 18S and to an uninfected healthy control brain. Changes in 
relative quantification (RQ) compared to controls are depicted as mRNA fold changes on the y-
axis. The RQ value of an uninfected control brain equals 1. Each gene was tested in triplicate. 
Data are represented as mean ± SD with n=3-4 mice per time point. 
 
 
Figure 5.12 Expression of IFN-β  and IFN-γ  in WNV infected brains by QPCR 
Mice were infected with WNV i.n. for 6 days, and brains were collected from infected and 
control mice. Absolute copy numbers were measured and normalized to the housekeeping gene 
TATA binding protein (TBP). Shown are the expression of (A) IFN-β and (B) IFN-γ. Data are 
presented as mean ± SD with n=3-4 mice per time point. Each sample was tested in triplicate. 
(Kruskal-Wallis test with Dunn’s post test; * p<0.05) 
 
5.5.1 Expression of CD45 
To evaluate the extent of leukocyte infiltration into the CNS on the mRNA level, 
the expression of the pan-leukocyte marker CD45 was assessed by TLDA and 
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QPCR. TLDA results demonstrated that CD45 is significantly upregulated by PID 4 
(p<0.05) and PID 6 (p<0.01) compared to healthy control mouse brains (Fig. 5.13 
A). Upregulation was highest on PID 6, with a 26-fold ±5.4 SD increase compared 
to resting mouse brains. This result is in agreement with results obtained by 
QPCR (Fig. 5.13 B). CD45 was, again, significantly upregulated by PID 4 (p<0.05) 
and PID 6 (p<0.01). Absolute copy numbers of CD45 were generally low in control 
samples. Thus, these results suggest that a large number of leukocytes infiltrate 
the brain during WNV infection.   
 
Figure 5.13 Absolute and relative expression of CD45 during WNV infection of the 
CNS 
Mice were infected i.n. with WNV strain NY99, and brains were collected on post infection day 
(PID) 2, 4, and 6, and from healthy control mice. (A) Absolute copy numbers of CD45 per 1x104 
TATA binding protein (TBP) were measured by QPCR. (B) mRNA fold changes of CD45 expression 
relative to the expression of an uninfected control brain were measured by TLDA. Data are 
presented as mean ± SD with n=3-4 mice per time point. Each sample was tested in triplicate. 
(One-way ANOVA with Tukey’s post test; * p<0.05, ** p<0.01) 
 
5.6 Discussion and summary 
Firstly, C57BL/6 mice were successfully infected with WNV. Similar to SFV 
infection, WNV infected mice developed a high viremia within 2 days of 
infection. Viremia remained elevated in WNV infected mice and was not cleared 
by PID 6. In support of this, mice infected with SFV strain L10 also had high viral 
titers in the blood which remained elevated throughout the course of infection 
while mice infected with strain A7(74) were able to clear the virus from the 
blood (Data shown in chapter 3). Viral titers in the brain during WNV were 
elevated by PID 4 and increased further by PID 6 when mice became terminally 
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ill. A similar result has also been observed during L10 infection where viral titers 
steadily rose until the death of the mice.  
Klein et al. have reported that WNV predominantly infects neurons and spreads 
throughout the brain (153). Histological analysis confirmed these findings and 
revealed an increasing number of infected neurons throughout the brain over the 
course of infection. Additionally, perivascular cuffings in the infected brain 
became evident, indicative of leukocyte infiltration. Previous studies have 
shown that a large number of leukocytes enter the brain during WNV infection, 
and therefore these findings are in agreement with the results presented here 
(20, 355, 375).  
One of the main aims of this study was to identify the form and magnitude of 
chemokine and cytokine expression during WNV infection, and to investigate 
whether chemokine expression was pathogen-specific. The data demonstrate 
that WNV infection results in a more rapid, broader based and higher-level, 
induction of chemokines and cytokines than avirulent SFV A7(74) infection, 
suggestive of a more aggressive CNS response to the virus comparable to that 
seen with SFV L10 infection. In brief, the following six chemokines have been 
identified as being highly upregulated during WNV infection: the CC-chemokines 
CCL2, CCL4, CCL5 and the CXC-chemokines CXCL2, CXCL9 and CXCL10. Within 
CC-chemokines CCL4 was the most upregulated chemokine followed by CCL5 and 
CCL2, and within CXC-chemokines induction of CXCL9 expression was highest 
followed by CXCL10 and CXCL2. 
Previous studies have reported that CXCL9 and CXCL10 are the most strongly 
induced chemokines during other viral infections of the brain using LCMV or MHV 
as models of infection (154, 427). In support of this another study using WNV as a 
model of viral encephalitis has demonstrated that CXCL10 is one of the earliest 
upregulated chemokines during WNV infection of the brain. The main source of 
CXCL10 has been shown to be neurons, and expression of this chemokine seems 
to vary within different brain areas (153, 375). Data presented in this chapter 
confirm previous findings that CXCL10 is rapidly, and strongly, induced during 
WNV infection of the brain.  
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Of interest is that CXCL9 expression on PID 6 is higher than CXCL10 expression. 
However on PID 2 and PID 4 CXCL10 was the highest induced chemokine during 
WNV infection.  It appears that once CXCL10 was upregulated by PID 4 the 
expression was not further increased by PID 6 whereas the expression of CXCL9 
increased 20-fold between PID 4 and 6. This suggests the possibility that the 
cellular source and regulation of expression of CXCL9 and CXCL10 is different 
and dependent on distinct factors. In support of this, Klein et al. have shown 
that CXCL10 is produced earlier than CXCL9, and that levels of CXCL9 expression 
exceeds levels of CXCL10 later during infection with WNV (153). Studies of 
neuroinflammation have demonstrated that many neural cells are capable of 
producing CXCL10 whereas CXCL9 was shown to be predominantly expressed by 
microglia and mononuclear cells in the infected brain (400). Additionally some 
studies have demonstrated that CXCL10 expression is induced in response to 
type-I and type-II interferon whereas the expression of CXCL9 is induced by IFN-γ 
only (242, 428). In agreement with these studies the TLDA data presented here 
demonstrate that IFN-α is the strongest upregulated cytokine during WNV 
infection and transcript levels were already increased by PID 2 compared to 
resting mouse brains. Similar to this, IFN-β was also highly and rapidly 
upregulated by TLDA and QPCR. In contrast to this the QPCR results show that 
the expression of IFN-γ is not increased by PID 2 but is significantly upregulated 
by PID 4 and PID 6. From this it appears that type-I interferon expression is 
induced earlier than type-II interferon expression. Thus the differential 
expression of IFNs could explain the higher expression of CXCL9 at later time 
points compared to CXCL10. 
Also of note is the strong upregulation of CCL4 expression during WNV infection 
of the brain. This result is in agreement with a previous study where CCL4, 
together with the other CCR5 ligands CCL3 and CCL5, was also highly 
upregulated during lethal WNV infection (358). Interestingly another study by 
Lim et al. has demonstrated that CCL4 is not induced by WNV infection (214). 
This discrepancy could be explained by the use of a different viral dose of WNV 
for the inoculation of mice. Lim et al. have used a low dose of 4x102 PFU of WNV 
whereas 2x104 and 1x105 PFU were used in this study and by Shirato et al., 
respectively (214, 358). 
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The expression of the other CCR5 ligand CCL5 was also strongly induced during 
WNV infection. This is in agreement with previous studies, identifying CCL5 as 
one of the key chemokines upregulated in the CNS during WNV encephalitis (54, 
197, 361). Consistent with WNV studies, CCL5 has also been shown to be strongly 
upregulated during other viral infections including SFV infection, as illustrated in 
chapter 3, as well as MHV or LCMV infection (319, 429).  
The strong induction of CXCL1 and CXCL2 during lethal WNV infection is also 
striking. A similar result was found during SFV infection of the brain, as 
discussed in chapter 3. However during avirulent infection with SFV, CXCL1 and 
CXCL2 were not, or only minimally, upregulated relative to resting mouse brains. 
Thus, it is possible that the expression of CXCL1 and CXCL2 is associated with 
more severe disease outcomes. CXCL1 and CXCL2 are both ligands for CXCR2+ 
neutrophils. In support of my results Kim et al. have demonstrated that the 
attraction of neutrophils in response to CXCL1 and CXCL2 expression during LCMV 
infection leads to fatal meningoencephalitis (138). This is in contrast to another 
study by Hosking et al. who have shown that infiltration of neutrophils in 
response to CXCL1, CXCL2 and CXCL5 expression during MHV infection is 
beneficial and leads to enhanced survival, decreased viral titers in the brain and 
increased T-cell migration to the CNS (340). Thus, the role of CXCL1 and CXCL2 
associated neutrophil attraction into the CNS during viral encephalitis is 
inconclusive and further studies are required to elucidate its role. 
The expression of CCL2 during WNV infection was also strongly upregulated in 
the CNS. This result, again, is consistent with results obtained from SFV infected 
mouse brains using strains L10 and A7(74). In comparison to other chemokines, 
and their receptors, the role of the CCL2-CCR2 axis has been well described in 
many models of viral encephalitis. For example, in WNV infection of the CNS, 
CCL2 has been shown to play a pivotal role for the attraction of CCR2+ 
monocytes into the CNS (106, 214, 401). Additionally Chen et al. have shown 
that the CCL2-CCR2 axis is important for trafficking of leukocytes into the brain 
during MHV infection for viral clearance and enhanced survival of the host (334). 
However, the role of CCR2 in mediating monocyte entry into the CNS is 
contentious, since it is hard to evaluate the role of CCR2 in CCR2-/- mice due to 
their monocytpenia. Therefore in chapter 6 pharmacological blockers of CCR2 
 Chapter 5. Characterization of chemokine and cytokine in CNS during WNV infection       209 
   
are used to investigate in more detail the role of CCR2 in monocyte trafficking 
into the CNS. 
In conclusion, the chemokine expression during WNV infection was very similar 
to that during SFV infection using the lethal strain L10. Chemokines were 
strongly upregulated compared to controls. Cytokines and PRRs were also 
strongly induced in WNV infection similar to that seen in L10 infection. The 
chemokine expression pattern during WNV differs from that seen during 
avirulent SFV infection in several ways. Firstly, chemokines were more rapidly 
and more highly increased during WNV infection. Secondly, chemokine 
expression was generally broader based. For example CXCL1, CXCL2 and CXCL3 
were not, or only minimally, expressed during A7(74) infection. Avirulent 
infection of the CNS induces a highly selective, and lower level induction of 
chemokines compared to virulent infection of the CNS using two different 
viruses, SFV L10 and WNV NY99. 
In the next chapter the role of key chemokines, identified through studies using 
SFV and WNV, shall be investigated in more detail in regard to leukocyte 
infiltration and pathogenesis. 
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Pharmacological intervention using 
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infection	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6.1 Introduction and aims 
Chemokine mediated influx of leukocytes into the CNS can act to clear infections 
but can also be responsible for deleterious bystander neuronal damage 
associated with morbidity and, in some cases, increased mortality. The outcome 
of disease depends not only on the virus strain used but also on a range of host 
factors, including immune status and age.  
In the previous chapters 3 and 5 a thorough chemokine expression analysis in the 
brain was performed, and I was able to identify key chemokines upregulated 
during SFV and WNV infection. These key chemokines are ligands for CCR2, CCR5 
and CXCR3. The role of these chemokine receptors during viral encephalitis has 
yet to be fully elucidated because it is not clear whether these receptors are 
beneficial or detrimental to disease outcome. A previous study has demonstrated 
that CCR2 is pivotal for the recruitment of monocytes to the brain where they 
play pathogenic roles during viral infection (106). This is in contrast to another 
study where CCR2+ monocytes were depleted which resulted in enhanced 
mortality, suggesting a protective role of CCR2+ monocytes during viral 
encephalitis (346).  
Similar contradictory results were obtained using CXCR3-/- mice. One study has 
reported that WNV or LCMV infected CXCR3-/- mice display enhanced CNS viral 
titers and mortality, and reduced CD8+ T-cell recruitment to the CNS which is 
associated with reduced viral clearance (375, 430). Another study by Hofer et al. 
has demonstrated that CXCR3-/- mice, infected with LCMV, display unaltered 
neurological disease and mortality, suggesting that CXCR3 is not pathogenic 
(431).  Likewise a putative role for CCR5 has also been suggested in the context 
of immune responses to WNV infection, although CCR5 is dispensable for 
responses to LCMV (173, 319, 336). Firm conclusions on the chemotactic basis by 
which leukocytes enter the CNS is difficult using gene deficient mice, in which 
deficiency in a particular chemokine receptor may exert its influence at multiple 
stages including developmental and homeostatic stage, and generation of 
primary immune responses, in addition to the process by which leukocytes enter 
the CNS. 
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In an attempt to understand the role of the chemokine receptors CCR2, CCR5 
and CXCR3 during viral encephalitis, SFV was used as a model of infection. The 
main aim in this chapter was to evaluate the hierarchy and relative importance 
of distinct chemokine receptors for CNS leukocyte influx and pathogenesis. This 
is the first time that a panel of chemokine receptor antagonists has been used in 
the context of viral encephalitis. 
To block CCR2, the chemokine receptor blocker RS504393 was used, which binds 
selectively to CCR2 with high affinity (218, 432). For the blockade of CCR5, two 
blockers, Maraviroc and DAPTA were used as both blockers have been shown to 
be highly efficient in blocking CCR5 during HIV infection (198, 223). Lastly, 
CXCR3 was blocked using the imidazo-pyrazine derivative, referred to as 
compound 21, which was kindly provided by Amgen. This blocker has been shown 
to be highly efficient in blocking CXCR3 in a mouse model of lung inflammation 
(232). All antagonists are discussed in depth in section 1.3.5 of the introduction. 
6.2 Characterisation of the role of CCR2 during viral 
encephalitis 
To investigate the role of CCR2 during SFV encephalitis the chemokine blocker 
RS504393 was used at a concentration of 5mg/kg in 6.6% DMSO in PBS twice a 
day. This dose was selected based on studies by Yang and Kitagawa et al. (218, 
432). Control mice were treated with vehicle control. This blocker has previously 
been shown to be efficient in blocking CCR2 recruitment to sites of inflammation 
in models of LPS induced lung inflammation and progressive kidney fibrosis.  
Before treatment, mice were first infected with SFV strain A7(74) unless stated 
otherwise. The drug, or vehicle control, was administered to infected mice by 
oral gavage twice daily between post infection days 3-7, to prevent interfering 
with monocyte numbers in the blood during the first phase of infection when 
virus disseminates throughout the body.  
6.2.1 Identification of monocytes in the blood during early 
stages of SFV infection 
For West Nile virus infection it has been reported that monocytes are highly 
elevated in the blood during the first 5 days of infection (214). This monocytosis 
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is pivotal for the infiltration of monocytes into the virally infected CNS. To 
investigate whether monocytosis also occurs during SFV infection, blood was 
collected from SFV infected mice between 24 hours to 7 days post infection, and 
analysed by flow cytometry. After inoculation of mice with SFV strain A7(74), 
titers rose quickly to high levels within 24 hours post infection. Viremia was 
almost completely cleared from the blood by PID 7, when viral transcript levels 
for E1 or nsp3 were very low (Fig. 6.1 A and B). 
 
Figure 6.1 Viral titers in the serum of SFV A7(74) infected mice 
Mice were inoculated i.p. with SFV strain A7(74) and serum was collected from infected mice at 
the time points indicated. Viral titers were measured by QPCR. (A) Copy numbers of viral genes 
E1 and (B) nsp3 were quantified in the serum of infected mice. n=5 mice per time point; 
(Kruskal-Wallis test with Dunn’s post test; * p<0.05) 
 
After analysis of viral titers in the blood of SFV infected mice, the proportion of 
myeloid cells in the blood was determined next. Overall, the percentage of 
CD11b+ cells was significantly elevated (p<0.05) 48 hours post infection 
compared to healthy controls (Fig. 6.2 A). Furthermore the level of CD11b+ cells 
in the blood significantly decreased again by PID 7 when levels of myeloid cells 
were similar to controls. The proportion of CD11b+Ly6ChiCCR2+ cells, identified 
as ‘inflammatory’ monocytes, was already significantly (p<0.05) increased by 24 
hours post infection, and returned to basal levels by PID 7 (Fig. 6.2 B and C).  
Antibody staining for Ly6C and Ly6G revealed that the proportion of Ly6C- and 
Ly6Chi and Ly6Cint cells within the CD11b+ compartment increased 24 hours post 
infection and often reached maximal levels 48 hours post infection (Fig. 6.2 D-
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G). The increase of Ly6C- cells and Ly6Chi cells was significant (p<0.05) by 48 and 
24 hours post infection, respectively, whereas the increase in Ly6Cint cells was 
not statistically significant by 24 and 48 hours post infection (Fig. 6.2 E-G). 
Lastly, the proportion of CD11b+Ly6G+ cells, identified as neutrophils, was not 
significantly changed in the blood over the time course of infection (Fig. 6.2 H). 
Thus, the proportions of monocytes are also elevated during SFV infection but 
the increase is less profound compared to WNV infection where monocyte 
numbers in the blood are approximately 3.5 fold higher during WNV infection 
compared to healthy control mice (214). 
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Figure 6.2 Identification of myeloid cells subsets in the blood during SFV infection 
Mice were infected with SFV strain A7(74) and blood was collected at the indicated time points 
(PID=post infection day). The proportions of myeloid cell subsets were determined by flow 
cytometry. (A) Proportions of CD11b+ cells and (B) CD11b+Ly6ChiCCR2+ monocytes within isolated 
leukocytes in the blood. (C) Representative dot plots of CD11b+Ly6ChiCCR2+ monocytes in the 
blood over the time course of infection, gated on CD11b+ cells.  (D) Representative dot plots of 
Ly6C and Ly6G expression by CD11b+ cells, revealing a distinct leukocyte population within each 
gate P1-P4. Proportions of (E) CD11b+Ly6Chi monocytes within the P4 gate, (F) CD11b+Ly6Cint 
monocytes within the P3 gate, (G) CD11b+Ly6C- cells within the P4 gate and (G) neutrophils 
(CD11b+Ly6G+) within the P1 gate amongst total live cells in the blood. Data are represented as 
mean ±  SD with n=5 mice per time point. (One-way ANOVA with Tukey’s post test; * p<0.05) 
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6.2.2 Inhibition of CCR2 leads to the reduction of leukocyte 
accumulation in the CNS during SFV A7(74) infection  
After infection of mice with SFV A7(74), and treatment of mice with vehicle or 
CCR2 blocker, the number of CD45hi cells was determined by flow cytometry. 
The data demonstrate that the extent of leukocyte infiltration into the brain of 
WT infected mice treated with CCR2 blocker was significantly reduced (p<0.001) 
(Fig. 6.3 A and B). Compared to untreated controls the proportion of CD45hi cells 
in the CNS of treated mice was up to 54% reduced. To further confirm the roles 
of CCR2 in leukocyte accumulation in the infected CNS, I also used CCR2-/- mice 
in this experiment in which leukocyte infiltration was significantly (p<0.001) 
reduced (approximately 76%) to a level similar to that observed in mice treated 
with RS504393. 
 
Figure 6.3 Reduction of leukocyte infiltration into the CNS during SFV infection in 
CCR2 deficient mice or mice treated with CCR2 blocker  
Wild type and CCR2 deficient mice were infected with SFV strain A7(74) for 7 days and brains 
were collected for analysis. The number of CD45hi leukocytes in each group was determined by 
flow cytometry. Mice were treated twice daily by oral gavage with vehicle (6.6% DMSO in PBS) 
(untreated and CCR2-/- group) or 5 mg/kg RS504393 (CCR2 blocker) (treated group) between post 
infection days 3-7. n= 4-7 pooled mouse brains per group from 1-3 individual experiments. 
Analysis in CCR2-/- mice was only performed once. (A) Representative dot plots of CD45 
expression on isolated brain cells in untreated, treated and CCR2-/- mice on post infection day 7. 
Cells were gated on CD45hi cells. (B) Proportion of CD45hi cells within total live brain cells. (C) 
Expression of the viral protein E1 in each group was measured and normalized to 1x104 copies of 
TATA-binding protein (TBP). Data are presented as mean ± SD (One-way ANOVA with Tukey’s 
post test; *** p<0.001) 
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To determine if the reduction of leukocyte infiltration has an effect on viral 
titers in the CNS, the expression of the viral protein E1 was measured by QPCR. 
The results show that viral titers were not significantly changed in CCR2 blocker 
treated or CCR2-/- mice compared to that in untreated wildtype control brains 
(Fig. 6.3 C).  
Next the leukocyte subsets entering the brain of CCR2 treated mice during viral 
encephalitis were investigated in more detail to determine which leukocyte 
population is specifically affected by the blockade of CCR2. As mentioned in the 
general discussion CCR2 is predominantly expressed on monocytes but can also 
be found on few activated NK-cells and T-cells, although this point of view is 
contentious (25, 211, 212). I have therefore selected markers for monocytes 
such as CD11b and Ly6C, and also for T-cells and NK-cells such as CD3 and NK1.1, 
respectively, for subsequent flow cytometry analysis. All three leukocyte subsets 
have been found to infiltrate the brain during SFV infection as demonstrated in 
chapter 4. 
 
6.2.2.1 T-cells and NK-cells entering the CNS during CCR2 
blockade of SFV infected mice 
Despite a 5.1-fold reduction of CD45hi leukocytes in CCR2 deficient mouse brains, 
the proportion of CD3+ T-cells was significantly (p<0.01) higher compared with 
proportions in brains of untreated and CCR2 blocker treated wild type mice (Fig. 
6.4 A and B). This discrepancy can probably be explained by the lack of 
monocytic cells entering the brain in CCR2-/- mice, resulting in high proportions 
of T-cells within the CD45hi compartment. Indeed, after determining the number 
of CD3+ T-cells per 105 brain cells it was demonstrated that the number of T-
cells entering the brain in CCR2-/- mice was significantly (p<0.05) lower 
compared with untreated wild type mouse brains (Fig. 6.4 B).  The proportion of 
CD3+ T-cells in CCR2 blocker treated mice was comparable to that of untreated 
mice, but the number of CD3+ T-cells was significantly (p<0.05) reduced in 
treated mice. Thus, the genetic or pharmacological blockage of CCR2 results in a 
significant reduction of T-cell numbers within the CNS. Within the CD3+ cell 
fraction the proportion of CD4+ cells was significantly lower (p<0.05) in control 
mice compared with CCR2-/- mice but the percentage of CD4+ T-cells was highest 
in treated mice. The proportion of CD8+ cells was significantly higher in control 
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mice compared to CCR2 deficient mice  and also higher in CCR2 blocker treated 
mice, but this result was not statistically significant (Fig. 6.4 C).  
 
 
Figure 6.4 Reduction of CD3+ T-cells and NK-cells within the brains of SFV infected 
mice in CCR2 deficient or CCR2 blocker treated mice 
Wild type and CCR2-/- mice were infected with SFV strain A7(74) for 7 days and brains were 
collected for analysis. The number of CD3+ T-cells and NK1.1+ cells was assessed by flow 
cytometry. Mice were treated twice daily by oral gavage with vehicle (6.6% DMSO in PBS) 
(untreated and CCR2-/- group) or 5 mg/kg RS504393 (CCR2 blocker) (treated group) between post 
infection days 3-7. n= 4-7 pooled mouse brains per group from 1-3 individual experiments. (A) 
Representative dot plots of CD3 expression on CD45hi cells in the brain in untreated, treated and 
CCR2 deficient mice on post infection day 7. (B) Proportions and numbers of CD3+ T-cells in the 
brain within each group. (C) Proportion of CD4+ and CD8+ T-cells within the CD3+ cell population 
(D) Proportions and numbers of NK1.1+ cells in the CNS within each group. All cells were gated on 
CD45hi cells. Data are presented as mean ± SD ((B and D) One-way ANOVA with Tukey’s post test 
and (C) Two-way ANOVA with Bonferroni’s post test; * p<0.05, ** p<0.01) 
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The proportion of NK-cells was not significantly different between untreated and 
CCR2 blocker treated wild type mice or CCR2 deficient mice (Fig. 6.4 D). 
However the number of NK-cells per 105 brain cells was significantly reduced in 
CCR2 blocker treated mice and CCR2 deficient mice (both p<0.05) compared 
with untreated wild type counterparts.  
6.2.2.2 Myeloid cells 
Having analysed the effect of CCR2 blockage on T-cell and NK-cell entry into the 
CNS, the number of CD11b+ cells in the brain of untreated, treated and CCR2-/- 
mice was determined. During SFV infection many monocytes/macrophages enter 
the CNS, and since CCR2 is highly expressed on these cells it was hypothesised 
that the number of monocytes and macrophages would be decreased. The 
number of CD11b+ cells per 105 isolated brain cells was significantly (both 
p<0.01) reduced in treated and CCR2-/- mice. However in CCR2-/- mice also the 
percentage of CD11b+ cells was significantly reduced (both p<0.01) compared 
with untreated mice (Fig. 6.5 A and B). Within CD11b+ leukocytes the proportion 
and number of Ly6Chi cells was significantly reduced in CCR2 blocker treated and 
CCR2 deficient mice (both p<0.001) (Fig. 6.5 C). However the proportion of Ly6C- 
cells within the myeloid cell compartment was significantly increased (p<0.001) 
in CCR2 blocker treated mice. These cells are probably macrophages based on 
their SSC and FSC properties. Contrary to this, the proportion of Ly6C- cells 
within CCR2-/- mice was significantly (p<0.01) decreased compared to untreated 
control mice (Fig. 6.5 D). Numbers of Ly6C- cells revealed similar results and 
show a significant reduction of Ly6C- cells in CCR2-/- mice compared to untreated 
and treated mice. 
The numbers of CD11b+Ly6ChiCCR2+ cells per 105 brain cells, previously described 
as ‘inflammatory monocytes’, were significantly reduced in CCR2 blocker 
treated and CCR2 deficient mice (both p<0.001) compared with untreated 
control mice (Fig. 6.6 A and B) (106). The proportion of CD11b+CCR2+ cells was 
almost completely reduced in CCR2 blocker treated mice, similar to the defect 
seen in CCR2 deficient mice, and resulted in a significant reduction of monocytic 
cells within the infected brain (both p<0.05). Thus, the pharmacological 
blockage of CCR2 with RS504393 results in the selective reduction of CCR2+ cells 
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within CD11b+ cells in the CNS of SFV infected mice, confirming the efficacy of 
this drug in blocking CCR2.  
6.2.2.3 Effect of CCR2 blocker on blood monocytes during SFV 
infection 
In a previous study using WNV it was reported that CCR2 plays an important role 
in the egress of monocytes from the bone marrow and return of monocytes from 
the blood to the bone marrow (214). To test the role of CCR2 in trafficking of 
monocytes to the CNS and to investigate if the observed reduction of monocyte 
numbers in the brain was due to monocytopenia, blood was taken from mice 
treated with RS504393 or vehicle control. The proportions of CD11b+ cells and 
CD11b+Ly6ChiCCR2+ cells, also described as ‘inflammatory monocytes’, were not 
significantly different after treatment with CCR2 blocker suggesting that the 
CCR2 blocker had no effect on the number of circulating monocytes within the 
blood. However, 24 hours after treatment, the proportion of monocytes was 
slightly higher compared with untreated counterparts (Fig. 6.7 A -C). This 
increase was not statistically significant. Furthermore within CD11b+ cells the 
proportions of Ly6Chi and Ly6Cint monocytes (P4 and P3 gate), Ly6C- cells (P2 
gate) and CD11b+Ly6G+ neutrophils (P1 gate) were not significantly different in 
mice treated with the CCR2 blocker compared with proportions in untreated 
mice (Fig. 6.7 D-H).   
Thus CCR2 plays a critical role in the accumulation of monocytes/macrophages 
and T-cells in the CNS during viral encephalitis with no significant effect on viral 
titers in the CNS.  
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Figure 6.5 Identification of myeloid cells in the CNS during SFV infection of CCR2 
deficient mice and mice treated with CCR2 blocker 
Wild type and CCR2 deficient mice were infected with SFV strain A7(74) for 7 days and brains 
were collected for analysis. The number of CD11b+ cells and myelomonocytic cells was 
determined by flow cytometry. Mice were treated twice daily by oral gavage with vehicle (6.6% 
DMSO in PBS) (untreated and CCR2-/- group) or 5 mg/kg RS504393 (CCR2 blocker) (treated group) 
between post infection days 3-7. n= 4-7 pooled mouse brains per group from 1-3 individual 
experiments. (A) Representative dot plot of CD11b expression on CD45hi cells within the brain of 
untreated, treated and CCR2-/- mice. (B) Proportions and numbers of CD11b+ cells gated on 
CD45hi cells. (C) Proportions and numbers of CD11b+Ly6C+ and (D) CD11b+Ly6C- cells within CD45hi 
cells. Data are presented as mean ± SD (One-way ANOVA with Tukey’s post test; ** p<0.01, *** 
p<0.001) 
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Figure 6.6 Expression of CCR2 on CD45hi cells in the brain of SFV infected mice in 
CCR2 deficient and CCR2 blocker treated mice 
Wild type and CCR2 deficient mice were infected with SFV strain A7(74) for 7 days and brains 
were collected for analysis. The number of CD11b+CCR2+ cells was determined by flow 
cytometry. Mice were treated twice daily by oral gavage with vehicle (6.6% DMSO in PBS) 
(untreated and CCR2-/- group) or 5 mg/kg RS504393 (CCR2 blocker) (treated group) between post 
infection days 3-7. n= 4-7 pooled mouse brains per group from 1-3 individual experiments. (A) 
Representative dot plot of CCR2 expression on CD11b+ cells, gated on CD45hi cells, in the brains 
of untreated, treated and CCR2-/- mice. (B) Proportions and numbers of CD11b+CCR2+ cells within 
leukocytes. Data are represented as mean ± SD (One-way ANOVA with Tukey’s post test; * 
p<0.05, *** p<0.001) 
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Figure 6.7 Identification of myeloid subsets in the blood of mice treated with the 
CCR2 blocker RS504393 
Wild type mice were treated twice daily by oral gavage with 5 mg/kg RS504393 (CCR2 blocker) 
and blood was collected at various time points as indicated. The number of myeloid subsets in 
the blood was determined by flow cytometry. Data are presented as mean ± SD with n=5 mice 
per time point. (A) Proportion of CD11b+ and (B) CD11b+Ly6C+CCR2+ cells within total live cells in 
the blood. (C) Representative dot plot of CCR2 and (D) Ly6C and Ly6G expression gated on 
CD11b+ leukocytes. Four distinct leukocyte populations were identified and numbered P1-P4. (E) 
Proportion of CD11b+Ly6Chi (monocytes) within the P4 gate, (F) CD11b+Ly6Cint cells within the P3 
gate, (G) CD11b+Ly6C- cells within the P2 gate and (H) CD11b+Ly6G+ cells (neutrophils) within the 
P1 gate in the blood. (One-way ANOVA with Dunnett’s post test; all data not significant) 
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6.2.3 Chemokine expression levels in the CNS of mice with 
genetic or pharmacological blockage of CCR2 
A previous WNV study has proposed the idea that in CCR5-/- mice the reduction 
in leukocyte numbers in the brain might lead to different chemokine and 
cytokine expression patterns that recruit other leukocyte subsets (173). To test 
whether chemokine expression levels and in particular CCL2, a selective ligand 
for CCR2, were also elevated during SFV infection after treatment with CCR2 
blocker, brain samples were analysed by TLDA or QPCR. 
The absolute copy numbers of CCL2 transcripts were significantly (p<0.05) 
increased in CCR2 blocker treated mice compared with untreated and CCR2-/- 
mice (Fig. 6.8). Additionally the number of CCL2 transcripts was not increased in 
CCR2-/- mice compared with untreated mice. 
 
Figure 6.8 Expression of CCL2 in the CNS of CCR2 deficient mice or mice treated 
with the CCR2 blocker 
Wild type and CCR2 deficient mice were infected with SFV strain A7(74) for 7 days and brains 
were collected for analysis. Mice were treated twice daily by oral gavage with vehicle (6.6% 
DMSO in PBS) (untreated and CCR2-/- group) or 5 mg/kg RS504393 (CCR2 blocker) (treated group) 
between post infection days 3-7. The absolute copy numbers of CCL2 was determined by QPCR 
and data was normalized to 1x 104 copies of TATA-binding protein (TBP). Data are presented as 
mean ± SD with n=4-7 mice per group. (One-way ANOVA with Tukey’s post test; * p<0.05) 
 
A thorough analysis of chemokine and cytokine expression by TLDA in SFV 
infected and untreated, treated and CCR2 deficient mice revealed that generally 
most chemokines were not significantly different in treated versus untreated, 
and CCR2-/- mice versus treated mice. (Appendix 4A, B, D and E). Exceptions 
were the expression levels of CCL2, CCL20 and CCL28. The QPCR results for the 
expression levels of CCL2 were confirmed by results obtained by TLDA analysis 
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showing significant higher expression levels of CCL2 in CCR2 blocker treated 
mice compared to untreated mice or CCR2-/- mice (Appendix 4). The expression 
level of CCL20 was significantly higher in CCR2-/- mice compared to CCR2 blocker 
treated mice (Appendix 4). The expression of CCL28 was significantly higher 
expressed in CCR2 blocker treated mice compared to untreated controls.  
Despite the minimal and not significant difference of most other chemokines 
expressed in untreated, treated and CCR2 deficient mice, in almost all cases the 
levels of chemokines were slightly higher in CCR2 blocker or CCR2 deficient 
mice. The expression levels of cytokines was, again, not significantly different 
between untreated, treated and CCR2-/- mice (Appendix 4 C and F). Thus, these 
data suggest that the blockade or the deficiency of CCR2 does not result in 
profound alterations of the chemokine and cytokine expression profiles in the 
brain of SFV infected mice. Other factors seem to be involved in the control of 
chemokine and cytokine expression during SFV encephalitis. 
6.2.4 The role of CCR2 for the pathogenesis of virulent 
infection of the brain with SFV strain L10 
Lim et al. have reported that CCR2 is critical for survival during WNV infection of 
the brain. To examine whether CCR2 is also important for the pathogenesis of 
lethal SFV infection, mice were inoculated with SFV strain L10 and survival was 
analysed. The results demonstrate that the survival in wild type untreated mice 
was 50% compared with 20% in CCR2 deficient mice (Fig. 6.9). Furthermore CCR2 
deficient mice died earlier compared with wild type mice but this difference was 
not statistically significant (Logrank test). Thus, these data suggest that CCR2 
might also play a role during L10 infection. However this experiment was only 
performed once and this result needs to be confirmed with repeat experiments. 
Due to time constraints the effect of CCR2 blocker RS504393 on the survival of 
L10 infected mice could not be pursued further and is part of future 
experiments. 
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Figure 6.9 Survival of CCR2 deficient mice infected with the virulent SFV strain 
L10  
Wild type and CCR2 deficient mice were infected i.p. with SFV strain L10 for 12 days. The 
survival of CCR2 deficient and wild type mice was assessed. Mice were euthanized once they 
became terminally ill. n=10 mice per group. (Logrank (Mantel-Cox test; not significant) 
 
6.3 Characterisation of the role of CCR5 during viral 
encephalitis 
CCR5 has been reported to be important for the migration of monocytes, 
macrophages, T-cells and NK-cells. Since CCR5 ligands were expressed in the SFV 
infected brain, I next examined the role of CCR5 in leukocyte accumulation 
during SFV-dependent encephalitis using CCR5 blockers Maraviroc and DAPTA. As 
discussed in detail in section 1.3.6 Maraviroc is an allosteric CCR5 inhibitor 
approved by the FDA, and is used for the treatment of HIV. DAPTA is another 
CCR5 antagonist, and is a synthetic peptide comprised of eight amino acids of 
the gp120 V2 region of HIV, which targets CCR5 selectively. Both blockers have 
been shown to be effective in blocking CCR5. 
6.3.1 Antagonism of CCR5 during SFV infection using Maraviroc 
Maraviroc was originally discovered after a high throughput screen by the 
pharmaceutical company Pfizer and is a selective imidazopyridine CCR5 ligand 
(198). As this drug has been shown to be a potent CCR5 blocker, this drug was 
used for blocking CCR5 during SFV infection with strain A7(74). A dose of 25 
mg/kg/day was administered to mice by intraperitoneal injections once daily 
between PID 3-7. This dose has been shown to be effective in blocking CCR5+ 
cells in a breast cancer mouse model, and therefore I have used 25mg/kg 
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Maraviroc or vehicle control for the treatment of SFV infected mice (433). To 
examine the role of CCR5 during viral encephalitis, leukocyte infiltration was 
measured by flow cytometry. 
 
Figure 6.10 Identification of CD45hi, CD3+ T-cells and NK-cells in SFV infected mice 
treated with the CCR5 blocker Maraviroc 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected. All mice were 
treated once daily by i.p. injection with vehicle (25% DMSO in PBS) or 25 mg/kg Maraviroc 
between post infection days 3-7. The number of CD45hi, CD3+ and NK1.1+ cells in both groups was 
determined by flow cytometry. Data are presented as mean ± SD with n=4-6 pooled mouse brains 
per group. Representative dot plots of (A) CD45hi cells, (C) CD3+ cells within CD45hi cells, and (E) 
NK1.1+ and CD3- cells within CD45hi cells. (B) Proportion of CD45hi cells within total live brain 
cells in both groups. (D) Proportions and numbers of CD3+ T-cells within CD45hi cells and 1x105 
live brain cells in untreated and treated mice. (F) Proportions and numbers of NK1.1+CD3- cells 
within CD45hi cells and 1x105 live brain cells in untreated and treated mice. (Student’s t-test; all 
not significant)  
 
The proportion of CD45hi cells within total live cells in Maraviroc treated mice 
was comparable with untreated mice (Fig. 6.10 A and B). Using further markers 
to identify other leukocyte subsets, the expression of CD3 and NK1.1 by CD45hi 
cells was examined. The proportion and numbers of CD3+ and NK1.1+ cells in 
Maraviroc treated mice were not significantly different from untreated mice 
(Fig. 6.10 C-F). Finally the number and proportion of CD11b+ cells within CD45hi 
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cells were determined and, again, no significant difference between untreated 
and treated mice could be observed (Fig. 6.11 A and B). To measure viral titers 
in the brain and to investigate the effect of Maraviroc on virus levels, E1 virus 
transcripts were measured by QPCR. The results show that viral titers were not 
significantly different between the groups (Fig. 6.11 C). Thus, Maraviroc did not 
have any effect on leukocyte infiltration and viral titer. Therefore another CCR5 
blocker, DAPTA was used in subsequent experiments to investigate the role of 
CCR5 during viral encephalitis. 
 
Figure 6.11 Identification of myeloid cells in the brain of SFV infected mice treated 
with the CCR5 blocker Maraviroc 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected. All mice were 
treated once daily by i.p. injection with vehicle (25% DMSO in PBS) or 25 mg/kg Maraviroc 
between post infection days 3-7. The number of CD11b+ cells was determined by flow cytometry. 
Data are presented as mean ± SD with n=4-6 pooled mouse brains per group. (A) Representative 
dot plot of CD11b expression on CD45hi cells in treated and untreated mice. (B) Proportions and 
numbers of CD11b+ cells in the brain of untreated and treated mice within the CD45hi population 
and 1x105 live brain cell population, respectively. (C) Expression of the viral protein E1 per 1x 
104 TATA-binding protein (TBP) in the brain of untreated and treated mice. (Student’s t-test; all 
not significant) 
 
 6.3.2 Antagonism of CCR5 during SFV infection using DAPTA 
Previous studies using rats have shown the efficacy of DAPTA in blocking CCR5 in 
a neuroinflammatory model of Alzheimers’s disease (225).  In this experiment, 
DAPTA was administered to mice subcutaneously at a concentration of 1 
mg/kg/day between PID 3-7 as this dose has previously been shown to be 
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effective in blocking CCR5 in chronically LPS inflamed mice (225). The 
proportion of CD45hi cells and the presence of leukocyte subsets in untreated 
and treated mice on PID 7 were determined by flow cytometry. 
The treatment of mice with DAPTA resulted in a modest (approximately 50%), 
but not significant, reduction of leukocyte recruitment to the CNS (Fig. 6.12 A 
and B). The reduction of leukocytes did not lead to a change in viral titers and 
the number of E1 transcripts was comparable between untreated and treated 
mice (Fig. 6.12 C). Importantly, however, the number and proportion of CCR5+ 
leukocytes was significantly reduced (both p<0.01) in DAPTA treated mice 
compared with untreated mice, confirming the effectiveness of DAPTA as a CCR5 
blocker (Fig. 6.12 D-F). After determining the effect of CCR5 on the infiltration 
of CD45hi cells into the CNS, I next set out to investigate the effect of CCR5 
blockade on the infiltration of distinct leukocyte subsets into the virally infected 
CNS. 
The proportion of CD3+ T-cells was significantly (p<0.05) reduced in DAPTA 
treated mice (Fig. 6.13 A and B). Consistent with this, the number of CD3+ T-
cells per 105 isolated brain cells was also reduced in treated mice, but this result 
did not reach statistical significance. Within the CD45hiCD3+ T-cell population, 
the proportion of CD4+ and CD8+ cells was also assessed. The proportion of both 
types of T-cells in treated mice was comparable to proportions in untreated 
mice, suggesting that CD4+ and CD8+ T-cells are equally reduced during CCR5 
blocker treatment of SFV infected mouse brains (Fig. 6.13 C). The proportion 
and number of NK1.1+ cells was not significantly different in treated mice 
compared with untreated mice suggesting that another chemokine receptor is 
involved in the attraction of NK-cells into the brain (Fig. 6.13 D-E). 
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Figure 6.12 Identification of CD45hi and CCR5+ cells in the brains of SFV infected 
mice treated with the CCR5 blocker DAPTA, and determination of viral 
titers 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected. All mice were 
treated once daily by s.c. injection with vehicle (water) or 1 mg/kg DAPTA between post 
infection days 3-7. The number of CD45+ and CCR5+ cells was determined by flow cytometry. 
Data are presented as mean ± SD with n=4-6 pooled mouse brains per group from 2 individual 
experiments. (A) Representative dot plots of CD45 expression on isolated brain cells of untreated 
and treated mice. All cells were gated on CD45hi cells. (B) Proportion of CD45hi cells within total 
live brain cells. (C) Expression of viral protein E1 in untreated and treated mice measured by 
QPCR. Absolute copy numbers of E1 were normalized to 1x104 TATA-binding protein (TBP). (D) 
Histogram showing CCR5 expression on CD45hi cells in isotype (grey), untreated (red) and treated 
(blue) murine brain samples. (E) Proportions and (F) number of CD45hi CCR5+ cells per 105 
isolated brain cells in untreated and treated mice. (Mann-Whitney U test; ** p<0.01) 
 
The number and proportion of CD11b+ cells within the leukocyte population in 
treated mouse brains was, similar to NK-cells, also comparable to untreated 
mouse brains (Fig. 6.14 A and B). However the number of CD11b+ cells was 
slightly reduced in treated mice.  Within the CD11b+ cell compartment, the 
proportion of Ly6C+ and Ly6C- monocytes/macrophages in DAPTA treated mice 
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was similar to that in untreated mice but the number of Ly6C+ and Ly6C- cells 
per 105 isolated brain cells was slightly reduced in treated mice (Fig. 6.14 C-F). 
However, this result did not reach statistical significance. 
Thus, CCR5 plays a role in the infiltration of leukocytes into the CNS during viral 
encephalitis, but the reduction of leukocytes within the CNS after treatment is 
less profound compared to treatment with the CCR2 blocker. The viral titer was 
unaffected by CCR5 blockade and the subsequent modest reduction of leukocyte 
subsets within the CNS. 
 
Figure 6.13 Identification of CD3+ T-cells and NK-cells in the brain of SFV infected 
mice treated with the CCR5 blocker DAPTA 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected. All mice were 
treated once daily by s.c. injection with vehicle (water) or 1 mg/kg DAPTA between post 
infection days 3-7. The number of CD3+ and NK1.1+ cells was determined by flow cytometry. Data 
are presented as mean ± SD with n=4-6 pooled mouse brains per group from 2 individual 
experiments. (A) Representative dot plots of CD3 expression by CD45hi cells in the brain of 
untreated and treated mice. (B) Proportions and absolute numbers of CD3+ T-cells in both groups 
and (C) proportions of CD4+ and CD8+ cells within CD3+ cells. (D) Representative dot plots of 
NK1.1+CD3- cells in the brain of untreated and treated mice. Cells were gated on CD45hi cells. (E) 
Proportions and absolute numbers of NK1.1+ cells in the brain of both groups. (student’s t-test; * 
p<0.05) 
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Figure 6.14 Identification of myeloid cells in the brains of SFV infected mice treated 
with the CCR5 blocker DAPTA 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected. All mice were 
treated once daily by s.c. injection with vehicle (water) or 1 mg/kg DAPTA between post 
infection days 3-7. The number of CD11b+ cells was determined by flow cytometry. Data are 
presented as mean ± SD with n=4-6 pooled mouse brains per group from 2 individual 
experiments. (A) Representative dot plots of CD11b expression by CD45hi cells in the brain of 
untreated and treated mice. (B) Proportions and absolute numbers of CD11b+ cells in the brain of 
both groups. (C) Proportions and (D) absolute numbers of CD11b+Ly6C+ cells in untreated and 
treated mice. (E) Proportions and (F) absolute numbers of CD11b+Ly6C- cells in the CNS of both 
groups.  
6.3.3 Chemokine expression levels in the CNS of SFV infected 
mice treated with the CCR5 blocker DAPTA 
Analysis by TLDA revealed that only three chemokines were significantly 
differently expressed in treated mice compared with untreated mice. These 
were CCL2, CCL7 and CXCL12, which were significantly higher in SFV infected 
DAPTA treated mice (Appendix 5 A and B). The CCR5 ligands CCL3-5, CCL8, 
CCL11 and CCL20 were not significantly differently expressed after blockade of 
the CCR5 receptor. Of note, all the chemokine expression levels in CCR5 treated 
mice were generally slightly higher compared with untreated mice, but the 
difference did not reach statistical significance. Furthermore the expression of 
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cytokines was not significantly different in treated mice compared with 
untreated mice but, again, the cytokine levels tended to be marginally higher in 
treated brain samples (Appendix 5 C). The expression levels of RIG-I and IRF7 
were similar to untreated mice (Appendix 5 D).  
6.4 Characterisation of the role of CXCR3 during viral 
encephalitis 
In the previous chapter I demonstrated that the CXCR3 ligands CXCL9 and 
CXCL10 were strongly upregulated in the brain during viral encephalitis 
compared with uninfected healthy control mouse brains. The CXCR3 blocker was 
obtained from Amgen Inc. and is referred to as ‘compound 21’. The efficacy of 
this drug has been evaluated in a previous study using a mouse model of lung 
inflammation (232). Compound 21 was administered to SFV infected mice at a 
concentration of 10 mg/kg once daily by subcutaneous injection, a dose 
previously suggested by Du et. al (232). The drug or vehicle control was 
administered to SFV infected mice from PID 3 until PID 7 when mice were culled. 
This timing of treatment was selected, again, based on the previous study using 
the mouse lung inflammation model. The effect of CXCR3 blockade on leukocyte 
infiltration into the CNS, and in particular of T-cells, which predominantly 
express CXCR3, was determined by flow cytometry. Furthermore viral titers in 
the brain were measured by QPCR to examine the effect of this chemokine 
receptor on virus levels.  
6.4.1 The effect of CXCR3 blockade on leukocyte infiltration 
into the CNS of SFV A7(74) infected mice 
The accumulation of CD45hi cells within the CNS of infected mice was 
substantially and significantly (p<0.01) reduced from 17.3% in untreated mice to 
2.6% in CXCR3 blocker treated mice (Fig. 6.15 A and B). This amounts to an 
approximately 84% reduction of leukocytes in treated mice. Consistent with this, 
the number and proportion of CXCR3+ cells within the CD45hi cell population was 
also significantly (p<0.05) reduced, confirming the efficacy of compound 21 in 
blocking CXCR3 (Fig. 6.15 C-E). Interestingly, despite the significant reduction of 
leukocyte infiltration, the number of SFV E1 transcripts in the brain was 
unaffected by CXCR3 blockade (Fig. 6.15 F).  
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Figure 6.15 Identification of CD45hi cells in the brains of SFV infected mice treated 
with the CXCR3 blocker compound 21, and determination of viral titers 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected for analysis. All 
mice were treated once daily by s.c. injection with vehicle (50% DMSO and 25% PEG400 in water) 
or 10 mg/kg compound 21 between post infection days 3-7. The number of CD45hi cells 
infiltrating the CNS was measured by flow cytometry and viral titers were examined by QPCR. 
Data are presented as mean ± SD, n=8 pooled mouse brains from 2 individual experiments. (A) 
Representative dot plots of CD45 expression on live brain cells in untreated and treated mice. All 
cells were then gated on CD45hi cells. (B) Proportion of CD45hi cells within total live cells. (C) 
Histogram showing the expression of CXCR3 by CD45hi cells from isotype (blue) and treated (red) 
mice. (D) Proportions and (E) numbers of CD45hiCXCR3+ per 105 brain cells of treated and 
untreated mice. (F) Expression of E1 viral protein by QPCR. Data was normalized to 1x 104 TATA-
binding protein (TBP). n=3 mice per group. ((B and E) Student’s t-test; * p<0.05, ** p<0.01 and 
(F) Mann-Whitney-U test; ns=not significant) 
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Within the CD45hi cell population the proportion (p<0.05) and number (p<0.01) of 
CD3+ T-cells was significantly reduced in compound 21 treated mice compared 
with untreated mice (Fig. 6.16 A and B).  Within the reduced T-cell population, 
compound 21 did not alter the proportion of CD4+ T-cells, although the number 
of CD4+ T-cells was significantly (p<0.01) lower in treated mice compared with 
untreated mice. The relative percentage and number of CD8+ T-cells was 
significantly (p<0.01) reduced after treatment with compound 21 (Fig. 6.16 C 
and D). After further analysis of CD3+ T-cells it was found that the number and 
proportion of CD44hiCD61Llo effector cells were significantly (p<0.01 and p<0.05, 
respectively) reduced in mice treated with the CXCR3 blocker compared with 
untreated mice (Fig. 6.16 E and F).  
To investigate whether the blockade of CXCR3+ cells also affects the infiltration 
of other leukocyte subsets, not or only minimally, expressing CXCR3, the 
proportion and number of NK1.1+ and CD11b+ cells was analysed in the CNS of 
both untreated and treated mice. The numbers of CD45hiCD11b+ and 
CD45hiNK1.1+ cells per 105 isolated brain cells were both dramatically reduced in 
the brain of treated mice (Fig. 6.17 A and B). However the relative percentage 
of both, NK1.1+ and CD11b+ cells was not different between untreated and 
treated mice (Fig. 6.17 C and D). A statistical significance could not be 
calculated as this experiment was only performed once. 
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Figure 6.16 Reduction of T-cells subsets within the CNS of SFV infected mice treated 
with the CXCR3 blocker compound 21  
Mice were infected with SFV strain A7(74) for 7 days and brains were collected for analysis. All 
mice were treated once daily by s.c. injection with vehicle (50% DMSO and 25% PEG400 in water) 
or 10 mg/kg compound 21 between post infection days 3-7. The number of CD3+ cells was 
determined by flow cytometry. Data are presented as mean ± SD with, n=8 pooled mouse brains 
per group from 2 individual experiments. (A) Representative dot plots of CD3 expression by 
CD45hi cells in the brain of untreated and treated mice. (B) Proportions and numbers of CD3+ T-
cells in both groups. (C) Representative dot plots of CD4+ and CD8+ cells within CD3+ T-cells. (D) 
Proportions and numbers of CD3+CD4+ and CD3+CD8+ cells in the CNS in both groups. (E) 
Proportions and (F) numbers of CD3+CD44hiCD62Llo cells within leukocytes in the CNS of treated 
and untreated mice. (Student’s t-test; * p<0.05, ** p<0.05) 
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Figure 6.17 Identification of myeloid and NK-cells in the brains of SFV infected mice 
treated with the CXCR3 blocker compound 21 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected for analysis. All 
mice were treated once daily by s.c. injection with vehicle (50% DMSO and 25% PEG400 in water) 
or 10 mg/kg compound 21 between post infection days 3-7. The number of NK1.1+ and CD11b+ 
cells was determined by flow cytometry. Data are presented as mean ± SD with n=8 pooled 
mouse brains per group from 1 individual experiment. (A) Number of NK1.1+NKp46+ cells and (B) 
CD11b+ cells per 105 brain cells in both treatment groups. (C) Representative dot plots of NK1.1 
and NKp46 expression by CD45hi cells in the brains of untreated and treated mice, and 
proportions of NK1.1+NKp46+ cells in untreated and treated mice. (D) Representative dot plots of 
CD11b+ expression by CD45hi cells in the CNS, and proportion of CD11b+ cells in the brains of both 
treatment groups. 
 
6.4.2 Chemokine expression levels 
In our lab I had later the opportunity to use bigger TLDA plates containing 64 
genes instead of 32. This allowed me to examine the expression of more 
chemokines, cytokines and genes involved in innate immunity in SFV infected 
mice treated with compound 21 or vehicle control. 
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The only chemokines that were significantly differently expressed in untreated 
and treated mice were CCL5, CCL9, CCL17, CXCL3 and XCL1 (Appendix 6 A-D). 
Overall, most chemokine expression levels were reduced in compound 21 treated 
mice compared with untreated mice, including the CXCR3 ligands CXCL9 and 
CXCL10. A QPCR was performed to validate some of the results obtained by 
TLDA. The absolute copy numbers of CXCL9 were not different in treated mice 
compared with untreated mice (Fig. 6.18 A). In contrast to this, the transcript 
numbers of CXCL10 were minimally but not significantly reduced after treatment 
with compound 21 compared to untreated mice, and the levels of CXCL10 
protein were unaffected (Fig. 6.18 B and C). Finally absolute copy numbers were 
also measured for CXCR3. The results show that CXCR3 transcript numbers are 
lower in treated mice compared with untreated mice but this was not 
statistically significant (p>0.05) (Fig. 6.18 D).  
 
Figure 6.18 Comparison of CXC-chemokine expression pattern in untreated and 
CXCR3 blocker treated mice, infected with SFV strain A7(74) 
Mice were infected with SFV strain A7(74) for 7 days and brains were collected for analysis. All 
mice were treated once daily by s.c. injection with vehicle (50% DMSO and 25% PEG400 in water) 
or 10 mg/kg compound 21 between post infection days 3-7. The expression of CXCL9, CXCL10 
and CXCR3 was assessed by QPCR. (A and B) Absolute copy numbers of CXCL9 and CXCL10 per 
1x104 TATA-binding protein (TBP). (C) Concentration of CXCL10 protein in the brain of untreated 
and treated mice measured by ELISA. (D) Absolute copy number of CXCR3 per 1x104 TBP. Data 
are presented as mean ± SD with of n=3-4 mice per group. Each gene was tested in triplicate. 
(Student’s t-test; all not significant) 
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The expression pattern of CX3CL1 was not different between untreated and 
CXCR3 blocker treated mice. The expression level of XCL1 was significantly 
(p<0.05) higher expressed in untreated mice compared to CXCR3 treated mice 
(Appendix 6 D).  
The levels of cytokines and genes involved in innate immune responses were 
generally also lower (not significant) in compound 21 treated mice compared 
with untreated mice with the exception of IL-6, RIG-I and PKR where expression 
levels were minimally, but not significantly, higher in CXCR3 treated mice 
(Appendix 6 E and F). Ifit-1, an interferon inducible gene, was the only innate 
immune response gene that was significantly higher expressed in untreated mice 
compared to CXCR3 blocker treated mice. 
6.4.3 Effects of blocking CXCR3 on mice infected with the 
virulent strain L10 
Next the impact of chemokine receptor blockade on disease outcome was 
examined using the virulent strain L10. Due to the profound effect of CXCR3 on 
leukocyte recruitment into the CNS of SFV A7(74) infected mice, the effect of 
compound 21 was tested in a virulent model of SFV, and survival of mice was 
analysed. Despite the ability of compound 21 to reduce leukocyte accumulation 
in the CNS during SFV A7(74) infection, no survival benefit was found in L10 
infected mice treated with the CXCR3 antagonist (Fig. 6.19 A).  
L10 infection of the brain typically results in such a severe pathology that it is 
possible that the blockade of CXCR3 alone is not sufficient to see any survival 
benefits. In the previous section it was shown that CCR2 blocker treated mice, 
infected with the avirulent strain A7(74), display reduced leukocyte infiltration 
compared with wild type mice. Additionally CCR2-/- mice infected with the 
virulent strain L10 died earlier compared with wild type infected mice. 
Therefore a combination of CCR2 and CXCR3 blockers was selected to examine 
the possible impact of both receptors on disease outcome. Compound 21 and 
RS504393 were administered to mice between PID 3-7. The results demonstrate 
that mice treated with both blockers had a significant survival benefit (p<0.05) 
compared with control mice that were treated with vehicle control (Fig. 6.19 B).  
Unfortunately due to time constraints an experiment using the CCR2 blocker 
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RS504393 alone was not performed. The CXCR3 blockade experiment was only 
performed once, and larger experimental groups are necessary to confirm this 
result. Thus, these data suggest that an interventionist strategy aimed at 
blocking CXCR3 alone during SFV L10 infection was ineffective at ameliorating 
the disease but co-blocking CCR2 and CXCR3 leads to better disease outcome. 
Therefore it is possible that leukocyte infiltration is detrimental and results in 
more severe pathology during encephalitis.  
 
Figure 6.19 Survival of mice infected with SFV strain L10, and treated with 
chemokine blockers 
Mice were infected with SFV strain L10 for 12-15 days and the survival of mice was determined. 
Mice were euthanized once they became ill. (A) Kaplan-Meier survival curve. Mice were treated 
once daily by s.c. injection with vehicle (50% DMSO and 25% PEG400 in water)(untreated group) 
or 10 mg/kg compound 21 between post infection days 3-7. (B) Kaplan-Meier survival curve. Mice 
were treated with compound 21 as described in (A), and twice daily by oral gavage with vehicle 
(6.6% DMSO in PBS) (untreated group) or 5 mg/kg RS504393 (CCR2 blocker) between post 
infection days 3-7. n=10 mice per group. (Logrank (Mantel- Cox) test; * p<0.05) 
 
6.5 Discussion and summary 
On the basis of the thorough chemokine expression analysis presented in chapter 
3, the chemokine receptors CCR2, CCR5 and CXCR3 were identified as possible 
candidates for interventionist strategies. The aim of the work in this chapter was 
to investigate the role of these three chemokine receptors in CNS recruitment 
and modulation of host immune responses, which may contribute to virus-
induced damage and mortality. During WNV infection it has been demonstrated 
that within the first 5 days post infection, monocytosis occurs which is critical 
for monocyte accumulation within the CNS, and this latter process of 
recruitment is not dependent on CCR2 (214). In contrast to this, monocytosis 
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itself is entirely CCR2 dependent. The results here show that circulating 
monocyte numbers in the blood were not affected by the CCR2 blockade and 
monocyte entry into the SFV infected CNS from PID 4 onwards was reduced in 
treated mice, suggesting that this process is dependent on CCR2 during SFV 
infection. Additionally monocytes increase in number in response to viral 
infection with SFV but the increase was less profound compared to studies using 
WNV as model of infection.  
In chapter 4 it was shown that monocytes enter the brain early (on PID 4) during 
viral infection of the CNS, while simultaneously many monocyte attracting 
chemokines were strongly induced as described in chapter 3. The data 
demonstrate that blocking CCR2 results in a significant decrease in CD45hi cells 
within the brain. Interestingly, despite decreased leukocyte numbers in the CNS, 
viral titers and chemokine expression patterns in the brain were not significantly 
changed in treated mice compared with untreated mice, suggesting that 
monocytes may be less critical for virus clearance, and the cellular source of 
chemokines is different from monocytes. This is in contrast to previous studies 
with WNV, which have shown that viral titers are increased in CCR2 deficient 
mice compared to wild type mice, suggesting a role of monocytes in virus 
clearance (214, 334). Furthermore it was proposed that the blockade of 
monocytes into the CNS of WNV infected mice results in a delay of T-cells 
entering the brain, and this could explain the reduced virus clearance in the CNS 
and higher mortality in CCR2 deficient mice (401).  
After phenotyping leukocyte subsets I noticed that the number of Ly6C+CCR2+ 
monocytes was significantly decreased to a similar extent as in CCR2 deficient 
mice. In support of this Getts et al. have shown that CCR2 is pivotal for 
trafficking of Ly6C+ cells into the CNS where they differentiate into microglia 
(106). Despite the fact that CCR2 is mainly expressed on monocytes, it was 
noted that the number of CD3+ T-cells and NK-cells was also reduced. In part this 
can be explained by the fact that some activated T-cells and NK-cells express 
CCR2 (434, 435). For instance, Nansen et al. have shown that activated CD8+ T-
cells express CCR2 and CCR5 during LCMV infection (319). However CCR2 is not 
known to be a principal regulator of T-cell migration and despite the 
publications by Rabin, Polentarutti and Nansen et al., there are numerous other 
studies in which T-cell migration is unaffected in CCR2-/- mice (319, 434-436). 
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Therefore another possible explanation for the reduction in T-cell and NK-cell 
number in CCR2 treated or CCR2-/- mice is that recruited monocytes in the CNS 
have an indirect action on T-cell and NK-cells entry by secreting chemokines or 
cytokines which are chemoattractant for T-cells and NK-cells infiltration. 
Therefore a reduction in monocyte infiltration would result in reduced T- and 
NK-cell accumulation within the CNS. However, the TLDA analysis revealed that 
this is not the case, as chemokine levels were mostly unaffected by the 
chemokine receptor blockade. Another possibility is that the passage of 
monocytes leads to changes at the BBB which facilitates transmigration of T-
cells and other leukocyte subsets into the brain parenchyma. Savarin et al. have 
shown that monocytes are dispensable for the migration of T-cells through the 
BBB during MHV infection of the CNS using CCL2 deficient mice (401). They have 
demonstrated that monocytes are capable of altering the BBB integrity allowing 
other leukocyte subsets to enter the CNS of infected mice.  
During L10 infection the mortality rate in CCR2 deficient mice was higher 
compared with wild type mice. Of note is also that the experimental group for 
this survival analysis was relatively small and therefore this experiment must be 
repeated to draw firm conclusions from these data. However in support of my 
result Lim et al. have shown that CCR2-/- mice infected with WNV exhibit a 
higher viral titer in the CNS due to reduced monocyte trafficking to the brain 
resulting in higher mortality, and Savarin et al. have reported that CCR2 
deficient mice die earlier due to the lack of monocytes and delayed T-cell 
trafficking across the BBB during viral encephalitis (214, 401). However Lim et 
al. have shown that the reduction of monocytes within the CNS of WNV infected 
mice is a result of prior monocytpenia, and they have suggested that CCR2 is 
dispensable for the trafficking of monocytes into the brain during viral 
encephalitis. This finding is in contrast to my results which show that the 
temporary blockade of CCR2 did not decrease circulating monocytes in the 
blood, but did block monocyte entry into the CNS, suggesting that leukocytes do 
use this chemokine axis to enter the virus infected CNS, and is not a mere 
consequence of monocytopenia. Of note is that most of these studies 
investigating the role of CCR2 have used CCR2 deficient mice instead of using a 
pharmacological CCR2 blocker, as used in this study, where monocyte trafficking 
can be better examined. Thus, based on my preliminary data I propose that 
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CCR2 is crucial for the recruitment of monocytes and other CCR2 expressing 
leukocyte subsets into the CNS.  
Two different CCR5 blockers were used in this study. Initially, the FDA approved 
CCR5 blocker Maraviroc was used in this study to block CCR5 during SFV infection 
of mice (199). However treatment with the drug did not result in a reduction of 
leukocyte recruitment to the CNS and did not have an effect on viral titers. 
Therefore another drug, referred to as DAPTA, was used. A study by Rosi et al. 
has demonstrated the efficacy of DAPTA in a chronic LPS induced inflammation 
model in rats (225). CCR5 blockade using DAPTA led to a reduction in leukocyte 
numbers in the brain, and in particular of CCR5+ cells, but the reduction of 
leukocytes was less profound than that seen with the CCR2 and CXCR3 blockers. 
This suggests that CCR5 plays a minor role in the pathogenesis of SFV infection of 
the brain.  
The inefficacy of Maraviroc compared to DAPTA could be due to the following 
reason: Firstly, DAPTA has been shown to be 34-180 times more potent than 
Maraviroc in inhibiting CCR5 due to high affinity binding of DAPTA to the CCR5 
binding site (198, 223). This could explain the better efficiency of DAPTA in 
binding CCR5 compared to Maraviroc during SFV infection. Secondly, murine 
CCR5 is 82% identical with the human form, and since most studies of Maraviroc 
have been carried out in humans and primates it is possible that Maraviroc binds 
to regions of CCR5 not present or less accessible in the murine form of CCR5, 
and this would explain why Maraviroc did not work well in the mouse model of 
SFV infection (437). In contrast to this, several studies have been conducted in 
mouse and rat models using DAPTA to block CCR5. Hence DAPTA is more suitable 
to block CCR5 in mice (223-225). Lastly, the dose of Maraviroc administered to 
mice during SFV infection might have been suboptimal. Neff et al. have used a 
dose of 62 mg/kg/ day in mice which is equivalent to the human dose of 300 
mg/day (438). However in my study a dose of only 25 mg/kg/day was used, and 
this could explain the inefficacy of Maraviroc used here. The efficiency of 
Maraviroc during SFV encephalitis needs to be determined in the future, by 
conducting dose-dependent experiments. 
This finding is in contrast to studies using WNV as a model of infection (362). 
CCR5 was one of the first chemokine receptors shown to play a clear role during 
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WNV encephalitis. CCR5 deficiency resulted in enhanced mortality and more 
severe pathology in the brain (197). CCR5-/- mice have been shown not to be 
able to control viral titers in the brain (173). Furthermore the non-functional 
CCR5Δ32 mutation in humans was associated with more severe onset of 
neurological symptoms during WNV infection. Thus, the use of Maraviroc for HIV 
could potentially increase risks for patients to develop severe neurological forms 
of WNV disease. Hence, chemokines play significant roles in the pathogenesis of 
viral infection. 
Due to high transcript levels of CXCL9 and CXCL10 in the brain of SFV infected 
mice and large numbers of infiltrating CD3+ T-cells, I next sought to determine 
the consequence of CXCR3 blockade on T-cell trafficking into the brain. It was 
demonstrated that compound 21 was highly effective at decreasing leukocyte 
recruitment to the CNS of infected mice. In particular T-cell numbers were 
strongly reduced in treated mice. Within the T-cell population the number of 
CD8+ T-cells was reduced whereas the reduction of CD4+ T-cells was less 
profound. This corresponds with results obtained from studies using WNV as a 
model of infection (140, 141, 375). In these studies CXCR3 was pivotal for the 
attraction of T-cells to the virally infected brain. Compound 21 was effective in 
blocking CXCR3 due to the decrease in the number and proportion of CXCR3+ 
cells within the CNS of treated mice.  
The decrease in numbers of other leukocyte subsets, not or only minimally 
expressing CXCR3, such as CD11b+ cells and NK-cells suggests that the reduction 
of T-cells in the brain may indirectly also lead to a reduction in these cells. For 
instance T-cell entry could perhaps mediate permeabilisation of the BBB and 
facilitate entry of other leukocyte subsets. Another possibility is that chemokine 
and cytokine levels in treated mice are altered in a way that results in a 
reduction of CD11b+ and NK-cell entry into the CNS. However the analysis of 
chemokine expression patterns in untreated and treated mice revealed that 
chemokines were not significantly differently expressed between both groups, 
but generally chemokine levels tended to be lower in CXCR3 treated mice. 
Therefore this possibility seems unlikely. In support of my results a previous 
study has shown that in chemokine deficient mice the number of other leukocyte 
subsets, not expressing the specific chemokine receptor are also decreased 
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compared with wild type mice (423). The reason for this remains unknown and 
needs to be experimentally addressed in the future. Of note is that this 
experiment was only performed once and therefore needs to be repeated 
multiple times to confirm these findings and to obtain statistical significance. 
Interestingly, while viral titers in the brain of CXCR3-/- mice were increased 
during WNV infection the viral titer in CXCR3 blocker SFV treated mice were 
unaffected and similar to untreated mice. So far, none of the receptor 
antagonists had a significant impact on viral titres, so the reduction in leukocyte 
recruitment is a direct result of receptor blockade and not a result of direct or 
indirect virus inhibition by the antagonists.  
The treatment of SFV L10 infected mice with compound 21 did not result in a 
significantly different disease outcome. However this is not entirely surprising as 
it was later noticed that the main leukocytes entering the brain of L10 infected 
animals were monocytes and macrophages and only few cells were T-cells. Since 
CXCR3 is mainly expressed on T-cells this could explain the inefficacy of 
compound 21 in this model of SFV infection despite high levels of CXCL9 and 
CXCL10 expression in the CNS of infected mice. Based on flow cytometry data a 
blockade of CCR2 would have been more appropriate but due to time constraints 
this experiments could not be conducted anymore. However CCR2-/- mice were 
infected with L10, and the results from this experiment show that CCR2-/- mice 
die earlier compared with wild type infected mice. Interestingly, simultaneous 
blockade of CXCR3 and CCR2 significantly ameliorated pathology suggesting that 
selective chemokine receptor blockade in combination could be used 
therapeutically for the treatment of viral encephalitis to overcome the 
redundancy of chemokine-receptor interactions. Furthermore it appears from 
these data that timing of therapeutic intervention is critical for survival. For 
instance CCR2 deficient mice die earlier compared to wild type mice whereas 
treatment with CCR2 and CXCR3 blocker starting on PID 3 results in enhanced 
survival. Importantly CXCR3 alone did not lead to a difference in survival 
between untreated and treated mice. Therefore it is possible that monocytes 
are critical in the early stages of SFV infection when the virus enters the host.  
In a previous study a similar trend has been observed for neutrophils during WNV 
infection. Bai et al. have shown that depletion of neutrophils prior to infection 
results in reduced viral titers in the blood and enhanced survival whereas 
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depletion shortly after WNV infection leads to increased viremia and higher 
mortality (350).  
Of note is that L10 mice infected for more than 7 days all survived despite 
establishing very high virus titres in the brain, suggesting that an effective 
immune response, developing by PID 7, is beneficial for survival. 
Overall, the results presented here demonstrate that the antagonism of CXCR3 
was the most potent among all three chemokine blockers in reducing leukocyte 
infiltration into the CNS. Antagonism of CCR2 and CCR5 also leads to the 
reduction of leukocytes in response to SFV infection but the extent of leukocyte 
reduction was less profound than that seen with CXCR3 blockade. Thus 
chemokine receptors present plausible targets for viral encephalitis. The role of 
CCR2, CCR5 and CXCR3 in the pathogenesis of viral encephalitis will be discussed 
in more depth in chapter 7.  
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7.1 Introduction  
The infiltration of leukocytes into the ‘immune sheltered’ CNS is a hallmark of 
viral encephalitis. For a long time it has been assumed that leukocyte 
recruitment into the brain is pivotal for virus clearance and recovery of the host. 
However it has also been shown that leukocytes are not always beneficial for the 
host during viral encephalitis and may paradoxically contribute to more severe 
pathology, including destruction of neuronal cells (439, 440). The infiltration of 
leukocytes into the brain is regulated by chemokines, as discussed in more detail 
in section 1.3. Despite having investigated the role of some chemokines during 
models of viral encephalitis such as WNV, MHV or LCMV infection, a clear picture 
of chemokine expression during viral brain infection has not yet been 
established.  
Therefore in an attempt to better understand the regulation of leukocyte 
recruitment into the virus infected brain, we have used mouse models of viral 
encephalitis, such as SFV and WNV, to define, in unprecedented detail, the form 
and magnitude of the chemotactic cues expressed by the virus infected brain, 
and the kinetics of entry of distinct leukocyte populations in relation to 
chemokine expression. Importantly, for the first time, we have utilised a panel 
of chemokine receptor (CKR) antagonists to evaluate the hierarchy and relative 
importance of distinct chemokine receptors for CNS leukocyte influx.  The use of 
these small molecule inhibitors is particularly important because most studies 
have been conducted using only gene deficient mice. The deficiency of one 
particular chemokine receptor may exert its influence at multiple stages 
including during development, and during homeostatic or inflammatory immune 
responses, and subsequently it is difficult to draw firm conclusions from these 
data. Additionally, the expression of cytokines was determined during avirulent 
and virulent SFV infection and compared to the expression of cytokines during 
WNV infection.  
In this chapter the main findings of this thesis will be briefly discussed and 
summarized, and conclusions and possible future directions presented.  
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7.2 Identification of chemokine expression patterns 
and determination of leukocyte recruitment into 
the CNS during viral encephalitis 
Using TLDA analysis, the key chemokines identified to be highly upregulated 
during SFV and WNV infection were the CC-chemokines CCL2, CCL5, CCL7, and 
the CXC-chemokines CXCL9 and CXCL10. The results demonstrate that the 
chemokine expression pattern during SFV and WNV infection is remarkably 
similar despite using different viruses or viral strains showing varying degrees of 
pathogenicity. In previous studies the same chemokines have been identified to 
be highly upregulated in the CNS of mice infected with other encephalitic viruses 
such as Sindbis virus, closely related to SFV, MHV and LCMV (128, 129, 441). 
Thus, a certain chemokine expression pattern is evident during viral encephalitis 
regardless of the pathogen used.  
Despite similar chemokine expression patterns during viral encephalitis using 
various encephalitic viruses, the magnitude of expression varies considerably 
depending on the degree of pathogenicity of the viral strain used. For instance 
chemokines were many fold more strongly induced during SFV L10 infection or 
virulent WNV infection compared to avirulent SFV A7(74) infection.  
Importantly, some chemokines such as the neutrophil attracting chemokines 
CXCL1 and CXCL2 were exclusively expressed during virulent SFV infection using 
strain L10, and virulent WNV infection using strain NY99. In support of this, Bai 
et al. and Perry et al. have shown that neutrophils enter the CNS only during the 
onset of severe forms of viral or bacterial brain infections (350, 415, 439, 440). 
Furthermore, due to the toxic properties of the granules within neutrophils, the 
recruitment of neutrophils into the CNS has been shown to lead to severe tissue 
damage (18, 128, 129, 441). During SFV infection using the avirulent strain 
A7(74) no neutrophils were detectable by immunohistochemistry, and this result 
is in agreement with my results demonstrating the lack of expression of 
neutrophil attracting chemokines during A7(74) infection. The strong induction 
of CXCL1 and CXCL2 expression during virulent L10 infection suggests that 
neutrophils might enter the CNS and it is therefore possible that the infiltration 
of neutrophils is in general associated with more severe disease outcomes. 
Further experiments are required to investigate this possibility. 
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Of note, the early induction of CXCL10 and, to a lesser extent CXCL9, expression 
during SFV and WNV infection suggests that these chemokines are most likely 
expressed by cells of the CNS such as neurons and glia during very early time 
points of brain infection. In support of this, Klein et al. have demonstrated that 
CXCL10 is predominantly and strongly expressed in neurons while Lane et al. 
have reported that CXCL10 is mainly expressed in astrocytes during MHV 
infection (129, 153). From these studies it is not clear which cells of the CNS are 
the ultimate source of CXCL10 but the induction of CXCL10 expression appears to 
be localised to cells infected by the virus, suggesting that virus infected cells of 
the CNS are a possible source of CXCL10. In the case of SFV this would involve 
mainly neurons and oligodendrocytes and not astrocytes, as these are the main 
cells becoming infected with SFV (293). 
Beyond CXCL9 and CXCL10, much chemokine expression in the brain is induced 
simultaneously with the appearance of viruses in the CNS, coinciding with the 
influx of leukocytes into the brain. This suggests that chemokines are 
predominantly expressed by infiltrating leukocytes. Whether leukocyte entry 
into the CNS is beneficial or detrimental for disease outcome is not yet clear. 
This is demonstrated in part by studies using WNV as a model of infection where 
leukocyte infiltration is pivotal for viral clearance and survival (442). In contrast 
to this, studies using LCMV as a model of infection have shown that leukocytes 
contribute to neuropathology and lead to higher mortality rates (371, 430). 
Fazakerley et al. have shown that specific leukocyte subsets such as CD4+ and 
CD8+ T-cells during SFV infection are pathogenic by contributing to the 
generation of lesions of demyelination and neuroinflammation (51, 301). In 
addition they have demonstrated that the presence of neutralizing IgG in the 
CNS of SFV infected SCID mice, devoid of B-cells and T-cells, is sufficient for 
viral clearance and survival of mice, suggesting that leukocytes are dispensable 
for survival and are mostly pathogenic (51, 443). Of note is the fact that CD45+ 
leukocyte influx in response to avirulent SFV infection was moderate compared 
to higher leukocyte infiltration during virulent SFV infection. Therefore it is 
possible that the extent of leukocyte infiltration determines whether leukocyte 
recruitment is pathogenic or beneficial during viral encephalitis. 
The use of small molecule inhibitors for CCR2 and CXCR3, or CCR2 deficient 
mice, resulted in a significant decrease in leukocyte recruitment to the CNS. In 
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the case of combined CCR2 and CXCR3 blockade disease outcome was better 
with more mice surviving otherwise lethal SFV L10 infection. This suggests that 
reducing leukocyte infiltration in the brain is beneficial. This is in contrast to 
data from CCR2 deficient mice, where reduction of leukocytes within the CNS 
correlated with worse disease outcome, suggesting that leukocytes are 
beneficial. The reason for this discrepancy will be discussed in more detail in 
section 7.4, but at this stage no firm conclusions can be drawn from my data 
about the role of leukocytes during viral encephalitis. However, it appears that 
the role of leukocytes during viral encephalitis depends on various factors 
including viral strain, type of leukocytes entering the CNS and timing of 
infiltration.  
One of the first leukocytes entering the brain during avirulent and virulent SFV 
infection were cells of the innate immune system such as NK-cells and CD11b+ 
myeloid cells, mainly Ly6Chi and Ly6C- monocytes and macrophages, 
respectively. The entry of innate immune cells into the CNS correlated with 
entry of SFV into the brain. The recruitment of NK-cells and myeloid cells into 
the brain coincides with the upregulation of the appropriate chemokines during 
early stages of infection. For instance CXCL9 and CXCL10 expression was strongly 
induced during early time points of infection, and in previous studies these 
chemokines have been shown to attract CXCR3+ activated NK-cells and T-cells 
(379, 444). The expression of CCL2 and CCL5 was also upregulated compared to 
healthy controls, and these chemokines have been shown to be important for the 
attraction of macrophages and monocytes (445).  The role of NK-cells during 
viral encephalitis is not yet clear, as studies have demonstrated that the 
depletion of NK-cells does not prevent mortality during virulent SFV or MHV 
infection (379, 417). NK-cells have been shown to secrete IFN-γ, and this 
cytokine could be partly responsible for the strong induction of CXCL9 expression 
and upregulation of MHC class II on myeloid cells during later time points of SFV 
infection. However the production of IFN-γ during early stages of brain infection 
can lead to the early induction of CXCL9 expression by brain endothelial cells or 
glial cells (242, 428).  
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Figure 7.1. Kinetics of leukocyte entry during SFV infection  
Mice were infected i.p. with SFV A7(74) for up 10 days. Diagram depicts leukocytes infiltration 
into the CNS  
The accumulation of monocytes and macrophages within the CNS has been 
shown to play a paradoxical role during the pathogenesis of viral encephalitis. 
Savarin et al. have demonstrated that impaired monocyte recruitment in CCL2 
deficient mice regulates trafficking of T-cells across the BBB during viral 
encephalitis, which subsequently leads to higher viral titers in the brains of 
infected mice and delays onset of disease (401). Getts et al. have shown that 
the CCL2 dependent infiltration of Ly6Chi inflammatory monocytes during WNV 
infection is pathogenic and increases mortality (106, 446). Importantly, in many 
studies of viral encephalitis, the attraction of CCR2+Ly6Chi inflammatory 
monocytes was dependent on CCL2 expression (23). Here it was demonstrated 
that a shift from Ly6C- to Ly6C+ cells occurred between 5 and 7 days post 
infection, suggesting that Ly6C+ cells accumulate increasingly in the brain during 
later stages of infection. The simultaneous expression of CCL2 in SFV infected 
brains is in line with the recruitment of CCR2+ monocytes and macrophages into 
the CNS.  
The second wave of leukocyte infiltration into the brain during avirulent SFV 
infection occurred after viral invasion of the brain, and comprised predominantly 
lymphoid cells. This second wave of leukocyte recruitment was not observed 
during virulent SFV infection because mice succumbed to the disease 
beforehand.  In addition to lymphoid cells, a small increase of plasmacytoid DCs, 
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described as CD11b+CD11c+pDCA+ cells, was also observed. These cells are 
capable of producing large amounts of type-I IFNs (447). Type-I interferons were 
simultaneously upregulated with the infiltration of pDCs into the brain. Thus, it 
is possible that these cells contribute to high levels of type-I interferon 
expression in the brain at this stage of infection. Plasmacytoid DCs have also 
been observed in the brain during other viral encephalitic infections such as 
WNV infection or during autoimmune diseases such as EAE or MS (144, 413, 421).  
The infiltration of T-cells coincided with high levels of CXCL9 and CXCL10 
expression, both of which are ligands for CXCR3. Therefore the role of CXCR3 
was investigated here and will be discussed in further detail in section 7.4. 
During avirulent SFV infection of the brain, a significant increase in CD8+ T-cell 
numbers was observed. However the number of CD4+ T-cells was also increased. 
In general T-cell infiltration into the CNS peaked on PID 10, concomitant with a 
significant reduction of viral titers and strong chemokine expression in the brain. 
The expression of CCL5 during SFV and WNV infection correlated with the 
accumulation of T-cells within the CNS. Thus, it is possible that CCL5 is 
predominantly expressed by T-cells. This is in agreement with a study by Lane et 
al. which revealed similar results to my findings (129). During L10 infection, T-
cells also infiltrated the brain on PID 5 but the majority of the cellular infiltrate 
consisted mainly of innate immune cells. During A7(74) infection many T-cells 
were capable of infiltrating deep into the brain parenchyma. T-cell infiltration 
was observed throughout the brain, whereas Subak-Sharpe et al. have observed 
foci of infection mainly in the cerebellum and corpus callosum of SFV infected 
mice (310). In support of this, Zhang et al. have shown that CXCL10 is 
differentially expressed in the brain and results in the attraction of T-cells to 
particular regions of the brain including the cerebellum (375). Thus, these data 
suggest that different regions of the brain respond differently to viral infection 
and attract distinct leukocyte subsets. 
Previous SFV studies have demonstrated that the T-cell response during SFV 
infection is pathogenic (378). CD8+ T-cells have been shown to be responsible for 
demyelination through the destruction of infected oligodendrocytes (51, 310). 
Furthermore it has been demonstrated that the depletion of CD4+ T-cells 
prevents the production of antiviral IgG, and results indirectly in increases of 
viral titer and neuroinflammation. The depletion of both CD8+ and CD4+ T-cells 
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in mice during SFV infection has been reported to prevent the development of 
CNS inflammation. Importantly, T-cells have been shown to be dispensable for 
viral clearance of SFV in the CNS (310). This is in contrast to studies using WNV 
as a model of infection where it has been demonstrated that T-cells are 
important for viral clearance and decrease of neuroinflammation (321). Further 
analysis of the data presented here revealed that most T-cells were effector T-
cells, and most of the T-cells expressed the chemokine receptors CXCR3 and 
CCR5. This is in agreement with results obtained by TLDA, showing high 
expression of the appropriate ligands prior to maximal T-cell infiltration.  
B-cells were detectable in the SFV infected brain by PID 10 and coincided with 
high expression of the chemokine receptor CXCR5 which is mainly expressed on 
B-cells. Before PID 10, B-cells were not detectable in the CNS. In this study 
mononuclear cell infiltration was not measured after PID 10 but a study by Morris 
et al. has demonstrated that B-cell numbers within the CNS of SFV infected mice 
were high between post infection day 14-21, although B-cells were already 
detectable in the brain by PID 7 (307). Immunoglobulin IgG is very important for 
the clearance of virus in the CNS while IgM is pivotal for the clearance of viremia 
(51, 298, 311). Antibody secreting cells have also been detected in the CNS 
during other alphavirus infections using Sindbis-virus (SINV) as a model of 
infection. (441).  
Overall, these data suggest that chemokines are highly and selectively 
upregulated during viral encephalitis. The chemokine expression pattern appears 
to be similar regardless of the pathogen used, facilitating the identification of 
therapeutic targets for the treatment of viral encephalitis. Chemokine 
expression coincided with increase in viral titers and leukocyte recruitment to 
the CNS. Despite recent reports that leukocyte entry during SFV infection is 
pathogenic, a clear conclusion from these data cannot be drawn yet.  
7.3 Cytokine expression patterns during SFV and WNV 
infection 
The cytokine expression pattern during SFV and WNV infection was similar, 
suggesting that the expression of these cytokines is not pathogen or cell type 
specific. Studies using WNV as a model of infection have shown that cytokines 
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can also be expressed by cells of the CNS (54). Our results demonstrate that a 
few cytokines are induced early during viral infection including TNF, suggesting 
that neurons and glial cells are capable of producing TNF. A study by Wang et al. 
has demonstrated that the expression of TNF is mediated by TLR-3, and that this 
cytokine is involved in the break-down of the BBB (448). TNF is not only highly 
induced in SFV infected brains but also in WNV infected brains. A study 
conducted by Shrestha et al. has reported that TNF deficient mice exhibit higher 
mortality and increased viral titers in the brain, associated with reduced 
numbers of CD8+ T-cells and macrophages within the CNS (87). Thus, TNF is 
important for controlling the pathogenesis of WNV induced encephalitis. 
Generally most other cytokines such as IFNs, IL-1β and IL-6 appear to be 
expressed concomitantly with increased infiltration of leukocytes into the CNS of 
A7(74) infected mice, between PID 7 and PID 10, suggesting that leukocytes are 
the main source of cytokines released. 
The expression of IFNs was strongly induced during SFV and WNV infection. 
However the magnitude of IFN expression was several-fold higher during virulent 
infection of the CNS. Levels of IFNs were very low in control mice, and were 
significantly increased after virus entry into the brain. The upregulation of type-I 
IFN parallels the increase of viral titers within the brain, peaking by PID 7. This 
is agreement with previous results demonstrating that IFN-production after 
infection with SFV increases concomitantly with viral titers (65). SFV is highly 
susceptible to IFN production and it has been demonstrated that mice deficient 
for type-I interferon receptor succumbed to SFV infection rapidly, and displayed 
augmented viral titers throughout the body, suggesting that type-I interferon is 
protecting mice from widespread infection and reducing mortality (65). During 
WNV infection type-I interferons peaked on PID 6 when viral titers reached 
maximal levels, and this induction of expression is similar to IFN expression 
during SFV infection. WNV infected mice lacking the type-I interferon receptor 
exhibit uncontrolled viral replication, rapid entry of virus into the brain and 
enhanced mortality, suggesting an antiviral role of type-I interferon during WNV 
infection (344). As mentioned before one of the sources of type-I interferon 
could be pDCs which infiltrate the brain during viral encephalitis (144). 
Furthermore Longhini et al. have shown that pDCs secrete high amounts of IFN-α 
(413). These cells have been detected during SFV infection by PID 7. Another 
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increase of type-I IFN could be achieved through the activation of IRF genes 
within neurons and glial cells (62). For example IRF7 was induced in the SFV 
infected brain prior to IFN production. Other IRFs and transcription factors can 
also induce the production of type-I IFN. Generally IFNs are reported to be 
important for viral clearance and induction of CXCL9 and CXCL10 during 
alphavirus infection (378, 449).  
IFN-γ is only upregulated during later time points correlating with the high 
induction of CXCL9 expression. This is in agreement with a study by Muller et al. 
who have shown that only IFN-γ, and not IFNα or IFN-β, induces CXCL9 
expression. NK-cells and CD8+ T-cells produce high levels of IFN-γ, both of which 
infiltrate the brain during SFV and WNV infection. The depletion of IFN-γ has 
been shown to have no effect on the susceptibility of mice to SFV infection (66). 
This is in contrast to another study using IFN-γ-/- or IFN-γ receptor deficient mice 
infected with WNV. These mice display enhanced viral titers in the blood, 
widespread dissemination of virus, and exhibit more rapid entry of virus into the 
CNS (347). Importantly in both studies leukocyte recruitment into the CNS was 
not altered in SFV and WNV infected mice, suggesting that IFN-γ is not important 
for the migration of leukocytes but is pivotal for antiviral immune responses such 
as virus clearance. 
In response to viral replication, the expression of ISGs was also highly induced 
during SFV L10 infection along with the expression of cytokines and innate 
immunity genes. The upregulation of ISGs during WNV infection was not assessed 
in this thesis but previous studies reported that ISGs are highly induced in the 
CNS in response to infection (72, 450). The expression of ISGs has been shown to 
differ within infected neurons, and the expression of OAS1 and Mx1, which were 
both upregulated during SFV infection, have been associated with increased risk 
of developing severe forms of WNV encephalitis (363).  
Altogether these data suggest that cytokines and ISGs are strongly induced 
during SFV and WNV infection, and that they often exert antiviral functions 
rather than modulating the recruitment of leukocytes to the CNS. Cells of the 
CNS can express many cytokines but the late and strong induction of cytokines 
suggests that the cellular sources are probably infiltrating leukocytes.  
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7.4 The role of chemokine antagonists during the 
pathogenesis of SFV and WNV infection of the CNS 
After identification of key chemokines upregulated during SFV infection, the role 
of the CCR2, CCR5 and CXCR3 axes during viral encephalitis was determined 
using small molecule inhibitors instead of gene deficient mice. The advantage of 
antagonists over gene deficient mice is that chemokine receptor functions can 
be blocked at any stage of the disease. In this thesis the antagonists were 
administered to mice on the day when virus started to invade the CNS, and 
therefore initial host immune responses to the virus were not altered using 
antagonists. 
These three selected chemokine receptors bind the major upregulated 
chemokines during SFV infection. In chapters 3 and 4 it was shown that 
chemokine expression coincided with leukocyte recruitment within the brain, 
and therefore it was hypothesised that blocking one of the chemokine receptors 
CCR2, CCR5 or CXCR3 would result in impaired leukocyte infiltration and would 
change pathogenesis of virulent infection. Interestingly, viral titers were 
unaffected by the blockade of chemokine receptors, suggesting that viral load is 
not directly related to pathogenesis and cellular immune responses. The 
presence of IgG has been shown to be the determining factor for viral clearance 
during SFV infection (51). A similar result has been found during studies of SINV 
infection (123, 451). Christensen et al. have demonstrated that MHV infected 
mice, deficient for CXCL10 or CXCR3, experienced no reduction in viral titers 
despite reduced leukocyte numbers entering the brains of these mice (322).  
Also of note is that chemokine expression patterns in the CNS of chemokine 
receptor blocker treated mice were not significantly different from untreated 
mouse brains. This is in contrast to a previous study which has reported that 
CCL2 ligands are more strongly expressed in the brains of CCR2 receptor 
deficient mice (214). It remains unclear why this is the case. Despite unaffected 
viral titers and similar chemokine expression levels in the CNS of treated and 
untreated mice, chemokine receptor blockers were capable of reducing the 
number of infiltrating leukocytes. This suggests that these antagonists 
specifically block recruitment of leukocyte subsets, although this does not result 
in antiviral properties. 
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The chemokine receptor CCR2 has been shown to be important for the exit of 
monocytes from the bone marrow (24). Furthermore ‘inflammatory’ monocytes 
exhibit high expression of CCR2 and are rapidly recruited to the site of 
inflammation during infection (20, 213). Getts et al. have shown that the 
majority of monocytes recruited to the brain during viral encephalitis are CCR2+ 
monocytes (106). Furthermore the authors have shown that the recruitment of 
CCR2+ monocytes to the brain is pathogenic, as depletion of CCL2, a specific 
ligand for CCR2, resulted in prolonged survival. This is in contrast to another 
study which has demonstrated that loss of CCR2 results in increased mortality 
(346). Using CCR2 deficient mice I demonstrated that mortality was not 
significantly different compared to wild type infected mice. Thus, from the L10 
data it appears that the recruitment of CCR2+ monocytes to the CNS of SFV 
infected mice does not affect pathogenesis. 
To establish a clearer picture regarding the role of monocytes during viral 
encephalitis, SFV infected mice, using strain A7(74), were treated with the CCR2 
antagonist RS504393. The results revealed that the number of leukocytes, and in 
particular CCR2+ monocytes, was significantly reduced in CCR2 blocker treated 
mice. Furthermore I demonstrated that antagonism of CCR2 did not affect the 
number of monocytes in the blood. Thus, CCR2 is important for the trafficking of 
monocytes into the CNS during SFV encephalitis, and is not a consequence of 
prior moncytopenia. This result is in contrast to a study conducted by Lim et al. 
which has demonstrated that CCR2 is not involved in monocyte trafficking to the 
CNS during WNV infection, and it was suggested that another chemokine 
receptor such as CCR5 might be involved at this level (214). The authors have 
demonstrated that the main determinant for monocyte accumulation in WNV 
infected brains is the preceding monocytosis. A slight increase in circulating 
monocyte numbers was also observed in SFV infected mice but this was less 
profound compared to monocytosis in WNV infected mice.  
The chemokine receptor CCR5 has been shown to be an important antiviral and 
survival determinant during WNV infection (173). In support of this another study 
has shown that a loss of function mutation of the CCR5 gene in humans 
correlates with more severe disease development and neuropathology during 
WNV infection (197). To investigate the role of CCR5 during SFV infection two 
different antagonists were used. Surprisingly the FDA approved CCR5 antagonist, 
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referred to as Maraviroc, did not result in a reduction of leukocyte recruitment 
to the CNS during SFV infection. Maraviroc is a highly efficient drug inhibiting 
entry of HIV into CCR5+ cells but from these data it appears that this drug is not 
efficient in reducing leukocyte recruitment during SFV encephalitis in the mouse 
(199). The reasons for this are discussed in chapter 6. 
Using the other CCR5 blocker, referred to as DAPTA, leukocytes were only 
minimally reduced but the number and proportion of CCR5+ cells was 
significantly and highly reduced in DAPTA treated mice. Thus, DAPTA is efficient 
in blocking CCR5+ cell recruitment. However, it appears from my data that CCR5 
plays a subordinate role in the attraction of leukocytes during SFV encephalitis. 
For example CCR2 and CXCR3 blockade were more efficient in reducing 
leukocyte recruitment compared to CCR5 blockade. In support of this, other 
studies using LCMV or MHV as models of infection have demonstrated that viral 
titers and mortality are not enhanced in CCR5 deficient mice compared to WT 
mice (319, 382). Thus, the role of CCR5 in the pathogenesis of viral encephalitis 
and antiviral host defense has only been shown so far for WNV infection (362). 
However, Glass et al. have shown that CCR5 is non-redundant during MHV 
infection as CCR5 has been shown to promote demyelination during MHV 
infection. However CCR5 is dispensable for leukocyte recruitment to the CNS 
during MHV infection (336, 382).  
Due to the strong induction of CXCL9 and CXCL10 and high numbers of T-cells 
infiltrating the brain during SFV infection it was hypothesised that blockade of 
CXCR3, expressed mainly on T-cells and binding CXCL9 and CXCL10, would result 
in a significant reduction of T-cells entering the CNS, and in turn lead to more 
severe onsets of viral encephalitis. Using the CXCR3 antagonist, compound 21, I 
have demonstrated that the number of leukocytes entering the CNS is highly, 
and significantly, reduced in treated mice compared to untreated mice. 
Compared to the other antagonists used, interfering with the CXCR3 axis led to 
the greatest reduction in leukocyte entry into the CNS during viral encephalitis. 
Within leukocytes the fraction of CD3+ T-cells was strongly reduced after 
treatment with compound 21.  
In particular the number of CD8+ T-cells was strongly reduced in treated mice. In 
support of this, previous studies have shown that the loss of CXCL10 or CXCR3, 
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using gene deficient mice, results in impaired CD8+ T-cell trafficking to the brain 
and leads to enhanced viral titers and mortality (153, 375). Surprisingly, my data 
demonstrate that the reduction of T-cells infiltrating the SFV infected brain of 
CXCR3 blocker treated mice does not reduce viral titers. In support of this, Amor 
et al. have shown that T-cells are pathogenic and are dispensable for viral 
clearance (51). Subak-Sharpe et al. have shown that CD8+ T-cells are pivotal for 
demyelination, and CD4+ T-cells are critical for the extent of neuroinflammation 
(310).  
The blockade of CXCR3 also resulted in a reduction of other leukocyte subsets. 
For instance the number of NK-cells was reduced after treatment with 
compound 21. A previous study has demonstrated that activated NK-cells also 
express CXCR3 and are recruited to the CNS in response to viral encephalitis 
(379). This would explain in part why NK-cell numbers are also reduced in SFV 
infected mice treated with compound 21. However the antagonism of CXCR3 also 
resulted in the reduction of numbers of CD11b+ myeloid cells which do not 
express CXCR3. This suggests that recruited T-cells within the CNS trigger the 
recruitment of other leukocyte subsets that respond to distinct chemotactic 
cues. T-cells may do this either directly by synthesising chemokines and 
cytokines themselves, or indirectly by inducing chemokine expression in resident 
neural cells, which in turn attract leukocyte subsets into the CNS as has been 
suggested during LCMV infection (154). 
Since compound 21 induces such a significant reduction in leukocyte 
recruitment, the role of this antagonist was also investigated during lethal SFV 
infection using strain L10. The blockade of CXCR3 did not result in an altered 
disease outcome, and the original hypothesis was therefore disproven. This 
result is in contrast to previous studies, using MHV or WNV as model of infection, 
which have demonstrated that CXCR3 is critical for T-cell accumulation within 
the infected brain parenchyma, resulting in an altered disease outcome (323, 
375). For instance, during WNV infection CXCR3 deficient mice experienced 
significantly higher mortality compared to WT mice (153, 375). In the case of 
SFV infection it is possible that the blockade of T-cell entry was not enough to 
alter mortality. This can be explained by the fact that it was mostly cells of the 
innate immune response, such as myeloid and NK-cells, which infiltrated the 
brain prior to the death of mice. Infection with the avirulent strain A7(74) 
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revealed that T-cells infiltrate the brain at later time points as observed on PID 
7 and PID 10. Thus, it is likely that the blockade of CXCR3 was not appropriate, 
and a blockade of myeloid cells or NK-cells would have been more suitable. 
Importantly, the simultaneous blockade of CXCR3 and CCR2 significantly 
enhanced survival. However CCR2 deficient mice experienced higher mortality. 
This suggests that the timing of chemokine receptor blockade is important. 
While CCR2 deficient mice have depleted numbers of circulating monocytes, the 
pharmacological blockade of CCR2 does not lead to altered numbers of 
monocytes circulating in the blood. Schall et al. have proposed the idea that 
target selection, time of intervention and functional dose are the key 
determinants for the development of successful chemokine receptor drugs for 
treatment of inflammatory diseases (207). Furthermore they have suggested that 
redundancy of the chemokine network is not the main hurdle for the successful 
development of drugs but rather the use of ineffective dosing or inappropriate 
target selection.  
 
Figure 7.2. The role of chemokine receptor antagonists during SFV infection 
Summary of the use of all chemokine receptor antagonists used in this thesis are shown. L10 
infections were survival experiments. A7(74) infections were avirulent and the extent of 
leukocyte infiltration into the virally infected CNS was measured. 
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Based on the chemokine receptor blocker data no firm conclusions can be drawn 
about the role of leukocyte infiltration during viral encephalitis. While CCR2 
deficient mice exhibit reduced leukocyte infiltration, mortality is not 
significantly different compared to wild type mice, but the combined blockade 
of CCR2 and CXCR3 resulted in reduced leukocyte infiltration and enhanced 
survival. It appears from these data that timing of blockade and target selection 
are indeed the main determinants, suggesting that leukocyte recruitment can be 
either beneficial or detrimental depending on the context. 
7.5 Conclusions  
The aim of this thesis was to identify chemokine receptors as plausible 
therapeutic targets during viral encephalitis, using SFV as a model of infection. 
Prior to identification of chemokine receptors as therapeutic targets an 
extensive analysis of chemokine expression was performed and leukocyte 
recruitment to the CNS was determined. Based on my data presented here, the 
following conclusions were reached: 
1. Chemokines are selectively and highly upregulated during viral encephalitis 
regardless of the pathogen used, although the magnitude of chemokine 
expression was several fold more strongly induced during virulent brain 
infection. Some chemokines are exclusively upregulated during severe forms of 
encephalitis. 
2. The extent of leukocyte recruitment is dependent on the viral strain used. 
During SFV infection the first cells entering the brain were cells of the innate 
immune system, followed by lymphoid cells. Compared to other leukocyte 
subsets, T-cells were capable of infiltrating deep into the brain parenchyma. 
3. Chemokine receptor antagonists are efficient in reducing leukocyte 
recruitment and altering disease outcome despite having no effect on viral 
titers. The CXCR3 axis was identified as a key instigator of CNS inflammation in 
response to alphavirus infection, placing it at the top of a hierarchical cascade 
that is followed by the CCR2 and CCR5 axes. 
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4. Combined treatment of mice with CCR2 and CXCR3 antagonists resulted in 
enhanced survival compared to untreated, or CCR2 deficient, mice. Importantly, 
treatment with CXCR3 blocker alone did not have an effect on disease outcome. 
Timing, and appropriate target selection, appears to be critical for the 
treatment of lethal SFV encephalitis. 
Overall the data presented in this thesis demonstrate that chemokines are 
highly, and selectively, upregulated during viral encephalitis coinciding with 
infiltration of leukocyte subsets, known to express the appropriate chemokine 
receptors. Chemokine receptor antagonists are highly efficient in reducing 
leukocyte recruitment and are therefore plausible therapeutic targets in viral 
encephalitis. 
7.6 Future directions 
In this thesis I was able to provide some answers regarding the identification of 
chemokine expression patterns and identification of chemokine receptors as 
therapeutic target during viral encephalitis. However, whether leukocyte 
recruitment into the brain is beneficial or detrimental for the pathogenesis, 
remains to be determined. In future experiments the role of specific leukocyte 
subsets should be investigated in more detail. For example, neutrophils appear 
to infiltrate the brain during severe forms of encephalitis, and my results have 
shown that neutrophil attracting chemokines are only expressed during lethal 
brain infection using SFV strain L10 and WNV strain NY99. Therefore it would be 
interesting to further investigate the role of neutrophils during viral encephalitis 
by depleting these cells in SFV or WNV infected mice, using antibodies or 
pharmacological blockers. 
In chapter 4 I was able to localise some of the leukocytes in the virally infected 
brain. However the chemokine antibodies (CCR2, CCR5, CXCL9 and CXCL10) for 
immunohistochemistry using paraffin sections did not work. It would therefore 
be helpful to use in-situ hybridisation in future experiments to localise 
chemokine expression within the brain. Of particular interest is if the majority 
of chemokines are produced by neurons, glial cells or leukocytes entering the 
blood during viral encephalitis. Additionally, in future experiments I would like 
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to perform IHC in L10 infected brains to localise leukocytes and virus within the 
infected CNS. 
Due to time constraints I was not able to examine the effect of CCR2 blockade 
alone on survival during SFV L10 infection. Although survival experiments using 
CCR2 deficient were conducted, it is possible that CCR2 blockade will result in a 
different disease outcome, as combined blocking with CXCR3 has proven to be 
beneficial for survival.  
Since I have proposed the idea that the dose of Maraviroc in this experiment was 
too low during treatment of SFV infected mice, it would be interesting to test a 
higher dose of this drug. Maraviroc is an already approved CCR5 blocker, and 
therefore it would be interesting to test its effect during viral encephalitis.  
Furthermore, the timing and dosing of the drug appear to be key to successful 
therapeutic intervention. In future experiments it should be investigated if 
timing is indeed such a crucial factor. Perhaps the drug could be given at various 
time points post infection or beforehand.   
Lastly, in this study only 3 chemokine receptor antagonists have been 
investigated. It would be interesting to determine if other chemokine receptor 
antagonists display similar efficiency in reduction of leukocyte recruitment. For 
instance the role of CCR1, CCR3 or CXCR2, binding to major upregulated 
chemokines during SFV and WNV infection, could be determined. Several CCR1 
antagonists have been developed and are currently tested in clinical trial for the 
treatment of chronic inflammatory diseases such as rheumatoid arthritis or 
psoriasis (452, 453). It is possible that these blockers are also efficient in the 
treatment of viral encephalitis. Future research will undoubtedly uncover new 
and exciting roles for chemokines and their receptors in the treatment of viral 
encephalitis. 
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1 A 
Gene Accession number 
CCL2	   Ccl2-­‐Mm00441242_m1	  
CCL3	   Ccl3-­‐Mm99999057_m1	  
CCL4	   Ccl4-­‐Mm00443112_m1	  
CCL5	   Ccl5-­‐Mm01302427_m1	  
CCL7	   Ccl7-­‐Mm00443113_m1	  
CCL8	   Ccl8-­‐Mm01297183_m1	  
CCL11	   Ccl11-­‐Mm00441238_m1	  
CCL20	   Ccl20-­‐Mm01268754_m1	  
CXCL1	   Cxcl1-­‐Mm00433859_m1	  
CXCL2	   Cxcl2-­‐Mm00436450_m1	  
CXCL3	   Cxcl3-­‐Mm01701838_m1	  
CXCL5	   Cxcl5-­‐Mm00436451_g1	  
CXCL9	   Cxcl9-­‐Mm00434946_m1	  
CXCL10	   Cxcl10-­‐Mm00445235_m1	  
CXCL12	   Cxcl12-­‐Mm00445553_m1	  
CXCL16	   Cxcl16-­‐Mm00469712_m1	  
CX3CL1	   Cx3cl1-­‐Mm00436454_m1	  
IL1-­‐β	   Il1b-­‐Mm00434228_m1	  
IL-­‐6	   Il6-­‐Mm01210733_m1	  
IL-­‐10	   Il10-­‐Mm00439616_m1	  
IFN-­‐α	   Ifna4-­‐Mm00833969_s1	  
IFN-­‐β	   Ifnb1-­‐Mm00439552_s1	  
IFN-­‐κ	   Ifnk-­‐Mm02529417_s1	  
IFN-­‐ε	   Ifne-­‐Mm00616542_s1	  
TNF	   Tnf-­‐Mm00443258_m1	  
TGF-­‐β	   Tgfb1-­‐Mm03024053_m1	  
IRF7	   Irf7-­‐Mm00516788_m1	  
RIG-­‐I	   Ddx58-­‐Mm00554529_m1	  
FGF2	   Fgf2-­‐Mm01285715_m1	  
CD45	   Ptprc-­‐Mm00448490_m1	  
TBP	   Tbp-­‐Mm00446971_m1	  
18S	   18S-­‐Hs99999901_s1	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1 B 
Gene Accession number 
CCL1	   Ccl1-­‐Mm00441236_m1	  
CCL2	   Ccl2-­‐Mm00441243_g1	  
CCL3	   Ccl3-­‐Mm00441259_g1	  
CCL4	   Ccl4-­‐Mm00443111_m1	  
CCL5	   Ccl5-­‐Mm01302428_m1	  
CCL6	   Ccl6-­‐Mm01302419_m1	  
CCL7	   Ccl7-­‐Mm01308393_g1	  
CCL8	   Ccl8-­‐Mm01297184_g1	  
CCL9	   Ccl9-­‐Mm00441260_m1	  
CCL11	   Ccl11-­‐Mm00441238_m1	  
CCL12	   Ccl12-­‐Mm01211783_g1	  
CCL17	   Ccl17-­‐Mm01244826_g1	  
CCL19	   Ccl19-­‐Mm00839967_g1	  
CCL20	   Ccl20-­‐Mm01268754_m1	  
CCL21	  
Ccl21a;Ccl21b;Gm1987;Gm13304;Gm10591;Ccl21c-­‐
Mm03646971_gH	  
CCL22	   Ccl22-­‐Mm00436439_m1	  
CCL24	   Ccl24-­‐Mm00444701_m1	  
CCL25	   Ccl25-­‐Mm00436443_m1	  
CCL26	   Ccl26-­‐Mm04204096_m1	  
CCL27	   Ccl27a;Gm2506;Ccl27b;Gm13306-­‐Mm01215829_m1	  
CCL28	   Ccl28-­‐Mm00445039_m1	  
CX3CL1	   Cx3cl1-­‐Mm00436454_m1	  
CXCL1	   Cxcl1-­‐Mm00433859_m1	  
CXCL2	   Cxcl2-­‐Mm00436450_m1	  
CXCL3	   Cxcl3-­‐Mm01701838_m1	  
CXCL5	   Cxcl5-­‐Mm00436451_g1	  
CXCL9	   Cxcl9-­‐Mm00434946_m1	  
CXCL10	   Cxcl10-­‐Mm00445235_m1	  
CXCL12	   Cxcl12-­‐Mm00445553_m1	  
CXCL13	   Cxcl13-­‐Mm01208154_g1	  
CXCL14	   Cxcl14-­‐Mm00444699_m1	  
CXCL15	   Cxcl15-­‐Mm00441263_m1	  
CXCL16	   Cxcl16-­‐Mm00469712_m1	  
CXCL17	   Cxcl17-­‐Mm00463791_m1	  
XCL1	   Xcl1-­‐Mm00434772_m1	  
IL-­‐1β	   Il1b-­‐Mm00434228_m1	  
IL-­‐4	   Il4-­‐Mm00445260_m1	  
IL-­‐6	   Il6-­‐Mm99999064_m1	  
IL-­‐10	   Il10-­‐Mm01288386_m1	  
IFN-­‐α	   Ifna4-­‐Mm00833969_s1	  
IFN-­‐β	   Ifnb1-­‐Mm00439552_s1	  
IFN-­‐γ	   Ifng-­‐Mm01168133_g1	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Gene Accession number 
TNF	   Tnf-­‐Mm00443259_g1	  
TGF-­‐β	   Tgfb1-­‐Mm00441729_g1	  
IRF3	   Irf3-­‐Mm01203177_m1	  
IRF7	   Irf7-­‐Mm00516788_m1	  
MDA5	   Ifih1-­‐Mm00459183_m1	  
Ifit-­‐1	   Ifit1-­‐Mm00515153_m1	  
RIG-­‐I	   Ddx58-­‐Mm00554529_m1	  
PKR	   Eif2ak2-­‐Mm00440966_m1	  
ISG15	   Isg15-­‐Mm01705338_s1	  
ISG20	   Isg20-­‐Mm00469585_m1	  
MX-­‐1	   Mx1-­‐Mm00487796_m1	  
Oas1a	   Oas1a-­‐Mm00836412_m1	  
Viperin	   Rsad2-­‐Mm00491265_m1	  
Zc3hav1	   Zc3hav1-­‐Mm00512227_m1	  
TLR3	   Tlr3-­‐Mm00628112_m1	  
TLR7	   Tlr7-­‐Mm00446590_m1	  
CD207	   Cd207-­‐Mm00523545_m1	  
CD209a	   Cd209a-­‐Mm00460067_m1	  
cAMP	   Camp-­‐Mm00438285_m1	  
Krtap	   Krtap16-­‐5-­‐Mm00652413_s1	  
eIF3f	   Eif3f-­‐Mm00517953_m1	  
18S	   18S-­‐Hs99999901_s1	  
Appendix 1. Genes selected for TaqMan low density array (TLDA) 
(A) 32 genes or (B) 62 genes selected for TLDA analysis. On the left: gene names; on the right: 
accession number taken from the gene database for the gene assayed. 
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2 A sample number virus strain used RIN value 
	  
control	  1	   A7(74)	   10	  
	  
control	  2	   A7(74)	   10	  
	  
control	  3	   A7(74)	   9.9	  
	  
control	  4	   A7(74)	   8.6	  
	  
PID3	  1	   A7(74)	   9.8	  
	  
PID3	  2	   A7(74)	   8.1	  
	  
PID3	  3	   A7(74)	   9.7	  
	  
PID3	  4	   A7(74)	   9.8	  
	  
PID4	  1	   A7(74)	   9.5	  
	  
PID4	  2	   A7(74)	   9.9	  
	  
PID4	  3	   A7(74)	   9.2	  
	  
PID4	  4	   A7(74)	   8.4	  
	  
PID5	  1	   A7(74)	   8.9	  
	  
PID5	  2	   A7(74)	   8.5	  
	  
PID5	  3	   A7(74)	   9.1	  
	  
PID5	  4	   A7(74)	   9.6	  
	  
PID7	  1	   A7(74)	   9.3	  
	  
PID7	  2	   A7(74)	   9.4	  
	  
PID7	  3	   A7(74)	   9.3	  
	  
PID7	  4	   A7(74)	   9.2	  
	  
PID7	  5	   A7(74)	   8.9	  
	  
PID10	  1	   A7(74)	   8.6	  
	  
PID10	  2	   A7(74)	   9.4	  
	  
PID10	  3	   A7(74)	   9.9	  
	  
PID10	  4	   A7(74)	   9.3	  
	  
PID10	  5	   A7(74)	   9.3	  
 
2 B sample number virus strain used RIN value 
	  
control	  1	   L10	   8.5	  
	  
control	  2	   L10	   8.4	  
	  
control	  3	   L10	   8.9	  
	  
PID4	  1	   L10	   9.8	  
	  
PID4	  2	   L10	   8.7	  
	  
PID4	  3	   L10	   9.4	  
	  
symptomatic	  1	   L10	   8.9	  
	  
symptomatic	  2	   L10	   8.5	  
	  
symptomatic	  3	   L10	   8.7	  
	  
symptomatic	  4	   L10	   8.6	  
	  
symptomatic	  5	   L10	   8.5	  
	  
symptomatic	  6	   L10	   9.1	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2 C sample number virus strain used RIN value 
	  
control	  1	   NY99	   8.2	  
	  
control	  2	   NY99	   8.4	  
	  
control	  3	   NY99	   8.5	  
	  
PID2	  1	   NY99	   8.5	  
	  
PID2	  2	   NY99	   8.8	  
	  
PID2	  3	   NY99	   8.4	  
	  
PID4	  1	   NY99	   8.2	  
	  
PID4	  2	   NY99	   8.1	  
	  
PID4	  3	   NY99	   8.4	  
	  
PID6	  1	   NY99	   9.1	  
	  
PID6	  2	   NY99	   8.6	  
	  
PID6	  3	   NY99	   8.8	  
Appendix 2. RNA quality measurements from SFV A7(74) and L10, and WNV samples  
Prior to TLDA analysis, the RNA quality of  (A) SFV A7(74), (B) SFV L10 and (C) WNV brain samples 
was measured using the Agilent Bioanalyser. The sample name, virus strain and RNA integrity 
number (RIN) are shown in the table. RIN>8 =high quality RNA. (A and B) Mice were infected i.p. 
(C) Mice were infected intranasally. PID= post infection day 
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Appendix 3. Comparison of gene expression in the CNS of SFV A7/74 and L10 
infected mice 
Mice were inoculated i.p with SFV strain A7/74 or L10 and RNA was isolated from infected brains 
at post infection day (PID) 3, 4, 5, 7 and 10 or shortly before the onset of symptoms 
(asymptomatic) and at the end stage of the disease (between PID 5-6). The fold change of gene 
expression compared to an uninfected healthy mouse brain is shown as mean of n=3-6 mice per 
group. Each sample was tested in triplicate. All samples were normalised to an endogenous 
control (TBP for A7/74 and Eif3f for L10). ND= not detectable 
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Appendix 4 
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Appendix 4. Chemokine and cytokine expression levels in the CNS of mice with 
genetic or pharmacological blockage of CCR2 
Wild type and CCR2 deficient mice were infected i.p. with SFV strain A7(74) for 7 days and brains 
were collected for analysis. The expression of chemokines and cytokines was measured by TLDA. 
Mice were treated twice daily by oral gavage with vehicle (6.6% DMSO in PBS) (untreated and 
CCR2-/- group) or 5 mg/kg RS504393 (CCR2 blocker) (treated group) between post infection days 
3-7. (A and D) CC-chemokine expression levels. (B and E) CXC-chemokine and (C and F) cytokine 
expression levels. Each gene was double normalised to an endogenous control Eif3f, and to an 
uninfected healthy control brain. The mRNA fold change compared to healthy controls is 
depicted on the y-axis. Data are shown as mean ± SD, n=3 mice per time point. Each gene was 
tested in triplicate. (student’s t-test; * p<0.05) 
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Appendix 5. Chemokine and cytokine expression levels in the CNS of mice after 
pharmacological blockage of CCR5 
Mice were infected i.p. with SFV strain A7(74) for 7 days and brains were collected for analysis. 
The expression of chemokines and cytokines was measured by TLDA. Mice were treated once 
daily by s.c. injection with vehicle (water) or 1 mg/kg DAPTA between post infection days 3-7. 
(A) CC-chemokine and (B) CXC-chemokine expression. (C) Cytokine expression and (D) 
transcription factor expression levels. Each gene was double normalised to an endogenous 
control Eif3f, and to an uninfected healthy control brain. The mRNA fold change compared to 
healthy controls is depicted on the y-axis. Data are shown as mean ± SD, n=3 mice per time 
point. Each gene was tested in triplicate. (student’s t-test; * p<0.05) 
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Appendix 6. Chemokine and cytokine expression levels in the CNS of mice after 
pharmacological blockage of CXCR3 
Mice were infected i.p. with SFV strain A7(74) for 7 days and brains were collected for analysis. 
The expression of chemokines and cytokines was measured by TLDA. Mice were treated once 
daily by s.c. injection with vehicle (50% DMSO and 25% PEG400 in water) or 10 mg/kg compound 
21 (CXCR3 blocker) between post infection days 3-7. (A and B) CC-chemokine, (C) CXC-
chemokine and (D) CX3C and XC chemokine expression levels in the brain. (E) Cytokine expression 
levels. (F) Expression levels of genes involved in innate immune responses. Each gene was double 
normalised to an endogenous control Eif3f, and to an uninfected healthy control brain. The 
mRNA fold change compared to healthy controls is depicted on the y-axis. Data are shown as 
mean ± SD, n=3 mice per time point. Each gene was tested in triplicate. (student’s t-test; * 
p<0.05) 
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